








































- Doutor	 Stephen	 David	 Marks,	 Reader,	 University	 College	 London,	 Consultant	 in	 Pediatric	
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my	 interest	 in	 research	arose	 from	taking	care	of	patients	with	 juvenile-onset	 systemic	
lupus	erythematosus.	 I	performed	a	study	on	major	 infections	 in	 this	group	of	patients	
and	 I	 realized	that	new	biomarkers	were	urgently	needed	to	guide	the	 judicious	use	of	
immunosuppressive	drugs,	as	well	as	new	treatment	strategies	with	fewer	side	effects.	I	
was	 certain	 that	 I	wanted	 to	participate	 in	 this	quest	and	 try	 to	bring	new	 light	 to	 the	
management	of	these	patients.		
	
In	 order	 to	 reach	 this	 goal,	 I	 needed	 to	 improve	 my	 scientific	 knowledge	 and	
become	 familiarized	 with	 the	 modern	 molecular	 biology	 and	 biocomputational	
techniques.	I	was	fortunate	to	be	a	part	of	the	Program	of	Advanced	Medical	Education	
from	the	Gulbenkian	Foundation.	This	Program	was	 specifically	designed	 for	physicians	
who	 wanted	 to	 increase	 their	 body	 of	 scientific	 knowledge	 and	 reasoning	 in	 order	 to	
answer	clinically	relevant	questions.		
	
I	 chose	 Dr.	 Sullivan’s	 laboratory	 at	 the	 Children’s	 Hospital	 of	 Philadelphia	 –	








lupus	 erythematosus:	 lupus	 nephritis	 and	 macrophage	 activation	 syndrome.	 The	
heterogeneous	clinical	outcome	of	patients	with	lupus	nephritis	always	intrigued	me	and,	
therefore,	 I	 wanted	 to	 study	 the	 kidney	 microRNA	 signature	 in	 order	 to	 better	
	
	 2	
understand	 its	 pathophysiology.	 The	 results	 from	 this	 project	 established	 new	 urinary	
biomarkers	that	reflect	cell	proliferation	in	lupus	nephritis	and	opened	new	avenues	for	




inflammatory	 state	 that	occurs	 in	macrophage	activation	 syndrome.	Collaborating	with	
Dr.	Behrens,	who	developed	a	mouse	model	of	secondary	hemophagocytic	syndrome,	 I	









numerous	 tangible	 and	 intangible	 assets	 I	 collected	 over	 the	 years,	 I	 have	 specifically	
learned	how	 to	 structure	my	 scientific	 reasoning,	 how	 to	design	 and	develop	 scientific	
projects	 and	 had	 first-hand	 experience	 with	 multiple	 techniques	 that	 I,	 personally,	
executed	and	ultimately	mastered.	 In	addition,	and	more	 importantly,	 I	had	the	unique	
opportunity	to	meet	extraordinary	and	inspiring	scientists	with	whom	I	learned	so	much	
and	with	whom,	I	am	certain,	I	will	find	ways	to	collaborate	in	future	projects.	All	in	all,	
now	 that	 I	 returned	 to	my	home	 institution,	my	 goal	 is	 quite	 simple:	 better	 the	 care	 I	










This	 thesis	 focuses	on	systemic	 lupus	erythematosus	and	tries	 to	bring	different	
scientific	approaches	to	the	study	of	chronic	inflammation.		
	
First,	 a	 brief	 overview	of	 the	 clinical	 characteristics	 of	 the	disease	 is	 presented,		






The	global	goals	of	 this	 thesis	are	enumerated	 in	chapter	4	and	the	subsequent	
chapters	are	the	result	of	original	work	performed	during	the	PhD:	
- The	 results	 from	 the	 clinical	project	on	major	 infections	 in	 juvenile-onset	 systemic	








activation	macrophage	 syndrome,	 one	 of	 the	most	 serious	manifestations	 of	 SLE.	
The	 content	 of	 this	 chapter	 was	 published	 in	 another	 paper	 in	 Arthritis	 and	
Rheumatology.	
	

























































































































































































































































































































complex	 etiopathogenesis	 and	 an	 unpredictable	 clinical	 course.	 In	 a	 large	 cohort	 of	
juvenile-onset	 SLE	 patients,	 we	 found	 that	 major	 infections	 were	 common,	 were	
associated	with	active	disease	and	its	treatment,	and	resulted	in	noteworthy	morbidity.	
New	 biomarkers	 to	 guide	 the	 judicious	 use	 of	 immunosuppressive	 drugs	 and	 new	
treatment	strategies	with	fewer	side	effects	would,	therefore,	have	an	enormous	impact	
in	the	management	of	these	patients.	In	order	to	reach	these	goals	we	used	the	modern	
tools	of	molecular	biology	and	 focused	on	 two	of	 the	most	 important	complications	of	
SLE:	lupus	nephritis	and	macrophage	activation	syndrome.	
Firstly,	 we	 identified	 the	 kidney	 lupus	 nephritis	 specific	 microRNA	 (miRNA)	
signature,	 which	 reflected	 mainly	 cell	 proliferation.	 MiRNAs	 are	 noncoding	 RNAs	
responsible	 for	 post-transcriptional	 gene	 silencing.	 These	 key	 regulatory	 molecules	
control	the	expression	of	multiple	genes,	so	its	dysregulation	can	contribute	to	sustained	
pathology.	We	 showed	 that	miR-26a	 and	miR-30b	 were	 significantly	 decreased	 in	 the	
kidneys	 and	 urine	 of	 lupus	 nephritis	 patients.	 In	 vitro,	 the	 knockdown	 of	miR-26a	 and	
miR-30b	caused	the	proliferation	of	human	mesangial	cells	and	increased	the	expression	
of	genes	related	to	the	cell	cycle,	including	CCNE2,	E2F8,	MAD2L1,	MYBL1	and	POLQ.		
The	Human	Epidermal	Growth	 Factor	 Receptor	 2	 (HER2)	 is	 a	 protein	 previously	
known	 to	 regulate	 miR-26a	 and	 miR-30b	 expression.	 Trastuzumab,	 a	 monoclonal	
antibody	 against	 HER2,	 used	 in	 breast	 cancer	 treatment,	 produces	 therapeutic	 actions	
precisely	by	up-regulating	miR-26a	and	miR-30b.	In	human	mesangial	cells	we	also	found	
that	trastuzumab	increases	these	two	miRNAs.	We	hypothesized	that	HER2	also	played	a	
role	 in	 the	 pathogenesis	 of	 lupus	 nephritis	 and	 indeed	 we	 identified	 a	 dramatic	
overexpression	 of	 HER2	 in	 the	 glomeruli	 and	 tubular	 compartments	 of	 the	 kidneys	 of	
lupus	 nephritis	 patients.	 The	 same	 pattern	 was	 not	 seen	 in	 the	 kidneys	 of	 healthy	
individuals	 or	 in	 other	 proliferative	 glomerulonephritides,	 including	 post-streptococcus	
glomerulonephritis,	IgA	nephropathy	and	granulomatosis	with	polyangiitis.	Furthermore,	
in	the	 lupus-prone	NZM2410	mice	we	 identified	a	highly	 increased	expression	of	HER2,	




higher	 in	 class	 III	 and	 class	 IV	 lupus	 nephritis	 and	 correlated	 with	 urinary	 protein-
creatinine	and	monocyte	chemoattractant	protein	1	 (MCP1)	and	vascular	 cell	 adhesion	
protein	 1	 (VCAM1)	 levels.	 We,	 therefore,	 	 established	 a	 strong	 rationale	 to	 use	
trastuzumab	to	block	HER2	and	decrease	cell	proliferation	and	damage	in	lupus	nephritis.		
Regarding	 the	 macrophage	 activation	 syndrome,	 we	 were	 interested	 in	 the	
characterization	 of	 hemophagocytes.	 These	 are	 activated	 macrophages	 that	 have	
engulfed	 other	 hematopoietic	 cells.	 Traditionally	 they	 have	 been	 associated	 with	 the	
development	 of	 cytopenias	 in	 several	 life-threatening	 cytokine	 storm	 syndromes.	 New	
data	 have	 challenged	 this	 concept,	 since	 pancytopenia	 occurs	 in	 the	 absence	 of	
hemophagocytosis	 in	 mice	 and,	 in	 humans,	 over	 40%	 of	 patients	 with	 macrophage	
activation	 syndrome	 do	 not	 have	 hemophagocytes	 in	 bone	 marrow	 aspirates.	 On	 the	
other	hand,	subclinical	hemophagocytosis	is	detected	in	more	than	50%	of	patients	with	
systemic	 juvenile	 idiopathic	 arthritis,	 but	 only	 10%	 develop	 a	 life-threatening	
macrophage	activation	syndrome.	Thus	the	function	and	significance	of	hemophagocytes	
remained	mysterious.		
Recent	 evidence	 demonstrated	 that	 environmental	 factors,	 particularly	 the	
cytokine	 milieu,	 determine	 the	 macrophage	 activation	 status	 in	 a	 continuum	 ranging	
from	 M1	 to	 M2.	 M1	 macrophages,	 driven	 by	 interferon	 γ,	 typically	 acquire	 pro-
inflammatory	 properties	 and	 are	 associated	 with	 tissue	 damage,	 whereas	 M2	
macrophages	 have	 more	 heterogeneous	 stimuli	 and	 functions,	 being	 associated	 with	
immunoregulation,	 tissue	 remodeling	 and	 fibrosis.	 Since	 interferon	 γ	 is	 the	 hallmark	
cytokine	 of	 hemophagocytic	 lymphohistiocytosis,	 one	 would	 expect	 to	 find	 that	
hemophagocytes	express	M1	surface	receptors.	
We	 characterized	 the	 transcriptional	 phenotype	 of	 mouse	 Toll-like	 receptor	 9	
(TLR9)	–	induced	hemophagocytes	and	described	the	surface	phenotype	of	human	bone	
marrow	 hemophagocytes.	 Interestingly,	 murine	 hemophagocytes	 had	 up-regulation	 of	
genes	 associated	 with	 the	 M2	 and	 not	 the	 M1	 phenotype.	 Immunohistochemical	
analyses	 in	 bone	 marrow	 samples	 from	 a	 uniquely	 diverse	 cohort	 of	 patients	 with	
hemophagocytic	 syndromes	 showed	 universal	 staining	 of	 hemophagocytes	 for	 the	M2	





Finally,	we	were	 interested	 in	 characterizing	 the	 transcriptome	of	 SLE,	 by	 RNA-
sequencing,	 in	 order	 to	 better	 understand	 the	 mechanisms	 that	 are	 responsible	 for	
chronicity.	 Monocytes	 from	 SLE	 patients	 exhibited	 a	 globally	 dysregulated	 gene	
expression.	The	transcriptome	was	not	simply	altered	by	the	activation	of	a	set	of	genes,	
but	 was	 also	 qualitatively	 different.	 Splicing	 patterns	 and	 polyadenylation	 were	
significantly	altered	and	SLE	monocytes	expressed	novel	 transcripts,	an	effect	 that	was	
replicated	 by	 exposing	 control	 monocytes	 to	 lipopolysaccharide	 (LPS).	 We	 further	
identified	 increased	 circulating	 endotoxin	 in	 SLE	 patients,	 suggesting	 that	 chronic	
microbial	translocation	could	contribute	to	the	immunologic	dysregulation	in	SLE,	a	new	
potential	disease	mechanism.	
In	 conclusion,	 with	 these	 different	 projects,	 which	 globally	 focused	 on	 the	
transcriptome	and	epigenome	of	SLE,	we	 identified	novel	pathways	and	challenged	the	
current	paradigms.	We	described	new	mechanisms	of	disease,	including	the	role	of	LPS	in	
transforming	 qualitatively	 the	 SLE	 transcriptome	 and	 a	 putative	 immunoregulatory	
function	 for	 hemophagocytes.	 We	 demonstrated	 that	 miR-26a,	 miR-30b	 and	 HER2	
control	 cell	 proliferation	 in	 lupus	 nephritis	 and	 that	 are	 promising	 biomarkers.	 Most	
importantly,	 our	work	 rose	 the	 possibility	 of	 using	 anti-HER2	 drugs	 for	 lupus	 nephritis	
management,	opening	the	door	to	a	new	treatment	strategy	in	this	disease.		
	



















O	 lúpus	 eritematoso	 sistémico	 é	 uma	 doença	 autoimune	 com	 uma	 patogénese	
complexa	 e	 uma	 apresentação	 clínica	 muito	 variável.	 Numa	 coorte	 de	 crianças	 e	
adolescentes	 com	 lúpus	 eritematoso	 sistémico	 demonstrámos	 que	 as	 infecções	major	




tentar	 atingir	 estes	 objectivos,	 focando-nos	 em	duas	 das	mais	 graves	 complicações	 do	
lúpus	eritematoso	sistémico:	a	nefrite	lúpica	e	a	síndrome	de	ativação	macrofágica.		
Em	 primeiro	 lugar,	 descrevemos	 o	 padrão	 renal	 de	 microRNAs	 (miRNAs)	
característico	 da	 nefrite	 lúpica.	 Os	miRNAs	 controlam	 a	 expressão	 de	múltiplos	 genes,	
impedindo	a	tradução	dos	mRNAs	aos	quais	se	 ligam.	Os	miRNAs	são,	assim,	moléculas	
reguladoras	 essenciais,	 cuja	 desregulação	 pode	 levar	 à	 doença	 e	 contribuir	 para	 a	 sua	




doentes	 com	 nefrite	 lúpica.	 Demonstrámos	 em	 células	 mesangiais	 humanas	 que	 a	
diminuição	destes	miRNAs	causa	um	aumento	da	expressão	de	genes	relacionados	com	o	
ciclo	 celular,	 incluindo	 CCNE2,	 E2F8,	 MAD2L1,	 MYBL1	 e	 POLQ,	 e,	 consequentemente,	
proliferação	celular.	
O	 receptor	 do	 factor	 de	 crescimento	 epidérmico	 humano	 2	 (HER2)	 regula	 a	
expressão	do	miR-26a	e	do	miR-30b.	O	trastuzumab,	um	anticorpo	monoclonal	contra	o	
HER2,	é	usado	no	tratamento	do	cancro	da	mama,	sendo	a	sua	ação	eficaz	 justamente	
porque	 aumenta	 os	 níveis	 de	miR-26a	 e	 de	miR-30b.	 Em	 células	mesangiais	 humanas	
constatámos	 que	 o	 trastuzumab	 também	 aumenta	 a	 expressão	 deste	 dois	 miRNAs.	





padrão	 não	 foi	 detetado	 em	 rins	 de	 pessoas	 saudáveis	 e	 em	 doentes	 com	
glomerulonefrite	 pós-estreptocócica,	 nefropatia	 IgA	 e	 granulomatose	 com	 poliangeíte.	
Acresce	 que	 em	 ratinhos	 NZM2410	 também	 encontrámos	 um	 aumento	 franco	 da	
expressão	 da	 proteína	 HER2,	 correlacionando-se	 esta	 com	 a	 atividade	 da	 doença.	
Finalmente,	 demonstrámos	 que	 a	 proteína	 HER2	 se	 encontra	 aumentada	 na	 urina	 de	
















ativação	 macrofágica	 num	 continuum	 de	 M1	 até	 M2.	 Os	 macrofágos	 M1	 têm,	
tipicamente,	 propriedades	 pró-inflamatórias	 e	 associam-se	 a	 lesão	 dos	 tecidos.	 Os	
macrófagos	M2	têm	funções	mais	variadas,	 incluindo	a	imunoregulação,	a	remodelação	
dos	tecidos	e	a	fibrose.	




Caracterizámos	 o	 transcriptoma	 de	 hemofagócitos	 de	 ratinho	 induzidos	 pela	
estimulação	 repetida	 de	 TLR9.	 Surpreendentemente,	 estes	 tinham	 um	 aumento	 da	
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expressão	 de	 genes	 associados	 ao	 fenótipo	 M2	 e	 não	 M1.	 Por	 imunohistoquímica	
estudámos	os	receptores	de	superfície	de	hemofagócitos	de	uma	coorte	diversificada	de	
doentes	 com	 síndromes	 hemofagocíticas.	 Demonstrámos	 que	 os	 hemofagócitos	
expressavam	 universalmente	 CD163,	 um	 marcador	 M2,	 e,	 em	 raras	 ocasiões,	
expressavam	 CD206	 e	 CD64.	 Globalmente	 estes	 dados	 apoiam	 a	 hipótese	 de	 que	 os	
hemofagócitos	 têm	 funções	 imunoreguladoras	 e	 abrem	 a	 porta	 à	 realização	 de	 novos	
estudos	sobre	a	função	destas	células.		
Finalmente,	 pretendíamos	 caracterizar	 o	 transcriptoma	 do	 lúpus	 eritematoso	
sistémico,	 usando	 a	 técnica	 de	 sequenciação	 de	 RNA,	 com	 o	 intuito	 último	 de	 tentar	




-se	 novos	 padrões	 de	 processamento	 de	 RNA	 e	 novas	 formas	 de	 RNA,	 que	 foram	
replicadas	 pela	 exposição	 de	monócitos	 de	 controlo	 ao	 lipopolissacarídeo.	 Finalmente,	
identificámos	 um	aumento	 em	 circulação	do	 lipopolissacarídeo	 em	doentes	 com	 lúpus	
eritematoso	sistémico.	A	translocação	microbiana	crónica	pode,	assim,	contribuir	para	a	
desregulação	imunológica	própria	desta	doença.	
Em	 conclusão,	 com	 estes	 diferentes	 projetos,	 que	 globalmente	 se	 focaram	 no	
transcriptoma	e	no	epigenoma	do	lúpus	eritematoso	sistémico,	identificámos	novas	vias	
e	 desafiámos	 alguns	 dos	 paradigmas	 vigentes.	 Descrevemos	 novos	 mecanismos	 de	
doença,	 incluindo	 o	 papel	 do	 lipopolissacarídeo	 na	 transformação	 qualitativa	 do	
transcriptoma	no	lúpus	eritematoso	sistémico	e	a	possibilidade	dos	hemofagócitos	terem	
funções	 imunoreguladoras.	 Demonstrámos	 ainda	 que	 miR-26a,	 miR-30b	 e	 HER2	
controlam	a	proliferação	celular	na	nefrite	lúpica	e	são	promissores	biomarcadores.	Mais	
importante	ainda	o	nosso	trabalho	levantou	a	hipótese	de	se	usarem	fármacos	anti-HER2	





























musculoskeletal	 and	 hematologic	 abnormalities.	 Some	 patients	 also	 have	 renal	 and	
central	nervous	system	involvement.		
The	effective	management	of	SLE	patients	requires	regular	clinical	monitoring	in	
order	 to	 assess	 disease	 activity	 and	 prevent,	 detect	 and	 promptly	 treat	 relapses.	 The	
prognosis	 of	 SLE	 patients	 improved	 in	 the	 past	 decades	 due	 to	 an	 earlier	 diagnosis,	 a	






Incidence	 rates	 of	 SLE	 range	 from	 1	 to	 10	 per	 100,000	 person-years	 and	
prevalence	rates	generally	range	from	20	to	70	per	100,000	persons	(1–13).	The	annual	
incidence	of	juvenile-onset	SLE	is	less	than	1	per	100,000	persons	(14).		
Notably,	 the	 SLE	 epidemiological	 studies	 differ	 not	 only	 by	 sampling	 and	
recruitment	methodologies,	but	also	by	the	criteria	used	to	define	SLE.	Furthermore,	the	
studies	conducted	at	hospital	settings	failed	to	capture	cases	of	mild	disease.	Despite	the	




The	 strongest	 risk	 factor	 for	 SLE	 is	 gender.	 It	 is	 well	 known	 that	 women	 are	
affected	more	 frequently	 than	men.	 This	 is	 an	 effect	 partially	 attributed	 to	 estrogens,	




3:1,	 while	 in	 women	 of	 child-bearing	 years	 the	 ratio	 ranges	 from	 7:1	 to	 15:1	 (1–13).	




with	 SLE	 have	 higher	 incidence	 of	 skin	 manifestations,	 cytopenias,	 serositis,	 nephritis,	
neurologic	involvement,	cardiovascular	disease	and	vasculitis	than	women	(16–18).		
Regarding	 age,	 juvenile-onset	 SLE	 tends	 to	 be	 more	 severe,	 with	 a	 higher	
incidence	 of	 nephritis,	 neurologic	 involvement,	 and	 hematologic	 abnormalities	 (19),	
while	 lupus	 tends	 to	 be	 milder	 in	 older	 adults	 (20).	 In	 this	 group	 there	 is	 a	 lower	
incidence	of	rash,	renal	and	hematologic	involvement,	while	there	is	a	greater	prevalence	
of	musculoskeletal	manifestations,	sicca	symptoms,	serositis	and	pulmonary	involvement	
(20).	 Interestingly,	 in	 older	 adults	 with	 SLE	 there	 is	 a	 lower	 prevalence	 of	
hypocomplementemia	and	of	anti-Sm	and	anti-RNP	antibodies	and	a	greater	prevalence	
of	rheumatoid	factor	(20).	It	has	been	speculated	that	older	patients	may	have	different	
genetic	 determinants	 of	 disease	 and	 may	 respond	 to	 different	 triggering	 mechanisms	
(19).	 The	 senescence	 of	 the	 immune	 system	 may	 also	 contribute	 to	 the	 clinical	
differences	(19).	
SLE	 has	 been	 described	 all	 over	 the	 world.	 Ethnicity	 incorporates	 genetic,	
geographic,	 cultural,	 social	 and	 other	 characteristics	 shared	 within	 a	 population.	 Not	
surprisingly,	 the	 incidence	 and	 phenotypic	 expression	 of	 SLE	 varies	 between	 different	
ethnic	 groups	 (1).	 Prevalence	 rates	 in	 people	 of	 African	 or	 Asian	 background	 are	
approximately	2	to	3	times	higher	than	in	Caucasians	(1).	In	the	United	States,	Americans	
of	 European	 descent	 have	 a	 lower	 lupus	 incidence	 than	 Asians,	 Afro-Americans,	 Afro-
Caribbeans,	and	Hispanic	Americans	(1).	




rural	 areas	 (21,22).	 Some	 data,	 however,	 suggest	 that	 rural	 populations	 experience	







Another	 interesting	 fact	 is	 that	 SLE	 is	 rare	 in	 Africa,	 but	 common	 in	 African	








The	 Euro-lupus	 cohort	 is	 composed	 of	 1,000	 unselected	 SLE	 patients	who	 have	
been	followed	prospectively	since	1991	(19).	This	study	determined	the	incidence	of	the	
different	clinical	manifestations	at	the	onset	of	the	disease	and	during	the	follow	up	and	
evaluated	 the	 response	 to	 treatment,	 damage	 and	mortality.	 The	 ultimate	 goal	 of	 the	








than	 80%	 of	 patients,	 and	 being	 associated	 with	 diminished	 ability	 to	 function	 (25).	
Interestingly,	 depression,	 pain	 and	 poor	 sleep	 quality	 were	 found	 to	 be	 positive	
predictors	of	fatigue	 in	SLE	patients	(25–27),	while	disease	activity	or	medication	usage	
were	not	(26,28).	Moreover,	perceived	social	support	correlates	negatively	with	fatigue,	





























The	 more	 classic	 presentation	 is	 the	 acute	 cutaneous	 localized	 lupus	
erythematosus,	 which	 is	 characterized	 by	 a	 facial	 eruption,	 after	 sun	 exposure,	 that	
presents	 in	 a	malar	 distribution	 over	 the	 cheeks	 and	 nose,	 but	 sparing	 the	 nasolabial	
folds.	It	may	precede	other	symptoms	of	SLE	by	months	or	even	years.	The	word	“lupus”	
(Latin	for	wolf)	is	attributed	to	the	thirteenth	century	physician	Rogerius	who	used	it	to	
describe	 the	 classic	malar	 rash	 that	was	 reminiscent	of	 a	wolf.	Despite	being	 the	most	
classic	symptom,	in	the	Euro-lupus	cohort	 less	than	50%	of	the	patients	presented	with	
the	typical	erythematosus	malar	rash	at	the	onset	of	the	disease	(19).		
Subacute	 cutaneous	 lupus	 erythematosus	occurs	 in	 approximately	 10%	 of	 SLE	
patients.	 The	 typical	 lesions	 are	 small,	 erythematous,	 slightly	 scaly	papules	 that	 evolve	
into	 either	 a	 papulosquamous	or	 annular	 form,	which	may	 coalesce	 to	 form	polycyclic	
patterns.	 The	most	 affected	 areas	 are	 the	 shoulders,	 forearms,	 neck,	 and	upper	 torso.	
The	face	is	usually	not	affected	(29).	
Chronic	discoid	lesions	occur	in	up	to	25%	of	SLE	patients,	but	may	also	occur	in	
the	 absence	 of	 any	 other	 SLE	 features	 (19).	 The	 lesions	 are	 usually	 discrete,	




After	an	active	 inflammatory	phase,	 the	 lesions	 tend	to	heal,	 leaving	depressed	central	
scars,	 atrophy,	 telangiectasias,	 and	 hyperpigmentation	 or	 hypopigmentation.	 Scarring	
alopecia	can	occur	in	this	group	of	patients.		
	Lupus	 profundus	 (lupus	 erythematosus	 panniculitis)	 consists	 of	 nodules,	 often	
painful,	which	may	 appear	 on	 the	 scalp,	 face,	 arms,	 chest,	 back,	 thighs,	 and	 buttocks.	
They	 usually	 resolve,	 but	 may	 leave	 a	 depressed	 area.	 These	 nodules	 consist	 of	 fat	
necrosis	with	mononuclear	cell	infiltration	and	lymphocytic	vasculitis.		
Chilblain	 lupus	erythematosus	presents	with	 tender,	 red	 to	blue	nodules	on	 the	
toes,	fingers,	nose,	or	ears	that	occur	in	cold	weather	and	may	ulcerate.	Approximately	
25%	of	patients	who	present	with	this	lesion	meet	SLE	criteria	(30).	
Patients	with	 localized	 discoid	 lupus	 erythematosus,	 hypertrophic	 discoid	 lupus	









and	 subacute	 cutaneous	 lupus	 erythematosus	 and	 in	 chronic	 discoid	 lupus	
erythematosus	 and	 lupus	 tumidus.	 The	 incidence	 is	 greater	 in	 those	 with	 anti-Ro/SSA	
antibodies	(35).	
The	majority	of	SLE	patients	have	hair	 loss	 that	can	 lead	 to	areas	of	alopecia	 in	
some	patients	 (36).	 It	can	precede	other	SLE	manifestations	and	may	 involve	the	scalp,	
eyebrows,	 eyelashes,	 beard	 and/or	body	hair.	Alopecia	 can	be	nonscarring	or	 scarring.	
The	latter	is	a	complication	of	discoid	lupus	erythematosus.	










Arthritis	 occurs	 in	 the	majority	 of	 SLE	 patients	 and	 is	 often	 one	 of	 the	 earliest	
clinical	manifestations	(19,40).	The	arthritis	is	usually	polyarticular	and	symmetrical,	with	
a	 predilection	 for	 the	 knees,	 carpal,	 metacarpophalangeal	 and	 interphalangeal	 joints.	
Symptoms	 in	 a	 particular	 joint	 can	 last	 less	 than	 24	 hours.	 Synovial	 effusions	 are	
infrequent,	but	when	occur	they	are	usually	small,	and	the	fluid	is	clear	or	slightly	cloudy	
and	 similar	 to	 a	 transudate	 (41).	 The	 degree	 of	 pain	 often	 exceeds	 objective	 physical	
findings,	and	tenderness	may	be	difficult	to	assess	in	some	patients	because	of	the	often	
coexistence	of	amplified	pain	syndrome.	
	It	 is	 typically	 a	non-erosive	and	non-deforming	arthritis,	 however	up	 to	10%	of	
the	patients	may	 show	deformities	 (Jaccoud	arthropathy).	 These	may	 result	 from	 soft-
tissue	 abnormalities,	 such	 as	 laxity	 of	 ligaments,	 fibrosis	 of	 the	 capsule,	 and	muscular	
imbalance.	Some	patients	may	show	overlapping	features	with	rheumatoid	arthritis	and	
develop	 erosions.	 The	 presence	 of	 antibodies	 to	 citrullinated	 peptides/proteins	 (anti-
CCP)	 antibodies,	 which	 are	 present	 in	 8%	 of	 SLE	 patients,	 is	 strongly	 associated	 with	
erosive	arthritis	(odds	ratio	of	23	for	anti-CCP	positive	versus	negative	patients)	(42).		
Myalgias	and	muscle	weakness	occur	 in	up	to	70%	of	SLE	patients,	but	atrophy,	
myositis	and	severe	muscle	weakness	are	 relatively	uncommon	 (19).	 In	addition	 to	SLE	




Hematologic	 abnormalities	 are	 common	 among	 patients	 with	 SLE,	 particularly	





of	 anemia	and	 should	be	 considered	 if	 there	 is	 an	elevated	 reticulocyte	 count	 and	 the	
direct	antiglobulin	test	is	negative.		
Leukopenia,	defined	as	a	total	white	blood	cell	count	less	than	4,000	/μL	(45,46),	





to	 a	 fall	 in	 the	 absolute	 lymphocyte	 count.	 Neutropenia	 is	 uncommon	 and,	 when	 it	
occurs,	is	usually	a	drug	effect	or	associated	with	severe	infection.	
Significant	 thrombocytopenia	 is	 characterized	 as	 a	 platelet	 count	 of	 less	 than	
100,000/μL	 in	 the	 American	 College	 of	 Rheumatology	 (ACR)	 guidelines	 (45,46).	 The	
prevalence	 of	 thrombocytopenia	 varies	 from	 10%	 to	 50%	 (43,47–49).	 The	 degree	 of	
thrombocytopenia	 is	 usually	mild	 and	 severe	 blending	 is	 rare	 (49).	 The	most	 common	
clinical	 manifestations	 of	 severe	 thrombocytopenia	 are	 petechiae,	 purpura	 and	
ecchymosis.	Epistaxis,	gum	bleeding,	menorrhagia	and	even	intracranial	hemorrhage	can	
also	occur,	but	are	rare.	










of	 lupus	nephritis	 is	higher	 in	African-Americans	(34%	to	51%),	Hispanics	 (31%	to	43%),	
and	 Asians	 (33%	 to	 55%)	 than	 it	 is	 in	 Caucasians	 (14%	 to	 23%)	 (53–55).	 Moreover,	
African-Americans	 and	 Hispanics	 present	 more	 frequently	 with	 severe	 underlying	
histopathology,	 higher	 serum	 creatinine	 concentrations,	 and	more	 proteinuria	 (56).	 In	
the	Euro-lupus	cohort	nephritis	occurred	in	28%	of	patients	(19),	a	lower	incidence	when	
compared	 with	 American	 series	 (40,52)	 and	 Asian	 series	 (57).	 These	 differences	 may	
reflect	not	only	genetic,	but	also	environmental	factors.	
Most	renal	abnormalities	occur	within	the	first	6	to	36	months	(53).	The	patients	









Tubulointerstitial	 disease	 is	 common	 in	 lupus	 nephritis	 and	 is	 almost	 always	
associated	 with	 concurrent	 glomerular	 disease.	 Patients	 present	 with	 a	 rising	 plasma	
creatinine	 concentration	 and	 a	 relatively	 bland	 urinalysis.	 Signs	 of	 tubular	 dysfunction	
may	 be	 present.	 The	 severity	 of	 the	 tubulointerstitial	 involvement	 is	 an	 important	
prognostic	 sign,	 correlating	 positively	 with	 the	 presence	 of	 hypertension,	 an	 elevated	
plasma	creatinine	concentration,	and	a	progressive	clinical	course	(58).		
Involvement	of	the	renal	vasculature	is	also	frequent	in	lupus	nephritis,	and	it	can	
also	 adversely	 affect	 the	 prognosis	 (59–61).	 The	 most	 frequent	 manifestations	 are	
thrombotic	microangiopathy,	 vasculitis	 and	 atherosclerosis	 (59–61).	 Rarely	 do	 patients	
with	lupus	nephritis	develop	renal	vein	thrombosis.	These	patients	are	typically	nephrotic	
and	have	high	antiphospholipid	antibody	levels.	
Finally,	 regarding	 lupus	 nephritis	 outcome,	 in	 a	 large,	 recent,	 multi-ethnic	
inception	 cohort	 of	 1,827	 SLE	 patients,	 of	whom	 700	 (38.3%)	 had	 lupus	 nephritis,	 the	
estimated	overall	10-year	 incidence	of	end	stage	renal	disease	was	4.3%	(95%	CI:	2.8%,	











controls,	 patients	 were	 more	 cognitively	 impaired,	 particularly	 on	 tests	 emphasizing	
psychomotor	 speed,	 complex	 attention,	 and	 memory	 (65).	 Other	 previous	 studies	 of	
cognitive	impairment	in	SLE	suggest	that	the	deficits	most	typically	involve	attention,	free	






























Headache	 is	 also	 a	 common	 complaint	 of	 SLE	 patients,	with	more	 than	 50%	of	
patients	 reporting	 headache	 (migraine	 32%	 and	 tension-type	 headache	 24%)	 (67).	











Approximately	 15%	 of	 SLE	 patients	 develop	 a	 peripheral	 neuropathy	 due	 to	
vasculopathy	 of	 small	 arteries	 supplying	 the	 nerves	 (71).	 Polyneuropathy	 is	 the	 most	




Autonomic	 neuropathy	 has	 also	 been	 reported,	 resulting	 in	 gastrointestinal,	




peripheral	 neuropathy	 does	 not	 typically	 occur	 early	 in	 the	 course	 of	 SLE.	 Cranial	
neuropathies	have	also	been	described,	causing	diplopia,	nystagmus,	ptosis,	visual	 field	
deficits,	trigeminal	neuralgia,	dysarthria,	facial	weakness	or	vertigo	(73).		
Optic	 neuritis	 and	 sensorioneural	 hearing	 defects	 in	 both	 low	 and	 high	
frequencies	have	been	noted	more	 frequently	 in	patients	with	 SLE	 than	 in	 the	general	
population	(74,75).	
Transverse	myelitis	 has	 also	been	described	 in	 SLE	patients	presenting	with	 the	
sudden	onset	of	 lower	extremity	weakness	and/or	 sensory	 loss,	plus	 loss	of	 rectal	 and	




Pleuritis	 is	 the	most	 frequent	pulmonary	manifestation	of	SLE,	but	pneumonitis,	
interstitial	lung	disease,	pulmonary	hypertension,	shrinking	lung	syndrome,	and	alveolar	
hemorrhage	can	also	occur.	





The	heart	 is	one	of	 the	most	 frequently	affected	organs	 in	SLE	 (80).	Any	part	of	
the	 heart	 can	 be	 affected,	 including	 the	 pericardium,	 myocardium,	 endocardium,	
coronary	arteries,	valves	and	the	conduction	system.	
	Pericarditis,	 with	 or	 without	 an	 effusion,	 is	 the	 most	 common	 cardiac	
manifestation	of	 SLE,	occurring	 in	 approximately	25%	of	patients	 at	 some	point	during	
their	 disease	 course	 (80).	 Myocarditis	 is	 uncommon,	 but	 may	 be	 severe	 and	 cause	
congestive	heart	 failure	(80).	Libman-Sacks	endocarditis	 is	usually	clinically	silent,	but	 it	
can	 produce	 valvular	 insufficiency,	 be	 a	 source	 of	 emboli	 and	 contribute	 to	 the	
occurrence	of	subacute	bacterial	endocarditis.		
Patients	 with	 SLE	 also	 have	 an	 increased	 risk	 of	 coronary	 artery	 disease,	 an	
important	cause	of	mortality	in	older	adult	patients	and	in	those	with	long-standing	SLE	






SLE	 is	 also	 associated	with	 stroke	 and	 premature	 death	 due	 to	 cerebrovascular	





SLE	 controls	 (83).	 Baseline	 disease	 activity,	 hyperlipidemia,	 and	 hypertension	 are	 the	
main	 risk	 factors	 (85).	 There	 is	 also	 a	 high	 association	 between	 antiphospholipid	
antibodies	and	stroke	in	SLE	(86).	Other	factors,	such	as	vasculitis,	valvular	heart	disease,	
infection,	 chronic	 steroid	 therapy,	 emboli,	 and/or	 thrombosis,	 can	 also	 contribute	
cerebrovascular	disease	(87,88).	
Vasculopathy	 can	 also	 be	 seen	 in	 SLE.	 Raynaud	 phenomenon,	 a	 vasospastic	
process	 induced	 by	 cold	 or	 emotion,	 occurs	 in	 up	 to	 50%	 of	 patients	 (19).	 Vasculitis	
prevalence	 ranges	between	11	and	36%	 (89).	Vessels	of	 all	 sizes	 can	be	 involved,	with	
cutaneous	 small	 vessel	 vasculitis	 being	 the	 most	 common.	 The	 latter	 can	manifest	 as	
palpable	 purpura,	 petechiae,	 livedo	 reticularis,	 panniculitis	 and	 ulcerations.	Livedo	
reticularis,	 which	 is	 caused	 by	 vasospasm	 of	 the	 dermal	 ascending	 arterioles,	 can	
progress	 to	 vascular	 occlusion,	 leading	 to	 ischemia	 and	 to	 tissue	 infarction,	 causing	
painful	ulcerations.	
Medium	 and	 large	 vessel	 vasculitis	 can	 also	 occur	 and	 cause	 life-threatening	
manifestations	 such	 as	 mesenteric	 vasculitis,	 coronary	 vasculitis,	 pulmonary	 bleeding,	
retinal	vasculitis	or	peripheral	or	central	nervous	system	vasculitis	(89).		
Thromboembolic	 disease	 can	 complicate	 SLE,	 particularly	 in	 the	 context	 of	
antiphospholipid	 syndrome.	 In	 a	 large	 cohort	 of	 554	 newly-diagnosed	 SLE	 patients	
followed	 for	 a	 median	 of	 6.3	 years,	 an	 arterial	 thrombotic	 event	 occurred	 in	 11%,	
whereas	 a	 venous	 thrombotic	 event	 occurred	 in	 5%	 (90).	 Arterial	 thromboemboli	may	









activity	 and	 can	 be	 the	 initial	 manifestation	 of	 SLE	 (91).	 Keratoconjunctivitis	 sicca	
associated	 with	 secondary	 Sjögren’s	 syndrome	 and	 retinal	 vasculopathy	 are	 the	 most	








SLE-related	gastrointestinal	 abnormalities	occur	 in	up	 to	40%	of	patients	during	
their	 lifetime	 and	 can	 involve	 almost	 any	 organ	 along	 the	 gastrointestinal	 tract	 and	
include	 esophagitis,	 peptic	 ulcer	 disease,	 intestinal	 pseudo-obstruction,	 protein-losing	
enteropathy,	mesenteric	vasculitis,	and	peritonitis	(92).		
Intestinal	 pseudo-obstruction	 is	 rare	 and	 is	 characterized	 by	 abdominal	 pain,	
bloating,	and	distension	in	the	absence	of	an	anatomic	lesion	obstructing	the	intestine.	It	
usually	 occurs	 in	 SLE	 patients	 with	 active	 disease	 (93).	 It	 can	 be	 caused	 by	 immune	
complex	 deposition	 in	 smooth	muscle	 cells,	 and/or	 vasculitis	 causing	 chronic	 ischemia	
and	hypomotility	(94,95).	




cause	 intense	 abdominal	 pain	 or	 chronically	 presenting	 with	 a	 gradually	 developing,	
painless,	ascites	(97).	
Liver	test	abnormalities	in	SLE	patients	are	common,	but	clinically	significant	liver	











Immunologic	 abnormalities,	 particularly	 the	 production	 of	 autoantibodies,	 are	
frequent	in	SLE.	The	presence	of	antinuclear	antibodies	in	the	serum	is	seen	in	the	great	
majority	of	SLE	patients.	Occasional	cases	of	SLE	patients	without	detected	anti-nuclear	
antibodies	 have	 been	 described	 (101),	 but	 alternative	 diagnoses	 should	 be	 sought	
vigorously	in	these	cases.	
Interestingly,	 autoantibodies	 are	 typically	 present	 many	 years	 before	 the	





Anti-Smith	 (anti-Sm)	 and	 anti-ribosomal	 P	 protein	 antibodies	 are	 also	 highly	
specific	 for	SLE,	but	 lack	sensitivity,	being	present	 in	 less	than	10%-30%	of	SLE	patients	
(19,103,104).	Anti-ribosomal	P	antibodies	are	associated	with	active	disease,	particularly	
neuropsychiatric,	 renal,	 or	 hepatic	 involvement,	 and	 are	 found	 more	 frequently	 in	
children	than	adults	with	SLE	(105,106).	
Anti-Ro/SSA	antibodies	occur	 in	20%	to	30%	of	patients	and	are	associated	with	
subacute	 cutaneous	 lesions,	 sicca	 syndrome	 and	 a	 lower	 prevalence	 of	
thrombocytopenia	 (19).	 Anti-La/SSB	 antibodies	 are	 present	 in	 20%	of	 SLE	 patients	 and	
are	 associated	with	malar	 rash,	 subacute	 cutaneous	 lesions,	 photosensitivity,	 arthritis,	
serositis	and	thrombosis	(19).		
Anti-U1-snRNP	 antibodies	 are	 detected	 in	 13%	 to	 25%	 of	 patients	 (19,104).	
Patients	 with	 these	 antibodies	 have	 a	 higher	 incidence	 of	 Raynaud’s	 phenomenon,	
myositis	and	lymphadenopathy	(19).	
The	presence	of	anti-Ro/SSA,	anti-La/SSB	and	anti-U1-snRNP	during	pregnancy	is	









elevation	 of	 the	 transaminases,	 hepatosplenomegaly,	 hepatitis	 and	 cholestasis	 (108).	
Aproximately	 half	 of	 the	mothers	 of	 newborns	with	 neonatal	 lupus	 are	 asymptomatic	
(108).	 The	 others	 have	 been	 diagnosed	 previously	 with	 SLE,	 Sjögren	 disease	 or	mixed	
connective	tissue	disease	(108).		




Finally,	 in	 two	 small	 case	 series,	 antibodies	 to	microtubule-associated	protein	2	
were	 found	 in	 a	 high	 percentage	 (63%	 to	 76%)	 of	 SLE	 patients	 with	 neuropsychiatric	
manifestations	and	not	 in	patients	with	other	neurologic	diseases,	SLE	patients	without	
neurolupus	or	healthy	controls	(110,111).	
In	 conclusion,	 SLE	 patients	 might	 have	 different	 auto-antibodies,	 which	 are	
associated	 with	 different	 clinical	 manifestations.	 Nevertheless,	 a	 perfect	 distinction	 of	
SLE	 subsets	 according	 to	 the	 profile	 of	 auto-antibodies	 is	 not	 possible.	 We	 need,	








pose	a	diagnostic	 challenge,	which	 is	 reflected	 in	 the	 long	delay	between	 the	onset	of	
symptoms	and	the	diagnosis	(2	years	in	adults	and	5	years	in	children)	(19).	The	diagnosis	
of	 SLE	 is	 generally	 based	 on	 clinical	 judgment,	 after	 excluding	 alternative	 diagnoses.	





1982,	 the	 American	 Rheumatism	 Association	 (ARA),	 now	 the	 American	 College	 of	
Rheumatology	(ACR),	developed	an	SLE	criteria	classification,	which	was	revised	in	1997	
(45,46).	The	patient	was	diagnosed	with	SLE	if	four	or	more	of	the	manifestations	were	
present,	 either	 serially	 or	 simultaneously	 (46,112).	 The	 ACR	 criteria	 are	 presented	 in	
Table	1.3.	
In	2012,	 the	Systemic	Lupus	 International	Collaborating	Clinics	 (SLICC)	proposed	
revised	SLE	criteria	that	were	developed	to	address	some	of	weaknesses	of	the	1997	ACR	
SLE	criteria	(113).	In	order	to	be	diagnosed	with	SLE	the	patient	has	to	satisfy	at	least	four	
of	 17	 criteria,	 including	 at	 least	 one	 of	 the	 11	 clinical	 criteria	 and	 one	 of	 the	 six	




The	 SLICC	 criteria	 were	 derived	 from	 a	 set	 of	 702	 expert-rated	 scenarios	 and	
validated	 in	 a	 new	 sample	 of	 690	 new	 patient	 scenarios	 (113).	 The	 new	 criteria	 had	
greater	 sensitivity	 (94%	 versus	 86%;	 p<0.0001)	 and	 equal	 specificity	 (92%	 versus	 93%;	
p=0.39)	when	compared	to	the	1997	ACR	criteria	(113).	
	





















Discoid	rash	 Erythematosus	 raised	 patches	 with	 adherent	 keratotic	 scaling	 and	
follicular	plugging	
Oral	ulcers	 Oral	or	nasopharyngeal	ulcers,	usually	painless	






Renal	disorder	 Persistent	proteinuria	greater	 than	500mg/24h	or	greater	 than	3+	 if	
quantification	not	performed	or	
Cellular	 casts	 –	 may	 be	 red	 cell,	 hemoglobin,	 granular,	 tubular,	 or	
mixed	






Antinuclear	antibodies	 An	abnormal	 titer	of	antinuclear	antibodies	by	 immunofluorescence	





of	 IgG	 or	 IgM	 anticardiolipin	 antibodies	 or	 a	 positive	 test	 result	 for	
lupus	 anticoagulant,	 or	 a	 false-positive	 serologic	 test	 for	 syphilis	
known	 to	 be	 positive	 for	 at	 least	 six	 months	 and	 confirmed	 by	
















Nonindurated	 psoriaform	 and/or	 annular	 polycyclic	 lesions	 that	










such	 as	 vasculitis,	 Behçet's	 disease,	 infection	 (herpesvirus),	
inflammatory	bowel	disease,	reactive	arthritis,	and	acidic	foods	
Nonscarring	alopecia	 Diffuse	 thinning	 or	 hair	 fragility	 with	 visible	 broken	 hairs	 in	 the	
absence	 of	 other	 causes,	 such	 as	 alopecia	 areata,	 drugs,	 iron	
deficiency,	and	androgenic	alopecia	










Pericarditis	 by	 electrocardiography	 in	 the	 absence	 of	 other	 causes,	
such	as	infection,	uremia	and	Dressler	syndrome	





















Lymphopenia	 (<1,000/µL	 at	 least	 once),	 in	 the	 absence	 of	 other	
known	causes,	such	as	glucocorticoids,	drugs,	and	infection	
Thrombocytopenia	 Thrombocytopenia	 (<100,000/µL)	 at	 least	 once	 in	 the	 absence	 of	


















In	 order	 to	 promptly	 diagnose	 lupus	 nephritis,	 SLE	 patients	 should	 undergo	
testing	 at	 regular	 intervals,	 including	 a	 urinalysis	 with	 examination	 of	 the	 urinary	
sediment,	a	spot	urine	protein-to-creatinine	ratio,	and	a	serum	creatinine.		
A	 kidney	 biopsy	 should	 be	 performed	 in	 SLE	 patients	who	 develop	 evidence	 of	
renal	 involvement	 in	 order	 to	 establish	 the	 diagnosis,	 including	 patients	 with	 acute	




basis	 of	 clinical	 features	 alone.	 Firstly,	 the	 kidney	 biopsy	 differentiates	 lupus	 nephritis	
from	 other	 non-lupus	 kidney	 diseases	 that	may	 also	 affect	 SLE	 patients,	 including,	 for	




Secondly,	 if	 lupus	 nephritis	 is	 indeed	 identified,	 the	 kidney	 biopsy	 is	 also	 important	 to	
classify	the	type	of	lesions	and	to	guide	the	treatment	strategies	used.	Determining	the	
diagnosis	based	only	on	the	clinical	presentation	may	be	difficult,	particularly	in	patients	
with	 low	 or	 moderate	 levels	 of	 proteinuria	 and	 without	 acute	 kidney	 injury.	 Such	 a	
presentation	 could	 be	 the	 result	 of	 mesangial	 lupus,	 a	 mild	 membranous	 lupus	 or	 a	
proliferative	lesion,	either	with	mild	activity	or	in	the	early	stages	of	a	more	active	lesion.	




Most	 patients	 with	 lupus	 nephritis	 have	 an	 immune	 complex-mediated	
glomerular	disease.	IgG	glomerular	deposits	and	co-deposits	of	IgA,	IgM,	C3,	and	C1q,	the	




	Determining	the	class	of	 lupus	nephritis	 is	 important,	 since	treatment	 is	guided	
by	 the	 histologic	 subtype	 and	 the	 clinical	 presentation	may	 not	 accurately	 reflect	 the	
severity	 of	 the	 histologic	 findings,	 as	 previously	 discussed.	Numerous	 serum	and	 urine	
markers	 have	 been	 studied	 as	 potential	 noninvasive	 determinants	 of	 lupus	 nephritis	
stages	(116),	including	anti-C1q	antibodies	(117),	tumor	necrosis	factor-like	weak	inducer	
of	 apoptosis	 (TWEAK)	 (118),	 and	 urinary	 neutrophil	 gelatinase-associated	 lipocalin	
(NGAL)	(119).	Nevertheless,	currently	no	marker	of	disease	activity	provides	the	degree	
of	information	that	is	gained	by	histopathology.		
The	 2004	 Renal	 Pathology	 Society/International	 Society	 of	 Nephrology	
classification	 divides	 SLE	 glomerular	 disorders	 into	 six	 different	 classes	 based	 upon	
kidney	biopsy	histopathology	(120,121):			
• Class	 I	 (Minimal	 mesangial	 lupus	 nephritis)	—	 It	 is	 characterized	 by	 the	
inexistence	 of	 abnormalities	 on	 light	 microscopic.	 Mesangial	 immune	 deposits	 are	




mildest	 form	 of	 glomerular	 involvement	 in	 SLE.	 Patients	 typically	 have	 a	 normal	
urinalysis,	or	minimal	proteinuria,	and	a	normal	serum	creatinine.		
• Class	II	(Mesangial	proliferative	lupus	nephritis)	—	Mesangial	hypercellularity	
and	 mesangial	 matrix	 expansion	 are	 the	 main	 features	 of	 this	 class.	 A	 few	 isolated	




extracapillary	 glomerulonephritis	 in	 less	 than	 50%	 of	 glomeruli	 studied	 by	 light	




• Class	 III	 (A)	 –	 It	 represents	 class	 III	 disease	with	 active	 lesions.	 It	 is	 also	
referred	to	as	focal	proliferative	lupus	nephritis.	




Patients	 usually	 have	 hematuria	 and	 proteinuria,	 and	 some	 patients	 have	
hypertension,	a	decreased	glomerular	filtration	rate,	and/or	nephrotic	syndrome.		
• Class	IV	(Diffuse	lupus	nephritis)	–	It	is	the	most	common	and	severe	form	of	
lupus	 nephritis.	 It	 is	 defined	 by	 proliferative	 and	 necrotizing	 lesions	 and	 crescents	 in	
more	 than	 50%	 of	 glomeruli.	 The	 marked	 deposition	 of	 immunoglobulins,	 particularly	
IgG,	 and	 complement	 results	 in	 thickening	 of	 the	 glomerular	 capillary	 wall,	 causing	 a	
pattern	 similar	 to	 a	 membranoproliferative	 glomerulonephritis.	 The	 lesions	 may	 be	
segmental	(class	IV-S,	involving	less	than	50%	of	the	glomerular	tuft)	or	global	(class	IV-G,	
involving	 more	 than	 50%	 of	 the	 glomerular	 tuft).	 The	 presence	 of	 diffuse	 wire	 loop	
deposits,	 with	 little	 or	 no	 glomerular	 proliferation,	 is	 also	 considered	 class	 IV	 disease.	
There	 are	 also	 subclasses	 of	 class	 IV	 lupus	 nephritis	 that	 are	 determined	 by	 the	
inflammatory	activity	or	chronicity	of	the	lesions,	 like	it	was	described	for	class	III	 lupus	




hypertension,	 and	 reduced	 glomerular	 filtration	 rate	 are	 frequently	 seen.	 Affected	
patients	 typically	 have	 significant	 hypocomplementemia,	 particularly	 C3,	 and	 elevated	
anti-dsDNA	antibodies	levels.	
• Class	 V	 (Lupus	 membranous	 nephropathy)	 –	 It	 is	 characterized	 by	 diffuse	
thickening	 of	 the	 glomerular	 capillary	 wall	 on	 light	 microscopy	 and	 by	 subepithelial	




nephrotic	 syndrome.	 Microscopic	 hematuria	 and	 hypertension	 may	 also	 be	 seen	 at	
presentation,	and	the	creatinine	concentration	is	usually	normal	or	only	slightly	elevated.		
• Class	VI	 (Advanced	 sclerosing	 lupus	nephritis)	–	 It	 is	characterized	by	global	
sclerosis	of	more	than	90%	of	glomeruli,	without	active	glomerulonephritis.	It	represents	
the	 advanced	 stage	 of	 chronic	 class	 III,	 IV,	 or	 V	 lupus	 nephritis.	 Patients	 usually	 have	







collapsing	 glomerulosclerosis	 and	 lupus	podocytopathy.	 The	 former	 is	 characterized	by	
the	 collapse	 of	 the	 glomerular	 capillary	 tuft	 with	 epithelial	 cell	 proliferation	 in	 the	
Bowman	 space.	 The	 patients	 usually	 have	 nephrotic	 syndrome,	 renal	 impairment,	 and	
rapid	progression	 to	 end-stage	 renal	 disease	 (122).	 Lupus	podocytopathy	 is	 defined	by	
diffuse	 epithelial	 cell	 foot	 process	 effacement	 without	 immune	 complex	 deposition,	
similar	 to	 what	 happens	 in	 minimal	 changes	 disease	 (123,124).	 It	 can	 be	 caused	 by	
cytokines	 toxic	 to	 podocytes,	 or	 podocyte	 injury	 driven	 by	 T	 cell	 dysfunction	 or	 drugs	
(123–125).		
The	 International	 Society	 of	 Nephrology	 /Renal	 Pathology	 Society	 appears	 to	
provide	 increased	 reproducibility	 compared	 to	 the	 modified	 1982	 World	 Health	




since	 it	 does	 not	 predict	 treatment	 response	 or	 prognosis.	 Furthermore,	 a	 significant	
percentage	of	patients	evolve	 from	one	class	of	 lupus	nephritis	 to	another,	 sometimes	
after	 therapy	 and	 sometimes	 spontaneously.	 Finally,	 the	 relatively	 small	 number	 of	
glomeruli	that	are	obtained	on	a	typical	percutaneous	renal	biopsy	may	cause	a	sampling	




on	 laboratory	 measures	 that	 accurately	 reflects	 the	 histologic	 lupus	 nephritis	 activity	
(128).	 The	 variables	 used	were	 the	 urinary	 levels	 of	NGAL,	monocyte	 chemoattractant	
protein	1	(MCP1),	ceruloplasmin,	adiponectin,	hemopexin,	and	kidney	injury	molecule	1	
standardized	 by	 urine	 creatinine	 (128).	 The	 RAIL	 quantifies	 the	 amount	 of	 histologic	
inflammation	seen	on	the	tissues,	as	measured	by	the	NIH	activity	 index	with	over	92%	
accuracy	 (128).	 Furthermore,	 the	 RAIL	 is	 minimally	 influenced	 by	 concurrent	 lupus	
nephritis	 chronicity	 and	 reflects	 both	 glomerular	 and	 tubulointerstitial	 inflammation	
(128).	 The	 concurrent	 use	 of	 medications,	 including	 drugs	 targeting	 the	 renin-
angiotensin-aldosterone	system,	does	not	decrease	the	accuracy	of	this	index	(128).	This	
index	seems	promising,	but	needs	to	be	further	validated.		
In	 conclusion,	 new,	 non-invasive,	 methods	 to	 diagnose	 lupus	 nephritis	 and	 to	
evaluate	its	activity	and	response	to	treatment	are	much	needed.	During	my	Ph.D.	one	of	
my	goals	was	precisely	to	contribute	to	the	quest	of	a	clinically	useful	biomarker	for	lupus	
nephritis.	 I	 developed	 a	 research	 project	 that	 allowed	 me	 to	 identify	 a	 new	 pathway	
responsible	for	the	control	of	mesangial	cell	proliferation	in	the	kidneys	of	patients	with	
lupus	nephritis.	This	work	made	possible	the	 identification	of	a	novel	urinary	marker	of	




Regarding	 neurolupus,	 its	 diagnosis	 is	 also	 challenging,	 since	 it	 can	 mimic	




disturbances.	Psychometric	 testing	 and	 psychiatric	 interviews	 can	 be	 helpful	 to	
differentiate	functional	from	organic	disease.		
Routine	evaluation	of	 the	cerebrospinal	 fluid	may	be	normal,	except	 in	cases	of	
aseptic	meningitis,	vasculitis,	and	transverse	myelitis.		
Computerized	tomography	(CT)	scans	and	magnetic	resonance	imaging	(MRI)	are	
useful	 for	 detecting	 structural	 abnormalities.	MRI	 is	 more	 sensitive	 than	 CT,	 and	may	
reveal	 changes	 that	 reflect	 focal	 neuropsychiatric	 lupus.	 Acute,	 reversible	 lesions	 are	
characterized	 by	 the	 lack	 of	 discrete	 borders,	 intermediate	 intensity	 on	 T2-weighted	
images,	 and	 overlying	 or	 adjacent	 gray	matter	 hyperintensity	 (129).	 Nevertheless,	 the	
diagnosis	of	neurolupus	is	difficult	by	MRI	since	white	matter	lesions	and	periventricular	
hyperintensities	 are	 also	 detected	 in	 SLE	 patients	 without	 neurolupus	 and	 even	 in	
healthy	individuals	(130).		




Angiography	 has	 limited	 sensitivity	 for	 detecting	 the	 small	 vessel	 disease	






Several	 infections,	 malignancies	 and	 other	 autoimmune	 diseases	 can	 cause	
clinical	manifestations	similar	to	SLE.	Cytomegalovirus	and	Epstein-Barr	virus	 infections,	
for	 instance,	 can	 cause	 fever,	 fatigue,	 lymph	 node	 enlargement	 and	
hepatosplenomegaly.	In	addition,	Epstein-Barr	infection	may	lead	to	positive	antinuclear	
antibodies	and	positive	anti-dsDNA	antibodies.	Human	parvovirus	B19	can	also	cause	flu-








Leukemias,	 lymphomas	 and	 myelodysplastic	 syndromes	 may	 present	 with	
constitutional	 symptoms,	 hematologic	 abnormalities,	 splenomegaly,	 lymphadenopathy	
and	 increased	 lactate	 dehydrogenase	 (LDH)	 levels,	 similar	 to	 what	 happens	 in	 SLE.	
Monoclonal	 expansion	 of	 B	 and	 T	 cells,	 monocytosis,	 and	 macrocytosis	 can	 help	 to	
distinguish	these	malignancies	from	SLE.		





cause	diagnostic	difficulties.	Early	 rheumatoid	arthritis,	 for	 instance,	may	be	difficult	 to	
distinguish	from	SLE,	since	both	conditions	can	cause	arthritis,	 fatigue,	sicca	symptoms,	
subcutaneous	 nodules,	 serositis	 and	 anemia.	 Features	 of	 later	 stages	 of	 rheumatoid	
arthritis,	including	swan	neck	deformities,	ulnar	deviation	and	soft	tissue	laxity,	can	also	
be	observed	in	some	SLE	patients	who	present	with	Jaccoud	arthropathy.	Furthermore,	
antinuclear	 antibodies	 may	 be	 positive	 in	 up	 to	 one-half	 of	 patients	 with	 rheumatoid	
arthritis	 and	 rheumatoid	 factor	 may	 be	 present	 in	 approximately	 one-third	 of	 SLE	
patients.	Some	clinical	features	and	laboratory	tests,	however,	may	help	distinguish	the	
two	 diseases.	 The	 joint	 deformities	 in	 SLE,	 for	 instance,	 are	 often	 reducible	 and	
infrequently	erosive	and	the	presence	of	anti-CCP	antibodies	 is	more	supportive	of	 the	
diagnosis	of	rheumatoid	arthritis.	
Systemic	 Juvenile	 Idiopathic	 Arthritis	 (sJIA)	 and	 adult	 Still’s	 disease	 can	 cause	




neurologic	 and	 pulmonary	 abnormalities,	 and	 the	 presence	 of	 antinuclear	 antibodies,	
which	may	mimic	 SLE.	 Keratoconjunctivitis	 sicca,	 xerostomia,	 characteristic	 findings	 on	





Mixed	 connective	 tissue	 disease	 has	 overlapping	 features	 of	 SLE,	 systemic	
sclerosis,	and	polymyositis.	The	features	occur	sequentially,	often	over	a	period	of	years,	








Dermatomyositis	 and	 polymyositis	 should	 also	 be	 considered	 in	 the	 differential	
diagnosis.	SLE	patients	can	present	with	low-grade	myositis,	but	usually	 it	 is	 less	severe	
than	 the	 overt	 proximal	 muscle	 weakness	 characteristic	 of	 dermatomyositis	 and	
polymyositis.	The	cutaneous	manifestations	are	also	 fairly	different.	Gottron	papules,	a	
heliotrope	 eruption	 and	 photodistributed	 poikiloderma	 are	 characteristic	 of	
dermatomyositis.	On	the	other	hand,	nephritis	and	hematologic	abnormalities	are	absent	




granulomatosis	 with	 polyangiitis,	 microscopic	 polyangiitis	 and	 Behçet	 disease	 may	
present	with	 constitutional	 symptoms,	 skin	 lesions,	 neuropathy	 and	 renal	 dysfunction.	
Usually	these	patients	do	not	have	antinuclear	antibodies	and	renal	lesions	do	not	have	
immune	deposits.	
Patients	 with	 undifferentiated	 connective	 tissue	 disease	 have	 clinical	
manifestations	 suggestive	 of	 a	 systemic	 autoimmune	 disease,	 but	 do	 not	 satisfy	 the	
criteria	 for	 a	 defined	 disease.	 The	 majority	 of	 these	 patients	 maintains	 an	 undefined	
profile	and	has	a	mild	disease	course,	but	a	few	may	progress	to	SLE	(133).	
Finally,	Kikuchi-Fujimoto	disease	can	also	present	in	a	similar	way.	This	is	a	benign	
form	 of	 histiocytic-necrotizing	 lymphadenitis,	 which	 may	 cause	 fever,	 myalgias,	





In	 conclusion,	 since	 SLE	 can	 cause	 a	 myriad	 of	 clinical	 manifestations,	 its	






Juvenile-onset	 SLE	 is	 fundamentally	 the	 same	 disease	 as	 adult-onset	 SLE,	 with	
globally	similar	etiology,	pathogenesis,	clinical	manifestations	and	laboratory	findings.	It	




The	 presenting	 manifestations	 of	 SLE	 in	 children	 are	 as	 diverse	 as	 they	 are	 in	
adults.	Some	children	present	with	low-grade	fever,	weight	loss	and	malaise	with	general	
deterioration	 over	 several	months,	while	 others	 present	with	 acute	 or	 life-threatening	
events.	As	previously	discussed,	patients	with	juvenile-onset	SLE	compared	to	adults	with	
SLE	 more	 often	 have	 severe	 organ	 involvement	 as	 a	 presenting	 manifestation,	
particularly	nephritis	(19).		
Table	 1.5	 shows	 the	most	 common	 presenting	manifestations	 in	 juvenile-onset	





























Globally,	 fever,	 nephritis,	 neurologic	 involvement,	 thrombocytopenia	 and	
hemolytic	 anemia	 are	 more	 common	 in	 juvenile-onset	 SLE,	 whereas	 Raynaud’s	
phenomenon,	 pleuritis	 and	 sicca	 symptoms	 are	 more	 common	 in	 adult	 onset	 SLE	
(19,136).		
The	diagnosis	 of	 juvenile-onset	 SLE	 is	 usually	 difficult,	 because	 the	most	 typical	
signs	 and	 symptoms	 are	 less	 common	 and	 doctors	 are	 reluctant	 to	 diagnose	 SLE	 in	
childhood.	In	the	Euro-lupus	cohort,	76	out	of	the	1,000	SLE	patients	(8%)	developed	the	
disease	 before	 the	 age	 of	 14	 (19)	 and	 in	 this	 group	 there	 was	 a	 5-year	 delay	 in	
establishing	the	diagnosis	(19).	
SLE	can	occur	at	any	age,	although	it	becomes	more	frequent	after	five	years	of	
age	 and	 is	 increasingly	 prevalent	 after	 the	 first	 decade	 of	 life	 (14).	 In	 retrospective	
reviews	 from	 France,	 Canada,	 and	 the	 United	 Kingdom,	 the	 median	 age	 of	 onset	 of	
juvenile-onset	 SLE	was	 12	 to	 13	 years	 (134,135,137).	 Childhood	 SLE	 affects	 girls	more	
often	than	boys	(8:1),	even	in	the	prepubescent	age	group	(4:1)	(14).	
The	 2012	 SLICC	 proposed	 revised	 SLE	 criteria	 are	 also	 used	 to	 classify	 children	
(138,139).	
During	 my	 PhD,	 I	 performed	 a	 high-throughput	 study	 of	 the	 kidney	 miRNA	
signature	 of	 lupus	 nephritis	 in	 a	 pediatric	 cohort.	 This	 was	 particularly	 informative,	
considering	 that	 children	with	 lupus	 nephritis	 have	 a	more	 aggressive	 disease	 and	 co-






be	 determined.	 Disease	 activity	 refers	 to	 the	 reversible	 manifestations	 related	 to	 the	
underlying	 inflammatory	process,	while	disease	 severity	 refers	 to	 the	 type	and	 level	of	






There	 is	 no	 consensus	 on	 what	 constitutes	 a	 disease	 flare,	 but	 most	 clinicians	
agree	that	a	moderate	or	severe	flare	refers	to	a	measurable	increase	in	disease	activity	
that	is	clinically	meaningful	enough	to	prompt	a	change	in	therapy	(140,141).	
In	 every	 clinical	 visit,	 disease	 activity	 and	 severity	 should	 be	 evaluated	 using	
clinical	history,	physical	examination	and	specific	tests.	The	physical	examination	should	
be	thorough,	including	the	complete	observation	of	the	skin,	in	order	to	identify	a	malar	
rash,	 discoid	 lesions	 or	 patchy	 alopecia.	 The	 clinician	 should	 also	 look	 for	 oral	 or	
nasopharyngeal	 ulcers	 and	 lymph	 nodes	 enlargement.	 The	 respiratory,	 cardiovascular,	
musculoskeletal	and	neurological	systems	should	all	be	evaluated.		
Regarding	 the	 laboratory	 tests	 required,	 it	 is	 recommended	 to	 check	 the	
complete	 blood	 count,	 erythrocyte	 sedimentation	 rate,	 C-reactive	 protein,	 serum	
creatinine,	urinalysis	with	examination	of	 the	urinary	 sediment,	 spot	urine	protein	and	
creatinine,	titers	of	anti-dsDNA	antibodies	and	complement	levels	(C3	and	C4).	Additional	
tests	are	required	according	with	organ	involvement.		
The	 frequency	 of	 the	 clinical	 visits	 and	 of	 the	 laboratory	 tests	 is	 adjusted	
according	to	the	patient’s	prior	symptoms	and	current	disease	activity	and	severity.	Even	
SLE	 patients	 with	 stable	 disease	 benefit	 from	 close	 follow-up	 at	 three-	 to	 four-month	
intervals	 (142).	 A	 study	 including	 over	 500	 SLE	 patients	 with	 mild	 or	 inactive	 disease	
found	 that	one	 in	 four	patients	 followed	over	a	 two-year	period	will	have	a	 laboratory	
abnormality	without	any	 clinical	 symptom	 that	 could	 lead	 to	a	 change	 in	management	
(143).	The	most	useful	laboratory	tests	to	predict	an	SLE	flare	are	an	increase	in	the	titer	
of	anti-dsDNA	antibodies	and	hypocomplementemia	(144–147).	
Several	 disease	 activity	measures	 and	 indices	 have	been	developed	 as	 research	
tools.	 Examples	 of	 scoring	 systems	 for	 disease	 activity	 include	 the	 Systemic	 Lupus	
Erythematosus	 Disease	 Activity	 Index	 (SLEDAI)	 (143),	 the	 Safety	 of	 Estrogens	 in	 Lupus	
Erythematosus:	National	Assessment-SLEDAI	(SELENA-SLEDAI)	(148),	the	Systemic	Lupus	
Activity	Measure	 (SLAM)	 (149),	 the	British	 Isles	Lupus	Assessment	Group	(BILAG)	 (150),	
the	European	Consensus	Lupus	Activity	Measurement	(ECLAM)	(151).		
The	 Systemic	 Lupus	 International	 Collaborating	 Clinics/American	 College	 of	









The	 treatment	 strategies	 used	 for	 the	 care	 of	 SLE	 patients	 are	 individualized	
according	 to	 the	 patients’	 preferences,	 clinical	 manifestations,	 disease	 activity	 and	
comorbidities.	The	main	goals	are	to	ensure	 long-term	survival,	prevent	organ	damage,	
minimize	drug	toxicity	and	improve	quality	of	life.		
As	previously	discussed,	 regular	clinical	monitoring	 is	essential	 to	assess	disease	
activity,	 prevent	 and	 treat	 relapses,	 monitor	 the	 side	 effects	 of	 the	 drugs	 used	 and	
encourage	adherence	to	treatment.		
Since	 multiorgan	 system	 involvement	 is	 frequent,	 a	 multidisciplinary	 team	 is	
usually	necessary	to	provide	the	best	possible	care	for	these	patients.		
It	is	also	essential	to	educate	patients	on	their	role	in	disease	management.	
Several	 nonpharmacologic	 measures	 are	 important	 for	 disease	 control.	 Sun	
protection	 is	one	of	 the	most	 important	measures	 to	prevent	a	disease	 flare.	 It	 is	well	
known	that	exposure	to	ultraviolet	(UV)	light	may	exacerbate	or	induce	the	disease	(154).	
It	is,	therefore,	recommended	that	patients	use	UV-A	and	UV-B	blocking	sunscreens,	with	
a	 sun	 protection	 factor	 ≥30.	 Medications	 that	 cause	 photosensitivity	 should	 also	 be	
avoided.		




Modifiable	 risk	 factors	 for	 coronary	 heart	 disease	 should	 always	 be	 addressed,	
including	 weight	 loss	 through	 dietary	 modification	 and	 exercise,	 use	 of	 statins	 and	
optimal	 blood	 pressure	 control.	 Smoking	 cessation	 should	 be	 recommended	 to	 all	
patients,	 since	 it	 increases	 the	 risk	 of	 active	 disease	 (156,157)	 and	 accelerated	
atherosclerosis	(158,159).	In	patients	with	nephritis	and/or	hypertension,	salt	restriction	
should	be	advocated.	






bone	demineralization	and	 loss	of	 stamina.	Graded	aerobic	exercise	 is	 the	best	 tool	 to	
improve	fatigue	in	SLE	patients	(160).	





Concerning	 cutaneous	 lupus,	 the	 goal	 of	 treatment	 is	 to	 prevent	 long-term	
sequelae,	namely	telangiectasia,	hyperpigmentation	or	hypopigmentation,	alopecia,	and	
scarring.	 For	 early	 superficial	 involvement,	 hydrocortisone	may	 be	 a	 good	 option,	 but	
more	 potent	 topical	 corticosteroids	 with	 or	 without	 occlusion	 or	 intralesional	




of	 the	 disease,	 the	 treatment	 strategy	 is	 highly	 individualized	 and	 is	 guided	 by	 the	
predominant	symptoms,	organ	involvement	and	response	to	previous	drugs.		
Generally,	patients	with	mild	SLE	manifestations	may	be	treated	with	antimalarial	
drugs,	 and/or	 short-term	 use	 of	 low-dose	 glucocorticoids	 (≤	 7.5	 mg	 prednisone/day).	
Patients	 with	moderate	 lupus	 involvement,	 with	 significant	 but	 non-organ-threatening	
disease	usually	respond	to	hydroxychloroquine	plus	short-term	therapy	with	5	to	15	mg	
of	 prednisone/day.	 A	 steroid-sparing	 immunosuppressive	 agent	 is	 often	 required	 to	
control	 symptoms.	 Patients	 with	 major	 organ	 involvement	 generally	 require	 an	 initial	
period	of	intensive	immunosuppressive	therapy	to	control	the	disease,	with	high	doses	of	
systemic	glucocorticoids	(intravenous	methylprednisolone	30mg/Kg	for	three	days)	used	
alone	 or	 in	 combination	 with	 other	 immunosuppressive	 agents,	 most	 frequently	
cyclophosphamide	 and	 mycophenolate	 mofetil.	 This	 induction	 phase	 is	 subsequently	
followed	 by	 a	 longer	 period	 of	 less	 intensive	 maintenance	 therapy	 to	 consolidate	
remission	and	prevent	flares.		







and	 inhibition	 of	 antigen	 presentation,	 prostaglandin	 synthesis,	 lipid	 peroxidation,	 and	
proinflammatory	cytokine	 synthesis	 (166).	The	benefits	of	antimalarial	drugs	 in	SLE	are	




mortality	 (165,167–170).	 In	 a	nested	 case-control	 study	 it	was	 shown	 that	 antimalarial	
drugs	were	 associated	with	 a	 68%	 reduction	 in	 the	 risk	 of	 all	 thrombovascular	 events,	





patients	 taking	placebo	 than	 in	 those	 continuing	 to	 take	hydroxychloroquine	 (16	of	 22	
patients	vs.	9	of	25	had	flares)	and	the	time	to	a	flare	was	shorter	(p	=	0.02)	(167).	The	
relative	risk	of	a	severe	exacerbation	of	disease	that	required	withdrawal	from	the	study	
was	 6.1	 times	 higher	 for	 the	 patients	 taking	 placebo	 (5	 of	 22	 patients	 vs.	 1	 of	 25	 had	
severe	exacerbations	of	the	disease)	(167).		
Toxicity	 related	 to	 antimalarial	 drugs	 is	 infrequent,	 mild	 and	 usually	 reversible	
(165).	 In	 conclusion,	 given	 the	 broad	 spectrum	 of	 beneficial	 effects	 and	 safety	 profile,	
hydroxychloroquine	 should	 be	 given	 to	 SLE	 patients	 during	 the	 course	 of	 the	 disease,	
irrespective	of	its	activity	or	severity	(165).	
For	 patients	 with	 refractory	 or	 persistent	 arthritis,	 methotrexate	 might	 be	 an	
option.	A	systematic	review	of	nine	studies	(three	of	which	were	randomized	controlled	
trials)	 including	 SLE	 patients	 with	 predominantly	 mucocutaneous	 or	 arthritis	 features	
found	 that	 treatment	with	methotrexate	was	associated	with	a	 significant	 reduction	 in	
disease	activity	as	well	as	in	the	average	dose	of	glucocorticoids	used	(171).	For	patients	
with	 persistent	 arthritis	 unresponsive	 to	 methotrexate	 after	 three	 to	 six	 months	 of	
therapy,	azathioprine	might	be	a	good	option	(172).		





which	 affects	 both	 cellular	 and	 humoral	 immune	 functions.	 Azathioprine	 (2–
3	mg/kg/day)	 is	 mainly	 used	 in	 SLE	 patients	 presenting	 with	 arthritis,	 mucocutaneous	
manifestations,	and	serositis,	and	as	maintenance	 therapy	 in	 lupus	nephritis	 (173).	The	
side	 effects	 of	 this	 drug	 include	 a	 mild	 increased	 risk	 for	 infections,	 bone	 marrow	
suppression,	hepatotoxicity	and	gastrointestinal	 intolerance.	Patients	with	 intermediate	
or	low	thiopurine	methyltransferase	activity	have	an	increased	risk	of	myelosuppression.	
It	 is,	 therefore,	 recommended	 genotyping	 or	 phenotyping	 the	 thiopurine	
methyltransferase	before	starting	azathioprine	(174).		
Cyclophosphamide	 is	an	alkylating	agent	that	 interferes	with	DNA	replication	by	
forming	DNA	crosslinks.	 In	a	1986,	NIH	 landmark	 study	of	 lupus	nephritis	 treatment,	 it	
was	 shown	 that,	 after	 10	 years,	 renal	 function	was	better	preserved	with	 combination	
therapy	of	prednisone	and	 intravenous	pulse	cyclophosphamide	than	prednisone	alone	
(175).	Cyclophosphamide	 is	 associated,	however,	with	 important	 side	effects,	 including	
major	 infections,	 infertility,	 bladder	 toxicity,	 and	 increased	 risk	 of	 malignancy	 (176).	
Some	of	 these	 toxicities	 are	dose-dependent	 (176).	 In	 a	 study	of	 216	women	with	 SLE	
who	had	been	 treated	with	cyclophosphamide,	 levels	of	 the	anti-müllerian	hormone,	a	
surrogate	 of	 ovarian	 reserve,	 were	 inversely	 correlated	 with	 the	 cumulative	 dose	 of	
cyclophosphamide	administered	(177).		
For	 the	 induction	 therapy	 of	 lupus	 nephritis,	 American,	 European	 and	 Asian	
guidelines	recommend	a	monthly	course	of	 intravenous	pulse	cyclophosphamide	for	six	
months	 (0.5	 g/m2	to	 a	maximum	of	 1.5	 g)	 (178–180).	 A	 lower-dose	 cyclophosphamide	






nephritis	 in	 the	 majority	 of	 the	 centers,	 considering	 its	 side	 effects.	 Nevertheless,	
cyclophosphamide	still	plays	an	important	role	in	the	management	of	patients	with	lupus	
nephritis	 with	 impaired	 or	 rapidly	 deteriorating	 renal	 function,	 as	 salvage	 therapy	 for	
recalcitrant	disease	and	in	patients	with	neuropsychiatric	involvement.	




enzyme	 inosine	 monophosphate	 dehydrogenase,	 an	 essential	 step	 in	 the	 de	 novo	
synthesis	 of	 guanosine	 nucleotides.	 The	 latter	 are	 required	 for	 DNA	 formation	 and,	
consequently,	 lymphocyte	 proliferation.	 As	 lymphocytes	 are	 highly	 dependent	 on	 this	
pathway	 for	 DNA	 synthesis,	 mycophenolate	 mofetil	 is	 considered	 to	 be	 a	 more	
lymphocyte-selective	 immunosuppressive	 agent	 than	other	 purine	 antagonists,	 such	 as	
azathioprine.	 The	 main	 adverse	 effects	 of	 mycophenolate	 mofetil	 are	 gastrointestinal	
intolerance,	bone	marrow	suppression,	and	increased	risk	of	infections.		
In	 recent	 years,	mycophenolate	mofetil	 has	emerged	as	 the	 first-line	option	 for	
induction	therapy	of	lupus	nephritis	(182,183).	A	pilot	study	showed	that	mycophenolate	
mofetil	(2	g/day)	was	equally	effective	at	12	months	as	sequential	oral	cyclophosphamide	
and	 azathioprine	 (184).	 Furthermore,	 two	 large	 randomized	 controlled	 trials	
demonstrated,	 at	 six	months,	 the	non-inferiority	of	mycophenolate	mofetil	 (3g/day)	 to	
the	 NIH	 intravenous	 pulse	 cyclophosphamide	 for	 the	 treatment	 of	 lupus	 nephritis	
(182,183).	 Furthermore,	 mycophenolate	 mofetil	 was	 found	 to	 be	 more	 effective	 than	
cyclophosphamide	 in	Hispanics	 and	African	Americans	 (response	 rate	 60%	versus	 39%;	
P=0.03)	 (183).	 In	 conclusion,	 considering	 the	 equivalent	 efficacy	 of	 mycophenolate	
mofetil	 to	 cyclophosphamide,	 with	 reduced	 gonadal	 toxicity	 and	 oncogenicity,	
mycophenolate	mofetil	 should	 be	 considered	 as	 first-line	 induction	 treatment	 of	 lupus	
nephritis.	 This	 is	 particularly	 important	 in	 women	 who	 wish	 to	 have	 children	 and	 in	
Hispanics	 and	 African	 Americans,	 since	 it	 is	much	 better	 tolerated	 and	more	 effective	
than	cyclophosphamide	in	this	group.		
Mycophenolate	 mofetil	 has	 also	 been	 used	 as	 maintenance	 therapy	 for	 lupus	
nephritis.	In	the	ALMS	study	(N	=	227)	mycophenolate	mofetil	(2	g/day)	was	shown	to	be	
superior	 to	 azathioprine	 in	 the	 prevention	 of	 renal	 flares,	 after	 3	 years,	 in	 those	who	
responded	 to	 induction	 therapy	 with	 either	 intravenous	 pulse	 cyclophosphamide	 or	
mycophenolate	 mofetil	 (185).	 On	 the	 other	 hand,	 recently,	 a	 randomized	 controlled	
study	 of	 Caucasian	 patients	 with	 proliferative	 lupus	 nephritis,	 who	 received	 the	 Euro-
Lupus	 cyclophosphamide	 regimen	 as	 induction	 (N	 =	 105),	 failed	 to	 show	 that	
mycophenolate	mofetil	was	superior	to	azathioprine	for	 lupus	nephritis	maintenance	at	






has	 long	been	used	 in	organ	 transplantation	 to	 reduce	 the	 risk	of	 rejection	and	 is	now	
also	 being	 tested	 for	 the	 treatment	 of	 lupus	 nephritis	 (176).	 A	 24-week	 randomized,	
open-label,	multicenter	 study	 analyzed	 the	effect	 of	 combining	mycophenolate	mofetil	
(1g/day)	 and	 tacrolimus	 (4mg/day)	 versus	 intravenous	 cyclophosphamide	 (0.5	 to	 1.0	
g/m2),	every	4	weeks,	for	six	months	(187).	After	24	weeks	of	therapy	more	patients	 in	
the	 multitarget	 group	 (46%)	 than	 in	 the	 cyclophosphamide	 group	 (26%)	 showed	
complete	remission	(P<0.0001)	(187).		
Tacrolimus	 is	 a	 calcineurin	 inhibitor	 that	 suppresses	 the	 transcription	 of	
interleukin	 (IL)	 2	 and,	 consequently,	 inhibits	 T	 cell	 activation.	 B	 cell	 activation,	 class-
switching	and	 immunoglobulin	production	are,	 as	 a	 result,	 compromised.	 Tacrolimus	 is	
also	thought	to	reduce	proteinuria	through	the	stabilization	of	the	actin	cytoskeleton	in	





Belimumab	 is	 a	 human	 monoclonal	 antibody	 that	 inhibits	 BLyS	 (B	 Lymphocyte	
Stimulator),	 also	 known	 as	 BAFF	 (B	 Cell	 Activating	 Factor).	 BLyS	 is	 elevated	 in	 SLE	
patients,	 and	 it	 may	 play	 a	 role	 in	 the	 pathogenesis	 of	 the	 disease	 by	 promoting	 the	
formation	 and	 survival	 of	 memory	 B	 cells	 and	 plasmablasts.	 A	 randomized,	 placebo-
controlled,	 phase	 3	 trial	 of	 867	 SLE	 patients	 showed	 that	 belimumab	 reduced	 disease	
activity	 (190).	 This	 drug	 is	 usually	 suggested	 to	patients	with	 active	musculoskeletal	 or	
cutaneous	 disease	 that	 are	 unresponsive	 to	 standard	 therapy.	 It	 is	 not	 recommended,	







(23%)	 patients,	 mainly	 infections	 (19%)	 (192).	 An	 analysis,	 in	 2010,	 of	 the	 French	




clinical	efficacy	 (193).	A	 systematic	 review,	performed	 in	2014,	 included	1,231	patients	
and	 clearly	 showed	 that	 rituximab	 decreased	 disease	 activity,	 improved	 arthritis	 and	
thrombocytopenia,	 increased	complement,	decreased	anti-dsDNA	antibodies	and	had	a	
steroid-sparing	 effect	 (194).	 Recent	 studies,	 however,	 have	 shown	 some	 disappointing	
results.	 The	 EXPLORER	 trial	 was	 a	 randomized,	 double-blind,	 phase	 II/III	 study	 that	
enrolled	 patients	 with	 moderately-to-severely	 active	 SLE	 (195).	 In	 this	 study	 no	
differences	 were	 noted	 between	 placebo	 and	 rituximab	 (195).	 In	 another	 randomized	
trial	144	patients	received	rituximab	or	placebo	(196).	Although,	rituximab	led	to	greater	
reductions	 in	anti-dsDNA	antibodies	and	 increased	C3	and	C4	 levels,	 it	did	not	 improve	
clinical	outcomes	after	1	year	of	treatment	(196).	Some	of	the	negative	results	obtained	
in	 clinical	 trials	 have	 been	 attributed	 to	 methodologic	 problems	 and	 also	 to	 the	
heterogeneity	 of	 the	 disease,	 which	 makes	 it	 difficult	 to	 show	 differences	 between	
treatment	 interventions	 and	 placebo.	 Despite	 the	 lack	 of	 success	 of	 the	 clinical	 trials	




trials	 studied	 32	 patients	 with	 SLE	 and	 an	 acute	 onset	 of	 severe	 neurologic	
manifestations	 (seizures,	 optic	 neuritis,	 neuropathy,	 coma,	 brainstem	 disease,	 or	
transverse	 myelitis).	 It	 compared	 treatment	 with	 methylprednisolone	 and	
cyclophosphamide.	 The	 great	 majority	 (18/19)	 of	 the	 patients	 receiving	
cyclophosphamide	 and	 7	 of	 the	 13	 receiving	 methylprednisolone	 had	 at	 least	 a	 20%	
improvement	 in	 a	 pertinent	 neurologic	measure	 (197).	 Response	 to	 cyclophosphamide	
was	 also	 assessed	 in	 another	 study	 of	 31	 patients	with	 severe	 neuropsychiatric	 lupus,	
90%	 of	 whom	 had	 failed	 previous	 treatment	 strategies.	 Eight	 patients	 received	
plasmapheresis	 in	addition	to	cyclophosphamide.	Substantial	 improvement	was	seen	 in	
61%	and	partial	improvement	was	seen	in	29%	(198).	Currently,	the	recommended	drugs	
for	 the	 control	 of	 acute	 neurologic	 symptoms	 are	 high-dose	 glucocorticoids	
(prednisolone	 1mg/Kg/day,	 with	 a	 tapering	 schedule	 of	 3-6	months	with	 or	 without	 a	
previous	 three	 days	 of	 intravenous	 methylprednisolone	 500-1000	 mg/day)	 and	





18	months,	 or	 other	 immunosuppressive	 therapy	 can	 be	 considered	 for	maintenance,	
including	 azathioprine	 and	 mycophenolate	 mofetil.	 Rituximab,	 intravenous	
immunoglobulins,	or	plasmapheresis	may	be	used	if	response	is	not	achieved	(200).		
The	 recommendations	 for	 primary	 and	 secondary	 cerebrovascular	 disease	
prevention	 in	 SLE	 patients	 are	 still	 under	 debate.	 The	 European	 League	 Against	
Rheumatism	 (EULAR)	 guidelines	 suggest	 anticoagulation	 for	 secondary	 prevention	 of	
arterial	 events	 in	 SLE	 patients	 with	 persistently	 positive	 moderate-to-high	 titers	 of	
antiphospholipids	 antibodies	 (199).	 Some	 authors	 suggest	 a	 target	 INR	 of	 2.0-3.0	 in	
patients	with	 antiphospholipid	 syndrome	 after	 a	 first	 venous	 event	 and	 >3.0	 for	 those	
with	recurrent	and/or	arterial	events	(201).	There	is	controversy,	however,	regarding	the	
INR	target.	Two	randomized	control	trials	of	114	and	109	patients	with	primary	and	SLE-
related	 anti-phospholipid	 syndrome	 have	 showed	 no	 superiority	 of	 high-intensity	




of	 severe	 autoimmune	 diseases,	 including	 SLE.	 It	 is	 recommended	 a	 nonmyeloablative	
immunosuppressive	 conditioning	 regime,	 usually	 high	 dose	 cyclophosphamide	 and	
another	 agent,	 such	 as	 anti-thymocyte	 globulin.	 Autologous	 rather	 than	 allogeneic	
hematopoietic	 stem	 cell	 transplantation	 has	 generally	 been	 preferred,	 because	 of	 the	
morbidity	and	mortality	associated	with	graft-versus-host	disease.		
Hematopoietic	 stem	 cell	 transplantation	 was	 examined	 in	 a	 phase	 I	 study,	 in	
which	 seven	 patients	 with	 severe	 SLE	 received	 high-dose	 chemotherapy	 followed	 by	
autologous	stem	cell	transplantation	(204).	These	patients	had	active	diffuse	proliferative	
glomerulonephritis,	 cerebritis,	 myelitis,	 and/or	 vasculitis	 despite	 six	 cycles	 of	
cyclophosphamide	 (204).	 At	 a	 median	 follow-up	 of	 25	 months,	 all	 patients	 were	 free	
from	 signs	 of	 active	 lupus	 and	 renal,	 cardiac,	 and	 pulmonary	 function	 and	 serologic	
markers	had	 improved	despite	either	no	 immunosuppression	or	small	residual	doses	of	
glucocorticoids.	 It	 is	 hypothesized	 that	 stem	 cell	 transplantation	 is	 beneficial	 in	 this	
setting,	 since	 it	 provides	 a	 period	 without	 memory	 T	 cell	 influence,	 during	 which	 the	
maturation	 of	 new	 lymphocyte	 progenitors	 can	 occur	 without	 recruitment	 to	 anti-self	




morbidity	 and	 mortality,	 thus	 the	 precise	 indications	 for	 this	 treatment	 should	 be	
carefully	addressed.	
High-dose	 cyclophosphamide	 (50mg/Kg/day	 for	 four	 consecutive	 days)	 without	
hematopoietic	 stem	cell	 rescue	has	 also	been	used	 in	 a	 variety	of	 severe	 autoimmune	






than	50%	of	patients	and	the	median	number	of	days	 in	 the	hospital	was	six	 (205).	No	
treatment-related	deaths	were	observed,	while	the	reported	100-day	transplant-related	
mortality	 was	 11%	 in	 patients	 with	 SLE	 (205).	 High-dose	 cyclophosphamide	 is	 not	
superior	to	monthly	pulse	dose	cyclophosphamide	and	it	is	not	recommended	as	first	line	
therapy	for	 lupus	nephritis.	Nevertheless,	high-dose	cyclophosphamide	can	be	effective	
salvage	 therapy	 for	 patients	 with	 refractory	 SLE,	 especially	 those	 with	 neurologic	
manifestations.	
In	 conclusion,	 nowadays	 we	 have	 a	 diverse	 group	 of	 drugs	 that	 act	 upon	 the	
imune	system	and	control	SLE	manifestations.	Nevertheless,	these	drugs	are	not	capable	









Overall	 improvements	 in	 medical	 care	 including	 the	 well-judged	 use	 of	
immunosuppressive	drugs	and	the	availability	of	antibiotics,	antihypertensive	drugs	and	
renal	 replacement	 therapy	 have	 led	 to	 increased	 survival	 of	 SLE	 patients	 in	 the	 past	








expectancy	 in	 this	 group	 is	 still	 below	 the	 one	 reported	 to	 other	 comparable	
demographic	 groups	 (1).	 SLE	 patients’	mortality	 rates	 are,	 indeed,	 2	 to	 5	 times	 higher	
than	 that	 of	 the	 general	 population	 (219,220).	 Cause	 of	 death	 varies	 depending	 on	
disease	duration	(219).	The	major	causes	of	death	 in	the	first	years	of	 illness	are	active	
disease	 and	 infection	 due	 to	 immunosuppression,	 while	 causes	 of	 late	 death	 include	
mainly	cardiovascular	disease	(19,221,222).	
Long-term	morbidity	 is	 also	 a	 major	 issue	 in	 SLE,	 since	 it	 affects	 the	 ability	 to	
work,	being	associated	with	a	significant	burden	of	direct	and	indirect	costs	(1).	Fatigue,	
cognitive	 dysfunction,	 glucocorticoid-induced	 avascular	 necrosis	 of	 the	 hips	 and	 knees	
and	chronic	pain	are	common	problems,	which	have	an	enormous	impact	on	the	quality	
of	life.	
Ethnicity	 has	 been	 reported	 as	 an	 important	 prognostic	 factor.	 As	 previously	
discussed,	 Hispanic,	 African	 American	 and	 Asian	 SLE	 patients	 tend	 to	 have	 more	
hematological,	 serosal,	 neurological	 and	 renal	 manifestations	 than	 Caucasian	 patients	
(54,213,216,223,224).	These	groups	also	accumulate	more	damage	over	time	(213)	and	
at	 a	 faster	 pace	 (225).	 Higher	mortality	 risks	 have	 been	 reported	 in	 African	 American,	
Hispanic	and	Native	American	groups.	Notably,	this	differential	risk	disappears	if	the	data	
are	adjusted	 for	 socioeconomic	status,	namely	 income,	 insurance	status	or	educational	




was	 found	to	be	an	 important	prognostic	 factor,	but	also	age	at	diagnosis	 (226).	Other	
poor	prognostic	factors	for	survival	in	SLE	also	include	high	disease	activity	at	diagnosis,	

























The	 break	 of	 self-tolerance	 is	 classically	 considered	 the	 central	 phenomenon	 in	
SLE	pathogenesis.	Several	mechanisms	may	contribute	to	this	central	event,	including	the	
imbalance	 between	 the	 production	 and	 the	 disposal	 of	 apoptotic	 material.	 Usually	
nuclear	 antigens	 are	 not	 accessible	 to	 the	 immune	 system.	 During	 the	 course	 of	
apoptosis,	 however,	 blebs	 appear	 that	 contain	 fragmented	 cellular	 material	 including	
nuclear	 antigens	 (228).	 In	 SLE	 there	 is	 an	 increase	 in	 apoptosis,	 which	 is	 further	
intensified	 by	 UV	 light,	 infections	 and	 toxins,	 which	 are	 well-known	 SLE	 triggers.	 In	
addition,	 SLE	 patients	 have	 defective	 mechanisms	 of	 apoptotic	 waste	 removal,	 which	




and	 production	 of	 autoantibodies	 and	 immune	 complexes,	 a	 unifying	 feature	 of	 SLE	
(229).	Once	activated,	B	cells	can	mature,	expand	and	begin	to	secrete	more	antibodies,	
thus	 enhancing	 the	 response.	 The	 autoantibodies	 identified	 in	 SLE	 are	 high	 affinity,	
somatically	mutated	and	IgG,	which	suggest	that	they	have	arisen	in	the	germinal	center,	
where	 T	 cells	 and	 B	 cells	 interact	 to	 promote	 class	 switching.	 The	 immune	 complexes	
activate	 complement	 and	 induce	 inflammation,	 causing	 tissue	 damage.	 Moreover,	







the	 overall	 inflammatory	 effect.	 SLE	 etiopathogenesis	 is,	 therefore,	 a	 vicious	 cycle	 of	
autoantigen	 exposure,	 autoantibody	 production,	 chronic	 inflammation	 and	 damage.	
Other	cytokines	also	participate	in	this	amplification	loop,	including	BAFF,	IL6,	IL10,	IL17	





This	 is	 still	 an	 imperfect	 perception	 of	 the	 pathogenesis	 of	 SLE	 and	 there	 are	
certainly	many	unanswered	questions	 regarding	 this	 subject.	One	of	 the	most	pressing	
topics	is	unveiling	the	phenomena	responsible	for	the	phenotypic	heterogeneity	in	SLE.		
In	 this	chapter	we	will	analyze	 the	currently	known	mechanisms	responsible	 for	







Changes	 in	 cell	 death	 pathways,	 including	 apoptosis	 and	 the	 neutrophil-specific	
kind	of	cell	death	called	NETosis	are	a	source	of	autoantigens	in	SLE	(229,230).		
Apoptosis	 is	 a	 normal	 process	 of	 tissue	 homeostasis,	 characterized	 by	 specific	
morphological	 features,	 including	 pyknosis,	 karyorrhexis,	 cytoskeleton	 remodeling	 and	
plasma	membrane	blebbing	(231).	Apoptosis	is	usually	an	immunologically	silent	process,	
because	 apoptotic	 cells	 are	 immediately	 phagocytosed	 and	 degraded.	 This	 clearance	
process	 starts	 when	 the	 apoptotic	 cell	 secretes	 mediators,	 including	 ATP,	 UTP,	
sphingosine-1-phosphate,	 lysophosphatidylcholine,	 and	 fractalkine	 (CX3CL1),	 which	
stimulate	migration	and	activation	of	 leukocytes	 (229).	 The	apoptotic	 cell	 also	exposes	
the	phospholipid	phosphatidylserine	on	the	outer	leaflet	of	the	plasma	membrane,	which	
enhances	recognition	and	engulfment	by	the	phagocytes.	The	uptake	of	apoptotic	cells	is	
followed	 by	 the	 secretion	 of	 anti-inflammatory	 cytokines,	 including	 IL10.	 The	 latter	
inhibits	the	further	recruitment	of	macrophages	to	the	site	(232,233).		
In	 SLE	 the	 clearance	 of	 apoptosis	 debris	 is	 impaired.	 Macrophages	 from	 SLE	
patients	 have	 reduced	 adherence,	 which	 may	 be	 mediated,	 at	 least	 in	 part,	 by	 a	
reduction	on	the	expression	of	the	cell	adhesion	receptor	CD	44	(234).	Furthermore,	 in	
vitro-differentiated	 macrophages	 from	 SLE	 patients	 have	 a	 decreased	 and	 delayed	
engulfment	capacity	for	autologous	apoptotic	material	(229,232,235).		
Dead	 cell	 clearance	 not	 only	 depends	 upon	 functioning	 phagocytes,	 but	 also	










inefficient	 clearance	 of	 apoptotic	 cells	 (232).	 Moreover,	 complement	 components	 are	
involved	in	the	clearance	of	immune	complexes.	It	has	been	shown,	for	instance,	that	C4-
deficient	 mice	 had	 a	 lupus	 like	 phenotype,	 characterized	 by	 delay	 in	 clearance	 of	
circulating	 immune	 complexes,	 glomerular	 deposition	 of	 immune	 complexes,	










Finally,	 DNase	 I	 participates	 in	 the	 clearance	 of	 nuclear	 debris,	 since	 it	 is	






NETosis	 is	 a	mechanism	of	neutrophil	 cell	 death.	 Following	 an	 activation	 signal,	
NADPH	 oxidase	 and	 superoxide	 dismutase	 generated	 H2O2	 promotes	 the	migration	 of	
elastase	 to	 the	 nucleus.	 This	 enzyme	 cleaves	 histones	 and	 elicits	 chromatin	
decondensation.	In	addition,	the	enzyme	peptylarginine	deiminase	4	(PAD4)	changes	the	









NETosis	 has	 multiple	 pro-inflammatory	 consequences,	 including	 stimulating	
plasmacytoid	dendritic	cells	to	produce	IFNα	(243).	NETs	contain	DNA	as	well	as	LL37	and	
HMGB1,	 neutrophil	 proteins	 that	 facilitate	 the	 uptake	 and	 recognition	 of	 DNA	 in	
plasmacytoid	 dendritic	 cells	 (244).	 NETs	 activate	 these	 cells	 to	 produce	 high	 levels	 of	
IFNα	 in	 a	 toll-like-receptor	 (TLR)	 9	 dependent	manner,	 contributing,	 therefore,	 to	 the	
type	 I	 IFN	 signature	of	 SLE	 (244,245).	 In	 turn	 IFNα	 primes	neutrophils	 for	NET	 release,	
suggesting	a	positive	feedback	loop	between	NETosis	and	IFN	signaling	(244).		
NETs	also	activate	the	NLRP3	inflammasome	in	macrophages	leading	to	enhanced	
IL1β	 and	 IL18	 production	 (246).	 The	 latter	 is	 able	 to	 stimulate	 NETosis,	 once	 again	
showing	the	existence	of	a	feed-forward	inflammatory	loop	(246).	
In	SLE	there	is	a	population	of	low	density	granulocytes,	which	have	a	propensity	
to	 form	 NETs,	 externalizing	 enhanced	 levels	 of	 autoantigens	 and	 immunostimulatory	
molecules	 (229).	 Interestingly,	NGAL	 is	a	granular	protein	externalized	 in	NETs	and	 is	a	
lupus	nephritis	biomarker,	correlating	with	disease	activity	(247,248).		
SLE	 patients	 were	 found	 to	 develop	 autoantibodies	 to	 both	 the	 self-DNA	 and	




The	NETosis	prone	 low-density	 granulocytes	 also	externalize	enhanced	 levels	of	
metalloproteinase	 9	 (MMP	 9),	 which	 activates	 MMP2	 in	 endothelial	 cells	 (249).	 This	
pathway,	 in	a	mouse	model,	specifically	 impairs	endothelium-dependent	vasorelaxation	
and	 induces	endothelial	cell	apoptosis	 (249),	contributing,	 therefore,	 to	endothelial	cell	
dysfunction	and	atherosclerosis.	Moreover,	 SLE	patients	 show	higher	 levels	of	 immune	
complexes	 containing	 MMP-9	 and	 anti-MMP-9	 antibodies	 that	 may	 potentiate	 this	
process	by	enhancing	NET	formation	(249).		
NETs	 can	 also	 contribute	 to	 atherosclerosis	 by	 other	mechanisms.	 Externalized	




active	oxidative	enzymes,	which	can	modify	 the	high-density	 lipoprotein,	 rendering	 the	
lipoprotein	proatherogenic	(251).		
In	analogy	to	the	deficient	clearance	of	apoptotic	cells,	the	inefficient	degradation	
of	 NETs	 can	 also	 be	 involved	 in	 the	 generation	 of	 autoantibodies	 (252).	 NETs	 are	 not	
efficiently	 degraded	 by	 sera	 from	 SLE	 patients,	 while	 healthy	 donor	 serum	 efficiently	
causes	 NET	 degradation	 (253).	 One	 possible	 explanation	 for	 this	 observation	 is	 the	
existence	of	anti-DNase	antibodies	in	SLE	patients.	Notably,	the	majority	of	SLE	patients	
are	positive	 for	anti-DNase	antibodies	 (254).	These	recognize	a	conserved	epitope	near	
the	 catalytic	 site	of	DNase	and,	 therefore,	protect	NETs	 from	degradation	 (254).	Other	
possible	mechanism	is	the	presence	of	DNase	inhibitors	(253).	NET-bound	autoantibodies	
cause	 C1q	 deposition,	 which	 directly	 inhibits	 DNase	 I	 and	 prevents	 NET	 degradation,	
exacerbating	the	exposure	of	auto-antigens	(252).		
Finally,	the	role	of	NETs	in	SLE	pathogenesis	was	also	highlighted	by	the	effect	of	
PAD	 inhibition	 in	 vivo	 (242).	 PAD4	 is	 required	 for	 NET	 formation	 and	 when	 it	 was	
inhibited	 in	 lupus-prone	 mouse	 models,	 there	 was	 significant	 improvement	 of	 skin,	
kidney	 and	 vascular	 disease	 (255,256).	 PAD	 inhibition	 in	 atherosclerosis-prone	 mouse	
models	 also	 decreased	 plaque	 formation,	 showing	 that	 NET	 inhibition	 can	 have	 a	
vasculoprotective	effect	(257).	
In	 conclusion,	 recent	 evidence	 suggests	 that	 NETs,	 like	 apoptotic	 debris,	 may	











trans-membrane	 glycoproteins,	which	 have	 an	 extracellular	 N-terminal	 domain	 and	 an	










Mouse	 and	 human	 studies	 consistently	 suggest	 that	 the	 intracellular	 TLRs	
contribute	to	SLE	pathogenesis.	 In	pristane-treated	mice,	 for	 instance,	TLR7,	a	 receptor	
for	 single-stranded	 RNA,	 was	 specifically	 required	 for	 the	 production	 of	 RNA-reactive	
autoantibodies	and	for	the	development	of	glomerulonephritis	(259).	Moreover,	in	MRL	
lpr	mice,	 a	 TLR7	 antagonist	 prevented	 kidney	 injury	 (260).	 Pharmacologic	 activation	 of	
TLR7	 in	MRL	 lpr/lpr	mice	 induced	 IFNα	 release,	 renal	 immune	 complex	deposition	 and	
renal	 tissue	 injury	 (261).	 In	 addition,	 a	 Tlr7	 translocation,	 which	 caused	 Tlr7	
overexpression,	 accelerated	 systemic	 autoimmunity	 in	 a	 lupus	 mouse	 model	 (262).	
Whereas	 a	 modest	 increase	 in	 Tlr7	 gene	 dosage	 promoted	 autoreactive	 lymphocytes	
with	 RNA	 specificities	 and	 myeloid	 cell	 proliferation,	 a	 substantial	 increase	 in	 Tlr7	
expression	caused	a	dramatic	dendritic	 cell	dysregulation	and	 fatal	 acute	 inflammatory	
injury	(263).		










dsDNA	 and	 antichromatin	 autoantibodies	 was	 specifically	 inhibited,	 while	 other	
autoantibodies	 levels,	 such	 as	 anti-Sm,	 were	 maintained	 or	 even	 increased	 (267).	
Notably,	TLR9	deficiency	exacerbated	disease	activity	in	MRL/lpr	lupus-prone	mice	(268),	





apparent	 paradox	 can	 be	 explained,	 because,	 upon	 activation,	 TLR7	 and	 TLR9	 are	
transported	from	the	endoplasmic	reticulum	to	endolysosomes	by	the	protein	UNC93B1	
(270).	 TLR9	 competes	with	 TLR7	 for	UNC93B1-dependent	 trafficking	 and	predominates	
over	 TLR7	 (270).	 TLR9	 depletion	 increases	 TLR7	 trafficking	 and	 signaling,	 resulting	 in	
systemic	autoimmunity	 (270).	 In	conclusion,	 the	role	of	TLR9	 in	SLE	 is	complex,	since	 it	
drives	DNA	autoantibody	production	and	suppresses	TLR7	signaling.		
In	 addition	 to	 TLR9,	 TLR	 8,	 a	 receptor	 for	 single-stranded	 RNA,	 also	 suppresses	
TLR7-mediated	 systemic	 autoimmunity.	 Tlr8(-/-)	 mice	 had	 increased	 serum	 levels	 of	
autoantibodies	 and	 glomerulonephritis,	 a	 phenotype	 not	 seen	 in	 Tlr8(-/-)Tlr7(-/-)	mice	
(271).	In	C57BL/6	mice	it	was	also	confirmed	that	TLR8	on	dendritic	cells	and	TLR9	on	B	
cells	 restrain	 TLR7-mediated	 spontaneous	 autoimmunity	 (272).	 Accordingly,	 in	MRL/lpr	
mice,	 B-cell-specific	 deletion	 of	 MyD88,	 a	 TLR7/TLR9	 adaptor,	 decreased	 dramatically	
autoantibody	 production,	 class	 switching	 and	 T-cell	 activation.	 Notably,	 only	 MyD88	
deficiency	in	B	cells,	but	not	in	dendritic	cells,	abrogated	lupus	nephritis	(273).	
TLR3,	another	 intracellular	TLR,	which	 is	 a	 receptor	 for	double-stranded	RNA,	 is	
also	 associated	 with	 SLE	 pathogenesis.	 In	 MRL/lpr	 mice,	 for	 instance,	 TLR3	 activation	




and	MDA5	 recognize	 double-stranded	 RNA	 and	 activate	 the	 IPS1	 dependent	 cytosolic	
signaling	pathway,	leading	to	the	synthesis	of	type	I	IFNs	and	inflammatory	proteins.		
Overall,	 the	main	 result	 of	 activation	 of	 these	 pathways	 and	 TLRs	 is	 type	 I	 IFN	
production.	 Important	 insights	have	 come	 from	 the	 study	of	 rare	monogenic	disorders	
with	a	lupus-like	phenotype	–	the	type	I	IFNopathies.	These	comprise	a	set	of	monogenic	
diseases	 linked	 by	 overproduction	 of	 type	 I	 IFN	 (276).	 One	 of	 the	 main	 phenotypic	








deficiency	 may,	 therefore,	 trigger	 autoimmunity	 through	 the	 accumulation	 of	 DNA	
species	 (276).	 These	are	 sensed	by	 cyclic	GMP-AMP	 (cGAMP)	 synthase,	which	produce	
cGAMP.	This	 is	a	 ligand	 for	stimulator	of	 IFN	genes	protein	 (STING),	which	 leads	 to	 the	
production	 of	 type	 I	 IFN	 via	 activation	 of	 TBK1–IRF3	 and	 possibly	 NF-κB	 (276).	 This	
syndrome	 is	 thus	 an	 argument	 in	 favor	 of	 the	 importance	 of	 the	 clearance	 of	 nuclear	





underlying	 immune	cell	dysfunction	and	 further	contributes	 to	 the	pathogenesis	of	 the	
disease	(277).		
As	 previously	 discussed,	 one	 of	 the	 hallmarks	 of	 SLE	 is	 the	 IFNα	 signature.	 SLE	
patients	have	higher	serum	levels	of	IFNα	(278)	and	an	overexpression	of	IFNα-induced	
genes	 in	peripheral	blood	 immune	cells	 (279–282).	 In	addition,	 transcripts	of	 IFNα	 and	
IFNα-induced	genes	have	been	detected	 in	 inflamed	kidney	and	skin	 from	SLE	patients	
(283,284).	Genetic	studies	further	link	the	type	I	IFN	to	SLE,	because	specific	haplotypes	
of	 IRF5	 and	 IRF7	 confer	 increased	 expression	 of	 IFNα	 as	well	 as	 increased	 risk	 for	 SLE	
(285–287).	 Epigenetic	 studies	 also	 reveal	 that	 type	 I	 IFN-induced	 genes	 are	
hypomethylated	in	SLE	patients	(288).	Finally,	a	direct	pathogenic	role	for	IFNα	in	lupus	is	
also	 supported	 by	 mouse	 models,	 in	 which	 exogenous	 administration	 of	 IFNα	
exacerbates	disease	(289–292).	
Different	 cells	 can	 produce	 small	 amounts	 of	 type	 I	 IFN,	 but	 the	 plasmacytoid	
dendritic	 cell	 is	 the	main	 cell	 type	 responsible	 for	 the	 production	 of	 this	 cytokine.	 As	
described	in	the	previous	sections	of	this	chapter,	IFNα	production	is	induced	by	viruses,	
bacteria	 or	 other	 microbes	 that	 stimulate	 pattern	 recognition	 receptors,	 including	
endosomal	TLRs,	the	cytoplasmic	RIG1	receptors	and	the	intracellular	dsDNA	sensors	DAI	
and	 cGAMP	 synthetase	 (293).	 Nucleic	 acids	 from	 endocytosed	 viruses	 stimulate	 the	
endosomal	TLR7	and	TLR9,	which	activate	the	MyD88-signalling	pathway	that	ultimately	
leads	 to	 the	phosphorylation	of	 IRF3,	 IRF5	and	 IRF7	and	 the	 transcription	of	 type	 I	 IFN	




consequently,	 contribute	 to	 an	 SLE	 flare.	Nevertheless,	 the	 high	 levels	 of	 this	 cytokine	
seen	 in	 SLE	 are	 caused	not	 by	 infections,	 but	 by	 endogenous	 inducers,	 namely	 nucleic	
acid-containing	immune	complexes	(293),	which	are	internalized	via	FcγRIIa	and	activate	
TLR7	 and	 TLR9	 in	 plasmacytoid	 dendritic	 cells	 (294).	 Such	 interferogenic	 immune	
complexes	 can	 be	 created	 in	vitro	 by	 combining	 purified	 IgG	 from	 SLE	 patients	 and	
apoptotic	 cell	 material	 (295).	 This	 is	 another	 factor	 linking	 the	 defective	 clearance	 of	
apoptosis	debris	with	SLE	pathogenesis.	





Interestingly,	 the	production	of	 type	 I	 IFNs	 in	plasmacytoid	 cells	 is	 increased	by	
estradiol	 in	 vivo	 through	 cell-intrinsic	 estrogen	 receptor	 α	 signaling	 (300).	 This	 may	
contribute,	at	least	in	part,	to	the	differences	in	SLE	prevalence	between	the	genders.	
Regarding	 the	 negative	 regulators,	 monocytes	 inhibit	 the	 increase	 of	 IFNα	
through	 the	 secretion	 of	 TNF,	 prostaglandin	 E2	 and	 reactive	 oxygen	 species.	 This	
regulatory	pathway	 is	defective	 in	SLE,	 since,	as	previously	mentioned,	 reactive	oxygen	
species	generation	 is	 impaired	(293).	C1q	is	another	negative	regulator,	since	there	 is	a	
preferential	 uptake	 of	 C1q-containing	 immune	 complexes	 by	 monocytes	 instead	 of	
plasmacytoid	dendritic	cells,	 thereby	decreasing	 type	 I	 IFN	production.	This	mechanism	
may	explain	the	association	between	C1q	deficiency	and	SLE	(293).		
Considering	the	effects	of	IFNα,	it	binds	the	ubiquitously	expressed	heterodimeric	
IFN	 α/β	 receptor	 (IFNAR),	 activating	 JAK1	 and	 TYK2	 and	 forming	 a	 transcription	 factor	
complex	consisting	of	STAT1,	STAT2	and	IRF9.	This	transcription	factor	complex	binds	to	
IFN-stimulated	 response	 elements	 in	 promoters	 of	 IFN-regulated	 genes	 and	 initiates	
transcription	(293).		
In	 addition	 to	 a	 direct	 antiviral	 effect,	 IFNα	 has	 multiple	 pro-inflammatory	
functions.	With	regard	to	the	innate	immune	system,	type	I	 IFN	enhances	Natural	Killer	
cell	cytotoxicity	and	 IFNγ	secretion,	promotes	the	maturation	of	monocytes	to	antigen-
presenting	 cells	 and	 induces	 the	 expression	 of	 MHC	 molecules	 and	 co-stimulatory	






cell	activation	 (301).	B	cells	are	also	directly	activated	by	 type	 I	 IFN,	generating	non-Ig-
secreting	plasma	blasts,	which	 further	differentiate	 into	 Ig-secreting	plasma	cells	when	
exposed	to	IL6	(302).	Finally,	type	I	IFN	exerts	a	positive	feedback	regulation	on	the	IFNα	
production	 through	 the	 upregulation	 of	 TLR7	 and	 IRF7	 expression	 in	 plasmacytoid	
dendritic	cells	(293).	
All	 these	findings	suggest	a	central	 role	 for	 IFNα	 in	the	pathogenesis	of	SLE	and	
have	prompted	the	study	of	drugs	targeting	 IFNα	 for	SLE	treatment.	 In	fact,	one	of	the	
most	 commonly	used	drugs	 for	 SLE	 treatment,	hydroxychloroquine,	downregulates	 the	
type	 I	 IFN	 signature	 (293).	Hydroxychloroquine	blocks	 the	binding	of	 TLR7/9	 to	nucleic	
acids	(303)	and	inhibits	the	DNA	sensor	cGMP	synthase	(304).		
The	 effect	 of	 anti-IFNα	 monoclonal	 antibodies	 has	 been	 evaluated	 in	 several	
clinical	trials	(305–308),	as	well	as	the	effect	of	antibodies	targeting	the	IFN	α/β	receptor.	







the	 serum	of	 SLE	patients	 promote	 autoantibody	production	 (309).	 In	 a	mouse	model,	
overexpression	 of	 BAFF	 promoted	 anti-dsDNA	 B	 cell	 maturation	 and	 secretion	 of	
antibodies,	suggesting	that	BAFF	rescues	a	subset	of	anti-dsDNA	B	cells	from	a	regulatory	
checkpoint	 in	 the	 transitional	 stage	 of	 development	 (310).	 A	 short	 course	 of	 selective	
blockade	of	BAFF	alone	was	 sufficient	 to	prevent	and	 treat	nephritis	 in	NZM2410	mice	
despite	 the	 formation	 of	 pathogenic	 autoantibodies	 (311).	 In	 humans	 prolonged	 BAFF	
inhibition	 decreases	 the	 survival	 of	 newly	 formed	 B	 cells,	 while	 not	 having	 the	 same	
effect	on	memory	B	cells	and	plasma	cells	 (312).	 It	 is	hypothesized,	 therefore,	 that	 the	








of	 this	 cytokine	 is	 regulated	 mainly	 at	 the	 transcriptional	 level	 by	 the	 binding	 of	
transcription	factors	to	the	IL2	promoter/enhancer	region	(313).	In	SLE	there	is	a	higher	
expression	 of	 CREMα,	 which	 binds	 to	 the	 IL2	 promoter	 in	 T	 cells	 and	 represses	 the	
transcription	of	the	IL2	gene	(314).	Treatment	of	normal	T	cells	with	SLE	serum	resulted	
in	 increased	expression	of	CREM	and	decreased	 IL2	production	 (314).	The	effect	of	SLE	
serum	 resided	 within	 the	 IgG	 fraction	 and	 was	 specifically	 attributed	 to	 anti-TCR/CD3	
autoantibodies	(314).		
Il2	plays	a	role	as	an	auto-	and	paracrine	growth	factor	during	the	first	48	to	72	h	
of	T	 cell	 activation	 (315).	Paradoxically,	 its	absence	has	been	 linked	 to	development	of	
lethal	 autoimmunity	 in	 mice	 (315).	 This	 apparent	 contradiction	 has	 been	 partially	
explained	by	the	fact	that	 IL2	 is	an	essential	cytokine	to	maintain	the	balance	between	
Th17	 and	 regulatory	 T	 cells	 (315).	 IL2	 promotes	 activation-induced	 cell	 death	 of	
lymphocytes,	generates	 regulatory	T	cells	and,	signaling	via	STAT5,	constrains	Th17	cell	
generation	 (316).	 Recently,	 it	 was	 shown	 in	 a	 lupus	 prone	 mouse	 model	 that	
administration	of	 low	dose	 IL2	 increased	 regulatory	T	cell	numbers	and	 function	and	 it	
suppressed	IL17	production	and	kidney	damage	(317).		
Globally,	 the	data	show	that	 the	 limited	 IL2	 levels	seen	 in	SLE	skew	the	balance	
between	regulatory	T	cells	and	Th17	in	favor	of	the	latter	(318).	In	SLE	there	is	indeed	an	
increased	number	of	Th17	cells,	as	well	as	higher	levels	of	IL17	(319,320).		
IL17	 is	 produced	 by	 Th17	 cells,	 TCRγδ	 and	 TCRαβ	 double	 negative	 T	 cells,	
macrophages	 and	 neutrophils	 (318).	 IL17	 induces	 the	 production	 of	 additional	
inflammatory	 cytokines	 and	 chemokines,	 recruiting	 monocytes	 and	 neutrophils	 to	 the	
organs	 (318).	 In	 recent	 years,	 several	 IL17A	 pathway	 inhibitors	 have	 advanced	 into	
clinical	 trials,	 including	 the	 anti-IL17A	monoclonal	 antibody	 and	 the	 anti-IL17	 receptor	
monoclonal	antibody.		
The	 differentiation	 of	 the	 Th17	 cells	 is	 dependent	 on	 IL23	 (318).	 There	 is	 also	
accumulating	evidence	 indicating	 the	 importance	of	 IL23	 in	 autoimmune	diseases.	 In	 a	
lupus	 prone	mice	 the	 clinical	 and	 pathology	 findings	 were	mitigated	 by	 IL23	 receptor	






IL6	 is	 a	 cytokine	 with	 major	 pro-inflammatory	 effects,	 including	 activation	 and	
differentiation	 of	 B	 cells,	 increased	 antibody	 production	 and	 differentiation	 and	
activation	of	T	cells.	IL6	is	increased	in	SLE	(324,325)	and	B	cells	from	SLE	patients	show	
upregulation	of	the	IL6	receptor	(326).	Constitutive	expression	of	IL6	receptors	on	B	cells	
in	 conjunction	 with	 spontaneous	 IL6	 production	 by	 B	 cells	 induces	 autocrine	 B	 cell	
activation,	 which	 may	 lead	 to	 B	 cell	 hyperactivity	 and	 autoantibody	 secretion	 in	 SLE	
patients	(326).	The	dysregulation	of	B	cell	activity	observed	in	patients	with	SLE	may	thus	
be,	 at	 least	 in	 part,	 independent	 of	 T	 cell	 activity	 (326).	 The	 depletion	 of	 IL6	 through	
genetic	deficiency	or	antibody-mediated	therapy	ameliorates	disease	in	mouse	models	of	
lupus	(327–329).	
Finally,	 it	 is	 also	 noteworthy	 to	 discuss	 the	 role	 of	 IL10	 in	 SLE	 pathogenesis.	
Polymorphisms	in	the	IL10	gene	have	been	linked	to	SLE	risk	(330,331).Furthermore,	it	is	
known	 that	B	 cells	 in	SLE	patients	produce	higher	 levels	of	 IL10,	which	 in	an	autocrine	
feedback	 loop	promote	B	cell	proliferation	and	production	of	autoantibodies	 (332).	On	
the	contrary,	IL10	inhibits	T	cell	function.	T	cells	from	SLE	produce	more	IL10	(333),	but	








Neutrophils	 display	 various	mechanisms	 of	 host	 defense,	 including	 expulsion	 of	
antimicrobial	peptides,	phagocytosis	of	the	microorganism	followed	by	their	degradation	
via	 acid	 or	 reactive	 oxygen	 species	 inside	 phagolysosomes,	 and	 trapping	 the	
microorganisms	 in	 neutrophil	 extracellular	 traps	 (NETs)(242).	 The	 latter,	 as	 previously	






function,	 including	 defective	 phagocytosis	 (229,336,337),	 which	may	 contribute	 to	 the	
susceptibility	 to	 infection	 seen	 in	 this	 disease.	 In	 addition,	 the	 production	 of	 reactive	
oxygen	species	may	also	be	impaired	(338).	 In	one	study,	neutrophils	from	SLE	patients	
demonstrated	 reduced	 reactive	oxygen	 species	production	 in	 response	 to	activation	ex	
vivo,	in	a	manner	that	correlated	with	disease	severity	and	end	organ	damage	(338).		
Notably,	 patients	 with	 chronic	 granulomatous	 disease,	 who	 have	 a	 defective	
NADPH	oxidase	 complex	and,	 therefore,	a	 compromised	production	of	 reactive	oxygen	
species,	have	an	increased	risk	for	SLE	(339).	In	a	registry	report	2.7%	of	the	patients	with	
chronic	granulomatous	disease	developed	discoid	lupus	and	0.5%	develop	SLE	(340).		
In	 addition,	 in	 the	 reactive	oxygen	 species-deficient	Ncf1	 (m1J)	mutated	mouse	
model	 it	 was	 found	 a	 type	 I	 IFN	 signature,	 production	 of	 autoantibodies,	 and	
glomerulonephritis	 (341).	 This	 connection	 provides	 further	 evidence	 of	 a	 link	 between	
defective	reactive	oxygen	species	generation	and	autoimmunity.	Interestingly,	it	was	also	
found	 that	 neutrophil	 apoptosis	 is	 aberrant	 in	 patients	 with	 chronic	 granulomatous	
disease	due,	at	least	in	part,	to	diminished	or	delayed	exposure	of	phosphatidyl	serine	on	
the	surface	(342).	This	is	an	essential	step	for	the	uptake	of	apoptotic	cells	by	phagocytes	
and	 may	 contribute	 to	 the	 development	 of	 autoimmunity	 seen	 frequently	 in	 chronic	
granulomatous	disease.	
Neutrophils	may	 also	 contribute	 to	 the	 break	 of	 self	 tolerance	 characteristic	 of	




peripheral	 blood	 and	 it	 correlates	with	 both	 higher	 autoantibodies	 and	 higher	 disease	
activity	(343).	Pronounced	alterations	in	B	cell	development	occur	in	SLE	in	the	presence	
of	 this	 changed	 milieu,	 including	 an	 inhibition	 in	 early	 B	 cell	 development	 and	 an	
expansion	of	B	cells	at	the	transitional	stage	(343).		
Patients	with	 SLE	 have	 a	 distinct	 population	of	 low	density	 granulocytes,	which	
display	 an	 activated	 phenotype	 (344).	When	 compared	 to	 normal	 density	 neutrophils,	








Dendritic	 cells	 have	 a	 central	 role	 in	 immunity,	 not	 only	 by	 presenting	 the	
antigens	to	B	and	T	cells,	but	also	by	determining	their	response.	Dendritic	cells	establish	
and	maintain	 peripheral	 tolerance	 via	 expression	 of	 negative	 co-stimulatory	molecules	
(345).	Dendritic	cell	dysregulation	can,	therefore,	promote	the	breakdown	of	B	and	T	cell	
tolerance	and	contribute	to	autoimmunity	(346).	
SLE	 patients	 have	 fewer	 circulating	 conventional	 dendritic	 cells,	 but	 increased	
numbers	 of	 plasmacytoid	 dendritic	 cells	 (347).	 As	 previously	 described	 in	 this	 chapter,	
the	plasmacytoid	dendritic	 cells	 are	 responsible	 for	 type	 I	 IFN	 secretion	 in	 response	 to	
TLR7	and	TLR9	activation	(348).	Another	critical	function	of	these	cells	is	the	activation	of	
T	 cells,	 which,	 in	 turn,	 promote	 plasmacytoid	 dendritic	 cells	 maturation	 in	 a	 positive	
feedback	loop	(349).		
In	 a	 lupus	mouse	model,	 depletion	 of	 dendritic	 cells	 generally	 ameliorated	 the	
disease	(350).	Dendritic	cells	were	crucial	for	the	expansion	and	differentiation	of	T	cells	
and	for	the	development	of	kidney	interstitial	infiltrates	(350).		
In	 normal	 settings,	 plasmacytoid	 dendritic	 cells	 are	 capable	 of	 inducing	 both	
antigenic	and	tolerogenic	responses.	The	PD-L1	glycoprotein,	expressed	on	the	surface	of	
antigen	presenting	cells	in	response	to	stimuli,	is	a	negative	co-stimulatory	molecule	with	
a	 tolerizing	 effect	 on	 T	 cells,	 mediated	 by	 binding	 to	 the	 PD-1	 receptor.	 PD-L1	





recognize	 pathogen-associated	 molecular	 patterns	 (PAMPs).	 Activation	 of	 these	







of	 dead	 cells,	 cellular	 debris,	 microbes,	 and	 other	 foreign	 material	 (351).	 Finally,	
monocytes	 have	 a	 central	 role	 in	 lupus	 nephritis	 and	 atherosclerosis,	 two	 of	 the	main	
causes	of	morbidity	and	mortality	in	this	group	of	patients.	
Regarding	nephritis,	in	SLE	there	is	a	milieu	that	favors	kidney	leucocyte	invasion,	
since	 monocytes	 display	 elevated	 surface	 levels	 of	 sialoadhesin	 and	 increased	 urinary	
levels	of	 ICAM1	and	VCAM1	were	found	in	 lupus	nephritis	patients	(352).	Furthermore,	
the	 accumulation	 of	 CD16+	 monocytes	 in	 the	 glomeruli	 of	 patients	 with	 active	 lupus	
nephritis	 correlates	with	 impaired	 renal	 function	 and	 anti-dsDNA	autoantibodies	 levels	
(353).	Interestingly,	type	I	IFN	increases	the	expression	of	sialoadhesin	(Siglec-1,	CD169)	
on	monocytes,	contributing,	therefore,	to	tissue	invasion	(354).	
Monocytes	 have	 FcγRs,	 which	 participate	 in	 phagocytosis,	 cytolysis,	
degranulation,	 and	 induction	 of	 inflammatory	 cytokines	 (355).	 The	 outcome	 of	
interactions	 with	 immune	 complexes	 is	 determined	 by	 the	 balance	 of	 activating	 and	
inhibitory	FcγRs	on	the	cell	surface	of	monocytes	(356).	Notably,	the	activating	receptor	
FcγRI	(CD64)	is	over-expressed	in	monocytes	from	SLE	patients,	particularly	in	those	with	




(358).	 Gamma	 chain-deficient	 NZB/NZW	 mice	 generated	 and	 deposited	 immune	







translocation	 of	 the	 endogenous	 nucleic	 acids	 into	 the	 endosomal	 compartment	
containing	TLR	7/8	and	TLR9	 (356).	 This	mechanism	may	be	 responsible	 for	 the	excess	







In	 addition,	 monocytes	 from	 SLE	 patients	 express	 greater	 levels	 of	 the	
costimulatory	molecule	 CD40	 (356).	 Concomitantly,	 CD40L	 expression	 is	 elevated	 on	 T	
and	B	 cells	 from	SLE	patients	with	active	disease	 (360).	 Interaction	between	CD40	and	
CD40L	 triggers	 lymphocyte	 activation,	 proliferation,	 and	 initiation	 of	 immunoglobulin	
isotype	 switch	 (356).	Accordingly,	 the	excess	of	CD40-CD40L	 interactions	may	promote	
the	proliferation	of	autoreactive	lymphocytes	and	production	of	autoantibodies.	
Monocytes	also	 contribute	 to	 the	 intrinsic	defect	 in	 the	clearance	of	dying	 cells	
seen	in	SLE.	In	vitro,	phagocytosis	of	autologous	apoptotic	cells	is	significantly	impaired	in	
monocyte-derived	macrophages	from	SLE	patients	(356).	Despite	normal	surface	binding	
of	apoptotic	 cells,	macrophages	 from	SLE	patients	display	 reduced	ability	 to	 internalize	
the	 targets	 (356),	 a	 defect	 due,	 at	 least	 in	 part,	 to	 the	 reduced	 surface	 expression	 of	
CD44	 (234).	 Furthermore,	 addition	 of	 serum	 from	 SLE	 patients	 to	 macrophages	 from	
healthy	controls	reduces	the	uptake	of	apoptotic	cells	(361).		
In	conclusion,	in	SLE	aberrant	monocyte	function	contributes	to	its	pathogenesis	




Depletion	 of	 T	 cells	 or	 blocking	 T	 cell	 activation	 mitigates	 the	 development	 of	




a	 hyperactive	 TCR	 signaling	 pathway	 (363,364).	 The	 downregulation	 of	 TCR/CD3	 zeta	
chain	 is	 not	 cell	 intrinsic	 and	 can	 be	 induced	 in	 normal	 T	 cells	 by	 SLE	 serum.	 This	
phenomenon	 is	 influenced	 by	 mTOR	 activation,	 since	 treatment	 of	 T	 cells	 from	 SLE	
patients	with	rapamycin	reverses	this	effect	(365).		
Despite	 this	 phenotype	 of	 increased	 activation,	 T	 cell	 production	 of	 IL2	 in	





the	 IL2	 promoter	 and	 actively	 suppresses	 IL2	 expression	 (313,314).	 Notably,	 CaMKIV	
activity	can	be	induced	in	normal	T	cells	by	serum	IgG	from	SLE	patients	(314).	




pro-inflammatory	 cytokine	 IL17.	 CaMK4	and	ROCK	 induce	 Th17	differentiation	 through	
mTORC1	signaling.	Recent	studies	have	shown	that	the	blockade	by	rapamycin	reverses	
the	 expansion	 of	 Th17	 cells	 in	 SLE	 patients	 (366)	 and	 that	 rapamycin	 blocks	
glomerulonephritis	in	lupus	prone	mice	(318).	
CD3+CD4-CD8-	double-negative	T	cells	are	also	expanded	in	SLE	patients	(367)	and	
contribute	as	well	 to	 the	 IL17	production	 (368).	Cells	 expressing	 IL17	have	been	 found	
infiltrating	the	kidneys	of	patients	with	lupus	nephritis	(367).	Double	negative	T	cells	also	
express	other	pro-inflammatory	 cytokines,	 including	 IL1β	 and	 IFNγ,	 and	promote	B	 cell	
differentiation	and	antibody	production.	In	a	lupus	murine	model,	CXCR5	is	important	for	
pathogenic	double	negative	T	cells	infiltration	into	lymphoid	organs	and	kidneys	(369).		
It	 is	 also	worth	mentioning	 that	 in	 SLE	 there	 is	 also	an	expansion	of	 T	 follicular	
helper	 cells,	which	correlates	with	 increased	disease	activity.	These	cells	 support	B	cell	
differentiation	 and	 antibody	 production	 (370,371).	 Recent	 evidence	 suggests	 that	 the	
expansion	of	T	follicular	helper	cells	in	SLE	is	directed	by	the	interaction	OX40-OX40L,	the	
latter	 expressed	 on	 myeloid	 antigen	 presenting	 cells	 and	 induced	 by	 TLR7	 activation	
(372).		
Finally,	 recent	 studies	 have	 focused	on	 T-B	 cell	 interactions.	 T	 cells	 represent	 a	
key	 checkpoint	 for	 autoreactive	B	 cells.	 In	 SLE	T-B	 interactions	occur	outside	 the	usual	











autoreactive	 follicular	 Th	 cells.	 This	 fosters	 the	 formation	 of	 autoreactive	 long-lived	
plasma	cells	and,	consequently,	autoantibody	production	(375).	







commitment	 is	 also	 triggered	 by	 TLR9	 which	 leads	 to	 a	 striking	 production	 of	
autoantibodies	 (377).	 Tolerance	 can	also	be	broken	by	B	 cell	 stimulation	via	 cytokines,	
including	BAFF.	BAFF	antagonism	in	mice	clearly	leads	to	improved	tolerance	to	self	and	
conversely	 BAFF	 overexpression	 leads	 to	 autoimmunity,	 as	 previously	 mentioned	
(378,379).		
In	 SLE	 the	 function	 of	 regulatory	 B	 cells	 is	 impaired	 (380),	 namely	 induced	
regulatory	B	cells	from	SLE	patients	are	less	effective	in	the	control	of	Th	cell	proliferation	
(380).	 The	 malfunctioning	 SLE	 regulatory	 B	 cells	 might	 allow	 the	 overstimulation	 of	
immune	responses	and	contribute	to	the	initiation	and	perpetuation	of	disease	(380).	
Recently,	 it	 was	 shown	 that	 a	 regulatory	 feedback	 between	 plasmacytoid	
dendritic	 cells	 and	 regulatory	 B	 cells	 is	 altered	 in	 SLE	 (381).	 In	 healthy	 individuals,	
plasmacytoid	dendritic	cells	drive	the	differentiation	of	immature	B	cells	into	regulatory	B	
cells	and	plasmablasts.	A	negative	 feedback	 loop	exists,	 since	regulatory	B	cells	 release	
IL10,	 controlling	 plasmacytoid	 dendritic	 cells.	 In	 SLE,	 this	 cross-talk	 is	 aberrant	 (381).	
There	is	evidence	that	plasmacytoid	dendritic	cells	promote	plasmablast	differentiation,	
but	do	not	induce	regulatory	B	cells	(381).	Interestingly,	the	plasmacytoid	dendritic	cells	
–	 regulatory	 B	 cell	 interactions	 seem	 to	 be	 normalized	 in	 SLE	 patients	 responding	 to	
rituximab	(381).		
Autoantibodies	 contribute	 to	 SLE	 through	 the	 formation	of	 immune	 complexes,	
which	can	activate	complement	and	drive	inflammation.	Antibody	production	in	general	
appears	to	favor	high	affinity	in	SLE	as	even	anti-influenza	antibodies	have	higher	affinity	





specific	 for	 dsDNA	 activate	 plasmacytoid	 dendritic	 cells	 (383).	 The	 concentration	 of	
dsDNA-specific	IgE	correlated	with	disease	severity	and	greatly	potentiated	the	function	
of	 plasmacytoid	 dendritic	 cells	 by	 triggering	 phagocytosis	 via	 the	 high-affinity	 FcɛRI	
receptor	for	IgE,	followed	by	TLR9	activation(383).		
Finally,	autoantibodies	can	also	directly	cause	tissue	injury.	Anti-dsDNA	antibodies	
that	 cross-react	 with	 the	 NMDA	 receptor	 have	 been	 found	 in	 the	 serum	 and	
cerebrospinal	 fluid	of	patients	with	neuropsychiatric	 lupus	 (384).	These	antibodies	may	






processes	 and	 they	 should	 be	 distinguished	 clinically.	 Physicians	 encounter	 frequently	
patients	with	high	titers	of	autoantibodies	without	evidence	of	active	organ	inflammation	
or	 damage.	 Data	 from	 mouse	 model	 support	 this	 concept.	 Autoimmunity	 and	 kidney	
damage	 in	 the	 NZM2328	 lupus-prone	 mouse	 are	 controlled	 by	 Agnz1	 and	 Cgnz1,	
respectively	 (387,388).	 Replacement	 of	 the	 pathologic	 Cgnz1	 variant	 with	 the	 normal	
allele	did	not	affect	the	expression	of	autoimmunity	but	prevented	kidney	failure	(387).	
In	 turn,	 when	 the	 gld.apoE(-/-)	 mouse,	 a	 lupus	 prone	 mouse	 with	 profound	
atherosclerosis,	was	 rendered	 IRF5	deficient,	 it	was	protected	 from	autoimmunity,	 but	





Immune	 complexes	 activate	 the	 local	 classical	 complement	 pathway,	 as	well	 as	
kidney	 macrophages	 and	 dendritic	 cells,	 causing	 local	 release	 of	 proinflammatory	
cytokines	 and,	 consequently,	 intrarenal	 inflammation	 and	 cell	 injury.	 The	 immune	
complexes	are	mainly	 formed	by	anti-dsDNA	antibodies,	which	bind	not	only	DNA,	but	





fix	 C1q.	 The	 subsequent	 binding	 of	 anti-C1q	 antibodies	 to	 C1q	 activates	 complement,	
resulting	in	an	influx	of	inflammatory	cells	(391–394).	
The	 location	 of	 the	 immune	 complexes	 determines	 the	 lupus	 nephritis	
histopathologic	class.	Large	intact	immune	complexes	or	anionic	antigens,	which	cannot	
cross	 the	 anionic	 charge	 barrier	 in	 the	 glomerular	 capillary	 wall,	 are	 deposited	 in	 the	
mesangium	and	subendothelial	space	(395).	Subepithelial	deposits	form	when	a	cationic	
antigen	 is	 present,	 which	 can	 cross	 the	 glomerular	 basement	 membrane	 or	 when	 an	
autoantibody	is	directed	against	epithelial	cell	antigens.	
Immune	complex	deposition	 in	 the	mesangium	causes	mesangial	 cell	 injury	and	
consequently	mesangial	 cell	 hyperplasia,	 a	 phenomenon	 characteristic	 of	 class	 II	 lupus	
nephritis.	 Subendothelial	 immune	 complex	 cause	 endothelial	 cell	 swelling,	 clotting,	
vascular	 necrosis,	 glomerular	 basement	 membrane	 rupture,	 parietal	 epithelial	 cell	
hyperplasia	and	crescent	 formation,	which	occur	 in	 class	 III	 and	 IV	 lupus	nephritis.	 The	
typical	 clinical	 manifestations	 are	 an	 active	 urine	 sediment	 (red	 cells,	 white	 cells,	 and	
cellular	 and	granular	 casts),	 proteinuria,	 and,	 often,	 an	 acute	decline	 in	 renal	 function.	




with	 and	without	 lupus	 nephritis	 and	 found	 the	 following	 gene	 loci	 highly	 enriched	 in	






in	 kidney	 tissue	 from	patients	with	 proliferative	 forms	of	 glomerulonephritis,	 including	
lupus	 nephritis	 (398).	 Furthermore,	 anti-PDGF	 antibodies	 inhibit	 mesangial	 cell	
proliferation	in	animal	models	of	glomerulonephritis	(399).		
The	association	between	ethnicity	and	lupus	nephritis	risk	has	also	been	profusely	
studied.	 One	 example	 is	 the	 identification	 of	 two	APOL1	 gene	 variants	 that	 are	 found	






The	 TLRs	 also	 have	 an	 important	 role	 in	 lupus	 nephritis.	 Tlr4-deficient	 mice	
exposed	 to	 pristane	 produced	 less	 inflammatory	 cytokines,	 had	 lower	 levels	 of	
autoantibodies	 and	 developed	 a	 less	 aggressive	 immune	 complex	 glomerulonephritis	
(401).	 In	 turn,	 exposing	 anti-dsDNA	 antibody	 transgenic	mice	 to	 the	 TLR4	 agonist	 LPS	
worsened	the	kidney	disease	(402).	Furthermore,	TLR4	up-regulation	at	protein	or	gene	
level	 caused	 increased	 production	 of	 anti-dsDNA	 antibodies	 and	 immune	 complex-
mediated	 glomerulonephritis	 (403).	 In	 C57BL/6	 (lpr/lpr)-	 TLR2	 or	 TLR4-deficient	 mice,	
glomerular	IgG	deposits	and	mesangial	cell	proliferation	were	significantly	decreased	and	
antinuclear,	 anti-dsDNA	 and	 anti-cardiolipin	 autoantibody	 titers	 were	 dramatically	
reduced	(404).		
Mesangial	cells	also	have	an	important	role	 in	 lupus	nephritis	pathogenesis.	 In	a	
lupus	mouse	model,	 danger-associated	molecular	 patterns	 can	 activate	mesangial	 cells	
via	the	TLR2/MYD88	pathway,	increasing	the	production	of	IL6	(405).	TLR3	signaling	also	
activates	 human	mesangial	 cells,	 inducing	 the	 expression	 of	 CXCL1,	 a	 chemokine	 that	
attracts	 neutrophils	 (406).	 Intense	 glomerular	 expression	 of	 CXCL1	 was	 observed	 in	
biopsy	 specimens	 from	 patients	 with	 lupus	 nephritis	 (406).	 A	 viral	 infection	 can,	
therefore,	trigger	a	lupus	nephritis	flare,	since	viral	dsRNA	can	activate	TLR3	in	resident	
renal	cells	and	cause	cytokine	release	(407).	 In	addition,	bacterial	LPS	is	also	capable	of	
inducing	 an	 exacerbation	 of	 lupus	 nephritis	 (408).	 TLR4	 activation	 contributes	 to	 this	
effect	 (409),	 since,	 in	 primary	 mesangial	 cells	 from	 NZB/W	 mice,	 TLR4	 activation	
increases	the	secretion	of	osteopontin	and	MCP1	(409).		
Interestingly,	 female	 mesangial	 cells	 express	 more	 TLR3	 and	 respond	 to	 TLR	
ligands	 with	 a	 significantly	 increased	 IL6	 production.	Moreover,	 in	mesangial	 cells	 the	










podocytes	 from	 BXSB-Yaa	 lupus-prone	 mice,	 when	 compared	 to	 control	 mice.	
Furthermore,	 the	 glomerular	 levels	 of	 Tlr8	 mRNA	 negatively	 correlated	 with	 the	
glomerular	 levels	 of	 podocyte	 functional	 markers	 (NPHS1,	 NPHS2	 and	 SYNPO)	 and	
positively	 correlated	 with	 urinary	 albumin	 levels	 (412).	 Podocytes	 and	 glomerular	
endothelial	 cells	 also	 express	 TLR2,	 a	 pathway	 activated	 by	 circulating	 bacterial	 wall	




In	 NZB/W	 mice	 and	 in	 patients	 with	 lupus	 nephritis,	 proximal	 tubular	 cells	
expressed	 TLR9	 and	 its	 levels	 correlated	 with	 tubulointerstitial	 injury	 (415).	 DNA	
containing	 immune	 complexes	 purified	 from	 the	 sera	 of	 SLE	 patients	 induced	 TLR9	 in	
cultured	proximal	tubular	cells	(415).	
In	 conclusion,	 in	 lupus	 nephritis	 renal	 parenchymal	 cells,	 including	 podocytes	
mesangial	cells,	endothelial	and	tubular	cells,	as	well	as	resident	and	infiltrating	immune	





precise	 mechanisms	 remain	 elusive.	 A	 recent	 meta-analysis	 indicated	 that	 genes	
associated	with	the	immune	complex	clearance,	such	as	the	FcγRIIIa,	FcγRIIIb	and	ITGAM,	
are	 associated	 with	 neuropsychiatric	 lupus	 (416).	 Polymorphisms	 in	 the	 TREX1	 gene,	
which	 encodes	 DNase	 III,	 have	 also	 been	 associated	 with	 central	 nervous	 system	
involvement	susceptibility,	particularly	with	seizures	(417).		
A	 central	mechanism	 of	 neuropsychiatric	 lupus	 is	 the	 dysfunction	 of	 the	 blood	
brain	barrier,	such	that	immunoglobulins,	cytokines,	and	immune	cells	can	gain	access	to	
the	brain	tissue.	This	was	demonstrated	by	the	increased	levels	of	immunoglobulins	and	
albumin	 in	 the	 cerebrospinal	 fluid	 of	 MRLlpr/lpr	 mice	 (418,419).	 Moreover,	 these	
markers	 correlate	with	 neurodegeneration	 in	 periventricular	 areas	 and	 disease	 activity	
(418).	Endothelial	cell	activation	and	the	overexpression	of	ICAM1,	VCAM1	and	E-selectin	






integrity	 in	 SLE.	 It	 was	 found	 that	 reactive	 oxygen	 species	 production	 was	 increased	
significantly	 in	 endothelial	 cells	 treated	 with	 lupus	 serum	 from	 MRL/lpr	 mice	 (419).	
Furthermore,	 increased	 permeability	 was	 detected,	 monitored	 by	 changes	 in	
transendothelial	 electrical	 resistance	 and	 cytoskeletal	 remodeling.	 These	 effects	 were	
alleviated	by	pretreating	cells	with	a	C5a	receptor	antagonist	or	a	C5a	antibody	(419).	In	
addition,	 MRL/lpr	 mice	 treated	 with	 C5a	 receptor	 antagonist	 had	 reduced	 neutrophil	
infiltration,	lower	ICAM,	TNF	and	iNOS	mRNA	expression	and	reduced	neuronal	apoptosis	
(419).	 Finally,	 the	 serum	 of	 MRL/lpr	 mice	 caused	 increased	 apoptosis	 in	 neurons,	
whereas	serum	pretreated	with	the	C5a	receptor	antagonist	did	not	(419).	
Auto-antibodies,	 including	antiphospholipid	antibodies	(421)	and	those	targeting	
ribosomal	 P	peptides	 (421),	 the	NMDA	 receptor	 (422),	 and	matrix	metalloproteinase	9	
(MMP9)	 (423)	 have	 been	 suggested	 to	 participate	 in	 neuropsychiatric	 lupus	
pathogenesis.	 The	 levels	 of	 autoantibodies	 in	 the	 cerebrospinal	 fluid	 correlate	 more	
closely	 with	 the	manifestation	 of	 neuropsychiatric	 lupus	 than	 the	 serum	 levels	 of	 the	
same	 antibodies	 (424).	 In	 MRL	 lpr/lpr	 mice	 levels	 of	 brain-reactive	 antibodies	 in	 the	
cerebrospinal	 fluid	 correlated	 with	 immobility	 in	 the	 forced	 swim	 test	 (425).	
Furthermore,	 these	 antibodies	 bounded	 directly	 to	 brain	 regions	 related	 to	 memory	
formation	and	emotional	reactivity	(425).	
Cytokines	modify	the	homeostatic	regulatory	mechanisms	and	participate	 in	SLE	
pathogenesis.	 TWEAK,	 for	 instance,	 has	 been	 associated	 with	 neuropsychiatric	 lupus	
(426).	 Through	 activation	 of	 its	 cognate	 receptor	 Fn14,	 TWEAK	 activates	 cellular	
proliferation,	 angiogenesis,	 inflammation	 and	 apoptosis	 (427).	 MRLlpr/lpr	 mice	 had	
depression-like	behavior,	impaired	cognitive	function	and	anhedonia,	manifestations	that	
improved	 in	 Fn14-deficient	mice	 (426).	 These	mice	 had	 significantly	 decreased	 cellular	
infiltrates	 in	 the	 choroid	 plexus	 and	 preserved	 blood-brain	 barrier	 permeability,	
attributable	to	lower	brain	levels	of	VCAM1/ICAM1	and	iNOS.	Moreover,	these	mice	had	
reduced	 IgG	 and	 complement	 deposition	 in	 the	 brain	 and	 neuron	 degeneration	 and	
hippocampal	gliosis	was	significantly	decreased	(426).	
In	 conclusion,	 in	 SLE	 there	 is	 a	profound	 immune	dysregulation	associated	with	










Imperfect	 disease	 concordance	 between	 monozygotic	 twins	 suggests	 that	
environmental	factors	have	a	role	in	SLE	(428).			





prolactin,	 its	 levels	 are	 increased	 in	 15%	 to	 33%	 of	 SLE	 patients.	 Disease	 activity	
correlates	 with	 prolactin	 levels	 and	 bromocriptine,	 a	 dopamine	 agonist	 that	 inhibits	
prolactin	secretion,	has	proven	therapeutic	effect.	These	findings	corroborate	the	role	of	
hormones	in	SLE.	
	 Ultraviolet	 light	 (UV)	 is	 thought	 to	 drive	 apoptosis,	 providing	 an	 immunologic	
stimulus	 for	 an	 increase	 in	 the	 production	 of	 autoantibodies.	 The	 subsequent	 antigen-
antibody	reaction	causes	a	 local	 inflammatory	reaction.	Furthermore,	after	exposure	to	
UVB	 irradiation	 there	 is	an	 increase	 in	 the	production	and	 release	of	pro-inflammatory	
cytokines,	 including	 IFNα	 (431),	 and	 reactive	 oxygen	 species	 (432).	 There	 is	 also	 a	
possible	 connection	 between	 sunlight	 and	 lupus-inducing	 drugs.	 For	 instance,	 UV	 light	
converts	propranolol	 into	a	proinflammatory	aryl	hydrocarbon	receptor	 ligand,	possibly	
explaining	its	association	with	SLE	(433).	
Infections	 have	 an	 undoubted	 impact	 on	 SLE.	 Epstein-Barr	 virus	 and	
cytomegalovirus	 are	 considered	 SLE	 triggers	 (434),	 while	 Helicobacter	 pylori	 (435),	
Hepatitis	B	virus	(436)	and	parasite	infections	are	thought	to	be	protective	(437).			
Other	 data	 support	 a	 role	 for	microbes	more	 generally.	 LPS	 is	 a	Gram-negative	











The	 importance	of	the	microbiome	to	health	 in	general,	and	SLE	 in	particular,	 is	
gaining	 interest	 as	 a	 critical	 facet	 of	 the	 disease	 process.	 There	 is	 a	 growing	 body	 of	
evidence	 indicating	 a	 role	 for	 the	 microbiota	 in	 the	 pathogenesis	 of	 autoimmune	
diseases,	 including	 inflammatory	 bowel	 disease	 (439),	 type	 1	 diabetes	 mellitus	 (440),	
multiple	 sclerosis	 (441)	 and	 rheumatoid	 arthritis	 (442).	 Data	 regarding	 the	 connection	
between	the	microbiota	and	SLE	are	still	scarce.	Recently,	the	dynamics	of	gut	microbiota	
in	the	SLE	mouse	model	MRL/Mp-Faslpr	were	studied	(443).	 In	female	 lupus	mice	 it	was	
found	a	marked	depletion	of	Lactobacilli	and	increase	of	Clostridial	species	compared	to	
age-matched	healthy	controls	 (443).	Moreover,	dietary	 strategies	 that	 restored	 the	gut	
colonization	improved	SLE	symptoms	(443).	A	higher	level	of	Bacteroidetes	was	found	in	
lupus-prone	 SNF1	 mice	 (444).	 In	 humans,	 it	 was	 shown	 that	 intestinal	 dysbiosis,	
characterized	by	a	 lower	Firmicutes	 to	Bacteroidetes	 ratio,	was	present	 in	women	with	
SLE	 (445).	The	mechanism	of	 the	effect	 is	not	 fully	understood	but	certain	gut	bacteria	
foster	 the	development	of	 regulatory	T	cells	 (446,447).	While	 therapeutic	 treatment	of	
the	 microbiome	 in	 humans	 has	 been	 limited	 to	 infections	 and	 inflammatory	 bowel	
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are	 thought	 to	comprise	only	about	1%	of	most	adult	 SLE	cohorts.	The	majority	of	 the	
identified	 genetic	 SLE	 risk	 factors	 are,	 therefore,	 common	 variants,	 with	 a	 modest	
magnitude	 of	 risk,	 which	 suggests	 that	 different	 mechanisms	 contribute	 to	 the	
pathogenesis	 of	 this	 disease,	 including	epigenetic	 factors,	which	 are	 just	 starting	 to	be	
identified.		
The	proteins	encoded	by	the	SLE-associated	genes	participate	in	a	multiplicity	of	
mechanisms	 that	 were	 described	 in	 the	 previous	 chapter.	 Some	 SLE	 susceptibility	
variants	are	also	associated	with	other	autoimmune	diseases,	which	may	reflect	common	
molecular	pathways.		
The	HLA	 region	 is	 the	most	gene-dense	 region	 in	 the	human	genome,	 including	
120	 functional	 genes,	 many	 of	 those	 with	 a	 role	 in	 immunity	 (449).	 This	 region	 was	
identified	 as	 the	 strongest	 determinant	 of	 SLE	 predisposition	 in	 all	 the	 genome-wide	




Factors	 related	 to	 the	 X	 chromosome	 may	 help	 to	 explain	 the	 differences	
between	 the	 genders.	 Three	 predisposing	 gene	 variants	 on	 X	 chromosome	 (IRAK1,	
MECP2,	 TLR7)	 were	 identified.	 Moreover,	 there	 is	 a	 gene	 dose	 effect,	 since	 the	
prevalence	 of	 XXY	 (Klinefelter's	 syndrome)	 is	 increased	 14-fold	 in	men	with	 SLE	when	
compared	 with	 the	 general	 population	 of	 men,	 whereas	 XO	 (Turner	 syndrome)	 is	
underrepresented	in	women	with	SLE	(455).		
In	 this	 chapter,	we	will	 focus	 on	 non-HLA	 genetic	 risk	 factors	 for	 lupus.	 Single-







Single	 gene	 defects	 have	 been	 recognized	 as	 causing	 lupus	 since	 the	 1970s.		
Specifically,	 complete	 deficiencies	 of	 C1q,	 C1r,	 C1s,	 C2,	 and	 C4	 are	 strongly	 associated	










The	 apoptotic	 pathway	 is	 also	 affected	 in	 autoimmune	 lymphoproliferative	
syndrome	(ALPS).	FAS	and	FASL	are	the	genes	related	to	classic	ALPS,	which	have	been	




(468).	 Cutaneous	 manifestations	 are	 common,	 but	 nearly	 all	 of	 the	 lupus	 end-organ	






	 In	this	section	and	 in	Table	3.1	SLE	associated	variants	are	 listed,	divided	by	










B-cells	 AFF1,	 BANK1,	 BLK,	 ETS1,	 FCGR2B,	 HLA-DR2,	 HLA-
DR3,	 IKZF1,	 IL10,	 IL21,	 IRF8,	 LYN,	 MSH5,	 NCF2,	
PRDM1,	PRKCB,	RASGRP3.		
T-cells	 AFF1,	 CD44,	 CD247,	 ETS1,	 FYB,	 HLA-DR2,	 HLA-DR3,	
IKZF1,	 IL10,	 IL21,	 PRDM1,	 PTPN22,	 STAT4,	 TNFSF4,	
TYK2,	UBASH3A.	
Signaling	
















In	 SLE	 there	 is	 an	 imbalance	 of	 apoptosis	 and	 the	 clearance	 of	 nuclear	 debris,	
which	 increases	 the	 availability	 of	 autoantigens,	 contributing	 to	 autoimmunity.	
Accordingly,	several	genes	related	to	these	mechanisms	have	been	associated	with	SLE.	
One	 example	 is	ATG5.	 Several	 variants	 of	 this	 gene,	which	 encodes	 for	 a	 protein	 that	
participates	 in	 caspase-dependent	 apoptosis	 and	 autophagy,	 have	 been	 described	 in	
European	SLE	patients	(452).		
Another	 example	 is	 TREX1,	 which	 was	 also	 mentioned	 in	 Chapter	 2.	 TREX1	
participates	 in	 DNA	 degradation,	 granzyme	 A	 activated	 apoptosis	 and	 oxidative	 stress	
response.	 TREX1	 null	 mutations	 are	 associated	 with	 familial	 chilblain	 lupus	 and	 the	
Aicardi-Goutieres	 syndrome,	 a	 rare	 pediatric	 neurologic	 condition	 featuring	 an	
inflammatory	encephalopathy,	with	intracranial	calcifications,	lymphocyte	infiltrates	and	
elevated	 type	 I	 IFN	 levels	 in	 cerebrospinal	 fluid	 (276,469).	Trex-1-deficient	mice	have	a	





case-control	 study,	 a	 TREX1	 haplotype	 was	 found	 to	 be	 associated	 with	 the	 risk	 of	
neurological	 manifestations	 in	 European	 SLE	 patients	 (472).	 Since	 TREX1	 metabolizes	
reverse-transcribed	 DNA	 of	 endogenous	 retroelements,	 TREX1	 deficiency	 may	 trigger	
autoimmunity	through	the	accumulation	of	nuclear	acids	(473).	
In	 addition,	 mutations	 in	 ACP5,	 which	 encodes	 a	 protein	 that	 participates	 in	
lysosomal	digestion,	were	shown	to	cause	bone	dysplasia,	as	well	as	an	IFNα	increase	and	
multiple	 autoimmune	 diseases,	 including	 SLE	 (474).	 Although	 polymorphisms	 in	 ACP5	
have	not	been	 identified	 in	GWAS,	 its	major	substrate,	osteopontin,	has	been	 found	 in	
several	 studies	 as	 disease	 associated	 (475).	 Finally,	 in	 a	 recent	 study	 of	 patients	 with	
African	 ancestry,	 several	 novel	 associations	 were	 found	 between	 variants	 of	 genes	
associated	 with	 the	 production	 of	 reactive	 oxygen	 species	 and	 SLE	 (476).	 Collectively,	




Genome-wide	 analysis	 and	 candidate	 gene	 association	 studies	 of	 murine	 lupus	
models	 and	 diverse	 human	 populations	 showed	 a	 consistent	 linkage	 to	 1q21.1-24,	 a	
region	 that	 includes	 the	 receptors	 that	 recognize	 the	 constant	 (Fc)	 portion	 of	
immunoglobulin	isotypes	(FcγRs).	
	 FcγRs	 can	 activate	 (FcγRI,	 FcγRIIA/C,	 FcγRIII)	 or	 inhibit	 (FcγRIIB)	 cellular	
functions,	such	as	phagocytosis,	antibody-dependent	cellular	cytotoxicity,	degranulation,	
antigen	 presentation,	 B-cell	 activation,	 cytokine	 production	 and	 immune	 complex	
clearance.	Numerous	single	nucleotide	polymorphisms	(SNP)	and	copy	number	variants	
have	 been	 characterized	 in	 the	 FcγR	 genes.	 Several	 of	 those	 variants	 have	 been	
associated	with	an	 increased	 risk	 for	SLE.	For	 instance,	H131R	of	FCGR2A	 is	a	 common	
variant	(477)	that	was	shown	to	have	lower	affinity	for	the	ligand,	leading	to	a	profound	
decrease	 on	 the	 phagocytosis	 of	 IgG2	 opsonized	 particles.	 The	 also	 lower	 IgG	 binding	
FCGR2A	allele	158F	was	associated	with	an	increase	risk	for	SLE	in	Caucasians	(478),	but	
not	 in	an	African-American	population	 (479).	Another	example	 is	 the	single	amino	acid	
substitution	that	occurs	on	the	I232T	variant	of	FCGR2B,	which	was	also	associated	with	
SLE	in	Asian	populations	(480,481),	but	not	in	Caucasians	(482).	Defective	signaling	by	the	




complexes,	 reduces	 the	 threshold	 for	 antigen	 presentation	 by	 dendritic	 cells	 and	
facilitates	autoreactive	B-cell	activation	(483),	thus	contributing	for	autoimmunity.		
FCGR	 variants	are	 not	 only	 associated	with	 disease	 susceptibility,	 but	 also	with	
disease	 progression	 and	 phenotypic	 features.	 Variants	 of	 FCGR3A,	 for	 example,	 were	
associated	with	end-stage	renal	disease	in	patients	with	lupus	nephritis	(484,485).		
	 Finally,	 copy	 number	 variation	 is	 common	 in	 regions	 of	 the	 genome	 coding	 for	




complement	 activation	 contributes	 to	 the	 pathogenesis	 of	 the	 glomerular	 injury	 that	
occurs	in	lupus	nephritis.	On	the	other	hand,	complement	participates	in	the	clearance	of	
immune	complexes	and	apoptotic	bodies.	As	previously	discussed,	complete	deficiencies	






Type	 I	 IFNs	 (α	 and	 β	 IFN)	 participate	 in	 anti-viral	 immune	 responses	 as	 key	
regulators	of	the	proliferation,	differentiation,	survival	and	activity	of	the	majority	of	the	
immune	 cells	 (488).	 Increased	 expression	 of	 IFNα	 and	 its	 regulated	 genes	 has	 been	
described	 in	 SLE	 (489–493)	 and	 propelled	 the	 development	 of	 IFNα	 inhibitors	 for	 the	
control	of	this	disease,	as	previously	mentioned	in	Chapter	2.	A	number	of	variants	in	the	






association	between	a	 functional	variant	of	TLR7	 and	SLE	 in	an	Asian	population	 (494).	






IRF5	 is	 a	 transcription	 factor	 that	 induces	 the	 expression	 of	 multiple	 pro-
inflammatory	 cytokines,	 including	 IFNα,	 TNF,	 IL6,	 IL17,	 IL23,	MCP1,	 and	 RANTES	 (496).	
IRF5	is	associated	with	SLE,	as	well	as	other	autoimmune	diseases,	including	rheumatoid	
arthritis,	Sjögren	syndrome,	systemic	sclerosis,	inflammatory	bowel	disease	and	multiple	
sclerosis	 (497).	 The	 IRF5	 locus	 was	 implicated	 in	 SLE	 through	 candidate	 gene	 analysis	
(498)	and	 later	confirmed	by	multiple	 independent	case-control	 cohorts	 (499–502)	and	
GWAS	 (451–454).	 Several	 IRF5	 insertion	 and	 deletion	 polymorphisms	 and	 SNPs	 have	
been	 described	 in	 association	 with	 increased	 or	 decreased	 levels	 of	 IRF5,	 IFNα	 and,	
consequently,	 SLE	 susceptibility	 (503,504).	 Interestingly,	 IRF5	 is	 necessary	 for	 the	
development	of	 lupus-like	disease	 in	mice,	which	demonstrates	 the	 importance	of	 this	
transcription	factor	in	SLE	pathogenesis	(505).			
IRF7	 variants	 also	 contribute	 for	 SLE	 predisposition.	 An	 IRF7	 SNP	 (Q412R)	 is	
associated	with	 an	 increase	 in	 IRF7	 levels	 and	 SLE	 risk	 in	 several	 ancestral	 populations	





ETS1	 is	 a	 transcription	 factor	 that	 binds	 the	 IFN-stimulated	 response	 elements,	
controlling	type	I	 IFN-induced	transcription.	 It	also	participates	in	the	inhibition	of	Th17	
and	B-cell	 differentiation.	 Evidence	of	 animal	models	 supports	 the	 role	 of	 ETS1	 in	 SLE,	
since	 Ets1-deficient	 mice	 develop	 a	 lupus-like	 phenotype,	 characterized	 by	 the	
production	 of	 autoantibodies,	 glomerulonephritis	 and	 local	 activation	 of	 complement	
(511).	 In	 humans,	 ETS1	 was	 identified	 as	 one	 of	 the	 loci	 associated	 with	 SLE	
predisposition	(453,512,513).		








Several	 genes	 that	 participate	 in	NFkB	 signaling	were	 associated	with	 SLE	 risk,	 namely	
IRAK1	 (515,516),	 TNFAIP3	 (450,453,517),	 TNIP1	 (453,509),	 SLC15A4	 (453)	 and	 PRKCB	
(518).	
IRAK1	 is	 involved	 in	 IFNα	and	 IFNγ	 induction	and	 is	 a	 central	 regulator	of	NFkB	
pathway.	Five	SNPs	spanning	 IRAK1,	an	X	chromosome-encoded	gene,	were	associated	
with	both	adult-	and	childhood-onset	SLE,	in	four	different	ethnic	groups	(515).	
TNFAIP3	 encodes	 A20,	 an	 ubiquitin-editing	 enzyme,	 which	 participates	 in	 the	
termination	 of	 NFkB	 signaling.	 TNFAIP3	 is	 an	 established	 susceptibility	 locus	 for	 SLE	
(519,520).	Recently,	a	novel	TT>A	polymorphic	dinucleotide	was	found	to	be	associated	
with	SLE	 in	subjects	of	European	and	Korean	ancestry	 (517).	This	haplotype	resulted	 in	
reduced	TNFAIP3	mRNA	and	A20	protein	 expression,	 and	 the	 enzyme	 variant	 bound	 a	
nuclear	protein	complex,	which	included	NFkB	subunits,	with	reduced	avidity	(517).		This	
haplotype	 is,	 thus,	 associated	 with	 a	 decreased	 inhibitory	 activity	 of	 A20,	 which	
consequently	causes	an	activation	of	the	NFkB	pathway.	Furthermore,	the	role	of	A20	in	







play	 essential	 roles	 in	 SLE	 pathogenesis,	 since	 they	 participate	 in	 lupus	 nephritis	 and	
atherosclerosis,	processes	responsible	for	considerable	morbidity	and	mortality	in	SLE,	as	
described	 in	 Chapter	 1.	 Increased	 interest	 in	 neutrophils	 arose	with	 the	 description	 of	
NETosis.	These	NETs	trap	microorganisms,	decreasing	their	ability	to	spread,	facilitate	the	
interaction	 with	 neutrophil-derived	 effector	 molecules	 and	 induce	 the	 production	 of	
cytokines,	 such	 as	 IFNα.	 A	 positive	 feedback	 loop	 occurs,	 since	 this	 cytokine	 increases	
NETosis.	 In	 SLE,	 circulating	 immune	 complexes	 activate	 neutrophils	 and	 lead	 to	 an	
increase	 in	 the	 production	 of	 NETs.	 The	 DNA	 present	 in	 the	 NETs	 is	 protected	 from	






and	 neutrophils	 have	 been	 associated	 with	 SLE.	 ITGAM	 (CD11b),	 a	 protein	 mainly	
expressed	 by	 macrophages,	 monocytes	 and	 neutrophils,	 encodes	 a	 leucocyte-specific	
integrin,	 important	 in	 the	 adherence	 of	 neutrophils	 and	 monocytes	 to	 stimulated	
endothelium.	This	receptor	also	participates	 in	the	phagocytosis	of	complement	coated	
particles	and	immune	complexes,	since	it	is	a	receptor	for	iC3b.	An	association	between	






players	 in	 the	 pathogenesis	 of	 this	 disease	 and	 the	 existence	 of	 effective	 drugs	 that	
target	 their	 function,	 as	 belimumab	 and	 rituximab,	 further	 supports	 their	 role	 in	 SLE.	
Numerous	 genes	 associated	 with	 B	 cell	 function	 and	 signaling	 have	 been	 found	 to	
predispose	to	SLE	(525),	including	BLK	(451–453),	BANK1	(454,526)	and	LYN	(452,527).		
The	SLE-risk	 variants	 found	 for	BANK1	 affect	 the	 regulatory	 sites	and	 functional	
domains	of	the	protein	and	contribute	to	sustained	B	cell	activation	through	a	change	in	
the	 intracellular	 calcium	 levels	 (526).	 LYN,	a	 src-tyrosine	kinase,	 is	 a	binding	partner	of	
BANK1,	whose	 variants	were	 also	 associated	with	 SLE	 in	 European-derived	 individuals,	
with	rs6983130	described	as	an	SLE	protective	factor	(527).	The	complement	receptor	2	
(CR2/CD21)	 is	 a	 membrane	 glycoprotein,	 mainly	 expressed	 on	 B	 cells	 and	 follicular	
dendritic	 cells,	 that	 has	 also	 been	 implicated	 in	 the	 tolerance	 to	 nuclear	 self-antigens	
such	 as	 single	 and	 dsDNA,	 chromatin	 and	 histones	 (528).	 Reduced	 levels	 of	 CR2	 have	
been	described	in	SLE	and	family-based	analysis	provided	evidence	for	an	association	of	




IKZF1	 is	 a	 transcription	 factor	 involved	 in	 the	 regulation	 of	 lymphocyte	
differentiation	and	proliferation,	and	B	cell	receptor	signaling.	 It	also	participates	 in	the	






IL10	 is	 a	 pivotal	 cytokine,	 responsible	 for	 globally	 down-regulating	 the	 immune	
response.	 Interestingly,	 IL10	 production	 by	monocytes	 and	 B	 cells	 has	 been	 shown	 to	




The	 role	 of	 T	 cells	 in	 the	 orchestration	 of	 the	 immune	 response	 cannot	 be	
overstated,	 so,	 as	 expected,	 several	 genes	 implicated	 in	 T	 cell	 function	have	also	been	
associated	with	SLE,	including	PTPN22,	TNFSF4,	STAT4	and	CD247.	
Polymorphisms	 in	 PTPN22,	 which	 encodes	 LYP,	 a	 phosphatase	 that	 negatively	
regulates	B	and	T	 cell	 receptor	 signaling,	have	been	variably	 reported	 to	affect	 risk	 for	
SLE.	 A	 PTPN22	 SNP	 (rs2476601)	 was	 associated	 with	 multiple	 autoimmune	 diseases,	







with	 the	exception	of	 regulatory	T	 cells,	whose	generation	and	 function	 is	 inhibited	by	
this	signal.	Protective	and	risk	haplotypes	of	TNFSF4	have	been	reported	for	SLE	(535).		
STAT4	is	a	key	regulator	of	IL3,	IL12,	IL17	and	IFNα	signaling,	having,	therefore,	a	
critical	 role	 in	 the	development	of	Th1	and	Th17	 immune	 responses.	Associations	with	













since	 variants	 of	 this	 gene	 have	 been	 associated	 with	 juvenile	 idiopathic	 arthritis,	
rheumatoid	 arthritis,	 systemic	 sclerosis,	 generalized	 vitiligo,	 alopecia	 areata,	 type	 1	
diabetes	mellitus,	Grave	disease,	Hashimoto	 thyroiditis,	myasthenia	gravis	and	Addison	
disease	(449).	Ramos	and	collaborators,	however,	showed	that	only	a	partial	pleiotropy	
exists	 among	 autoimmune	diseases	 (539).	 For	 instance,	 genes	 like	 ITGAM	 and	TNFSF4,	
which	have	been	clearly	associated	with	SLE,	were	not	found	to	be	associated	with	other	






The	 phenotype	 of	 a	 cell	 is	 broadly	 determined	 by	 the	 epigenomic	 landscape,	
which	modulates	gene	expression	and	may	serve	to	perpetuate	pathologic	mechanisms.	
The	term	epigenetic	typically	refers	to	the	study	of	durable	changes	 in	gene	expression	
that	 are	 not	 accompanied	 by	 alterations	 to	 the	 nucleotide	 sequence.	 Operationally,	
epigenetics	 is	 a	 term	 that	 refers	 to	 DNA	 methylation,	 histone	 modifications,	 and	
regulatory	 RNAs.	 Epigenetic	 mechanisms	 are	 particularly	 important	 for	 autoimmunity,	
since	the	expression	of	pro-inflammatory	genes,	like	TNF,	is	regulated	at	chromatin	level	
(540).	
DNA	methylation	 and	 histone	modifications	 change	 the	 chromatin	 structure	 to	
allow	 or	 prevent	 the	 access	 of	 the	 transcription	machinery	 to	 DNA.	 DNA	methylation	
refers	 to	 the	 addition	 of	 a	 methyl	 group	 to	 a	 cytosine	 at	 the	 5’	 position	 of	 the	 CpG	
dinucleotide,	converting	the	cytosine	to	methylcytosine.	CpG	dinucleotides	cluster	in	CpG	
islands,	 regions	 of	 more	 than	 200	 bases	 with	 a	 GC	 content	 of	 at	 least	 50%,	 where	





The	 process	 of	 DNA	 methylation	 is	 mediated	 by	 methyltransferaces.	 DNMT1	
maintains	 the	 methylation	 status	 during	 cell	 replication,	 while	 DNMT3A/B	 induces	 de	
novo	methylation.	DNA	demethylation	is	regulated	by	the	TET	family	of	demethylases.		
A	very	well	characterized	phenomenon	seen	in	SLE	is	the	hypomethylation	of	DNA	
in	 T	 cells,	 causing	 a	 state	 of	 euchromatin	 and,	 consequently,	 a	 global	 activation	 of	
transcription,	which	correlates	with	disease	activity	(541).	Notably,	CD4+	T	cells	from	SLE	
patients	 with	 active	 disease	 have	 more	 extensive	 demethylation,	 but	 the	 effect	 seen	
during	a	flare	was	also	seen	in	quiescent	disease,	supporting	its	durability,	which	can	set	




patients	 and	 controls	 found	 significant	 hypomethylation	 in	 IFN-regulated	 genes	 (542).	
Hypomethylation	 is,	 therefore,	 another	 mechanism	 responsible	 for	 the	 characteristic	
type	I	IFN	hyper-responsiveness	seen	in	lupus	T	cells.		





DNA	 methylation	 and	 this	 may	 be	 one	 mechanism	 by	 which	 diet	 contributes	 to	 SLE	
susceptibility	(544).		
Regarding	 histone	 modifications,	 there	 are	 several	 types	 of	 post-translational	
modifications	and	multiple	amino	acid	targets.	Acetylation	and	methylation	are	the	best	
characterized,	 but	 phosphorylation,	 ubiquitination,	 SUMOylation,	 ribosylation,	
deimination,	 and	 proline	 isomerization	 also	 occur.	 Each	modification	 is	 regulated	 by	 a	
“writer”	and	“eraser”	enzyme.	There	are,	 therefore,	histone	acetyltransferases,	histone	
methyltransferases,	and	corresponding	eraser	enzymes	such	as	histone	deacetylases	and	









to	 define	 the	 genome	 wide	 changes	 in	 histone	 modifications.	 ChIP-seq	 (chromatin	
immunoprecipitation	 sequencing)	 and	 ATAC-seq	 (assay	 for	 transposase-accessible	
chromatin	sequencing)	are	the	methods	used.	The	former	measures	the	enrichment	of	a	
specific	histone	modification,	while	the	latter	measures	chromatin	accessibility.		
Histone	 modifications	 were	 initially	 analyzed	 in	 murine	 lupus	 models	 where	
histone	 deacetylase	 (HDAC)	 inhibitors	 were	 found	 to	 improve	 disease	 features	 (545).	
Furthermore,	 HDAC6	 was	 found	 to	 be	 overexpressed	 in	 MRL/lpr	 mice	 and	 treatment	
directed	 at	 normalizing	 HDAC6	 improved	 disease	 features	 (546).	 The	 mechanisms	 by	
which	 these	 agents	 worked	 are	 controversial	 because	 they	 appear	 to	 be	 highly	
immunosuppressive.		
In	 humans	 global	 histone	modifications	 were	measured	 and	 were	 found	 to	 be	
aberrant	in	the	T	cells	from	SLE	patients	and	corrected	by	treatment	with	mycophenylate	
mofetil	(547).		
H4	 acetylation	 is	 a	 histone	 modification	 associated	 with	 activation	 of	
transcription.	 This	 epigenomic	 mechanism	 was	 found	 to	 be	 overall	 increased	 in	
monocytes	from	SLE	patients	(548).	This	is	concordant	with	the	DNA	methylation	studies.	
Both	would	be	predicted	 to	drive	over-expression	of	 target	genes.	Notably,	63%	of	 the	
genes	with	a	higher	H4	acetylation	had	the	potential	of	IRF1	regulation	(548).	IRF1	is	an	
IFN-induced	 weak	 transcription	 factor,	 which	 regulates	 the	 transcription	 of	 genes	
involved	 in	 immune	modulation.	 Interestingly,	 IRF1	can	 interact	with	p300	 to	acetylate	
histones,	which	could	explain	 the	globally	 increased	H4	acetylation	pattern	seen	 in	SLE	
(549).	This	finding	ties,	once	again,	the	altered	epigenome	to	the	known	influence	of	type	
I	IFNs.			
Some	 histone	 modifications	 persist	 after	 stimulation,	 “bookmarking”	 genes	 for	
facilitated	 re-expression.	 This	 feature	 may	 also	 contribute	 to	 disease	 chronicity	
(550,551).			
Regarding	 enhancers,	 these	 were	 globally	 altered	 in	 SLE	 monocytes,	 certainly	






model,	 again	 demonstrating	 the	 power	 of	 genome-wide	 approaches	 to	 identify	 novel	
therapeutic	targets	(553).	
MiRNAs	are	non-coding	RNAs	responsible	for	post-transcriptional	gene	silencing,	
by	blocking	 translation	or	causing	mRNA	degradation.	MiRNAs	can,	 therefore,	 tune	 the	
abundance	of	multiple	mRNAs.	These	regulatory	molecules	are	involved	in	essential	cell	
mechanisms,	 including	 proliferation,	 differentiation	 and	 apoptosis.	 MiRNAs	also	 exert	
control	 on	 the	 immune	 system,	 particularly	 on	 the	maintenance	 of	 immunological	
tolerance,	participating	in	the	regulation	of	T	cell	selection	in	the	thymus,	B	cell	selection	
in	germinal	centers,	and	development	of	regulatory	T	cells.	
Changes	 in	miRNAs	 have	 been	 identified	 in	 peripheral	 blood	mononuclear	 cells	
and	 renal	 tissue	 from	patients	with	 SLE.	 Several	 of	 the	miRNAs	 appear	 to	have	effects	
that	are	central	to	the	lupus	process	and	impact	TLR	signaling	and	IFN	susceptible	genes.			
miR-146a,	which	inhibits	type	I	IFN	expression	by	targeting	IRF5	and	STAT1	(554),	
was	 found	 to	 be	 decreased	 in	 SLE	 (554),	 contributing,	 therefore,	 for	 the	 high	 levels	 of	
type	I	IFN	characteristic	of	this	disease.	Another	example	is	miR-3148,	which	was	found	
to	modulate	 the	 allelic	 expression	 of	 a	TLR7	 variant	 associated	with	 SLE	 (555).	 Finally,	
miR-148a	 is	 frequently	 increased	 in	 SLE	 patients	 and	 lupus-prone	mice	 (556).	 Elevated	
miR-148a	levels	promoted	the	survival	of	immature	B	cells	by	inhibiting	the	expression	of	
the	 autoimmune	 suppressor	 GADD45α,	 the	 tumor	 suppressor	 PTEN	 and	 the	 pro-
apoptotic	protein	BIM	(556).	The	overall	effect	of	an	increased	miR-148a	expression	was	




nomenclature,	 categorization	 and	 functional	 study	 is	 in	 its	 infancy.	 lncRNAs	 were	
originally	 analyzed	 in	 the	 context	 of	 malignancy,	 but	 increasing	 evidence	 has	
demonstrated	 that	 they	 are	 involved	 in	 diverse	 biological	 processes.	 New	 studies	 will	
certainly	 focus	 on	 this	 class	 of	 RNAs	 and,	 hopefully,	 we	 will	 better	 understand	 SLE	
pathogenesis	when	their	function	is	unveiled.	
Finally,	 it	 is	 also	 interesting	 to	 study	 transcripts	 related	 to	 retroviruses,	 which	






become	 activated	 in	 mammalians.	 L1	 expression	 is	 highly	 regulated	 and	 the	 DNA	 is	
usually	fully	methylated	to	prevent	expression.	Recently,	L1	levels	were	demonstrated	to	




Histone	modifications	 and	 DNA	methylation	 can	 regulate	 the	 expression	 of	miRNAs	 in	
SLE,	 as	 is	 the	 case	 of	 miR-142	 expression	 on	 T	 cells	 from	 lupus	 patients	 (557),	 while	
miRNAs,	 like	 miR-21	 and	 miR-148,	 which	 are	 increased	 in	 T	 cells	 from	 SLE	 patients,	
decrease	the	expression	of	the	methyltransferase	DNMT1	(558).	These	findings	suggest	
that	the	epigenome	is	globally	affected	in	SLE	and	that	the	persistence	of	the	epigenomic	






The	 heritability	 of	 SLE	 has	 been	 long	 recognized.	 The	 higher	 concordance	 rate	
between	monozygotic	twins	compared	to	dizygotic	twins	and	the	high	sibling	recurrence	
risk	 ratio	 all	 support	 a	 strong	heritability.	 The	 first	 risk	 locus	 identified	was	 that	of	 the	
MHC	and	still	today,	alleles	within	the	MHC	constitute	the	strongest	genetic	susceptibility	
for	 SLE	 in	 the	 general	 population.	 This	 seminal	 finding	 supports	 a	 disease	 process	 in	
which	T	cells	play	a	central	role	since	their	activation	is	dependent	on	MHC.			
In	 the	 last	 decade,	 numerous	 GWAS	 have	 been	 performed.	 These	 use	 a	 high	
throughput	 technology	 to	 analyze	 hundreds	 of	 SNPs	 and	 capture	 genome	 common	
variants.	 Through	 this	 approach,	 the	 joint	 effect	 of	many	weakly	 contributing	 variants	
across	different	loci	can	be	studied	and	gene	variants	associated	with	different	complex	
diseases	can	be	identified.	Interestingly,	variants	rarely	impact	the	coding	exons	and	are	





GWAS	 are	 particularly	 tailored	 for	 complex	 polygenic	 associations,	 being	
drastically	 more	 sensitive	 than	 family	 studies.	 In	 comparison	 to	 linkage	 analysis	 and	
sequencing,	however,	GWAS	have	less	power	in	cases	of	allelic	heterogeneity	and	may	be	
affected	by	the	occurrence	of	epistasis.		
The	 majority	 of	 the	 variants	 associated	 with	 SLE	 susceptibility	 only	 cause	 a	




An	 additional	 source	 of	 information	 has	 come	 from	 gene	 expression	 studies.	
These	 early	 studies	 were	 performed	 on	 peripheral	 blood	 mononuclear	 cells	 or	 whole	










Even	though	the	genetics	of	SLE	has	ben	unveiled	 in	 the	past	decade,	 there	are	
still	 innumerous	 challenges.	 Predictive	 mathematical	 models	 integrating	 the	 weakly	
contributing	loci	will	be	certainly	helpful.	 In	addition,	 it	 is	necessary	to	understand	how	
specific	 genetic	 variants	 are	 responsible	 for	 the	 association	 and	 the	 biological	 effect.	
Finally,	fine	mapping	and	resequencing	studies	are	necessary,	as	well	as	new	tools	for	the	




Further	 studies	 are	 necessary	 to	 understand	 how	 the	 identified	 susceptibility	 variants	




SLE	 genetics	 were	 performed	 in	 European	 and	 Asian	 populations.	 Since	 SLE	 is	 more	
frequent	and	more	severe	in	other	groups,	namely	Hispanic	and	African-American,	new	
studies	focusing	on	these	populations	are	essential.	The	trajectory	of	our	understanding	
of	 the	 disease	 pathogenesis	 has	 been	 extraordinarily	 rapid	 since	 the	 introduction	 of	



































This	 project	 clearly	 defined	 the	 need	 for	 new	 biomarkers	 and	 new	 treatment	
strategies	 with	 fewer	 side	 effects.	 These	 conclusions	 propelled	 all	 the	 subsequent	
translational	 studies,	which	used	 the	modern	 tools	 of	molecular	 biology	 to	 unveil	 new	
clinically	relevant	pathways.		
	




- To	perform	a	high	 throughput	 analysis	of	 the	 kidney	miRNA	 signature	of	 lupus	
nephritis;	
- To	 identify	 differently	 expressed	miRNAs	 in	 lupus	 nephritis	when	 compared	 to	
healthy	controls	and	explore	their	biological	functions	in	vitro;	
- To	 study	 the	 role	 of	 urinary	miRNAs	 as	 potentially	 useful	 biomarkers	 in	 lupus	
nephritis.	
	
Concerning	 the	 macrophage	 activation	 syndrome	 project,	 the	 main	 objectives	
were:	














using	 different	methodologies,	with	 the	 fundamental	 goal	 of	 better	 understanding	 the	

























patients	 with	 SLE	 have	 an	 increased	 death	 rate	 from	 infection	 (560).	 In	 a	multicenter	
study	of	1,000	SLE	patients	followed	over	10	years,	infections	were	the	cause	of	death	in	





of	 infection	 in	 juvenile-onset	 SLE	 would	 be	 expected	 to	 be	 even	 higher,	 inasmuch	 as	




the	 intrinsic	 risk	 of	 infection	 that	 occurs	 in	 SLE	 patients	 (563).	 Immunosuppressive	
agents,	which	have	become	the	standard	for	the	treatment	of	major	organ	involvement	
in	 SLE,	 also	 increase	 this	 risk.	 Moreover,	 it	 has	 been	 reported	 that	 recurrent	 major	
infections	 predict	 poorer	 disease	 outcome	 in	 juvenile-onset	 SLE	 (564).	 Prevention	 and	
careful	 monitoring	 for	 infections	 is	 thus	 a	 major	 challenge	 in	 managing	 patients	 with	
juvenile-onset	SLE.		
	
Clinical	 features	 and	 treatment-related	 factors	 predisposing	 juvenile-onset	 SLE	
patients	to	major	infection	have	not	been	adequately	delineated.	Furthermore,	therapy	
for	 patients	 with	 juvenile-onset	 SLE	 has	 recently	 shifted	 to	 include	 increased	 use	 of	


















A	 retrospective	 chart	 review	was	 performed	 of	 the	 clinical	 courses	 of	 juvenile-
onset	SLE	patients	from	the	time	of	diagnosis	or	first	encounter	until	December	2009	or	
loss	to	follow-up	(1991-2009).	The	inclusion	criteria	were:	diagnosis	of	SLE	before	the	age	
of	 18,	 disease	 duration	 ≥	 6	 months	 and,	 at	 least	 three	 clinical	 encounters	 during	 the	
period	 2007	 to	 2009	 in	 the	 Pediatric	 Rheumatology	 Division	 of	 New	 York-
Presbyterian/Morgan	Stanley	Children’s	Hospital	-	Columbia	University	Medical	Center.		
A	 diagnosis	 of	 SLE	 was	 defined	 by	 the	 presence	 of	 four	 or	 more	 of	 the	 1997	




renal	 and	 neuropsychiatric	 manifestations;	 co-morbidities	 and	 treatment	 strategies	
employed.	Renal	lesions	were	categorized	according	to	the	WHO	classification	system	for	
lupus	nephritis	(120).	Lupus	activity	was	assessed,	using	the	Safety	of	Estrogens	in	Lupus	
Erythematosus	 National	 Assessment	 (SELENA)	 version	 of	 SLE	 Disease	 Activity	 Index	
(SLEDAI)	(148).	
The	Systemic	Lupus	International	Collaborating	Clinics	(SLICC)	Damage	Index	(SDI)	
score	 was	 calculated	 at	 the	 conclusion	 of	 the	 study	 (565,566).	 The	 SDI	 measures	
irreversible	 changes	 secondary	 to	 inflammation,	 adverse	 effects	 of	medication	 and	 co-
morbid	conditions,	which	occurred	since	the	onset	of	SLE,	and	are	present	for	at	least	6	
months.	Patients	who	died	were	excluded	from	the	analysis	of	damage.	






Major	 infections	 were	 defined	 as	 those	 requiring	 treatment	 with	 parenteral	
antimicrobial	 agents	 or	 a	 course	 of	 oral	 antibiotics	 lasting	 one	 week	 or	 more,	 as	
previously	described	(564,567,568).	To	diagnose	an	infection,	it	was	necessary	to	identify	
a	causative	agent,	or	to	have	a	diagnosis	made	by	a	pediatric	infectious	disease	specialist,	




Potential	 factors	 associated	 with	 major	 infection	 were	 studied,	 using	 the	 Chi-
square	test	and	the	Mann-Whitney	U	test.	In	order	to	account	for	the	effect	of	multiple	
comparisons,	 the	 Holm-Bonferroni	 correction	 was	 applied.	 Multivariate	 logistic	
regression	 was	 performed	 using	 Forward	 Stepwise	 Likelihood	 Ratio	 (LR)	 and	 Enter	
methods	 to	 identify	 possible	 confounding	 or	 effect-modifying	 factors,	 and	 to	 estimate	
adjusted	 odds	 ratios	 (OR)	 and	 95%	 confidence	 intervals	 (95%	 C.I.).	 Time	 free	 of	major	
infection	according	 to	 juvenile-onset	 SLE	disease	activity	 and	 treatment	was	 compared	
with	 actuarial	 analysis	 and	 expressed	 graphically	 by	 Kaplan-Meier	 survival	 curves.	 The	
paired	t-test	was	used	to	detect	differences	in	SLE	activity	during	and	after	an	infection.	







During	 the	 study	 period,	 120	 patients	 with	 juvenile-onset	 SLE	 fulfilled	 the	











































































At	 time	 of	 diagnosis,	 the	 mean	 SLEDAI	 was	 9.6	 ±	 6.5,	 7%	 of	 the	 patients	 had	
leukopenia	(white	blood	cells	<	3.0	x	109/L)	and	64%	had	lymphopenia	(lymphocytes	<	1.5	
x	109/L).	
During	 the	 course	 of	 the	 disease,	 lupus	 nephritis	was	 diagnosed	 in	 59	 patients	





dysfunction	 was	 the	 most	 common	 manifestation,	 followed	 by	 significant	 headache,	
seizures,	 psychosis,	 and	 focal	 neurologic	 signs.	 Neurolupus	 was	 diagnosed	 in	 the	 first	
year	 of	 the	 disease	 in	 10	 patients	 (67%).	 Abnormalities	 on	 brain	 magnetic	 resonance	
imaging	were	documented	in	10	patients	(67%).	Cerebrovascular	accidents	occurred	in	6	
patients	(5%).		
All	 patients	 in	 this	 cohort	 were	 treated	 with	 hydroxychloroquine.	 The	 mean	
cumulative	 prednisone	 dose	was	 14.4	 ±	 18.6g	 (range:	 0-126g).	Mycophenolate	mofetil	
was	used	in	67	(56%),	azathioprine	in	55	(46%),	cyclophosphamide	in	44	patients	(37%),	
and	rituximab	in	6	(5%).	Four	patients	(3%)	required	plasmapheresis.		
Two	 patients	 died	 during	 the	 study.	 The	 causes	 of	 death	 were	 disseminated	
cytomegalovirus	 infection	 in	 one	 patient	 and	 macrophage	 activation	 syndrome	 in	 the	
other.	
5.4.3	Frequency	and	types	of	infections	
During	 the	 study	 period,	 101	 major	 infections	 were	 diagnosed,	 affecting	 44	
patients	 (37%),	 as	 shown	 in	 Table	 5.2.	 Twenty-three	 patients	 (19%)	 had	 recurrent	
episodes	 of	 major	 infections	 (≥2	 episodes).	 The	 incidence	 of	 major	 infection	 was	
169/1,000	patient-years	of	follow-up	(C.I.	95%=	139/1,000	-	205/1,000).	Major	infection	
occurred	on	average	4.3±3.1	years	after	juvenile-onset	SLE	diagnosis.		
The	 most	 common	major	 infections	 were	 skin	 and	 soft	 tissue	 infections	 (n=19	
episodes),	pneumonias	 (n=17),	urinary	 tract	 infections	with	 fever	 (n=13),	 sepsis	 (n=10),	
and	herpes	zoster	(n=8).	The	causal	agent	of	infection	was	established	in	49	cases	(48%).	
The	 majority	 of	 the	 cases	 of	 herpes	 zoster	 was	 localized	 and	 did	 not	 require	
hospitalization.	 No	 cases	 of	 Pneumocystis	 jiroveci	 pneumonia	 were	 observed	 in	 our	
cohort.	
The	 SLEDAI	 at	 time	 of	 infection	 (8.2±5.6)	 was	 significantly	 higher	 than	 that	 six	
months	 following	 (5.8±5.7)	 the	episode	 (mean	difference	2.4,	 95%	C.I.	 0.8-4;	 p=0.004).	
The	median	 SLEDAI	 at	 the	 time	of	 infection	with	 herpes	 zoster	was	 four	 and	only	 one	
patient	with	zoster	had	an	SLEDAI	≥	8.	
Leukopenia	 (white	 blood	 cells	 <	 3.0	 x	 109/L)	 was	 present	 at	 time	 of	 major	

















































*	Other	 infections:	 3	 cases	 of	 cervical	 adenitis;	 1	 case	 of	 orbital	 cellulitis;	 1	 case	 of	 sacroiliitis	
















major	 infection	 in	our	 cohort	 (Table	5.3).	 In	order	 to	 reduce	 the	 confounding	effect	of	
treatment	with	 both	medications,	we	 analyzed	 the	 effect	 of	mycophenolate	mofetil	 in	
the	 subgroup	 of	 patients	 who	 had	 never	 received	 cyclophosphamide.	 In	 this	 group	 as	
well,	 treatment	with	mycophenolate	mofetil	was	 associated	with	major	 infection	 (O.R.	
4.0;	 95%	 C.I.	 1.4-12.0;	 p=0.01).	 The	 association	 between	 mycophenolate	 mofetil	 and	
major	infection	remained	statistically	significant	even	after	adjusting	for	the	effect	of	the	
cumulative	dose	of	prednisone	and	disease	duration	(Table	5.3).	Finally,	the	duration	of	
treatment	with	mycophenolate	mofetil	 was	 also	 associated	with	major	 infection,	 with	
the	 risk	 increasing	 16%	 (O.R.	 1.2;	 95%	 C.I.	 1.0-1.3)	 after	 6	 months	 and	 34%	 after	 12	
months	 of	 treatment	 with	 this	 drug	 (O.R.	 1.3;	 95%	 C.I.	 1.1-1.6).	 On	 the	 other	 hand,	
neither	 treatment	 with	 azathioprine	 (Table	 5.3)	 nor	 its	 duration	 of	 administration	
increased	the	occurrence	of	major	infections	significantly	(Table	5.4).	
Use	 of	 cyclophosphamide	 was	 associated	 with	 the	 occurrence	 of	 more	 severe	




















































































































































































































5.2	±	10.0	 7.7	±	13.6	 0.246	 0.764	 0.348	
Cumulative	dose	of	
prednisone	(g)	













from	 major	 infection	 (p=0.037;	 p<0.0001,	 respectively).	 Patients	 treated	 with	
mycophenolate	mofetil	or	those	with	a	cumulative	dose	of	prednisone	at	the	end	of	the	
study	 higher	 than	 15g	 also	 had	 a	 significant	 decrease	 on	 the	 time	 free	 from	 major	
infection	(p=0.015,	on	both	cases).	
The	 variables	 included	 in	 the	 logistic	 regression	 (Forward	 Stepwise	 Likelihood	















Damage	 (SDI	≥1)	was	present	at	 the	conclusion	of	 the	study	 in	33%	(39/118)	of	
the	 surviving	 patients	 after	 a	mean	 disease	 duration	 of	 5.3±3.2	 years.	 Damage	 to	 the	
musculoskeletal	 system	 was	 observed	 most	 frequently	 (9%),	 followed	 by	
neuropsychiatric	 (7%),	 ocular	 (7%),	 skin	 (7%),	 pulmonary	 (5%)	 and	 renal	 (5%)	 systems.	












The	 remarkable	 improvement	 in	 survival	of	 juvenile-onset	SLE	patients	over	 the	




With	 this	 increase	 in	 life	expectancy,	patients	are	 faced	with	morbidities	due	to	
sequelae	 of	 disease	 and	 adverse	 effects	 of	 medication,	 including	major	 infection.	 The	
focus	 of	 management	 has	 now	 shifted	 from	 prevention	 of	 premature	 death	 to	
minimizing	 permanent	 organ	 damage.	 Identification	 of	 risk	 factors	 that	 lead	 to	 major	
infection	 and	 long-term	 damage	 is	 therefore	 of	 increasing	 concern.	 In	 our	 cohort,	 a	
statistically	 significant	 association	 between	major	 infection	 and	 damage	was	 detected.	




In	 our	 study,	 37%	 of	 patients	 had	 at	 least	 one	 episode	 of	major	 infection.	 In	 a	
prospective	 and	 controlled	 study	 of	 another	 110	 patients	 with	 SLE	 and	 220	 controls,	
Bosch	and	colleagues	 found	that	36%	suffered	at	 least	one	 infection	versus	22%	 in	 the	
control	 group,	 RR	 1.63	 (p<0.05)	 (572).	Others	 have	 reported	 rates	 of	 infection	 ranging	
from	 38%,	 among	 adults	with	 SLE,	 to	 57%,	 among	 children	 (564).	 In	 a	 large	 cohort	 of	
33,565	 SLE	 patients,	 7,113	 of	 whom	 had	 lupus	 nephritis,	 the	 incidence	 rate	 per	 100	
person-years	 of	 serious	 infections	 requiring	 hospitalization	was	 10.8	 in	 the	 SLE	 cohort	
and	23.9	in	the	lupus	nephritis	subcohort	(573).		
Variation	 in	the	rate	of	 infection	 is	most	 likely	due	to	differences	 in	age	groups,	
duration	 of	 follow-up,	 disease	 activity,	 severity	 of	 organ	 involvement	 and	
immunosuppressive	regimens	employed.	Furthermore,	 the	definitions	of	 infection	have	
also	 been	 heterogeneous,	 with	 many	 studies	 including	 minor	 infections.	 Despite	 the	






literature	 (560,564,572,574,575).	 In	 addition	 to	 unusual	 opportunistic	 infections,	
juvenile-onset	 SLE	 patients	 also	 experienced	 infections	 caused	 by	 common	 pathogens	
that	behaved	more	aggressively.	For	example,	a	case	series	suggested	an	 increased	risk	
of	nontyphoidal	Salmonella	infection	in	SLE	patients,	in	association	with	cellular	immune	














We	did	not	 encounter	 any	 case	of	Pneumocystis	 jiroveci	 infection,	 even	 though	
we	 do	 not	 routinely	 provide	 prophylaxis	 against	 this	 organism.	 Gupta	 et	 al.	 have	 also	
shown	 that	 the	 number	 of	 reported	 infections	with	 this	 agent	 in	 SLE	 patients	 treated	
with	cyclophosphamide	is	very	low	(15.88/10,000	patients)(585).	Our	data	complements,	
therefore,	 the	 growing	 body	 of	 evidence	 against	 the	 need	 for	 prophylaxis	 against	
Pneumocystis	jiroveci	in	juvenile-onset	SLE.		
Disease	activity	was	clearly	associated	with	the	occurrence	of	major	 infection	 in	
this	 study,	 as	 a	 higher	 SLEDAI	 at	 diagnosis,	 renal	 involvement,	 and	 neuropsychiatric	
manifestations	were	all	identified	in	univariate	analysis	as	factors	associated	with	major	
infection.	Others	have	 found	 lung	and	 renal	 involvement	 (573,574)	and	SLEDAI	>	12	at	
diagnosis	 to	 be	 predictors	 of	 infection	 (567).	 In	 addition,	 similar	 to	 our	 findings,	 low	
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complement	 levels	 (C3	 <	 90mg/dl)	 have	 been	 documented	 as	 predictors	 of	 major	
infection	(567,572).		
In	 our	 cohort,	 use	 of	 cyclophosphamide	 was	 associated	 with	 major	 infection.	
Although	Bosch	and	colleagues	also	documented	this	association	(572),	 it	has	not	been	
consistently	noted	by	others	(560,567).		
We	 found	 that	 mycophenolate	mofetil	 treatment	 was	 strongly	 associated	 with	
major	 infection	 in	 juvenile-onset	 SLE,	 even	 in	 the	 subgroup	of	patients	who	had	never	
been	 treated	with	 cyclophosphamide	 and	 after	 adjusting	 for	 the	 effects	 of	 cumulative	
dose	of	prednisone	and	disease	duration.	Furthermore,	 the	duration	of	 treatment	with	
mycophenolate	 mofetil	 was	 also	 found	 to	 be	 a	 risk	 factor	 for	 major	 infection	 in	 the	
univariate	analysis	(p=0.005).	On	the	other	hand,	azathioprine	treatment	and	its	duration	
were	not	associated	with	major	infection.	
The	 cumulative	 dose	 of	 prednisone	was	 associated	with	major	 infection	 in	 our	
cohort	 as	 described	 in	 other	 series	 (567,572,573).	 Ruiz-Irastorza	 and	 colleagues	
concluded	that	an	increase	of	10	mg	per	day	of	prednisone	caused	an	11-fold	increase	in	
the	risk	of	serious	infection	(574).		
In	 this	 cohort,	 according	 to	 multivariate	 analysis,	 the	 combined	 effect	 of	
treatment	 with	 cyclophosphamide	 and	 cumulative	 dose	 of	 prednisone	 was	 strongly	
associated	with	major	infection,	which	once	again	supports	the	need	of	a	thoughtful	use	
of	these	drugs.		
This	 study	had	 limitations.	This	was	a	 retrospective	 study	with	 the	potential	 for	
missing	data	and	lack	of	standardized	treatment.	Our	center	serves	as	a	tertiary	referral	
center,	which	most	 likely	 increases	the	severity	of	disease.	Moreover,	 in	our	cohort	the	
majority	of	the	patients	are	Hispanic	or	African-American,	which	represent	groups	known	




Finally,	 many	 variables	 (e.g.,	 lupus	 activity,	 hypocomplementemia,	 renal	 disease,	













In	 this	 large	 cohort	 of	 urban	 North	 American	 children	 and	 adolescents	 with	
juvenile-onset	 SLE,	major	 infections	 were	 found	 to	 be	 common,	 were	 associated	 with	
active	 disease	 and	 its	 treatment,	 and	 resulted	 in	 noteworthy	 morbidity.	 In	 order	 to	
ensure	 optimal	 patient	 outcomes,	 it	 is	 essential	 to	 perform	 regular	 surveillance	 for	
infections,	 with	 frequent	 visits,	 particularly	 in	 patients	 with	 more	 active	 disease	 and	
undergoing	 treatment	 with	 immunosuppressive	 drugs,	 and	 to	 promptly	 initiate	
treatment	on	presumption	of	infection.	In	a	recent	review	of	patients	with	SLE	admitted	
to	 an	 Intensive	 Care	 Unit,	 a	 delay	 in	 adequate	 antimicrobial	 therapy	 of	more	 than	 24	
hours	was	associated	with	increased	mortality	(586).		
Lastly,	 many	 infections	 can	 be	 prevented	 with	 timely	 immunization,	 reducing	
exposure	to	contagious	contacts,	screening	for	latent	infection,	and	minimizing	exposure	
to	 immunosuppressive	 drugs,	 which	 are	 essential	 to	 achieve	 optimal	 control	 of	 SLE	
activity,	but	the	judicious	use	of	which	is	equally	important	to	avoid	infections	and	other	
associated	adverse	effects	(587).	These	measures	will	help	to	reduce	the	burden	of	major	
infections	 in	 juvenile-onset	 SLE	 patients	 and	 consequently	 improve	 patient	 outcomes.	



























patients	 led	me	to	pursue	the	study	of	 its	pathogenesis.	 I	was	particularly	 interested	 in	
exploring	the	kidney	miRNA	pattern	of	lupus	nephritis	in	order	to	identify	new	clinically	
relevant	pathways.	
As	 previously	 described	 in	 Chapter	 3,	 cellular	miRNAs	 are	 single-stranded,	 non-
coding,	 RNAs,	 which	 have	 a	 key	 role	 in	 the	 post-transcriptional	 regulation	 of	 gene	
expression.	pri-miRNAs	are	 long	primary	transcripts	 that	undergo	sequential	processing	
by	 the	 endonucleases	 Drosha	 and	 Dicer	 in	 order	 to	 become	 mature	 miRNAs	 (~20-23	
nucleotides).	These	guide	the	RNA-induced	silencing	complex	(RISC)	to	mRNA	targets	by	
imperfect	 complementary	 base	 pairing,	 mostly	 at	 the	 3ʹ-untranslated	 region	 (3’-UTR).	
The	 target	 mRNAs	 undergo	 accelerated	 turnover	 or	 translational	 repression,	 causing	








The	 previous	 studies	 of	 the	 SLE	 miRNA	 pattern	 have	 identified	 miRNAs	 with	
aberrant	 expression	 associated	with	 different	mechanisms	 known	 to	 participate	 in	 the	
disease	pathogenesis,	 including	 innate	 immunity	and	 type	 I	 IFN	signaling,	 inflammation	
and	 dysregulation	 of	 apoptosis	 (589–591).	 It	 was	 identified	 in	 SLE,	 for	 instance,	 a	
dysregulation	of	miR-146a,	which	is	involved	in	the	control	of	type	I	IFN	signaling	(592).	
Another	example	is	miR-125a,	which	is	down-regulated	in	SLE.	One	of	its	targets	is	KLF13,	
whose	 levels	 are	 increased,	 as	 expected,	 with	 the	 down-regulation	 of	 miR-125a.	 This	
leads	to	an	increase	of	RANTES	and,	consequently,	to	inflammation	(593).		
The	 down-regulation	 of	 miR-181a,	 which	 was	 reported	 in	 pediatric	 SLE	 (594),	





In	 SLE	miRNA	 dysregulation	 is	 also	 associated	with	 changes	 in	 other	 epigenetic	
control	mechanisms,	including	DNA	methylation	and	histone	modifications.	One	example	
of	this	type	of	interaction	in	SLE	is	miR-126,	which	is	overexpressed	in	CD4+	T	cells	of	SLE	
patients.	 This	 decreases	 the	 expression	 of	 the	 methyltransferase	 DNMT1	 and	 causes	
CD11A	and	CD70	demethylation,	contributing	to	T	and	B	cell	hyperactivity	(595).	miR-21	
is	also	up-regulated	in	CD4+	T	cells	of	SLE	patients	and	lupus-prone	MRL/lpr	mice	and	its	
expression	correlates	with	disease	activity	 (596).	miR-21	 represses	DNMT1	 as	well,	but	
indirectly	 through	 the	down-regulation	of	RasGRP1.	miR-21	up-regulation	 is,	 therefore,	
also	associated	with	hypomethylation.	Notably,	procainamide	and	hydralazine,	two	drugs	
known	to	induce	lupus-like	syndromes,	were	both	found	to	inhibit	DNMT1,	which	shows	
the	 importance	 of	 DNA	 hypomethylation	 and	 global	 activation	 of	 transcription	 in	 SLE	
etiopathogenesis,	as	previously	described	in	Chapter	2.	
Several	studies	of	miRNAs	in	SLE	have	been	performed	in	plasma	(597),	peripheral	
blood	 mononucleated	 cells	 (598–600)	 and	 in	 the	 kidneys	 of	 lupus	 nephritis	 patients	
(601,602).	 However,	 they	 have	 been	 limited	 and	 have	 not	 used	 an	 unbiased,	 high	




lupus	nephritis	progress	 to	 renal	 failure	over	a	10-year	period,	which	 is	 significant	 in	a	
young	population	(603).	
In	addition,	the	definitive	diagnosis	of	lupus	nephritis	is	still	based	on	renal	biopsy	





(604),	 as	 previously	 shown	 in	 Chapter	 5,	 and	 infertility	 (605,606).	 The	 identification	 of	
new	biomarkers	 to	 guide	 the	use	of	 these	 therapeutic	 agents	 and	 the	development	of	

















Paraffin-embedded	 kidney	 samples	 were	 selected	 from	 pediatric	 patients	 with	
lupus	 nephritis	 or	 post-streptococcal	 glomerulonephritides.	 The	 controls	 were	 normal	
kidney	samples	from	adult	donors	and	one	sample	of	normal	kidney	tissue	from	a	child	
with	nephroblastoma.	Table	6.1	summarizes	the	demographic	and	clinical	characteristics	
of	 the	 lupus	nephritis	 cohort.	A	Pathologist	 confirmed	 the	diagnoses	and	 classified	 the	
lupus	 nephritis	 findings,	 according	 to	 the	 International	 Society	 of	 Nephrology	 and	 the	




RNA	 was	 extracted	 with	 the	 formalin-fixed	 paraffin-embedded	 miRNeasy	 kit	
(Qiagen)	 and	 analyzed	 using	 a	 NanoDrop	 2000	 spectrophotomer.	 High	 purity	 samples	





















































































Name	 Company	 Catalog	Number	 Code	
hsa-miR-26a	 Applied	Biosystems	 4427975	 000405	
hsa-miR-30b	 Applied	Biosystems	 4427975	 000602	








Urine	 samples	 were	 collected	 from	 healthy	 individuals	 and	 adult	 patients	
followed	 at	 the	 Hospital	 of	 the	 University	 of	 Pennsylvania.	 All	 of	 the	 patients	 had	
demonstrated	 clinical	 and	 laboratory	 evidence	 of	 active	 lupus	 nephritis	 (hematuria,	




kept	 at	 -80°C.	 RNA	 was	 extracted	 from	 these	 samples	 using	 Qiagen	 miRNeasy	
serum/plasma	 kit.	 miR-26a	 and	 miR-30b	 were	 measured	 by	 qRT-PCR,	 as	 previously	
























































































podocytes,	 kindly	 provided	 by	 Dr.	 Holzman	 at	 the	 University	 of	 Pennsylvania,	 were	







miRNA	 inhibitors	 complementary	 to	 the	 targeted	 mature	 miRNA	 sequence	 under	 the	
control	 of	 the	 H1	 promoter.	 Green	 fluorescent	 protein	 and	 the	 puromycin	 resistance	
gene	 were	 under	 the	 control	 of	 the	 cytomegalovirus	 (CMV)	 promoter.	 The	 infection	





Name	 Company	 Catalog	Number	 Code	
hsa-miR-26a	 abm	 mh35378	 LentimiRa-Off-hsa-
miR26a	
hsa-miR-30b	 abm	 mh35422	 LentimiRa-Off-hsa-
miR30b	
hsa-miR-4286	 abm	 mh35785	 LentimiRa-Off-hsa-
miR4286	






(Agilent).	 The	 transcriptome	was	amplified	with	Ovation	Pico	WTA	System	V2	 (Nugen).	













Name	 Company	 Code	 Description	
ACTIN	 Applied	Biosystems	 4331182	 Hs99999903_m1	
CCNE2	 Applied	Biosystems	 4448892	 Hs00180319_m1	
E2F8	 Applied	Biosystems	 4448892	 Hs01079645_g1	
FADD	 Applied	Biosystems	 4448892	 Hs04187499_m1	
IL32	 Applied	Biosystems	 4448892	 Hs00992441_m1	
IL7R	 Applied	Biosystems	 4448892	 Hs00902338_g1	
IRF1	 Applied	Biosystems	 4448892	 Hs00971960_m1	
MAD2L1	 Applied	Biosystems	 4448892	 Hs00277143_m1	
MCP-1	 Applied	Biosystems	 4331182	 Hs00234140_m1	
MYBL1	 Applied	Biosystems	 4448892	 Hs00277143_m1	
PARP2	 Applied	Biosystems	 4448892	 Hs01003785_g1	
POLQ	 Applied	Biosystems	 4448892	 Hs00981375_m1	
PTGR2	 Applied	Biosystems	 4448892	 Hs01584044_m1	





miR-26a	 and	miR-30b	 (OriGene).These	 cells	were	maintained	 in	 20%	 calf	 serum.	 Gene	
expression	was	evaluated	by	qRT-PCR,	as	previously	described.	
Cell	 proliferation	 was	 analyzed	 using	 the	 MTT	 (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium	 bromide)	 assay.	 The	 cells	 were	 seeded	 at	 a	 density	 of	 100,000	
cells/well,	cultured	for	three	days	and	treated	according	to	the	manufacturer’s	protocol	
(Sigma).	The	number	of	 viable	 cells	was	 calculated	according	 to	a	 standard	curve.	As	a	
validation	 strategy,	 cell	proliferation	was	also	measured	after	 six	days	of	 culture,	using	


















throughput	 methodology.	 The	 principal	 component	 analysis	 showed	 that	 broadly	 the	
three	groups	clustered	in	different	parts	of	the	diagram	(Figure	6.1).	No	differences	were	
seen	 between	 the	 different	 types	 of	 controls.	 These	 findings	 suggested	 that	 the	 renal	



























unsupervised	 clustering	 of	 samples	 showed	 that	 healthy	 controls	 (N=6;	 black	 dots),	 children	with	 lupus	
nephritis	 (N=12;	 red	 dots)	 and	 children	with	 post-streptococcal	 glomerulonephritis	 (N=2;	 grey	 dots)	 had	
distinctive	patterns	of	miRNA	expression.	The	top	two	principal	components	accounted	 for	about	half	of	
the	total	variance	and	their	plot	suggested	that	the	three	sample	groups	had	different	miRNA	signatures.	
The	 lupus	nephritis	 samples	clustered	 together	on	 the	diagram,	while	 the	normal	 samples	and	 the	post-
streptococcal	glomerulonephritis	samples	were	further	apart,	also	forming	clusters.	The	normal	and	post-












patients	when	compared	 to	controls	 (p<0.05;	Table	6.6).	According	 to	 IPA,	 the	miRNAs	
decreased	in	lupus	nephritis	were	associated	with	cell	cycle	(p=	8.21E-05	-	2.11E-02).		
	
We	 selected	 3	 miRNAs	 for	 further	 study	 (miR-26a,	 miR-30b,	 and	 miR-4286)	
(Figure	 6.2A)	 based	on	 the	magnitude	of	 their	 differential	 expression	 and	p	 values	 (p<	
0.0001,	p= 0.0045,	and	p<	0.0001,	respectively).	There	were	no	significant	differences	in	
the	expression	of	these	miRNAs	according	to	sex,	ethnicity,	age,	or	 immunosuppressive	
regimen	 used.	 Patients	 without	 previous	 treatment	 also	 had	 a	 statistically	 significant	




We	 next	 focused	 our	 functional	 analyses	 on	 miR-26a	 and	 miR-30b,	 since	 miR-
4286	was	recently	described	and	its	cellular	functions	are	still	unknown.		
	
The	 fragmented	 RNA	 from	 the	 paraffin-embedded	 samples	 could	 not	 be	
interrogated	 to	 confirm	 a	 transcriptome	 signature	 related	 to	 dysregulation	 of	miR-26a	
and	miR-30b;	however,	we	performed	an	in	silico	analysis	of	data	available	publicly	(17).	
The	 transcriptome	 in	 lupus	 nephritis	 glomeruli	 showed	 a	 significant	 de-repression	 of	
predicted	miR-26a	and	miR-30b	targets	(Figure	6.3).		
	
DAVID	 terms	 enriched	 in	 the	 miR-26a	 targets	 up-regulated	 in	 lupus	 nephritis	
glomeruli	were	blood	pressure,	transmembrane	proteins,	defense	response,	response	to	
wounding,	 immune	 response,	 and	 lipoproteins	 (p<10-4).	 For	 miR-30b,	 the	 terms	 were	
immune	 response,	 disulfide	 bond,	 regulation	 of	 blood	 pressure,	 and	 regulation	 of	






































































































































miRNA	 signature	 and	 proliferation	 is	 a	 hallmark	 of	 lupus	 nephritis.	 We,	 therefore,	
investigated	 whether	 these	miRNAs	 directly	 regulated	 cell	 cycle	 transcript	 abundance.	
We	 knocked	 down	 each	 implicated	miRNA	 in	 human	mesangial	 cells	 and	 analyzed	 the	
gene	 expression	 by	 arrays.	 According	 to	 IPA,	 the	 KD	 of	 miR-26a	 led	 to	 increased	
expression	 of	 genes	 associated	 with	 cell	 cycle	 (p=9.98E-09	 –	 1.98E-02)	 and	 DNA	
replication,	 recombination	 and	 repair	 (p=1.10E-08	 –	 1.98E-02).	 Similar	 results	 were	
obtained	for	miR-30b	KD	(p=1.47E-20	–	1.11E-02	for	both	types	of	genes)	and	miR-4286	
KD	(p=9.39E-22	–	1.15E-02	for	both	types	of	genes).	These	findings	suggest	that	miR-26a,	
miR-30b	 and	miR-4286	 are	 directly	 regulating	 the	 expression	 of	 genes	 involved	 in	 cell	
proliferation.	The	expression	levels	of	10	genes	were	validated	by	qRT-PCR	(Figure	6.4),	
confirming	 that	 genes	 associated	 with	 the	 cell	 cycle	 such	 as	 CCNE2,	 E2F8,	MAD2L1,	
MYBL1	 and	POLQ,	were	 increased	 in	at	 least	one	of	 the	miRNA	KD	when	compared	 to	
mesangial	cells	transduced	with	the	lentivirus	control.			
Conversely,	when	miR-26a	and	miR-30b	overexpression	vectors	were	transfected	
into	mesangial	 cells,	we	 saw	decreased	 expression	 of	 the	 cell	 cycle	 genes	 (Figure	 6.5).	








Figure	 6.4	 -	Mesangial	 cells	 with	 knockdown	 of	miR-26a,	miR-30b,	 or	miR-4286	 have	 higher	
expression	 of	 genes	 related	 to	 cell	 cycle	 and	 proliferate	more.	A.	 Expression	of	different	miRNA	
targets	 in	 mesangial	 cells	 with	 knockdown	 of	 miR-26a,	 miR-30b,	 or	 miR-4286	 and	 in	 vector-transduced	
control	 cells	 was	 evaluated	 by	 qRT-PCR.	 B.	 MTT	 assays	 were	 performed	 to	 study	 cell	 proliferation	 in	













We	 directly	 examined	 proliferation	 by	 performing	 MTT	 assays.	 A	 statistically	
significant	increase	in	the	number	of	viable	mesangial	cells	was	seen	with	knockdown	of	
miR-26a,	miR-30b,	or	miR-4286	compared	to	cells	transduced	with	the	lentivirus	control	
(P=0.0072,	 P<0.0001,	 and	 P<0.0001,	 respectively)	 (Figure	 6.4B	 and	 Figure	 6.6).	 These	
data	 were	 further	 confirmed	 using	 propidium	 iodide	 to	measure	 DNA	 content	 (Figure	
6.7).		
	
Figure	 6.6	 –	Human	mesangial	 cells	 after	 three	days	 of	 culture.	A.	Lentivirus	control.	B.	miR-26a	












inflammatory	 cells,	 a	well-known	 process	 in	 lupus	 nephritis	 pathogenesis.	 Our	 in	 silico	
studies	identified	VCAM1	as	a	possible	miR-30b	target	in	lupus	nephritis	kidneys	(Figure	
6.3).	We	therefore	examined	MCP1	and	VCAM1	levels	in	mesangial	cells	overexpressing	
miR-26a	 and	miR-30b,	 and	we	 found	 significantly	 decreased	 expression	 of	 both	MCP1	
and	VCAM1	in	cells	overexpressing	miR-26a	and	decreased	expression	of	VCAM1	in	cells	
overexpressing	miR-30b	(Figure	6.8).		


















Gene	 expression	 is	 regulated,	 on	 the	 post-transcriptional	 level,	 by	 miRNAs.	 A	
broad	 change	 in	 the	 miRNA	 pattern	 of	 a	 cell	 can,	 therefore,	 lead	 to	 the	 global	
dysregulation	of	 its	mechanisms	and	contribute	to	disease	pathogenesis	and	chronicity.	










reflected	 mainly	 cell	 proliferation.	 Moreover,	 the	 lupus	 nephritis	 miRNA	 pattern	 was	





Using	 a	 high	 throughput	 methodology	 we	 identified,	 for	 the	 first	 time,	 a	
significant	decrease	in	miR-26a,	miR-30b	and	miR-4286	in	the	kidneys	of	lupus	nephritis	
patients.		







The	miRanda	algorithm	(www.microrna.org)	predicted	 that	 seven	 (CCNE2,	E2F8,	
FADD,	MAD2L1,	MYBL1,	POLQ	and	PTGR2)	out	of	the	ten	target	genes	identified	through	
the	array	study	of	the	KDs	had	possible	alignment	sequences	with	miR-26a,	miR-30b	or	
miR-4286.	 In	 some	 cases	 there	were	more	 than	 one	 possible	 alignment	 sequence	 and	
more	than	one	of	these	three	miRNAs	involved.	The	case	of	CCNE2	is	paradigmatic,	since	
the	miRanda	algorithm	identified	one	possible	sequence	alignment	for	miR-26a	and	two	





Our	 data	 showed	 that	 in	 the	 kidneys	 of	 lupus	 nephritis	 patients	 there	 is	 a	
significant	decrease	of	miR-26a,	miR-30b	and	miR-4286	and	that	these	miRNAs	regulate	






be	 down-regulated	 in	 several	malignancies,	 including	 nasopharyngeal	 carcinoma	 (611),	
esophageal	 adenocarcinoma	 (612),	 pancreatic	 duct	 adenocarcinoma	 (613),	 liver	 cancer	
(614–617),	 breast	 cancer	 (618–620),	 lung	 cancer	 (621–623),	 thyroid	 cancer	 (624,625),	
prostate	 cancer	 (626–628),	 clear	 cell	 renal	 cell	 carcinoma	 (629),	 bladder	 cancer	








(VEGF)	 (640,641).	 Furthermore,	 delivery	 of	 miR-26a	 by	 adeno-associated	 virus	 was	
shown	to	reduce	cancer	cell	progression	and	cause	tumor-specific	apoptosis	in	vivo	(614),	
indicating	 that	miR-26a	 is	 involved	 in	 the	 regulation	of	cell	proliferation	and	apoptosis.	
Interestingly,	 it	 was	 also	 reported	 that	 down-regulation	 of	 miR-26a	 promotes	 mouse	
hepatocyte	proliferation	during	liver	regeneration	in	association,	once	again,	with	CCNE2	
overexpression	(642).		
Data	 regarding	 other	 malignancies	 should	 also	 be	 mentioned.	 Ectopic	 miR-26a	
was	 reported	 to	 inhibit	 cell	 proliferation	 and	 induce	 cell	 cycle	 arrest	 at	 G1	 phase	 in	






40%	 and	 0%,	 respectively,	 in	 the	 miR-26a-negative	 group,	 but	 were	 50%	 and	 6%,	
respectively,	 in	 the	 miR-26a-positive	 group.	 The	 multivariate	 survival	 analysis	 of	
conventional	 clinical	 prognostic	 factors	 showed	 that	 miR-26a	 is	 an	 independent	
prognostic	 factor	 in	 pancreatic	 cancer	 (613).	 Finally,	 the	 in	 vitro	 and	 in	 vivo	 assays	




inhibition	 and	 a	 decrease	 in	 tumor	 growth,	 phenomena	 associated	 once	 again	 with	
CCNE2	 downregulation.	 Similar	 results	 were	 found	 for	 breast	 and	 gastric	 cancer	
(618,620,643).		
The	genome-wide	miRNA	expression	profile	of	thyroid	anaplastic	carcinomas	and	
normal	 thyroid	 tissue	 identified	a	significant	decrease	on	miR-26a	 levels	on	the	tumors	
(624).	 These	 results	 were	 confirmed	 by	 Northern	 Blot	 and	 qRT-PCR	 (624).	 Transgenic	
mice	 expressing	 SV40	 large	 T	 oncogene	 under	 the	 transcriptional	 control	 of	 the	
thyroglobulin	promoter	developed	undifferentiated	thyroid	carcinomas	(644)	and	these	





cell	 lines	derived	of	bladder	cancer	(631),	 lymphoma	(633)	and	acute	myeloid	 leukemia	
(645).	In	the	latter	the	control	of	cell	proliferation	is	once	again,	at	least	in	part,	mediated	
by	CCNE2	down-regulation	(645).	
Interesting	 data	 connect	 miR-26a	 to	 the	 MYC	 pathway.	 Koh	 and	 collaborators	
reported	 that	 in	 the	 mouse	 prostate	 and,	 in	 vitro,	 in	 human	 prostate	 cancer	 cells,	
upregulation	of	MYC	was	associated	with	a	decrease	on	miR-26a	and	an	overexpression	
of	 EZH2.	 These	 data	 suggest,	 therefore,	 that	 MYC	 participated	 in	 prostate	 tumor	
initiation	and	disease	progression	through	a	mechanism,	at	least	in	part,	related	to	miR-
26a	(626).	It	was	also	reported	that	MYC	can	directly	bind	upstream	of	EZH2	and	activate	
its	 transcription.	 EZH2	 is	 a	 histone	 lysine	 methyltransferase	 that	 catalyzes	 the	 tri-
methylation	of	histone	3	on	lysine	27	(H2K27me3),	leading	to	chromatin	remodeling	and	
gene	silencing.	Some	of	the	genes	whose	expression	is	controlled	by	EZH2	are	homeobox	
genes	 involved	 in	 differentiation.	 The	 overexpression	 of	 EZH2	 is,	 therefore,	 associated	
with	the	promotion	of	cell	proliferation,	invasion	and	metastasis	formation.	According	to	
this	 group,	 the	 pathway	MYC-miR-26a-EZH2	 has	 an	 important	 role	 in	 prostatic	 cancer	
tumorigenesis	(626).	
A	 CHIP	 assay	 demonstrated	 that	 MYC	 also	 recruited	 EZH2	 to	 the	 miR-26a	












In	 human	 esophageal	 adenocarcinoma	 miR-26a	 expression	 was	 significantly	




that	 seem	 to	 be	 involved	 in	 the	 process	 of	 metastasis	 formation.	 By	 qRT-PCR,	 it	 was	
confirmed	that	miR-26a	expression	was	significantly	decreased	in	liver	and	lymph	nodes	
metastases	 compared	 to	 primary	 esophageal	 adenocarcinoma	 tissues	 (612).	 Zhang	 YF	
and	collaborators	further	tested	the	hypothesis	of	miR-26a	being	involved	in	metastasis	
formation,	by	performing	in	vitro	studies	with	OE33	and	OE33/AR	cells	(612).	The	former	
is	 a	 cell	 line	 of	 esophageal	 adenocarcinoma,	 and	 the	 latter	 is	 a	 subpopulation	 that	
acquired	resistance	to	anoikis.	They	showed	that	antisense-mediated	suppression	of	miR-
26a	expression	in	OE33	cells	resulted	in	significant	inhibition	of	anoikis,	while	increasing	
miR-26a	 levels	 by	 transfection	of	miR-26a	mimics	 increased	 the	 sensitivity	 of	OE33/AR	
cells	 to	 anoikis	 (612).	 It	 was,	 therefore,	 	 suggested	 a	 role	 for	 miR-26a	 not	 only	 in	
tumorigenesis	 of	 esophageal	 adenocarcinoma,	 but	 also	 in	 the	 control	 of	 anoikis-
resistance	and	in	the	formation	of	metastasis	(612).	
The	spectrum	of	functions	of	miR-26a	is	even	broader,	considering	that	 in	other	




alone	 promotes	 transformation	 and	 growth	 and	 that	 it	 markedly	 enhances	 the	
transcription	of	VEGF	in	vitro	and	promotes	tumor	angiogenesis	in	vivo	(650).		




because	different	 groups	have	presented	 contradictory	 results.	 This	 is	 the	 case	of	 lung	
cancer.	Dang	X	and	collaborators	showed	that	miR-26a	expression	was	down-regulated	
in	 human	 lung	 cancer	 specimens	 and	 that	 the	 overexpression	 of	miR-26a	 in	 the	 A549	
human	lung	cancer	cell	line	caused	a	dramatic	inhibition	of	cell	proliferation,	G1/S	phase	
block,	activation	of	apoptosis	and	inhibition	of	invasion	and	metastasis	formation	(623).	
Liu	B	et	al.	 also	 found	 that	miR-26a	was	down-regulated	 in	 lung	cancer	 specimens	and	
cell	 lines,	but,	unexpectedly,	 this	group	 found	 that	miR-26a	was	up-regulated	 in	 lymph	
node	metastasis	when	compared	with	primary	tumors	(622).	Moreover,	it	was	shown	in	
three	 different	 human	 lung	 cancer	 cell	 lines	 that	 the	 ectopic	 expression	 of	 miR-26a	
dramatically	 enhanced	 lung	 cancer	 cell	 invasion	 and	migration	 (622).	 It	was	 suggested	
that	 these	 phenomena	 occurred,	 at	 least	 in	 part,	 by	 decreasing	 PTEN	 expression	 and	
increasing	 the	 expression	 of	 VEGF,	 Twist,	 β-catenin	 and	 matrix	 metallopeptidase	 2	
(MMP2)	 (622).	 These	 proteins	 participate	 in	 mechanisms	 that	 are	 essential	 for	
tumorigenesis	and	metastasis	 formation.	New	data	are,	 therefore,	necessary	 to	 further	
clarify	the	real	role	of	miR-26a	in	the	lung	cancer	pathogenesis.	
Apart	 from	 cancer,	 miR-26a	 dysregulation	 has	 also	 been	 associated	 with	
idiopathic	 pulmonary	 fibrosis	 (651,652)	 and	 autoimmune	 diseases,	 like	 primary	 biliary	
cirrhosis	(653)	and	rheumatoid	arthritis	(654).	In	a	rat	model,	miR-26a	represses	TLR3	in	
macrophages	and	improves	the	severity	of	pristine	induced	arthritis	(655).		
Finally,	 miR-26a	 also	 seems	 to	 be	 important	 for	 the	 normal	 functioning	 of	 the	
kidneys.	By	microarray	expression	profiling	and	 in	situ	hybridization,	mmu-miR-26a	was	
identified	as	having	a	pan-glomerular	expression	pattern	in	the	kidneys	of	wild-type	mice	
(607).	 Furthermore,	 another	 group	 showed	 that	 miR-26a	 was	 the	 most	 abundantly	
expressed	 miRNA	 in	 the	 glomerulus	 of	 normal	 C57BL/6	 and	 that	 its	 glomerular	
expression	 in	B6.MRLc1	mice	was	 significantly	 lower	 (656).	Moreover,	 glomerular	miR-
26a	 correlated	 negatively	 with	 the	 urinary	 albumin	 levels	 and	 podocyte	 specific	 gene	
expression	(656).		
In	conclusion,	 these	 findings	suggest	 that	 the	role	of	miR-26a	 is	 tissue	and	time	
specific,	 so	 that	 in	 different	 cell	 contexts	 this	 miRNA	 can	 have	 different	 biologically	






Regarding	 miR-30b,	 there	 is	 also	 evidence	 that	 it	 is	 down-regulated	 in	 several	
malignancies,	including	colorectal	cancer	(657,658),	squamous	cell	lung	carcinoma	(621)	
and	 invasive	bladder	 carcinoma	 (659).	Regarding	 colorectal	 cancer,	 it	was	documented	
that	 miR-30b	 was	 significantly	 down-regulated	 in	 primary	 tumor	 specimens	 (657,658)	
and	in	 liver	metastasis	tissues	(658).	 In	vitro	studies	of	miR-30b	overexpression	showed	
an	inhibition	of	cell	proliferation,	migration	and	invasion	(657,658),	with	induction	of	G1	
arrest	 and	apoptosis	 (657).	A	 reduction	of	 tumor	 growth	was	 reported	 in	 a	nude	mice	






30b	 was	 reported	 in	 the	 skin	 of	 these	 patients	 and	 in	 mice	 with	 bleomycin-induced	
dermal	 fibrosis	 (660).	 In	 vitro	 studies	 showed	 that	 TGFβ	 down-regulated	 miR-30b	
expression	 in	dermal	 fibroblasts,	which	caused	an	 increase	on	PDGFRβ	expression	and,	
subsequently,	 collagen	 production.	 Transfection	 of	 dermal	 fibroblasts	 with	 a	 miR-30b	
mimic	 repressed	 PDGFRβ	 expression,	 inhibited	 collagen	 synthesis	 and	 impaired	 the	
differentiation	of	dermal	fibroblasts	into	myofibroblasts	(660).		
In	 conclusion,	 there	 is	 robust	 evidence	 in	 the	 literature	 supporting	 the	 roles	 of	
miR-26a	and	miR-30b	as	key	regulatory	molecules	for	the	control	of	cell	proliferation	and	
apoptosis.	 Moreover,	 new	 data	 show	 that	 these	 miRNAs	 may	 also	 inhibit	 pro-fibrotic	
signals.	In	our	study	we	found	a	significant	decrease	of	these	miRNAs	in	lupus	nephritis,	a	
disease	whose	pathogenesis	is	characterized	precisely	by	cell	proliferation	and	fibrosis.	
The	 stability	 of	 miRNAs	 in	 urine	 and	 the	 feasibility	 of	 obtaining	 such	 samples	
make	 these	 regulatory	molecules	 promising	 candidates	 as	 non-invasive	 biomarkers	 for	










that	 these	 would	 also	 be	 a	 possibility	 in	 lupus	 nephritis.	 Nevertheless,	 the	 utility	 of	
therapies	 that	 target	 specific	miRNAs	should	be	carefully	addressed,	 considering	 that	a	
single	 miRNA	 regulates	 the	 expression	 of	 multiple	 genes	 and	 may	 affect	 several	
mechanisms	 in	 different	 cells.	 Kota	 and	 collaborators	 hypothesized	 that	 the	 most	
therapeutically	 useful	miRNAs	 will	 be	 the	 ones	 expressed	 in	 low	 levels	 in	 tumors	 and	
highly	 expressed	 and,	 therefore,	 tolerated,	 in	 normal	 tissues.	 This	 group	 showed	 that	
adenovirus	mediated	miR-26a	delivery	suppressed	cancer	cell	proliferation	and	activated	
tumor-specific	 apoptosis	 in	 a	 hepatocarcinoma	mouse	model,	 without	 causing	 toxicity	











signature.	 Furthermore,	 we	 showed	 that	 miR-26a	 and	 miR-30b	 are	 significantly	
decreased	 in	 the	kidneys	and	 in	 the	urine	of	 these	patients	and	that	 these	miRNAs	are	
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As	 further	 discussed	 in	 Chapter	 6,	 in	 prostatic	 cancer	 cell	 lines	MYC	 decreased	
miR-26a	 expression	 by	 direct	 binding	 at	 the	 promoter	 regions	 of	CTDSPL	 and	CTDSP2,	
genes	 whose	 introns	 harbor	 the	 miR-26a	 primary	 transcripts	 (626).	 In	 a	 murine	
lymphoma	model	with	the	MYC	transgene	expression	controlled	in	a	Tet-off	system,	the	
miRNA	 expression	 profiling,	 performed	 with	 microarrays,	 also	 showed	 that	 MYC	
repressed	miR-26a	(661).	Moreover,	a	CHIP	assay	demonstrated	that	MYC	recruited	EZH2	
to	 a	miR-26a	 promoter	 and	 cooperatively	 repressed	miR-26a	 expression	 in	 lymphoma	
cell	 lines	 (633).	Other	mechanisms	of	miR-26a	control	have	also	been	described.	 It	was	
shown,	 for	 example,	 in	 prostate	 cancer	 cell	 lines	 that	 miR-26a	 suppression	 was	
associated	with	the	hypermethylation	of	the	miR-26a	locus	(627).		
In	 breast	 cancer	 cells,	 it	 was	 found	 that	 trastuzumab,	 a	 monoclonal	 antibody	
against	 the	Human	Epidermal	Growth	Factor	Receptor	2	 (HER2),	 caused	a	G1	 arrest	by	




















HER2	 expression	 was	 analyzed	 by	 immunohistochemistry.	 HER2-positive	 breast	
cancer	tissue	was	used	as	a	positive	control.	For	every	sample,	negative	staining	controls	
were	 executed	 without	 the	 use	 of	 primary	 antibody.	 Fully	 automated	
immunohistochemistry	 was	 performed	 on	 a	 Leica	 Bond-Max,	 with	 rabbit	 anti-HER2	
(1:500;	1	hour	staining;	Sigma-Aldrich),	after	antigen	retrieval	at	low-pH	for	20	min.	The	
Bond	 polymer	 refine	 detection	 system	 was	 used,	 as	 described	 by	 the	 manufacturers	




HER2	 expression	was	 studied	 in	 NZM2410	mice	 (662),	 a	 lupus	 nephritis	mouse	





Features	 NZM2410	 Balb/c	 B6	



















retrieval	 with	 a	 low-pH	 citrate	 solution	 (Vector	 Labs).	 Amplification	 with	 Vectastain	




number	 of	 HER2-positive	 cells	 in	 the	 glomeruli	 of	 NZM2410	 mice	 was	 compared	 to	
controls	 (Balb/c	and	B6	mice).	On	average,	113	glomeruli	were	analyzed	per	mouse.	A	







Mesangial	cells	were	treated	with	 IFNα	(Biomedical	Laboratories)	 for	 three	days	
(100	U/mL)	and	HER2	expression	was	evaluated	by	qRT-PCR	and	 compared	 to	 the	one	
presented	by	mock-treated	cells	(primer	Hs01001580_m1;	Applied	Biosystems	).		
IRF1-puromycin	 plasmids	 and	 vector-only	 plasmids	 were	 transfected	 into	
mesangial	 cells,	using	 the	Amaxa	Cell	 Line	Nucleofector	Kit	V	 (Lonza).	 IRF1	 transfection	
was	confirmed	by	qRT-PCR	and	also	by	immunofluorescence,	using	as	primary	antibody	
mouse	 anti-human	 IRF1	 (1:50;	 1h	 incubation;	 Santa	 Cruz)	 and	 as	 secondary	 antibody	
Alexa	 Fluor	546	goat	 anti-mouse	 IgG	 (Invitrogen).	 The	 corrected	 total	 cell	 fluorescence	
was	calculated	using	Image	J	(NIH).	HER2	expression	was	evaluated	by	qRT-PCR.	MiR-26a	








Urine	 samples	 from	 lupus	 nephritis	 patients	 were	 obtained	 from	 the	 Johns	






















































































































Samples	 from	 patients	 with	 active	 lupus	 nephritis	 were	 also	 compared	 with	













GraphPad	 Prism	 5.0.	 was	 used	 for	 the	 statistical	 analysis.	 Unpaired	 t	 tests	 and	
Mann-Whitney	 U	 tests	 were	 used	 for	 comparisons	 between	 samples.	 The	 relationship	
between	HER2	 and	 the	 other	 urinary	 biomarkers	was	 defined	by	 Pearson’s	 correlation	






7.4.1	 Trastuzumab	 increases	 miR-26a	 and	 miR-30b	 levels	 and	 decreases	 the	
expression	of	cell	cycle	related	genes	
Trastuzumab,	 a	monoclonal	 antibody	 against	HER2,	 causes	 a	G1	 phase	 arrest	 in	
breast	 cancer	 cells	 by	 increasing	 miR-26a	 and	 miR-30b	 (619).	 We	 hypothesized	 that	
trastuzumab	might	also	increase	miR-26a	and	miR-30b	in	mesangial	cells	and	affect	their	










Figure	 7.1	 –	 Levels	 of	 miRNAs	 were	 measured	 by	 qRT-PCR	 after	 treatment	 with	 8	 μg/ml	
trastuzumab	for	24	hours.	Values	are	the	mean ± SEM.		
	
Furthermore,	 trastuzumab	 treated	 cells	 had	 decreased	 expression	 of	 genes	
related	 to	 cell	 cycle	 (p	 values	 of	 3.96	 x	 10-5	 to	 2.70	 x	 10-2)	 and	 DNA	 replication,	
recombination,	and	repair	(p	values	of	1.39	x	10-8	to	2.70	x	10-2).		




7.4.2	 HER2	 is	 dramatically	 increased	 in	 lupus	 nephritis,	 but	 not	 in	 other	
proliferative	glomerulonephritides		
The	effects	of	 trastuzumab	 led	us	 to	hypothesize	 that	 increased	HER2	might	be	
regulating	miRNA	expression	in	lupus	nephritis.	No	prior	studies	of	HER2	expression	had	
been	performed	in	this	disease.	
A	 dramatic	 increase	 in	 HER2	 expression	 was	 observed	 in	 the	 kidneys	 of	 lupus	
nephritis	patients,	not	only	in	the	tubular	compartment,	but	also	in	the	glomeruli,	where	
mesangial	cells,	endothelial	cells	and	podocytes	were	strongly	stained	(Figure	7.2).		
Normal	 kidneys	 and	 kidneys	 from	 patients	 with	 other	 proliferative	
glomerulonephritides	 (IgA	 nephropathy,	 poststreptococcal	 glomerulonephritis,	 and	



















7.4.3	 The	 number	 of	 HER2	 positive	 cells	 is	 increased	 in	 the	 glomeruli	 of	
NZM2410	mice	and	is	associated	with	higher	proteinuria	and	higher	BUN	levels	
To	further	examine	HER2	in	lupus	nephritis,	immunohistochemistry	studies	were	
also	conducted	 in	NZM2410	mice	and	 the	control	B6	and	Balb/c	mice	 (Figure	7.3).	The	
NZM2410	 mice	 developed,	 as	 expected,	 an	 early	 onset,	 aggressive,	 lupus-like	 diffuse	
proliferative	 glomerulonephritis.	 While	 in	 healthy	 humans	 HER2	 staining	 was	 almost	




number	 of	 HER2+	 cells	 per	 glomerulus	 was	 significantly	 higher	 in	 NZM2410	mice	 with	






was	significantly	higher	 than	 in	Balb/c	 (N=3)	or	B6	mice	 (N=10).	A.	A	negative	control	performed	
without	the	use	of	the	primary	antibody	on	NZM2410	mouse	kidneys.	B.	HER2	immunohistochemistry	on	
the	kidneys	of	B6,	Balb/c	mice	and	NZM2410	mice.	C.	The	number	of	HER2	positive	cells	per	glomerulus	in	








Our	 data	 suggested	 a	 model	 whereby	 increased	 HER2	 expression	 drives	
decreased	 miR-26a	 and	 miR-30b	 levels,	 allowing	 for	 de-repression	 of	 cell	 cycle	
transcripts.	 We	 then	 wished	 to	 understand	 the	 etiology	 of	 the	 increased	 HER2	
expression.	 Since	 type	 I	 IFNs	 have	 been	 implicated	 in	 SLE,	 we	 analyzed	whether	 IFNα	
could	regulate	HER2	expression.		
Firstly,	we	examined	the	expression	of	HER2	in	several	types	of	human	renal	cells	
by	 immunofluorescence	and	we	verified	 that	human	podocytes,	mesangial	 and	 tubular	








We	 found	 that	mesangial	 cells	 exposed	 to	 IFNα	 indeed	 had	 significantly	 higher	
expression	of	HER2	than	did	control	cells	(P=0.02)	(Figure	7.5D).	
IRF1	 is	 a	 key	 transcription	 factor	 induced	 by	 IFNα.	 We	 therefore	 decided	 to	
examine	 its	 effect	 on	 HER2	 expression.	 IRF1	 transfection	 was	 confirmed	 by	
immunofluorescence	 and	 qRT-PCR,	 as	 shown	 in	 Figure	 7.5A.	 HER2	 expression	 was	
significantly	 increased	 in	 IRF1–transfected	 cells	 (P=0.0009)	 (Figure	 7.5B).	 Furthermore,	
decreased	 levels	 of	 miR-26a	 and	 miR-30b	 were	 seen	 in	 IRF1–transfected	 cells	 (Figure	
7.5C).	 These	 data	 suggested	 that	 lupus-associated	 factors	 such	 as	 IFNα	 and	 IRF1	















7.4.5	 HER2	 is	 increased	 in	 the	 urine	 of	 patients	 with	 lupus	 nephritis	 and	 is	
associated	with	disease	activity	
The	 dramatic	 overexpression	 of	 HER2	 in	 lupus	 nephritis	 renal	 tissue	 suggested	
that	it	could	be	a	useful	biomarker.	We,	therefore,	examined	the	urine	from	patients	and	
controls.	HER2	was	found	to	be	significantly	increased	in	the	urine	of	adult	patients	with	
active	 lupus	 nephritis	 when	 compared	 to	 sex	 and	 age-matched	 healthy	 controls	
(p=0.0002;	 Figure	 7.6A).	 Moreover,	 when	 analyzing	 HER2	 levels	 longitudinally,	 it	 was	
found	 that	 they	 were	 significantly	 increased	 during	 lupus	 nephritis	 flares	 (p=0.0270;	
Figure	7.6B).	HER2	was	also	significantly	 increased	 in	the	urine	of	patients	with	class	 III	
and	 class	 IV	 lupus	 nephritis	 when	 compared	 with	 class	 V	 (p=0.0374;	 p=0.0004,	
respectively;	 Figure	 7.6C).	 Finally,	 HER2	 levels	 correlated	 with	 the	 urine	 protein:	









Figure	 7.6	 –	 HER2	 is	 increased	 in	 the	 urine	 of	 patients	 with	 active	 lupus	 nephritis	 and	 it	 is	
associated	with	disease	activity.	A.	HER2	levels	(pg/mL)	were	measured	by	ELISA	in	the	urine	of	adult	
patients	with	active	 lupus	nephritis	 (N=47)	and	 in	sex	and	age-matched	healthy	controls	 (N=26).	B.	HER2	
levels	(pg/mg	Cr)	were	analyzed	in	14	patients	from	two	different	time-points:	non-active	 lupus	nephritis	









Trastuzumab	 targets	 the	HER2	extra-cellular	domain	and	blocks	 its	downstream	
pathways	 by	 inhibiting	 the	 homo/hetero	 dimerization	 of	 HER2	 and	 by	 promoting	 the	




of	 patients	with	 lupus	 nephritis,	we	 hypothesized	 that	HER2	might	 also	 have	 a	 role	 in	
lupus	 nephritis	 pathogenesis.	 The	 immunohistochemistry	 studies	 showed	 indeed	 a	
dramatic	 increase	 of	 HER2	 expression	 in	 the	 kidneys	 of	 NZM2410	 mice	 and	 in	 lupus	
nephritis	 patients.	 Furthermore,	mesangial	 cells	 exposed	 to	 trastuzumab	 had	 a	 down-
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regulation	 of	 genes	 associated	 with	 mitosis	 and	 cell	 proliferation.	 Thus,	 HER2	 may	
represent	a	new	therapeutic	target.	
The	Epidermal	growth	factor	receptor	(EGFR)	family	of	transmembrane	receptor	
tyrosine	 kinases	 is	 comprised	 of	 four	 members:	 EGFR	 (ErbB1),	 HER2	 (ErbB2),	 HER3	
(ErbB3),	 and	HER4	 (ErbB4),	where	 the	HER	 and	 ErbB	 nomenclatures	 generally	 refer	 to	





of	 other	 types	of	 kidney	disease	 indicate	 that	 the	 role	 of	 EGFR-family	 receptors	 in	 the	
kidney	is	complex.	Early	work	suggested	that	exogenous	EGF	could	promote	renal	repair	
in	 renal	 ischemia-reperfusion	 injury	 (666),	 mercury-induced	 renal	 damage	 (667),	 and	
unilateral	ureteral	obstruction	 (668).	More	 recently,	Chen	and	collaborators	 found	 that	
either	erlotinib	(an	EGFR	kinase	inhibitor)	or	the	genetic	deficiency	of	EGFR	in	the	renal	
proximal	tubule	cells	delayed	renal	recovery	after	ischemia-reperfusion	injury,	suggesting	
that	 EGFRs	 are	 required	 for	 tissue	 repair	 in	 the	 kidney	 (669).	 EGFR	may	 also	 have	 an	
important	 regulatory	 role	 as	 the	 EGFR	 ligand	 amphiregulin	 enhances	 regulatory	 T	 cell	
functions	 (670).	 These	 studies	 suggest	 that	 EGFR	 signaling	 is	 protective	 during	 kidney	
damage.	
In	 contrast,	 other	 work	 suggests	 that	 EGFR-family	 signaling	 exacerbates	 kidney	
disease.	EGFR	inhibition	with	erlotinib	limits	angiotensin	II	–	induced	renal	fibrosis	(671);	
EGFR	blockade	reduces	unilateral	ureteral	obstruction	–	induced	renal	fibrosis	(672);	and	
transgenic	mice	 expressing	 a	 dominant-negative	 EGFR	 have	 reduced	 pathology	 in	 two	
different	murine	models	of	renal	injury,	subtotal	nephrectomy	and	renal	ischemic	injury	
(673).		
In	 a	 crescentic	 glomerulonephritis	 mouse	 model,	 the	 activation	 of	 EGFR	 in	
podocytes	 resulted	 in	 the	 development	 or	 progression	 of	 the	 disease,	 while	 the	
pharmacological	blockage	or	genetic	deletion	of	one	of	its	ligands	improved	the	course	of	
the	 disease	 and	 prevented	 the	 infiltration	 of	 inflammatory	 cells	 (674).	 Moreover,	
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activation	 of	 EGFR	 in	 cultured	 podocytes	 led	 to	 proliferation,	 dedifferentiation	 and	
migration,	processes	that	are	thought	to	occur	in	crescent	formation	in	vivo	(674).		
Current	evidence	suggests,	therefore,	that	EGFR-family	signaling	mediates	kidney	
disease.	 The	 disparate	 effects	 of	 EGFR-family	 signaling	 in	 murine	 kidney	 disease	 may	
have	many	technical	causes,	although	some	have	suggested	that	EGFR-family	signaling	is	
protective	 in	 acute	 kidney	 injury	 and	 becomes	 maladaptive	 in	 chronic	 renal	 disease	
(675,676).	
Since	 lupus	 nephritis	 often	 involves	 a	 chronic	 proliferative	 component,	 we	
hypothesized	 that	 pharmacologic	 blockade	 of	 EGFR-family	 receptors	 would	 limit	
maladaptive	proliferation	and	renal	disease	in	lupus	nephritis.	
Interestingly,	 we	 did	 not	 find	 HER2	 overexpression	 in	 other	 types	 of	
glomerulonephritides	 also	 characterized	 by	 mesangioproliferation,	 such	 as	 IgA	
nephropathy,	 post-streptococcal	 glomerulonephritis	 and	 granulomatosis	 with	




signature	 (279,677,679).	 Lupus	 prone	 mice	 also	 demonstrate	 this	 IFN	 signature,	 even	
before	the	onset	of	autoimmunity	(680,681).	Moreover,	multiple	groups	have	shown	that	
knocking	 out	 type	 I	 IFN	 receptor	 (IFNAR)	 in	 lupus-prone	 strains	 largely	 stifles	 disease	
progression	(682,683).	In	addition,	a	single	iv	dose	of	an	adenoviral	vector	that	expresses	
murine	 IFNα	 can	drastically	 accelerate	 the	onset	of	 autoimmunity	 in	 lupus	prone	mice	
and	the	progress	to	nephritis	(289,292,684).		
As	 previously	 described	 in	 Chapter	 3,	 SLE	 susceptibility	 is	 associated	 with	
functional	 polymorphisms	 in	 genes	 in	 the	 type	 I	 IFN	 pathway,	 including	 IRF5	
(285,286,685–687)	 and	 IRF7	 (287,688,689).	 Moreover,	 IRF1,	 an	 IFN-induced	 weak	
transcription	factor,	also	seems	to	be	associated	with	SLE	pathogenesis.	Previous	studies	
performed	 in	 our	 laboratory	 documented	 an	 overall	 increase	 on	 histone	 4	 acetylation	
and,	 consequently,	 on	 global	 gene	 transcription	 in	 monocytes	 from	 patients	 with	
systemic	 lupus	 erythematosus.	 Interestingly,	 63%	 of	 the	 genes	 with	 increased	 H4	
acetylation	had	 the	potential	 for	 IRF1	 regulation	 (549).	 The	ChIP-Seq	data	 available	on	
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UCSC	 Genome	 Bioinformatics	 platform	 are	 consistent	 with	 the	 binding	 of	 IRF1	 to	 the	
HER2	 promoter	 region	 in	 K562	 cells,	 which	 further	 supports	 our	 hypothesis	 that	 IRF1	
controls	HER2	expression.		




Urinary	 HER2	 levels	 were	 also	 significantly	 correlated	 with	 urine	 protein	 to	 creatinine	
ratio,	MCP1	and	VCAM1	levels,	well	established	lupus	nephritis	biomarkers	(690–692).		
In	the	kidney,	MCP1	is	secreted	in	response	to	pro-inflammatory	stimuli	including	
TNF	and	 it	 recruits	 inflammatory	cells	 to	 the	glomeruli	 (690).	VCAM1	 is	a	cell	adhesion	
molecule	 involved	 in	 the	 acute	 phase	 of	 inflammation	 when	 leucocytes	 are	 being	
recruited	 to	 the	 kidneys.	 Urinary	 VCAM1	 levels	 are	 strongly	 associated	with	 the	 renal	
pathology	 activity	 index	 and	 class	 IV	 and	 are	 negatively	 correlated	with	 the	 chronicity	
index.	VCAM1	is,	therefore,	a	reliable	indicator	of	the	activity:	chronicity	ratio	(691,693).		
The	correlation	between	HER2	and	MCP1	and	HER2	and	VCAM1	shows	that	the	
etiopathogenesis	of	 lupus	nephritis	 is	 complex	 and	 that	 the	different	mechanisms	 that	
contribute	 to	 kidney	 damage,	 namely	 cell	 proliferation,	 chemotaxis	 and	 invasion	 of	
inflammatory	cells,	are	all	interconnected.	Moreover,	the	disruption	of	the	normal	kidney	
architecture	 contributes	 to	 the	 occurrence	 of	 kidney	 damage	 and	 proteinuria,	 being	
HER2	levels	also	associated	with	the	proteinuria:	creatinuria	ratio.	
HER2	levels	likely	capture	a	distinct	pathologic	mechanism	in	lupus	nephritis	and	
while	 the	 association	 between	 biomarkers	 is	 statistically	 robust,	 there	 are	 clear	
differences	 between	 the	 inflammatory	mediator	 detection	 and	 HER2	 detection,	 which	
will	require	additional	investigation.		
This	 study	 identified	 potential	 biomarkers	 and	 a	 novel	 therapeutic	 target	 using	
multiple	confirmatory	strategies.	There	are,	however,	some	limitations.	While	our	initial	








miRNAs	 are	 associated	with	 the	 control	 of	mesangial	 cell	 proliferation.	 In	 addition,	we	
analyzed	 the	 expression	of	HER2,	 a	 known	 regulator	 of	miR-26a	 and	miR-30b	 levels	 in	
breast	cancer	cells.	We	reported	the	existence	of	a	significant	overexpression	of	HER2	in	
the	kidneys	of	lupus	nephritis	patients	and	in	a	lupus	nephritis	mouse	model,	but	not	in	
other	 proliferative	 glomerulonephritides.	 In	 vitro,	 we	 identified	 that	 exposure	 to	 IFNα	
and	 transfection	 with	 IRF1	 caused	 a	 significant	 increase	 in	 HER2.	 These	 factors	 can,	
therefore,	 contribute	 for	 the	 HER2	 overexpression	 seen	 in	 lupus	 nephritis.	 Finally,	 we	
reported	 that	 HER2	 was	 not	 only	 increased	 in	 the	 urine	 of	 patients	 with	 active	 lupus	
nephritis,	but	also	correlated	with	disease	activity	and	the	levels	of	other	lupus	nephritis	
biomarkers.	 These	 findings	 raise	 the	 possibility	 of	 urinary	miR-26a,	miR-30b	 and	HER2	










of	 lupus	 nephritis	 with	 a	 poor	 prognosis	 and	 the	 identification	 of	 this	 pathway	
established	 strong	 foundations	 for	 the	 use	 of	 urinary	 miR-26a,	 miR-30b	 and	 HER2	 as	
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Hemophagocytic	 syndromes	 are	 characterized	 by	 overwhelming	 inflammation	
due	 to	massive	 secretion	 of	 proinflammatory	 cytokines	 and	 uncontrolled	 activation	 of	
macrophages	 and	 T	 lymphocytes	 (694–696).	 The	 hallmark	 of	 these	 syndromes	 is	 the	
appearance	 in	 the	bone	marrow	of	hemophagocytes:	activated	macrophages	 that	have	
engulfed	other	hematopoietic	cells.			
Hemophagocytic	 syndromes	 can	 be	 primary,	 also	 known	 as	 familial	
hemophagocytic	 lymphohistiocytosis,	 a	 group	 of	 rare	 genetic	 diseases	 caused	 by	
impaired	cellular	cytotoxicity,	or	secondary	to	multiple	inflammatory	disorders,	including	
infections,	 malignancies,	 and	 rheumatic	 diseases.	 The	 term	 macrophage	 activation	
syndrome	is	often	used	when	referring	to	the	latter.		








A	 high	 level	 of	 clinical	 suspicion	 is	 necessary	 for	 diagnosis.	 Typically,	 patients	
become	acutely	 ill	with	 the	 sudden	onset	of	non-remitting	high	 fever,	 cytopenias,	 liver	
function	abnormalities,	neurologic	symptoms	and	multiorgan	failure	(698–700).			
Notably,	 in	 patients	 with	 systemic	 juvenile	 idiopathic	 arthritis	 (sJIA)	 the	 high	
spiking,	intermittent,	fever	pattern,	typical	of	active	disease,	shifts	to	a	continuous	non-
remitting	pattern	at	the	onset	of	the	macrophage	activation	syndrome	(698).				
The	 most	 common	 clinical	 manifestations	 are	 hepatosplenomegaly	 and	
generalized	lymphadenopathy	(698–703).	
Skin	manifestations	can	be	varied.	These	 include	 rashes,	petechiae	and	purpura	
(699,703).	 Patients	 may	 also	 have	 easy	 bruising	 and	mucosal	 bleeding	 (698–700,703).	


























for	 a	 hemophagocytic	 syndrome,	 but	 less	 specific,	 while	 a	 ferritin	 level	 higher	 than	
10,000	ng/mL	was	90%	sensitive	and	96%	specific,	with	very	minimal	overlap	with	sepsis,	




seen	 in	 50%	 to	 90%	 of	 patients	 with	 hemophagocytic	 syndromes	 (715,716).	 Higher	
bilirubin	and	gamma	glutamyl	transferase	levels	have	also	been	reported	(699,703,712),	






In	 patients	 with	 hemophagocytic	 syndromes	 there	 is	 usually	 an	 abnormal	
coagulation	 profile,	 with	 prolonged	 prothrombin	 time	 and	 prolonged	 partial	
thromboplastin	 time,	 hypofibrinogenemia	 and	 the	 presence	 of	 fibrin	 degradation	
products	(698,699,703,712).		
Low	 sodium	and	albumin	 levels	 are	 also	observed	 consistently	 (699,702,703).	A	




necessary	 laboratory	 tests	 to	 identify	 a	macrophage	 activation	 syndrome.	 It	 has	 been	
suggested	that	a	ratio	ferritin	to	ESR	higher	than	80	has	a	high	sensitivity	and	specificity	
to	differentiate	between	new-onset	sJIA	and	macrophage	activation	syndrome	(719)	.	
New	markers	of	 hemophagocytic	 syndromes	have	been	 recently	described.	 The	
soluble	 IL2	 receptor	 α	 (sIL2Rα	 /	 sCD	 25)	 is	 highly	 increased	 in	 the	 acute	 phase	 of	
macrophage	activation	syndrome	compared	to	untreated	new-onset	sJIA	(720).		
CD163,	 a	 haptoglobin	 scavenger	 receptor,	 which	 is	 a	 specific	 marker	 for	
macrophages,	 is	highly	 increased	 in	 serum,	bone	marrow	and	 in	 the	 spleen	of	patients	
with	 hemophagocytic	 syndromes	 (720,721).	 Furthermore,	 sCD25	 and	 soluble	 CD163	
were	 found	 to	 correlate	 with	 disease	 activity,	 reflecting	 the	 degree	 of	 activation	 of	 T	
lymphocytes	and	macrophages,	respectively	(720).		
FSTL1	is	a	protein	produced	by	cells	of	mesenchymal	origin	that	is	thought	to	be	a	
mediator	of	the	 innate	 immunity	pathways	that	cause	arthritis	 in	sJIA	(722–724).	FSTL1	
was	 found	 to	 be	 elevated	 in	 active	 sJIA	 and	 to	 be	 even	 more	 increased	 during	
macrophage	activation	syndrome	(719).	The	levels	of	FSTL1	correlated	with	the	levels	of	
sCD25	and	ferritin	and	normalized	after	treatment	(719).	
Neopterin	 is	 an	 acute	 phase	 reactant	 produced	 by	 activated	macrophages	 as	 a	
byproduct	 of	 nitric	 oxide	 synthesis.	 Neopterin	 is	 increased	 in	 patients	 with	
hemophagocytic	syndromes	and	its	levels	also	correlated	with	ferritin	levels	(725).	
CD107a	or	LAMP1	 is	a	membrane	protein	expressed	on	the	surface	of	cytotoxic	




lymphohistiocytosis	 have	 genetic	 defects	 that	 impair	 degranulation	 which	 cause	
defective	 CD107a	 mobilization	 to	 the	 cell	 surface.	 Evaluation	 of	 CD107a	 mobilization	




A	 bone	 marrow	 examination	 is	 often	 used	 in	 the	 diagnostic	 algorithm	 of	 a	
critically	ill	patient	with	cytopenias.	The	bone	marrow	specimens	should	be	cultured	and	
examined	 for	 infectious	 organisms	 and	 evidence	 of	 lymphoid	 malignancy.	 In	
hemophagocytic	 syndromes	 the	 macrophages	 do	 not	 have	 the	 atypical	 features	
associated	 with	 malignant	 histiocytes	 and	 they	 are	 clearly	 different	 from	 the	 CD1a-
staining	 Langerhans	 cells	 identified	 in	 patients	 with	 Langerhans	 cell	 histiocytosis.	 In	
addition	to	CD68	immunostaining,	 it	 is	recommended	to	stain	the	bone	marrow	for	the	
hemoglobin-haptoglobin	 scavenger	 receptor	 CD163	 to	 better	 identify	 the	
hemophagocytes	(712).		
The	presence	of	hemophagocytosis	in	the	bone	marrow	aspirate	or	biopsy	might	
be	 helpful,	 but	 it	 is	 not	 sufficient	 or	 necessary	 for	 the	 diagnosis	 of	 a	 hemophagocytic	
syndrome.		
Notably,	hemophagocytosis	is	not	always	demonstrable	in	the	initial	stages	of	the	
disease	 (712).	A	 study	of	 21	pediatric	marrow	 specimens	 showed	 that	 the	numbers	of	







the	 quantity	 of	 hemophagocytes	 in	 58	 adult	 patients	 with	 and	 without	 secondary	
hemophagocytic	 syndromes,	 many	 of	 whom	 initially	 presented	 with	 similar	 signs	 and	
symptoms	 (730).	 It	 was	 found	 that	 marrow	 histologic	 findings	 alone	 did	 not	 reliably	









A	 hemophagocytic	 syndrome	 may	 be	 triggered	 by	 a	 multiplicity	 of	 stimuli,	
including	a	rheumatic	disease,	a	malignancy,	an	infection	or	an	immunodeficiency.	It	can	
also	 occur	 due	 to	 genetic	 defects	 in	 cytotoxicity,	 as	 is	 the	 case	 with	 familial	
hemophagocytic	lymphohistiocytosis.	Patients	with	one	of	these	rare	diseases	start	with	
symptoms	during	 infancy	or	early	childhood.	The	median	survival	 is	 less	than	2	months	
after	 diagnosis	 if	 untreated	 (731).	 The	onset	 of	 primary	 hemophagocytic	 syndromes	 in	
adolescents	and	adults	has	more	recently	been	reported	and	is	associated	with	a	milder	
phenotype	(732).	
Regarding	 rheumatic	 diseases,	 macrophage	 activation	 syndrome	 is	 particularly	
common	in	patients	with	sJIA,	occurring	in	at	least	7%	to	13%	of	patients	(698,701,712).	
Some	 studies	 suggest	 that	 the	 syndrome	may	 occur	 subclinically	 or	 in	 a	 mild	 form	 in	
another	30%	to	40%	of	patients	(712,720).	The	reported	prevalence	in	patients	with	SLE	
is	 lower,	 ranging	 from	 0.9%	 to	 4.6%	 (733).	Macrophage	 activation	 syndrome	 can	 also	
occur	 in	 patients	 with	 Sjögren	 disease	 (734),	 Sarcoidosis	 (734),	 Kawasaki	 Disease	




and	the	occurrence	of	macrophage	activation	syndrome	was	4	months	 (700).	 It	 is	clear	
that,	 even	 though	 macrophage	 activation	 syndrome	 can	 occur	 in	 patients	 with	
longstanding	 rheumatic	 diseases	 or	 be	 the	 first	 manifestation	 of	 a	 rheumatic	 disease	
(698,700,701,735),	it	tends	to	occur	in	the	earlier	stages	of	the	disease	(700).		
Macrophage	activation	syndrome	may	occur	spontaneously	or	may	be	triggered	
by	 an	 infection,	 a	 change	 in	 the	 medication	 regimen	 or	 by	 the	 toxic	 effect	 of	 a	 drug	
(700,701).	
In	addition	to	rheumatic	diseases,	malignancies	can	also	trigger	a	hemophagocytic	
syndrome,	 frequently	also	 in	association	with	an	 infectious	trigger	 (738).	The	 likelihood	




associated	 malignancies	 are	 T	 lymphocyte	 and	 Natural	 Killer	 Cell	 leukemias	 and	
lymphomas,	diffuse	large	B	lymphocyte	lymphoma	and	Hodgkin	lymphoma	(739–741).	In	
children,	 T	 cell	 malignancies	 predominate,	 namely	 peripheral	 T	 cell	 lymphomas,	
particularly	 subcutaneous	panniculitis-like	T	cell	 lymphoma,	primary	cutaneous	ΥδT	cell	
lymphoma,	 anaplastic	 large	 cell	 lymphoma	 and,	 less	 commonly,	 lymphoblastic	
lymphomas	 (738,742).	 The	 hemophagocytic	 syndrome	 may	 occur	 at	 the	 onset	 of	 the	
identification	of	the	malignancy	(741)	and	it	can	also	happen	in	the	setting	of	iatrogenic	
immunosuppression	from	chemotherapy	(738).		
Viral	 infections,	 particularly	 Epstein-Barr	 virus,	 may	 trigger	 primary	 as	 well	 as	
secondary	 forms	 of	 hemophagocytic	 syndromes	 (698,743,744).	 Other	 known	 viral	
triggers	 include	 cytomegalovirus	 (744),	 parvovirus	 B19	 (698,745),	 herpes	 simplex	 virus	




there	 was	 a	 high	 prevalence	 of	 mutations	 associated	 with	 familial	 hemophagocytic	
lymphohistiocytosis,	 including	 mutations	 in	 PRF1	 and	 LYST	 (756).	 It	 was,	 therefore,	
suggested	 that	 these	 mutations	 are	 risk	 factors	 for	 mortality	 among	 individuals	 with	
influenza	 A	 (H1N1)	 infection	 (756).	 This	 implies	 that	 the	 individual’s	 genetically	
determined	 immune	 response	 plays	 an	 important	 role	 in	 the	 development	 of	 an	
infectious	triggered	hemophagocytic	syndrome.	
Although	less	common,	hemophagocytic	syndromes	can	also	occur	in	the	setting	
of	 bacterial	 infections,	 including	 infections	 caused	 by	 Staphylococcus	 aureus	 (744),	
Escherichia	 coli	 (744),	 Salmonella	 enteritidis	 (698),	 Mycoplasma	 pneumoniae	 (757),	
Ehrlichia	 chaffeensis	 (758),	 Brucella	 mellitensis	 (744)	 and	Mycobacterium	 tuberculosis	
(744).		
Parasites,	 including	 Leshmania	 amastigotes	 (744)	 and	 Plasmodium	 falciparum	








In	 the	 course	 of	 Langerhans	 cell	 histiocytosis,	 Chédiak-Higashi	 Syndrome	 (764),	
Griscelli	 type	 2	 syndrome	 (765)	 and	 Hermanski-Pudlak	 type	 2	 syndrome	 (766)	 a	
hemophagocytic	syndrome	can	occur.		
Acquired	 immunodeficiencies	have	also	been	associated	with	 the	occurrence	of	
hemophagocytic	 syndromes,	 including	 HIV/AIDS,	 hematopoietic	 cell	 transplantation	
(767)	 and	 kidney	 and	 liver	 transplantation	 (768–770).	 The	 hemophagocytic	 syndrome	
may	occur	in	the	setting	of	a	concurrent	infection	or	a	lymphoproliferative	disease	(770).	
Patients	 with	 lysinuric	 protein	 intolerance	 (771),	 severe	 combined	
immunodeficiency	(772),	Omenn	syndrome	(772,773)	and	chronic	granulomatous	disease	
(772)	 may	 present	 in	 a	 similar	 way	 to	 patients	 with	 familial	 hemophagocytic	
lymphohistiocytosis.	 Usually	 infections	 are	 the	 triggers	 for	 the	 hemophagocytic	
syndrome	 in	 patients	 with	 primary	 immunodeficiencies	 (772).	 Interestingly,	
hemophagocytic	 syndromes	 have	 not	 been	 described	 in	 other	 congenital	 defects	 in	
phagocytes	and	only	rarely	in	other	defects	in	innate	immunity	(772).		
There	are	several	conditions	that	may	resemble	a	hemophagocytic	syndrome.	The	
autoimmune	 lymphoproliferative	 syndrome	 (ALPS)	 is	 one	 of	 them.	 ALPS	 is	 caused	 by	
genetic	defects	in	the	machinery	of	FAS-mediated	apoptosis,	which	leads	to	expansion	of	
some	 autoreactive	 lymphocyte	 populations.	 Patients	 may,	 therefore,	 present	 with	
hepatosplenomegaly,	 rash,	and	autoimmune	cytopenias.	An	autoimmune	hepatitis	or	a	
Guillain	Barré	 syndrome	may	also	occur	and	may	contribute	 to	 the	difficult	differential	
diagnosis.	 Patients	 with	 ALPS,	 however,	 typically	 do	 not	 have	 multiorgan	 failure,	
extremely	high	ferritin	levels	or	severe	liver	failure.		
Thrombotic	 thrombocytopenic	 purpura,	 hemolytic	 uremic	 syndrome,	 or	 drug-
induced	 thrombotic	 microangiopathy	 may	 also	 present	 with	 similar	 manifestations.	
These	 conditions	 are	 characterized	 by	 endothelial	 damage,	 microvascular	 thrombosis,	
and	anemia.	 Fever,	 neurologic	 findings,	 or	 renal	 failure	may	occur.	 Patients	with	 these	
conditions	 generally	 do	 not	 have	 rising	 ferritin	 or	 liver	 function	 abnormalities	 and	 the	
anemia	is	microangiopathic.	
Primary	 liver	 disease,	 like	 hemophagocytic	 syndromes,	 can	 present	 with	
hepatomegaly	 and	 elevated	 liver	 function	 tests.	 Both	 can	 cause	 a	 coagulopathy	 with	
prolonged	prothrombin	time	and	prolonged	partial	thromboplastin	time,	low	fibrinogen,	




hemophagocytic	 syndromes	 typically	 have	 more	 extensive	 organ	 involvement,	
cytopenias,	extremely	high	ferritin,	and	neurologic	findings.		
In	conclusion,	the	diagnosis	of	a	hemophagocytic	syndrome	is	indeed	challenging.	
The	 physician	 must	 differentiate	 it	 from	 other	 conditions	 that	 may	 have	 similar	
presentation,	must	distinguish	between	primary	and	secondary	forms,	and	must	perform	




The	 criteria	 proposed	 by	 the	 Histiocyte	 Society	 in	 2004,	 followed	 by	 specific	
genetic	 testing,	 remain	 the	gold	 standard	 for	 the	diagnosis	of	primary	hemophagocytic	




history	 or	 molecular	 diagnosis	 is	 consistent	 with	 familial	 hemophagocytic	
lymphohistiocytosis	 (774).	These	criteria	are	not	 tailored,	however,	 for	 the	diagnosis	of	
other	 hemophagocytic	 syndromes,	 since	 they	 do	 not	 perform	 well	 in	 distinguishing	
macrophage	activation	syndrome	from	a	flare	of	rheumatic	diseases	or	from	sepsis.		
In	2009,	the	Pediatric	Rheumatology	European	Society	published	the	results	of	a	
multinational,	 multicentric	 study	 of	 patients	 with	 juvenile	 onset	 SLE	 who	 developed	




























International	League	of	Associations	 for	Rheumatology	 for	 the	diagnosis	of	 sJIA	 include	
fever,	 hepatosplenomegaly	 and	 lymphadenopathy,	 all	 of	 which	 are	 also	 hallmarks	 of	
macrophage	 activation	 syndrome	 (776).	 Patients	 with	 this	 disease	 also	 have	 elevated	
ferritin	 levels	 (777),	D-dimers	 (778)	 and	prothrombin	 time	 (779).	 There	 is,	 therefore,	 a	
large	degree	of	overlap	between	both	entities.	Moreover,	it	was	found	that	53%	of	sJIA	
patients,	 who	 did	 not	 have	 clinical	 evidence	 of	macrophage	 activation	 syndrome,	 had	
hemophagocytosis	on	the	bone	marrow	aspirate	(712).	It	was	thus	hypothesized	that	sJIA	
and	 macrophage	 activation	 syndrome	 could	 be	 a	 single	 entity	 within	 a	 spectrum	 of	















These	 criteria	 were	 established	 using	 a	 consensus	 process	 and	 a	 statistical	
approach	 comparing	 groups	 of	 patients	 with	 or	 without	 macrophage	 activation	
syndrome	 in	 the	 context	 of	 rheumatological	 diseases.	 Interestingly,	 the	 criteria	 do	 not	
include	clinical	manifestations,	with	the	exception	of	fever.	This	reflects	the	notion	that	
clinical	 symptoms	are	often	delayed	and	similar	 to	 those	observed	 in	other	 conditions.	




600mg/dL).	 A	 paradoxically	 normal	 fibrinogen	 level	 in	 the	 setting	 of	 prominent	
inflammation	should,	therefore,	raise	the	suspicion	of	macrophage	activation	syndrome.	














Epstein-Barr	 virus,	 cytomegalovirus,	 herpes	 simplex	 virus,	 varicella	 zoster	 virus,	
parvovirus,	influenza,	adenovirus,	hepatitis	B,	hepatitis	C	virus	and	HIV	(781).		





Flow	 cytometry	 screening	 for	 perforin	 deficiency	 is	 recommended	 (782).	 If	 the	
screening	 results	 suggest	 it,	 it	 should	 be	 performed	 a	 genetic	 testing	 for	 the	 known	
familial	 hemophagocytic	 lymphohistiocytosis	 associated	 mutations,	 including	 	 PRF1,	




Since	 hemophagocytic	 syndromes	 are	 rapidly	 progressive	 and	 often	 life-
threatening	 conditions,	 a	 prompt	 initiation	of	 treatment	 is	 essential	 for	 the	 survival	 of	
affected	 patients.	 A	 complete	 mechanistic	 understanding	 of	 the	 different	 types	 of	
hemophagocytic	 syndromes	 is	 needed	 in	 order	 to	 better	 select	 effective	 therapeutic	
strategies.	Until	new	data	are	available	regarding	the	pathogenesis	of	these	syndromes,	
treatment	strategies	are	based	on	anecdotal	experience	and	consensus	protocols.		
	In	 patients	 who	 are	 clinically	 stable	 and	 have	 a	 recognized	 trigger	 for	 the	
hemophagocytic	 syndrome,	 it	 is	 recommended	 to	 initiate	 treatment	 directed	 to	 the	
triggering	 condition.	 Infection	 should	 be	 diagnosed	 rapidly	 and	 empiric	 antibiotic,	
antifungal,	antiviral	or	antiparasitic	therapy	should	be	started	according	to	the	suspected	
organism.	 When	 Epstein-Barr	 infection	 infection	 is	 identified,	 rituximab	 375	 mg/m2	
weekly	for	one	to	four	weeks	is	recommended.	
The	 Histiocyte	 Society	 Protocol	 for	 the	 treatment	 of	 Hemophagocytic	
Lymphohistiocytosis	(HLH-94)	is	the	most	well-known	and	used	treatment	strategy.	This	
protocol	 was	 used	 in	 a	 large	 prospective	 pediatric	 study	 conducted	 by	 the	 Histiocyte	
Society	 in	 patients	 with	 less	 than	 16	 years	 with	 no	 history	 of	 malignancy	 or	
immunosuppression.	It	includes	an	eight-week	induction	phase	with	dexamethasone	and	
etoposide	(706).	 If	neurological	symptoms	are	present,	patients	also	receive	 intrathecal	
methotrexate.	 This	 treatment	 strategy	 was	 effective	 in	 prolonging	 survival	 of	 patients	
with	familial	hemophagocytic	lymphohistiocytosis,	in	some	cases	more	than	5	years	after	
onset	 (783).	 Ultimately,	 allogenic	 hematopoietic	 stem	 cell	 transplantation	 can	 provide	
the	cure	for	this	condition	(784–786).		
This	protocol	underwent	a	small	revision	(HLH-2004),	in	which	cyclosporine	A	was	
included	 in	 the	 induction	 phase.	 Notably,	 the	 triple	 drug	 induction	 with	 etoposide,	






In	 2015,	 the	 first	 prospective	 clinical	 trial	 was	 performed	 in	 adults	 with	
hemophagocytic	 syndromes,	 triggered	mainly	 by	malignancy	 or	 infection	 (788).	 In	 this	
study	etoposide	and	dexamethasone	were	used	in	the	induction	phase	and	if	the	patients	
did	not	achieve	partial	remission	after	two	weeks,	treatment	with	doxorubicin,	etoposide	
and	methylprednisolone	was	 initiated	 (788).	An	overall	 response	of	76%	was	achieved,	
which	seems	promising	(788).	
Patients	 with	 macrophage	 activation	 syndrome	 should	 be	 treated	 initially	 with	
steroids	 alone	 and	 typically	 do	 not	 require	 etoposide.	 When	 the	 response	 is	 not	
adequate,	 additional	 immunosuppressive	 agents	 tailored	 to	 the	 underlying	 rheumatic	
disease	should	be	used	rather	than	the	HLH-94	or	the	HLH-2004	protocol	(781).	
Full	 remission	 on	 steroid	monotherapy	 has	 been	 achieved	 in	many	 episodes	 of	
macrophage	 activation	 syndrome	 (698,789),	 with	 remission	 rates	 of	 up	 to	 71%	
(698,789,790).	
Cyclosporine	 A	 suppresses	 T	 lymphocyte	 activation,	 reduces	 the	 macrophage	
production	 of	 inflammatory	 cytokines	 and	 inhibits	 the	 expression	 of	 cell	 surface	
costimulatory	molecules	in	dendritic	cells	(791–794).	It	has	been	shown	that	cyclosporine	
A	 is	effective	 in	 the	treatment	of	primary	hemophagocytic	syndromes	and	of	severe	or	
corticosteroid-resistant	 macrophage	 activation	 syndromes	 (698,700,701,795–798).	 In	
some	patients	 this	 drug	 causes	 resolution	of	 fever	 and	 improvement	of	 the	 laboratory	
abnormalities	within	12	to	24	hours	(796).	These	data	led	some	authors	to	propose	using	














1-2mg/Kg/day	 (808,814).	 The	 exact	 cause	 and	 effect	 was	 difficult	 to	 establish	 and	
permanent	discontinuation	of	anakinra	was	unnecessary	for	any	of	the	patients.	This	may	
be,	 therefore,	 a	 case	 of	 confouding	 by	 indication.	 In	 fact,	 some	 of	 these	 patients	
improved	on	higher	doses	of	anakinra.	Considering	the	overall	published	experience	with	
this	 drug,	 anakinra	 is,	 therefore,	 recommended	 for	 the	 treatment	 of	 refractory	
macrophage	activation	syndrome	(695).	
Another	 IL1	blocker,	 canakinumab,	 a	monoclonal	 antibody	 that	blocks	 IL1β,	has	
been	shown	to	reduce	disease	activity	in	patients	with	sJIA	(815).	Canakinumab	has	also	
been	 used	 for	 the	 treatment	 of	 macrophage	 activation	 system	 at	 higher	 doses	 (7.5-
12.5mg/Kg)	 than	 usually	 utilized	 for	 the	 treatment	 of	 sJIA	 (4	 mg/Kg),	 with	 rapid	 and	
complete	resolution	of	symptoms	and	without	side	effects	1.		
A	 recent	 study	 showed	 that	 treatment	with	 canakinumab	does	not	 significantly	
change	the	risk	of	macrophage	activation	syndrome	(816),	since	the	latter	occurs	even	in	
patients	 whose	 sJIA	 is	 well	 controlled	 with	 canakinumab	 (816).	 Infections	 remain	 the	
most	common	trigger	in	this	group	of	patients	(816).	
Tocilizumab,	a	monoclonal	antibody	against	 IL6	receptor,	has	been	shown	to	be	
highly	 effective	 in	 the	 treatment	 of	 sJIA	 (817,818).	 It	 is	 not	 clear	 if	 tocilizumab	 is	 as	
helpful	 for	 patients	 with	 macrophage	 activation	 syndrome.	 Furthermore,	 there	 have	
been	several	cases	of	macrophage	activation	syndrome	attributed	to	IL6	blockade	(819–
821).		
As	previously	stated,	 there	 is	 some	concern	that	biological	 therapies	can	trigger	
hemophagocytic	 syndromes	 (710).	 Recently,	 it	was	 reported	 the	 clinical	 characteristics	
and	 outcomes	 of	 30	 adult	 patients	 who	 developed	 a	 hemophagocytic	 syndrome	 after	
receiving	biological	 therapies.	 It	was	 found	 that	biologic	agent-induced	 infections	were	
more	likely	to	be	the	cause	of	the	hemophagocytic	syndrome	than	the	drug	itself	(744).		
Rituximab,	 a	 monoclonal	 antibody	 against	 CD20,	 is	 a	 B	 cell	 depleting	 agent,	
originally	 developed	 for	 B	 cell	 lymphoma	 treatment.	 Rituximab	 has	 been	 shown	 to	 be	
helpful	 for	 the	 treatment	 of	multiple	 diseases,	 including	 SLE	 and	 refractory	 sJIA	 (822–
																																																								
1	A	report	in	2014,	by	Kostik	and	collaborators,	was	published	on	a	Russian	scientific	journal,	not	available	on	Pubmed.	






824).	 Rituximab	 has	 also	 been	 used	 to	 effectively	 treat	 Epstein-Barr	 associated	
hemophagocytic	syndrome	(825).		
Etoposide	 was	 also	 able	 to	 induce	 rapid	 recovery	 in	 cases	 of	 steroid	 and	
cyclosporine	A	resistant	macrophage	activation	syndrome	(798,813).	Nevertheless,	with	
the	 availability	 of	 biologic	 agents,	 etoposide	 is	 nowadays	 used	 less	 frequently	 to	 treat	






frequently	used	 for	 the	 treatment	of	macrophage	activation	 syndrome.	Most	 clinicians	
start	 with	 intravenous	 methylprednisolone	 pulse	 therapy	 (30mg/Kg)	 for	 three	
consecutive	 days,	 followed	 by	 2-3mg/Kg/day	 in	 2-4	 divided	 doses.	 If	 response	 to	
corticosteroids	 is	 not	 immediately	 evident,	 parenteral	 administration	of	 cyclosporine	A	
(2-5mg/Kg/day)	 is	 initiated	 (827).	 In	 patients	 refractory	 to	 this	 treatment,	 there	 is	 a	
growing	body	of	evidence	that	biological	therapies,	particularly	IL1	inhibitors,	are	useful	
(828).		
Patients	 with	 gene	 mutations	 consistent	 with	 familial	 hemophagocytic	
histiocytosis,	 hematologic	 malignancies,	 relapsing	 symptoms,	 and/or	 central	 nervous	
system	 disease	 will	 require	 allogenic	 hematopoietic	 stem	 cell	 transplantation.	 It	 is	
recommended,	 therefore,	 that	 all	 patients	 and	 appropriate	 family	 members	 should	
undergo	 HLA	 typing	 and	 testing	 for	 familial	 hemophagocytic	 histiocytosis	 associated	
mutations	 in	order	to	exclude	that	the	donor	does	not	have	an	undiagnosed	condition.	
The	 prognosis	 is	 better	 if	 the	 patient	 is	 in	 remission	 at	 the	 time	 of	 the	 transplant	
(713,826).	Alemtuzumab,	 a	monoclonal	 antibody	against	CD52,	 a	protein	expressed	on	
the	 surface	 of	 T	 and	 B	 lymphocytes,	 natural	 killer	 cells,	 monocytes,	 macrophages,	
dendritic	cells	and	eosinophils,	has	shown	promise	in	patients	with	refractory	disease	and	






Novel	 treatment	 modalities,	 such	 as	 gene	 therapy	 for	 correction	 of	 perforin	
defects,	are	currently	being	developed.	Preliminary	data	on	perforin	gene	 transfer	 into	
hematopoietic	 stem	 cells	 of	 a	 mouse	 model	 of	 perforin-deficiency	 have	 shown	
encouraging	results	(833,834).		
In	 two	 different	 mouse	 models	 of	 primary	 and	 secondary	 hemophagocytic	
syndromes,	treatment	with	ruxolitinib,	a	Janus	kinases	(JAK)	1	and	2	 inhibitor,	 lessened	
the	clinical	and	laboratory	manifestations,	including	weight	loss,	organomegaly,	anemia,	
thrombocytopenia,	 hypercytokinemia	 and	 tissue	 inflammation.	 These	 data	 support	 the	
use	of	JAK	inhibitors	in	future	clinical	trials	(835).	
Currently,	an	anti-human	IFNγ	monoclonal	antibody	is	in	phase	I	trial	for	patients	
with	 reactivated	 familial	 hemophagocytic	 lymphohistiocytosis.	 Patients	 with	 secondary	
forms	 were	 excluded.	 It	 is	 known	 that	 blocking	 IFNγ	 can	 increase	 susceptibility	 to	
infections.	 This	 could	 be	 deleterious	 in	 patients	 with	 recurrent	 hemophagocytic	
syndromes,	since	they	are	often	triggered	by	infections.	
In	 the	 past	 decade,	 based	 on	 the	 knowledge	 gained	 from	 basic	 science,	 anti-
cytokine	 therapies	 have	 been	 used	 sporadically	 in	 different	 forms	 of	 secondary	
hemophagocytic	syndromes	and	now	we	are,	excitingly,	entering	an	era	where	placebo-




Timely	 diagnosis	 and	 prompt	 treatment	 are	 essential	 to	 avoid	 progressive	
multiorgan	 failure	 and	 death	 related	 to	 hemophagocytic	 syndromes.	 Those	 with	 an	
inherited	 mutation	 in	 a	 gene	 associated	 with	 familial	 hemophagocytic	
lymphohistiocytosis	 had	 a	 survival	 of	 approximately	 two	months	 after	 diagnosis,	 if	 not	
treated	 (731,783).	 Patients	 with	 a	 hemophagocytic	 syndrome	 treated	 with	 the	 1994	
protocol	from	the	Histiocyte	Society	had	a	median	survival	of	54%	at	6.2	years	(713,826).	










The	survival	 is	much	better	 if	 the	hemophagocytic	syndrome	occurs	 in	a	patient	
with	 an	 underlying	 rheumatic	 disease.	 Recent	 studies	 found	 a	mortality	 rate	 of	 8%	 in	
patients	with	sJIA	who	develop	macrophage	activation	syndrome	(700).		
Very	 high	 ferritin	 levels	 and	 failure	 of	 the	 ferritin	 to	 fall	 dramatically	 with	
treatment	are	poor	prognostic	signs	across	all	types	of	hemophagocytic	syndrome	(837).		
Relapses	 can	 occur,	 particularly	 in	 patients	 with	 familial	 hemophagocytic	
lymphohistiocytosis.	Relapse	 is	more	 likely	within	a	year	of	 the	 initial	acute	 illness.	The	
risk	of	relapse	should	be	minimized	by	reducing	exposure	to	triggering	conditions.	Since	
recurrences	 following	 vaccination	 have	 been	 reported,	 it	 is	 recommended	 to	 avoid	
vaccination	for	the	first	six	months	after	treatment	and	then	administer	vaccinations	one	
at	a	time	(838).	
Improvements	 in	 survival	 are	 expected	 to	 come	 from	 increased	 disease	






In	 1998,	 it	 was	 found	 that	 patients	 with	 familial	 hemophagocytic	
lymphohistiocytosis	 had	 defective	 natural	 killer	 cell	 function	 (839).	 Soon	 afterwards,	 it	
was	described	for	the	first	time	the	association	with	perforin	gene	mutations	(840).	It	is	
estimated	 that	 15%-40%	 of	 patients	 with	 familial	 hemophagocytic	 lymphohistiocytosis	
have	mutations	in	the	gene	encoding	perforin	(840).	
Perforin	 is	 localized	 in	 the	 granules	 of	 natural	 killer	 cells	 and	 cytotoxic	 T	
lymphocytes	and	is	secreted	upon	conjugation	between	effector	and	target	cells.	 In	the	
presence	of	calcium,	 it	 is	able	to	 insert	 into	the	membrane	of	the	target	cells,	where	 it	
polymerizes	 to	 form	 a	 cell	 death-inducing	 pore.	 The	 effector	molecule,	 granzyme	 B,	 a	
serine	protease	also	found	in	cytotoxic	cells,	is	delivered	into	target	cells	via	the	porelike	
structures	produced	by	perforin	and	induces	apoptosis.		
Data	 from	 animal	 models	 indicate	 that	 perforin	 is	 important	 for	 the	 defense	




perforin	 controls	 lymphocyte	 proliferation	 (840,843).	 Recently,	 it	 has	 been	 shown	 that	
defects	in	perforin-mediated	killing	of	target	cells	prolongs	the	synapse	time	between	the	
killer	 and	 its	 target	 cell	 by	 5-fold	 and	 this	 results	 in	 a	 proinflammatory	 cytokine	 storm	
(844).	A	perforin	deficiency	may	therefore	contribute	to	persistent	lymphocyte	activation	
and,	consequently,	to	the	production	of	proinflammatory	cytokines,	including	IFNγ,	that	
activate	 macrophages.	 These	 cells	 may	 then	 produce	 high	 levels	 of	 pro-inflammatory	
cytokines.		
Mutations	in	the	gene	UNC13D,	which	encodes	the	protein	MUNC13-4,	have	been	
implicated	 in	 10%-30%	 of	 patients	 with	 familial	 hemophagocytic	 lymphohistiocytosis	
(845).	This	protein	participates	 in	the	docking	and	fusion	of	the	cytotoxic	granules	with	
the	cytoplasm	membrane.			
Mutations	 in	STX11	 (Syntaxin	 11)	 and	STXBP2	 (Syntaxin	 Binding	 Protein	 2),	 two	
genes	 encoding	 proteins	 important	 for	 the	 trafficking	 of	 cytotoxic	 granules,	 have	 also	
been	linked	to	the	development	of	primary	hemophagocytic	syndromes	(846–848).	Other	
genes	essential	for	cytotoxicity	have	been	associated	with	genetic	disorders	that	can	be	
complicated	 by	 a	 hemophagocytic	 syndrome,	 namely	 RAB27A	 mutations	 have	 been	
linked	to	Griscelli	 syndrome	type	2	 (849)	and	LYST	mutations	have	been	 identified	as	a	
cause	of	Chédiak-Higashi	syndrome	(850).	
X-linked	lymphoproliferative	syndromes	type	1	and	2	are	caused	by	mutations	in	
SH2D1A	 and	 XIAP,	 respectively.	 These	 are	 two	 other	 hereditary	 immunodeficiencies	
associated	with	 hemophagocytic	 syndromes,	 usually	 triggered	 by	 an	 Epstein	 Barr	 virus	
infection	(851,852).	The	genetic	defects	in	X-linked	lymphoproliferative	syndromes	cause	
an	 aberrant	 apoptosis	 of	 immune	 cells,	 leading	 to	 prolonged	 survival	 of	 lymphocytes	
(851,852).	
In	 2014,	 two	 reports	 described	 patients	 with	 periodic	 fevers	 and	 episodes	 of	
hemophagocytic	 syndrome	 linked	 to	 a	 gain	 of	 function	mutation	 in	NLRC4,	 associated	
with	IL1β	and	Il18	overproduction	and	pyroptosis	(853,854).	
In	 conclusion,	 since	 the	 description	 of	 the	 role	 of	 perforin	 in	 familial	
hemophagocytic	 lymphohistiocytosis,	multiple	other	proteins	related	to	the	production,	
exocytosis	and	function	of	cytotoxic	granules	from	CD8+	T	lymphocytes	and	Natural	Killer	





























Recently,	 it	 was	 published	 a	 report	 on	 500	 patients	 with	 hemophagocytic	
syndromes	 from	 the	 Italian	 registry	 (865).	 Interestingly,	 from	 the	 281	 (56%)	 patients	
classified	 as	 non	 familial,	 43	 (15%)	 had	 monoallelic	 mutations	 in	 one	 of	 the	 genes	
associated	 with	 familial	 hemophagocytic	 lymphohistiocytosis	 (865).	 Patients	 with	











A	 whole-exome	 sequencing	 study	 was	 performed	 in	 14	 patients	 with	 sJIA	 and	
macrophage	activation	syndrome	and	their	parents	(866).	This	study	allowed	to	identify	
rare	 protein-altering	 variants	 in	 known	 familial	 hemophagocytic	 lymphohistiocytosis	
associated	genes	as	well	as	in	new	candidate	genes	(866).	
Conceptually,	 these	 data	 are	 consistent	 with	 a	 two-hit	 or	 multi-hit	 model	 of	
hemophagocytic	syndromes:	genetically	susceptible	individuals	when	exposed	to	certain	
triggers	develop	overwhelming	 inflammation	 (836).	All	 these	data	allow	us	 to	conclude	
Disease	 Gene	 Protein	 Protein	Function	 Notable	Clinical	
Findings	
Familial	Hemophagocytic	Lymphohistiocytosis		









FHL4	 STX11	 SYNTAXIN	11	 Vesicle	docking	 Mild	and	recurrent	
HLH	and	colitis	








Chédiak-Higashi	syndrome	 LYST	 LYST	 Vesicle	trafficking	 Bleeding	tendency;	
pyogenic	infections,	
neuropathy	
Griscelli	syndrome	type	II	 RAB27A	 RAB27A	 Vesicle	fusing	 	
Hermansky-Pudlak	syndrome	
type	II	
AP3B1	 AP3B1	 Vesicle	trafficking	 Bleeding	tendency	
Other	primary	immune	defects	associated	with	high	risk	of	Epstein-Barr	virus	infection	















BIRC4	 XIAP	 Caspase	inhibition	 Mild	and	recurrent	
HLH	and	colitis	








that	cytotoxic	 function	 is	not	only	 important	for	effector	 immune	function,	but	also	for	
resolution	of	inflammation	(836).	
Mouse	 models	 helped	 us	 to	 better	 understand	 the	 pathogenesis	 of	
hemophagocytic	 syndromes.	 Perforin-deficient	 mice	 (Prf-/-)	 infected	 with	 lymphocytic	
choriomeningitis	 virus	 exhibit	 the	 clinical	 characteristics	 of	 human	 hemophagocytic	
syndromes,	including	the	development	of	pancytopenia.	Interestingly,				Prf-/-	mice	that	
were	 also	 IFNγ	 deficient	were	 protected	 from	 severe	 anemia	 (867).	 Furthermore,	 IFNγ	
alone,	 delivered	 via	 osmotic	 pump,	 in	 wild	 type	 mice	 was	 sufficient	 to	 cause	
hemophagocytosis	and	anemia,	in	a	dose-dependent	manner	(867).	Transgenic	mice	that	
selectively	 express	 a	 dominant-negative	 mutant	 IFNγ	 receptor	 in	 macrophage	 lineage	
cells	 and	 have	 a	 near	 complete	 block	 of	 IFNγ	 signaling	 in	 these	 cells	 do	 not	 develop	
hemophagocytosis	and	are	protected	 from	anemia	when	challenged	with	 IFNγ	 infusion	
(867).	 These	 data	 suggest	 that	 IFNγ	 must	 act	 directly	 on	 macrophages	 in	 order	 for	
hemophagocytosis	 to	occur	 in	 vivo.	 Interestingly,	 as	 little	as	20%	of	wild-type	perforin-
expressing	CD8+	T	cell	chimerism	is	able	to	ameliorate	the	clinical	picture	in	these	animals	
(868).	 Elimination	 of	 antigen-presenting	 dendritic	 cells	 can	 also	 protect	 against	 the	
occurrence	of	 hemophagocytic	 syndrome	 like	manifestations	 in	 perforin-deficient	mice	
(869).	
Mice	deficient	in	MUNC13-4	and	RAB27A	also	develop	a	primary	hemophagocytic	
syndrome	 like	 phenotype	 upon	 infection	 with	 the	 lymphochoriomeningitic	 virus	 in	 an	
IFNγ	dependent	manner	(870–872).	
According	 to	 the	 current	 model	 of	 primary	 hemophagocytic	 syndromes,	 the	
defective	natural	killer	cells	and	cytotoxic	T	lymphocytes	fail	to	kill	infected	cells,	causing	




Il16	 and	 IL18	 (873–876).	 As	 a	 result	 of	 continuous	 stimulation	 with	 proinflammatory	
cytokines,	mainly	IFNγ,	macrophages	will	become	hemophagocytic	(695,877).			
A	recent	case-control	study	highlighted	the	importance	of	another	cytokine:	IL18	





macrophage	 activation	 syndrome	 (878).	 During	 the	 macrophage	 activation	 syndrome,	
IL18	levels	were	significantly	increased	(878).	Furthermore,	patients	with	active	sJIA	who	
developed	 macrophage	 activation	 syndrome	 during	 the	 course	 of	 the	 disease	 had	 a	
significantly	 higher	 level	 of	 IL18	 when	 compared	 with	 those	 who	 did	 not	 develop	
macrophage	activation	syndrome	(878).	
Recently,	 the	 role	 of	 another	 cytokine,	 IL33,	was	 highlighted	 in	 a	mouse	model	
(879).	Il33	is	an	alarmin	that	activates	an	inflammatory	response	in	the	context	of	tissue	
damage.	 It	 was	 shown	 that	 perforin-deficient	 mice	 (Prf-/-)	 infected	 with	 lymphocytic	
choriomeningitis	virus	had	upregulation	of	IL33	and	its	receptor	-	ST2		(879).	ST2	signaling	
promoted	 CD8+	 and	 CD4+	 T	 cell	 activation	 and	 production	 of	 IFNγ,	 leading	 to	 lethal	
inflammation	 (879).	Blockade	of	ST2	 improved	survival	and	reduced	the	severity	of	 the	
illness	and	the	IFNγ	levels	(879).	
Another	mouse	model	uses	transgenic	mice	that	carry	a	human	IL6	transgene	and	
constitutively	produce	high	 levels	of	 IL6	 (880).	These	 transgenic	mice,	when	stimulated	
with	 TLR	 ligands,	 have	 an	 increased	 fatality	 rate,	 when	 compared	 to	 wild	 type	 mice,	
indicating	that	prolonged	exposure	to	IL6	leads	to	an	exaggerated	inflammatory	response	
to	TLR	ligands	(880).	These	data	lead	to	speculation	regarding	the	possible	pathogenesis	
of	 macrophage	 activation	 syndrome	 in	 the	 setting	 of	 sJIA.	 High	 circulating	 IL6	 levels,	
typical	 of	 this	 disease,	 may	 predispose	 to	 hyperresponsiveness	 to	 infections	 (880).	
Furthermore,	 a	 recent	 study	 showed	 that,	 in	 both	 mice	 and	 humans,	 IL6	 down-
modulated	the	cytotoxic	activity	of	natural	killer	cells,	reducing	perforin	and	granzyme	B	
levels	 in	 the	 absence	 of	 altered	 granule	 exocytosis	 (881).	 This	 is	 a	 new	 interesting	
connection	between	secondary	and	primary	hemophagocytic	syndromes.	
A	different	murine	model	of	macrophage	activation	system	induced	by	repeated	
stimulation	 of	 TLR9	 has	 contributed	 to	 a	 better	 understanding	 of	 this	 condition	 (882).	
This	 mouse	 model	 is	 important	 since	 it	 is	 not	 dependent	 on	 a	 genetically	 mediated	
cytotoxic	defect	or	a	viral	 infection,	resembling	more	closely	what	happens	 in	Humans.	
As	previously	discussed	in	Chapter	2,	TLR9	is	a	receptor	for	DNA	containing	unmethylated	
CpG	 sequence	motifs.	 There	 are	multiple	 studies	 connecting	 TLR9	 hyperactivation	 and	
macrophage	 activation	 syndrome.	 In	 sJIA	 patients	 there	 is	 a	 gene	 signature	 consistent	
with	 chronic	 TLR/IL1β	 signaling	 (883)	 and	 polymorphisms	 of	 IRF5,	 a	 molecule	 that	




syndrome	 in	 these	 patients	 (884).	 TLR9	 also	 seems	 to	 participate	 in	 SLE	 pathogenesis,	
since	 the	 number	 of	 TLR9-expressing	 B	 cells	 and	monocytes	 is	 higher	 in	 patients	with	





Mice	 submitted	 to	 TLR9	 stimulation	 develop	 features	 similar	 to	 macrophage	
activation	syndrome	(882).	The	disease	in	this	model	is	fulminant,	if	there	is	a	concordant	
IL10	 blockade	 (882).	 Interestingly,	 polymorphisms	 of	 IL10	 associated	 with	 decreased	
function	are	associated	with	sJIA,	showing	that	IL10	may	play	a	protective	role	(886,887).	
Unlike	 what	 is	 seen	 in	 mouse	 models	 for	 primary	 hemophagocytic	 syndromes,	 in	 the	
TLR9	hyperactivation	model,	depletion	experiments	revealed	that	T	cells,	Natural	Killer	T	




This	 mouse	 model	 also	 helped	 us	 understand	 the	 link	 between	 TLR9-induced	
hyperinflammation	and	decreased	B	cell	lymphopoiesis	(889).	It	is,	therefore,	possible	to	
speculate	 that	B	 cell	 autoimmunity	 in	 SLE	might	 in	part	 arise	 from	dysfunctional	B	 cell	
lymphopoiesis	due	to	TLR	stimulation	(889).			
Another	 important	 contribution	 from	 this	model	 was	 the	 dissociation	 between	
anemia	and	hemophagocytosis.	Repeatedly	CpG-treated	wild	type	mice	exhibited	anemia	
in	the	absence	of	hemophagocytosis,	while	CpG-treated	IFNγ	-/-	mice	with	IL-10	blockade	
had	 hemophagocytosis,	 without	 anemia	 (882,888).	 These	 data	 suggest	 that	 IFNγ	





studies	 suggest	 that	 hemophagocytes	 may	 have	 a	 regulatory	 function.	 The	









(891).	 When	 hemophagocytosis	 is	 blocked	 or	 hemophagocytes	 are	 incapable	 of	
producing	 IL10,	 viral	 induced	 mortality	 is	 increased	 (891).	 Hemophagocytes	 may	




model,	 where	 genetically	 susceptible	 individuals	 develop	 uncontrolled	 inflammation	
when	 exposed	 to	 certain	 triggers.	 This	 happens	 not	 only	 in	 the	 cases	 of	 familial	
hemophagocytic	 lymphohistiocytosis,	 who	 have	 inherit	 defects	 on	 cytotoxicity,	 and	
develop	a	hemophagocytic	 syndrome	after	an	 infection	 trigger,	as	well	as	 in	 secondary	




approach	 of	 hemophagocytic	 syndromes.	 New	 criteria	 were	 established	 and	 new	
treatment	strategies	were	tested.	We	are	living	in	an	exciting	new	era	for	diagnosis	and	
treatment	of	these	conditions	that	hopefully	will	improve	the	survival	of	these	patients.	
There	 are	 still,	 however,	 pressing	 questions	 to	 be	 answered.	 The	 function	 of	
hemophagocytes	is	certainly	one	of	them.		
Morphologically,	 hemophagocytes	 are	 macrophages	 that	 have	 engulfed	 other	
hematopoietic	cells.	Macrophages	reside	in	organs	throughout	the	body	where	they	are	
involved	 in	 diverse	 functions	 including	 pathogen	 sensing,	 pro-	 and	 anti-inflammatory	
immune	 responses,	 and	 wound	 healing.	 Recent	 evidence	 demonstrates	 that	
environmental	 factors,	 particularly	 the	 cytokine	 milieu,	 determine	 the	 macrophage	
activation	 status	 in	 a	 continuum	 ranging	 from	M1	 to	M2	 (892–896).	M1	macrophages,	
driven	by	IFNγ	and	LPS,	typically	acquire	pro-inflammatory	properties	and	are	associated	








help	 us	 determine	whether	 hemophagocytes	 contribute	 to	 the	 disease	 progression	 or	






The	 goal	 of	 this	 study	 was	 to	 analyze	 the	 transcriptional	 program	 of	
morphologically	identified	murine	hemophagocytes	and	to	describe	the	surface	markers	







Fulminant	 macrophage	 activation	 syndrome	 was	 induced	 with	 repeated	 TLR9-
stimulation,	via	CpG	administration,	and	IL10	receptor	blockade	as	previously	described	
(888).	 Splenic	 touch	 preps	 were	 made	 on	 nuclease	 free	 polyethylene	 naphthalate	
membrane-coated	 slides	 (Zeiss)	 and	 immediately	 Wright-Giemsa	 stained.	 A	 pediatric	
hematopathologist	 with	 expertise	 in	 hemophagocytic	 syndromes	 morphologically	
identified	hemophagocytes	from	TLR9-stimulated,	IL10	receptor-blocked	mice	or	resting	
macrophages	 from	saline-treated	mice.	 From	each	mouse,	 twenty	 cells	were	 captured,	














Affymetrix	 Expression	 Console	 software	 was	 used	 to	 perform	 quality	 control,	
excluding	two	chips	from	each	group	and	leaving	four	biological	replicates	per	group	for	
analysis.	 Microarrays	 were	 preprocessed	 using	 robust	 multiarray	 analysis	 (897)(Gene	




1.5-fold	 difference	 in	 expression	 in	 hemophagocytes	 versus	 resting	 macrophages.	
Differentially	 expressed	 genes	were	 tested	 for	 statistical	 significance	 using	 Student’s	 t-
test	 with	 multiple	 testing	 correction	 using	 false	 discovery	 rate	 (FDR).	 Functional	
enrichment	 analysis	 among	 differentially	 expressed	 genes	 was	 performed	 using	 the	
Database	 for	 Annotation,	 Visualization	 and	 Integrated	 Discovery	 (DAVID)	 v6.7	 (898).	
Gene	 ontology	 terms	 for	 biological	 pathways,	 molecular	 function	 and	 cellular	





Gene	 sets	 were	 identified	 by	 searching	 the	 Molecular	 Signatures	 Database	
(MSigDB)	 for	 the	 term	 “inflammation”	 (9).	 Gene	 sets	 with	 substantial	 overlap	 were	
excluded.	 Initially,	 17	 gene	 sets	 were	 included	 in	 this	 analysis,	 but	 the	 “Phagocytosis”	










We	 performed	 an	 unbiased,	 retrospective	 search	 of	 the	 pathology	 database	 of	
The	Children’s	Hospital	of	Philadelphia	for	bone	marrow	specimens	performed	between	
1998	 and	 2011	whose	 clinical	 report	 documented	 excessive	 hemophagocytosis.	 Thirty-
seven	 samples	 from	 34	 patients	 were	 identified	 and	 verified	 as	 having	 excess	
hemophagocytosis.	These	samples	had	been	decalcified,	fixed	in	acetic	acid-zinc-formalin	





Monocytes	 from	healthy	donors	were	cultured	 in	vitro	and	stimulated	 for	 three	
days	 with	 IFNγ	 or	 IL4.	 Their	 phenotype	 was	 analyzed	 by	 flow	 cytometry	 and	
immunohistochemistry.	We	also	evaluated	these	receptors	by	immunohistochemistry	in	




Immunohistochemistry	 was	 performed	 for	 CD64	 (1:25;	 clone	 10.1,	 Abcam),	
CD163	 (900)	 (1:200;	 clone	 10D6;	 Vector	 Laboratories)	 and	 CD206	 (1:500;	 clone	 5C11,	
Abnova/Novus	 Biologicals).	 Heat	 antigen	 retrieval	 was	 utilized	 for	 CD64,	 at	 pH	 6,	 and	
CD163,	 at	 pH	 9.	 Avidin-biotin	 complex	 signal	 amplification	 was	 used	 for	 CD206	 and	 a	
polymeric–based	 method	 for	 CD64	 and	 CD163.	 Detection	 was	 performed	 with	
horseradish	 peroxidase	 and	 3,3'	 Diaminobenzidine	 (DAB)	 chromogen,	 and	 the	 sections	
were	counterstained	with	hematoxylin.	Adequate	positive	and	negative	staining	controls	
were	performed	in	AZF	fixed	tonsils.	Patient	sections	were	evaluated	for	the	presence	or	











8.4.1	 Genes	 associated	 with	 macrophage	 activation	 and	 regulation	 of	
inflammation	 are	 among	 the	 most	 upregulated	 in	 murine	 TLR9-induced	
hemophagocytes	
Forty-five	genes	met	our	criteria	for	differential	expression	(Table	8.2).		
No	 genes	 with	 decreased	 expression	 in	 hemophagocytes	 were	 found	 to	 be	
significant.	Genes	encoding	 the	 ribosomal	 subunits	Rps20	and	Rpl35a	were	 among	 the	
most	 highly	 upregulated,	 suggesting	 regulation	 of	 global	 protein	 synthesis	 by	
hemophagocytes.	Consistent	with	this,	a	functional	enrichment	analysis	of	all	differential	
expressed	 genes	 suggested	 that	 “translation”	 was	 a	 significant	 biological	 function	 of	
hemophagocytes	 (Gene	Ontology	biological	process	annotation,	Benjamini-corrected	p-
value=0.002).	 We	 further	 found	 the	KEGG	 “Ribosome”	 pathway	 was	 significantly	
enriched	(Benjamini-corrected	p-value=1.6x10-7).		
Another	 group	 of	 upregulated	 genes	 were	 related	 to	 cellular	 energetics.	 Two	
genes	encoding	subunits	of	the	mitochondrial	respiratory	protein	complex	cytochrome	c	
oxidase	 (COX6C,	 COX6A1)	were	 upregulated,	 as	 well	 as	 the	 glycolytic	 enzyme	 GAPDH.	
Accordingly,	the	KEGG	“Oxidative	Phosphorylation”	pathway	was	significantly	enriched	in	




the	 most	 differentially	 expressed.	 β2-microglobulin	 and	 IFITM2	 are	 upregulated	 with	
anti-viral	responses,	while	SAA3	and	calcyclin	are	parts	of	the	acute	phase	response.		
	
Upregulation	 of	 the	 ferritin	 light	 chain	 (FTL)	 gene	 by	 hemophagocytes	 is	
consistent	 with	 the	 hyperferritinemia	 characteristic	 of	 hemophagocytic	 syndromes.	












Rps20	 Ribosomal	Protein	S20	 22.6	 0.0063	 0.146	
β2m	 β-2	microglobulin	 12.5	 0.0292	 0.206	
Rpl35a*	 Ribosomal	Protein	L35A	 8.5	 4.29e-4	 0.055	




Cox6c	 Cytochrome	c	oxidase,	subunit	Vic	 6.2	 0.0238	 0.174	
Ftl*	 Ferritin	light	chain	 5.8	 0.0028	 0.055	








































Proteasome	 43	 2.42	 <	0.001	 <	0.001	
Upregulated	in	M2	vs	M1	 73	 1.85	 <	0.001	 0.009	
NOD-like	Receptor	Signaling	 54	 1.74	 0.002	 0.022	
Innate	Immunity	Signaling	 97	 1.49	 0.015	 0.133	
Actin	Regulation	 195	 1.48	 0.007	 0.116	
Cytosolic	DNA	Sensing	 46	 1.48	 0.058	 0.101	
TLR	Signaling	 90	 1.41	 0.044	 0.127	
Upregulated	in	M1	vs	M2	 76	 1.32	 0.080	 0.188	
Endocytosis	 160	 1.23	 0.12	 0.283	
TLR3	Cascade	 56	 1.04	 0.391	 0.545	
TLR4	Cascade	 25	 0.93	 0.556	 0.717	
IL10	Pathway	 17	 0.84	 0.663	 0.839	
Integrin	Pathway	 37	 0.61	 0.963	 1	
TLR9	Cascade	 20	 0.54	 0.969	 0.989	
Inflammatory	Pathway	 25	 -0.95	 0.547	 1	
IL1R	Pathway	 30	 -0.67	 0.921	 0.946	
	




In	 humans,	 we	 identified,	 through	 immunohistochemistry	 and	 flow	 cytometry,	
surface	markers	 of	macrophage	 activation	 status.	We	 identified	 CD64	 as	 a	M1	marker	
and	CD206	as	a	M2	marker	by	immunohistochemistry	(Figure	8.1	and	Figure	8.2).	CD64	
was	increased	when	human	monocytes	were	exposed	to	IFNγ	and	it	was	overexpressed	





















A.	 Bowel	 from	 a	 patient	 with	 Crohn	 disease.	 B.	 Hernial	 sac	 from	 a	 patient	 infected	 with	 Schistosoma	
mansoni.	
	








Figure	 8.4	 –	 Immunohistochemistry	 for	 CD206	 in	 two	 different	 models	 of	 macrophage	
















	We	 identified	 a	 longitudinal	 cohort	 of	 human	 bone	 marrow	 samples	 that	 on	
biopsy	 or	 aspirate	 showed	 excess	 hemophagocytosis	 regardless	 of	 diagnosis.	 These	
samples	 represented	 hematologic	 malignancies	 (lymphoma-1,	 Langerhans-cell	
histiocytosis-3,	 and	 post-transplant	 lymphoproliferative	 disease-3),	 infections	 (Epstein	
Barr	 virus-6,	 bacterial-2,	 parvoviral-1,	 and	 fungal-1),	 immunodeficiencies	 (paroxysmal	
nocturnal	hemoglobinuria-1	and	MUNC13-4	deficiency-1),	 rheumatic	diseases	 (systemic	
and	 other	 forms	 of	 JIA-9	 and	 dermatomyositis-1)	 and	 idiopathic	 causes	 of	
hemophagocytosis-9).		
	
Regardless	 of	 disease	 of	 origin	 or	 treatment	 stage,	 bone	 marrow	 samples	
demonstrated	 positive	 staining	 of	 hemophagocytes	 for	 CD163	 in	 all	 tested	 samples	

















Figure	 8.6	 –	 Murine	 and	 human	 hemophagocytes.	 A.	 Laser	 capture	 microdissection	 of	 a	 resting	
murine	 splenic	 macrophage.	 B.	 Laser	 capture	 microdissection	 of	 a	 murine	 hemophagocyte.	 C.	 Positive	
controls	for	immunohistochemical	stains	in	tonsil	tissue	from	patients	without	hemophagocytic	disease.	D.	






Hemophagocytes	 are	 enigmatic	 cells	 appearing	 in	 a	 variety	 of	 inflammatory	
contexts.	 Their	 presence	 often	 influences	 important	 medical	 decisions	 regarding	
evaluation	 and	 treatment.	 However,	 our	 poor	 understanding	 of	 the	 function	 of	 these	
cells	makes	 the	 interpretation	of	 their	presence,	or	absence,	confusing.	Our	analysis	of	
the	 transcriptional	 program	 of	 morphologically	 –	 identified	 murine	 TLR9-induced	
hemophagocytes	suggests	that	they	are	alternatively	activated.	
The	“fulminant	TLR9-macrophage	activation	syndrome”	model	was	chosen	due	to	









inflammatory	 transcripts	 in	 sJIA	 (883).	 Both	 ferritin	 and	 SAA3	 production	 have	 been	
associated	with	anti-inflammatory	activity	in	macrophages	(721,903).		
We	 also	 found	 that	 cytochrome	 oxidase	 genes,	 oxidative	 phosphorylation	
pathways,	 and	 the	 canonically	 glycolytic	 enzyme	 GAPDH	 were	 upregulated	 in	
hemophagocytes.	 While	 this	 might	 suggest	 induction	 of	 both	 glycolysis	 and	 oxidative	
phosphorylation,	 GAPDH	 is	 increasingly	 associated	 with	 a	 variety	 of	 non-glycolytic	
functions	including	inhibition	of	cytokine	translation	(904).		
The	M2	versus	M1	gene	set	was	generated	by	evaluating	genes	upregulated	by	in	
vivo	 skewed	M2	macrophages	 compared	 to	M1	skewed	macrophages	 (899).	We	 found	
that	this	M2-associated	gene	set,	but	not	the	M1	gene	set,	was	strongly	associated	with	
genes	 differentially	 upregulated	 by	 hemophagocytes,	 supporting	 alternative	 activation.	
The	other	enriched	gene	sets,	nod-like	receptor	signaling	and	proteasome	activity,	may	
be	 associated	with	 scavenger	 receptor	 activity	 (905)	 or	 the	 degrading	 requirements	 of	
hemophagocytosis,	respectively.		
RNA	 from	 laser-captured	macrophages	 served	 as	 the	 basis	 for	 our	microarrays.	
Our	gene	expression	analyses	were	 limited	by	 the	necessary	pooling	of	 individual	cells’	
RNA	from	any	single	mouse,	and	by	small	input	amounts	of	RNA.	Thus,	the	potential	for	
M1	 versus	 M2	 heterogeneity	 exists	 within	 mice	 and	 even	 within	 individual	 cells.	
Additionally,	 these	 results	 have	 not	 been	 validated	 by	 quantitation	 of	 specific	 targets.	
The	 limited	 starting	 material	 made	 protein	 quantitation	 impossible.	 Additionally,	 the	
process	 of	 amplifying	 small	 input	 RNA	has	 limited	our	 ability	 to	 quantitate	 at	 the	RNA	
level:	the	RNA	fragments	that	result	from	this	process,	while	of	ideal	size	for	microarray,	
were	of	insufficient	length	of	conventional	quantitative	PCR.	However,	our	analyses	were	
able	 to	 detect	 changes	 associated	 with	 macrophage	 activation.	 Specifically,	 our	
transcriptomic	 data	 suggest	 that	 the	 dominant	 program	 of	 murine	 hemophagocytes	
induced	 by	 TLR9	 stimulation	 and	 IL10R	 blockade	 is	 skewed	 towards	 alternative	
activation.	 Accordingly,	 recent	 data	 support	 the	 notion	 that	 TLR9-driven	





Immunohistochemistry	 for	 selected	 markers	 in	 human	 bone	 marrow	 samples	
supported	CD163	expression	by	hemophagocytes	 in	a	cohort	that,	to	our	knowledge,	 is	







We	 have	 shown	 transcriptional	 evidence	 for	 alternative	 activation	 of	 murine	
hemophagocytes	 from	 an	 infection-free	 model,	 as	 well	 as	 immunohistochemical	
evidence	that	human	hemophagocytes	from	a	diversity	of	sources	express	CD163.	These	
data	 support	 the	 notion	 of	 hemophagocytes	 as	 alternatively-activated	 macrophages	
occurring	as	a	common	response	to	systemic	inflammation.		
In	 hemophagocytic	 syndromes	 there	 is	 likely	 heterogeneity	 in	 macrophage	
function,	and	therapeutically	depleting	all	macrophages	could	actually	be	detrimental.		
There	has	been,	therefore,	a	complete	change	in	the	way	we	interpret	the	role	of	
hemophagocytes	 in	 these	 syndromes.	Not	only	 they	are	not	necessary	 for	 the	anemia,	
they	 may	 even	 have	 a	 regulatory,	 anti-inflammatory,	 function.	 Perhaps	 a	 new	
nomenclature	 should	 be	 used	 to	 define	 these	 syndromes,	 considering	 that	
hemophagocytosis	 is	 no	 longer	 the	 most	 important	 step	 on	 its	 pathogenesis.	 Further	
studies	 are	 warranted	 to	 better	 understand	 the	 induction	 of	 hemophagocytosis,	 the	




Tratamento	 da	 Síndrome	 Hemofagocítica,	 which	 was	 published	 in	 the	 journal	 Acta	
Pediátrica	 Portuguesa.	 In	 this	 paper	 it	 is	 reviewed	 the	 diagnosis	 and	 treatment	 of	 the	
different	types	of	hemophagocytic	syndromes.	
The	Appendix	 A.5	 includes	 the	 paper	 Alternative	 Activation	 of	 Laser-Captured	
Murine	 Hemophagocytes,	 which	 was	 published	 in	 the	 journal	 Arthritis	 and	




















implicated	 in	 renal	 damage,	 which	 is	 the	 major	 cause	 of	 morbidity	 in	 SLE,	 and	 in	
atherosclerosis,	which	 is	the	major	cause	of	mortality	 in	SLE	(353,906–908).	Monocytes	
are	therefore	central	to	the	disease	process	but	are	also	of	interest	because	they	respond	
to	 environmental	 stimuli,	 alter	 their	 function	 accordingly,	 and	 reflect	 that	 information	
















Investigators	 at	 Johns	 Hopkins	 University	 School	 of	 Medicine	 obtained	 written	
informed	consent	and	HIPAA	Authorization	of	study	subjects	for	all	SLE	samples.	The	IRB	
at	 Johns	 Hopkins	 reviewed	 and	 approved	 the	 study	 of	 SLE	 patients.	 The	 use	 of	 the	
anomyzed	Red	Cross	samples	was	approved	by	the	Red	Cross	IRB.	Control	samples	were	
also	obtained	from	The	Center	For	Aids	Research,	which	supplies	blood	samples	on	a	fee	
for	 service	 basis.	 They	 have	 obtained	 consent	 for	 the	 use	 of	 the	 samples	 and	 their	
protocols	were	approved	by	the	University	of	Pennsylvania	Institutional	Review	Board.	
Primary	 human	monocytes	were	 purified	 using	 elutriation	 and	 adherence	 from	





and	 patients	 were	 female,	 with	 an	 average	 of	 approximately	 40	 years	 of	 age.	 All	 SLE	
patients'	 disease	 activity	was	mild	 to	moderate	 and	no	one	was	on	high-level	 immune	
suppression	 (Table	 9.1).	 All	 subjects	 were	 provided	 informed	 consent,	 except	 the	 Red	
Cross	serum	samples	which	were	provided	as	anomyzed	discarded	samples.	
	
Table	 9.1	 –	 Clinical	 characteristics	 of	 the	 patients	 studied.	ACL-	Anticardiolipin	antibodies;	ANA	–	




Total	 RNA	 was	 isolated	 from	 2-3	 million	 primary	 monocytes	 using	 the	 Qiagen	
RNeasy	kit	and	DNA	was	removed	by	on-column	DNase	digestion	(Qiagen,	Valencia,	CA).	
This	method	recovers	predominantly	RNA	species	>200bp.	One	microgram	of	total	RNA	
was	 used	 to	 prepare	 the	 library	 with	 the	 SOLiDTM	 whole	 transcriptome	 analysis	 kit	
(Applied	Biosystems).	The	procedure	followed	the	instructions	of	the	manufacturer.	For	
miRNA	 validation,	we	 used	miRNeasy	 kit	 (Qiagen).	 The	OD	 260/280	 ratio	 ranged	 from	
1.80–1.98.	The	RNA	quality	and	counts	were	not	different	between	patients	and	controls.	
	







2	 0	 Skin,	arthritis	 Hydroxychloroquine	
NSAID	
ANA,	Anti-dsDNA	
3	 0	 Arthritis	 Hydroxychloroquine	
NSAID	
ANA,	Anti-dsDNA	































qRT-PCR	 was	 used	 to	 define	 quantitative	 differences	 in	 RNA	 abundance.	 The	
Clontech	 Advantage	 RT	 for	 PCR	 kit	 (Clontech)	 was	 used	 to	 generate	 cDNA.	 Gene	
expression	 was	 detected	 by	 RT-PCR	 using	 the	 TaqMan	 9600.	 Transcript	 levels	 were	
normalized	 to	 the	 18S	 or	 βactin	 signal.	 Mature	 miRNAs	 were	 detected	 with	 Taqman	
miRNA	 assays.	 Relative	 quantification	 was	 performed	 using	 spiked	 Caenorhabditis	
elegans	miRNA-238	as	an	exogenous	control	(Qiagen	Syn-cel-miR-238-3p	miScript	miRNA	
Mimic).	 Commercially	 available	 primers	 were	 purchased	 from	 Applied	 Biosystems	 for:	
cel-miR-238	(248	primer	for	isoform	cel-miR-238-3p	-	MIMAT0000293);	hsa-miR-212	(515	
primer	for	 isoform	hsa-miR-212-3p	-	MIMAT0000269	and		461768_mat	for	 isoform	hsa-
miR-212-5p	 -	 MIMAT0022695);	 and	 CCR2	 (Hs00174150	 primer	 for	 CCR2	 isoform	
NM_001123041.2	 and	 Hs00704702_s1*	 for	CCR2	 isoform	NM_001123396.1)	 and	 from	






Monomac	6	 cells	 and	primary	monocytes	 from	healthy	donors	were	 stimulated	
with	 100U/ml	 IFNα2	 (PBL	 Biomedical	 Laboratories),	 10ng/ml	 IFNγ	 (R&D	 Systems),	
10ng/ml	TNF	(Sigma)	for	16	hours,	or	1mg/ml	of	LPS	for	two	hours.	SB203580	was	used	














We	used	 the	Tophat-Cufflinks	pipeline	and	 further	 refinements	 to	assemble	 the	
monocyte	transcriptome	and	detect	novel	loci	and	isoforms,	followed	by	mapping	short	
reads	 to	 a	 collection	 of	 reference	 RNA	 sequences,	 including	 isoforms	 of	 coding	 genes,	
small	 RNAs,	 long	 non-coding	 RNAs	 (lncRNAs),	 and	 repetitive	 elements.	 The	 number	 of	
reads	mapped	to	each	transcript	was	used	for	evaluating	differential	expression	between	
control	 and	 SLE	 samples.	 Data	 has	 been	 submitted	 to	 GEO	 as	 GSE53419.	 Loess	
adjustment	was	 applied	by	 assuming	 an	equal	 amount	of	 total	 RNA	between	 samples.	





steps:	 calculate	 the	 correlation	 coefficients	 between	 genes	 in	 control	 and	 SLE	 groups	
separately;	convert	correlation	coefficients	to	z	scores	using	Fisher's	transformation;	take	
the	 average	 of	 z	 scores,	 and	 convert	 the	 average	 z	 score	 back	 to	 a	 single	 combined	







Monocyte	 transcriptome	 of	 nine	 female	 SLE	 patients	 and	 eight	 female	 healthy	
controls	were	studied	using	RNA-seq.	Our	first	goal	 in	this	study	was	to	reconstruct	the	
human	monocyte	 transcriptome	using	 the	entire	dataset.	The	Tophat-Cufflinks	pipeline	
reported	 four	 major	 classes	 of	 transcripts	 (Figure	 9.1),	 including	 10,313	 isoforms	 of	
known	 genes	 and	 10,200	 transcribed	 loci	 not	 included	 in	 the	 RefSeq	 annotation.	 The	
novel	 isoforms	had	a	more	 complex	 structure.	On	 the	other	hand,	 the	novel	 loci	were	
shorter	on	average	than	known	genes	and	over	97%	of	them	included	only	one	exon.	To	
further	define	the	monocyte	transcriptome,	we	counted	the	total	number	of	reads	solely	






Figure	 9.1	 –	 Overall	 transcriptome	 characteristics.	A.	 The	 Tophat-Cufflinks	 pipeline	 identified	 four	
major	 classes	 of	 transcripts	 from	 17	 RNA-seq	 libraries.	 RefSeq	 genes	 constituted	 the	 majority	 of	 the	
transcripts.	B.	Novel	 isoforms	and	 loci	were	different	 from	known	 transcripts	 in	 terms	of	average	 length	
and	numbers	of	exons	on	average.	C.	Coding	RNA	was	the	most	abundant	RNA	species	(except	ribosomal	





three	 classes	 evenly	 shared	 the	 remaining	 reads	 (Figure	 9.1C).	 Small	 RNAs	 had	 the	
highest	molar	concentration	after	read	counts	were	adjusted	by	the	total	 length	of	 the	





The	 classifications	 of	 transcripts	were	 refined.	We	 identified	 4,000	 high-novelty	
isoforms	that	were	not	present	in	seven	additional	annotated	databases	and	included	at	
least	 one	 unknown	 exon-exon	 junction,	 as	well	 as	 2,271	 high-novelty	 loci	 that	 had	 no	
overlap	 with	 either	 exons	 or	 introns	 of	 any	 previously	 reported	 transcripts.	 We	 then	
defined	1,327	high-confidence	 isoforms,	having	at	 least	10	uniquely	mapped	 reads	not	
mapped	 to	 any	 other	 genes	 or	 isoforms	of	 the	 same	 gene	 in	 at	 least	 six	 samples,	 and	
3,725	high-confidence	novel	loci	having	at	least	10	uniquely	mapped	reads	in	at	least	six	
samples	and	more	than	10X	overall	sequencing	depth.	After	this	refinement,	448	novel	
isoforms	 and	 778	 novel	 loci	 that	 had	 both	 high-novelty	 and	 high-confidence	 were	






at	 least	 one	 unknown	 exon-exon	 junction	 or	mapped	 by	 ≥10	 unique	 reads	 in	 at	 least	 six	 libraries	were	
considering	 as	 having	 high-novelty	 or	 high-confidence,	 respectively.	 B.	 Novel	 loci	 not	 overlapping	 any	
known	 transcribed	 region	 or	 mapped	 by	 ≥10	 unique	 reads	 in	 at	 least	 six	 libraries	 were	 considering	 as	



















transcriptome	 in	 SLE	 as	 a	 strategy	 to	 improve	 our	 understanding	 of	 the	 pathogenic	
mechanisms.	 A	 large	 number	 of	 known	 protein	 coding	 genes	 expressed	 in	 normal	
monocytes	 were	 found	 to	 be	 silenced	 in	 SLE	 (Figure	 9.3A).	 These	 genes	 were	 highly	
enriched	with	the	ones	related	to	embryo	development	(p=6.0E-60),	suggesting	that	SLE	
monocytes	 are	 more	 differentiated.	 Antisense	 transcripts	 were	 also	 more	 likely	 to	 be	




Figure	 9.3	 –	 Comparison	of	 SLE	 and	 control	 transcriptomes.	 The	Venn	diagrams	demonstrate	the	





by	Cufflinks,	 lncRNAs,	 small	RNAs,	 repetitive	elements,	and	 the	antisense	 transcripts	of	
coding	 genes.	 These	 genes/transcripts	 were	 filtered	 by	 a	 statistical	 analysis	 so	 all	 the	
remaining	 33,760	 were	 mapped	 by	 at	 least	 three	 sequencing	 reads	 in	 at	 least	 three	




















pri-miRNAs	 was	 dramatically	 increased	 by	 38%	 (p=0.01).	 The	 three	 classes	 of	 small	
nucleolar	 RNAs	 were	 all	 downregulated	 in	 SLE	 patients	 (Figure	 9.4B).	 The	 overall	 up-
regulation	 of	 pri-miRNAs	 and	 down-regulation	 of	 coding	 genes	 jointly	 suggested	 a	
modified	miRNA	regulatory	system	in	SLE.		
	
Subclasses	of	 repetitive	 elements	 also	had	different	 directions	of	 change	 in	 SLE	
(Figure	 9.4C).	 All	 endogenous	 retroviral	 (ERV)	 subclasses	 were	 consistently	




Class	 Total	Tested	 Higher	in	SLE	 Lower	in	SLE	
Known	coding	gene	 14,501	 324	 329	
Novel	loci	 8,732	 659	 56	
lncRNA	 3,482	 29	 60	
Small	RNA	 379	 2	 1	
Repetitive	element	 847	 11	 61	
















Most	 noticeably,	 differentially	 expressed	 genes	 upregulated	 in	 SLE	were	 enriched	with	
genes	 related	 to	 immune	 response	 and	 cytokine	 activity	 while	 the	 downregulated	






		 Gene	Set	 Count	 Enrichment	 P	Value	 Representative	Genes	
Higher	in	SLE	
Cytokine	activity		


















protein	(PIRSF005680)	 3	 31.25	 3.5E-03	 IFIT1,	IFIT2,	IFIT3	
Lower	in	SLE	
Granules		






























In	 addition,	 the	 combined	 gene	 set	 of	 upregulated	 and	 downregulated	
differentially	expressed	genes	was	enriched	with	potential	targets	of	transcription	factors	




(p=1.4E-3),	 and	 IRF2	 (p=1.3E-3).	 We	 selected	 six	 differentially	 expressed	 genes	 to	 be	





Figure 9.5 - Validation of differential gene expression by RT-PCR. The	 differential	
expression	 of	 six	 coding	 genes	 in	 SLE	 was	 validated	 by	 qRT-PCR.	 The	 samples	 consisted	 of	 11	 controls	






Polyadenylation,	along	with	mRNA	cleavage	and	 termination,	are	 regulated	 in	a	
gene-specific	 manner	 and	 these	 steps	 appear	 to	 be	 particularly	 important	 for	 the	
regulation	 of	 genes	 involved	 in	 inflammation	 (912–914).	 Tissue-specific	 and	
developmentally-regulated	 polyadenylation	 have	 been	 described	 with	 differentiation	
favoring	 longer	3ʹ	UTRs	 (915–917).	We	examined	 the	 structure	of	 the	 coding	 genes	by	
defining	the	3ʹ	untranslated	region	for	each	gene.	Sixty-seven	genes	had	longer	3ʹUTRs	in	
patients	compared	to	controls	and	54	genes	had	shorter	3ʹUTRs	in	patients	(defined	by	a	



















Figure	 9.6	 –	 3ʹ	 UTR	 length	 networks.	 A.	 The	 genes	 with	 longer	 3ʹUTRs	 in	 SLE	 patients	 were	
networked	 using	 Ingenuity.	 The	 two	most	 dominant	 networks	 are	 shown.	 NFκB,	 AKT,	 and	 UBC	 are	 the	
dominant	nodes.	B.	 The	genes	with	 shorter	3ʹUTRs	 in	 SLE	patients	were	networked	using	 Ingenuity.	 The	
two	most	dominant	networks	are	 shown.	MAP	kinases	and	UBC	were	 the	dominant	nodes.	Data	output	
from	Ingenuity	is	shown	in	the	Tables	below.	
Long UTR Pathway Analysis 
Category P value # molecules 
Cancer 1.5 X 10-4 29 
Antimicrobial Response 3.9 X 10-5 3 
Cell Morphology 2.2 X 10-5 13 
Cellular Assembly 2.3 X 10-4 9 
Short UTR Pathway Analysis 
Category P value # molecules 
Cancer 3.2 X10-3 9 
Cell Cycle 6.4 X 10-4 9 









controls	 together,	 the	 total	 number	 of	 reads	mapped	 to	 the	 antisense	 transcripts	was	
about	1/30	of	 the	 total	number	of	 reads	mapped	 to	 the	 sense	 transcripts.	However,	 a	






















had	 a	positive	 correlation	on	 average,	 regardless	of	whether	 the	 lncRNAs	were	on	 the	
same	 strand	 as	 the	 coding	 genes	 or	 not.	 The	 correlation	 increased	 as	 the	 distance	
between	 lncRNAs	 and	 coding	 genes	 became	 closer.	 On	 the	 other	 hand,	 when	 the	
lncRNAs	were	 located	downstream	of	coding	genes,	 there	was	no	association	between	
the	two	classes	of	transcripts	if	they	were	on	the	opposite	strands,	and	there	was	a	much	
stronger	 association	 if	 they	 were	 on	 the	 same	 strand.	 The	 latter	 might	 suggest	 the	
misclassification	of	extended	3’	UTR	transcription	of	coding	genes	as	lncRNAs.		
Although	 lncRNAs	 were	 less	 likely	 to	 change	 in	 SLE	 compared	 to	 other	 RNA	
classes,	the	locations	of	some	significantly	changed	lncRNAs	suggested	their	involvement	
in	SLE.	For	example,	both	HIVEP2	itself	and	a	lncRNA	about	800	to	1,500	bases	upstream	
of	 its	 transcription	 start	 site	were	 significantly	 upregulated	 in	 SLE,	 although	 their	 RNA	
abundance	was	 over	 50	 times	 different.	 There	were	 also	 two	 significantly	 upregulated	
lncRNAs	located	within	50kb	of	each	other	on	chromosome	6	and	surrounded	by	a	group	










Figure	 9.8	 –	MiRNA	–	 target	 correlation.	Ten	pri-miRNAs	and	their	predicted	targets	had	a	negative	
correlation	in	monocytes.	The	correlation	was	calculated	using	normalized	read	counts	of	pri-miRNAs	and	
target	coding	genes.	The	correlation	coefficients	of	each	miRNA-target	pair	were	obtained	from	the	control	


















Two	pri-miRNAs	were	 significantly	 increased	 in	 SLE	 samples	with	 concomitantly	
diminished	 target	mRNA	 levels.	MiR-193a	 regulates	k-ras	and	cell	 survival	and	miR-212	
regulates	 apoptosis,	 two	processes	 known	 to	 be	 aberrant	 in	 SLE	monocytes	 (920,921).	
We	 validated	mature	miR-212-3p	 differential	 expression	 in	 SLE	 using	 qRT-PCR	 on	 new	
samples	 from	 six	 controls	 and	 13	 SLE	 patients	 (Figure	 9.9).	 An	 exogenous	 control	was	
used	 because	 we	 could	 not	 identify	 an	 miRNA	 in	 monocytes	 that	 was	 unaffected	 by	







The	 predicted	 targets	 of	 miR-193a-3p,	 miR-193a-5p	 and	 miR-212	 were	

































































There	 were	 substantially	 more	 repetitive	 elements	 downregulated	 in	 SLE	 than	





with	 the	 downregulated	 repetitive	 elements	 were	 potential	 targets	 of	 transcription	






compared	 between	 the	 control	 and	 SLE	 samples	 to	 evaluate	 differential	 isoform	
transcription.	 Therefore,	 this	 analysis	 only	 considered	 the	 change	 of	 relative	 isoform	
abundance	 while	 ignoring	 the	 gene-level	 differential	 expression.	 This	 comparison	




SNAPC3	 encodes	 a	 subunit	 of	 a	 protein	 complex	 that	 activates	 snRNA.	 It	 was	
previously	 known	 as	 having	 a	 single	 isoform	while	 our	 Cufflinks	 assembly	 identified	 a	
novel	 splicing	 site	within	 its	 3'UTR	 (Figure	 9.11).	 The	 relative	 abundance	 of	 these	 two	
alternative	transcripts	was	changed	by	12%	(p=0.003).	
	
We	 observed	 that,	 on	 average,	 isoforms	 where	 the	 relative	 abundance	 was	
increased	 in	 SLE	 had	 significantly	 more	 exons	 than	 those	 with	 decreased	 relative	














Figure	9.12	–	 Isoforms	with	 increased	expression	 in	SLE	are	more	complex.	The	isoforms	where	
the	relative	abundance	was	increased	in	SLE	had	a	higher	number	of	exons	than	those	where	the	relative	
abundance	was	 decreased	 (p = 0.007).	 On	 average,	 the	 SLE-favored	 isoforms	 had	 about	 0.5	 exons	more	
than	the	control-favored	isoforms.	



































As	 shown	 in	 Table	 9.2,	 92%	 differentially	 expressed	 novel	 loci	 had	 higher	
transcription	in	SLE.	Many	of	the	novel	loci	formed	clusters	located	close	to	each	other.	
For	example,	three	of	the	four	novel	loci	located	within	a	5kb	region	on	chromosome	18	
were	 among	 the	 most	 significantly	 upregulated	 transcripts.	 Another	 example	 was	 a	




were	 significantly	 upregulated	 in	 SLE	 and	 none	 of	 which	 were	 downregulated.	 We	















772,	 and	 775)	 were	 amplified	 using	 11	 controls	 (8	 new	 controls	 and	 3	 controls	 used	 for	 the	 RNA-seq	










Figure	 9.15	 –	 LPS	 stimulation	 of	 monocytes.	A.	MonoMac	 6	 cells	were	 stimulated	 for	 16	 hours	 as	






9/25	 (fold	change	>1.5),	 IFNα	 led	 to	upregulation	of	7/25	 (fold	change	>1.5),	 IFNγ	 led	 to	upregulation	of	
9/25	(fold	change	>1.5),	and	LPS	led	to	upregulation	of	23/25	(fold	change>1.5).	Pre-treatment	of	cells	with	
the	p38	inhibitor,	SB203580	led	to	markedly	diminished	induction	of	expression	by	LPS.	Three	experiments	
with	 duplicates	 or	 triplicates	were	 averaged.	 The	 error	 bars	 indicate	 standard	 deviation.	C.	 The	 average	
fold	 change	 for	 the	 aggregated	 novel	 upregulated	 loci	 in	 SLE	 were	 calculated	 for	 MonoMac	 6	 cells.	D.	






The	 fact	 that	 these	 loci	 were	 preferentially	 or	 exclusively	 transcribed	 in	 SLE	
monocytes	 indicates	 they	 are	 very	 cell-specific	 and	 why	 they	 were	 not	 previously	
detected	 in	other	 cell	 types	and	normal	monocytes.	 To	examine	potential	mechanisms	
driving	expression,	we	 initially	 treated	Monomac	6	 cells	with	TNF,	 IFNα2,	 IFNγ,	or	 LPS.	
Time	course	experiments	identified	the	optimal	stimulation	time.	Only	LPS	replicated	the	
pattern	of	expression	of	novel	loci	seen	in	the	SLE	samples	(Figure	9.15).	These	findings	





Figure	 9.16	 –	 Concordance	of	 LPS,	 IFN	 and	 SLE	 gene	expression.	 Five	LPS	data	sets	were	created	
from	four	GEO	monocyte	data	series.	The	coding	genes	shown	to	be	upregulated	in	SLE	were	analyzed	for	
upregulation	 after	 LPS	 stimulation	 and	 IFNα	 treatment.	 A.	 All	 LPS	 data	 sets	 demonstrated	 that	 LPS	
treatment	 also	 increased	 expression	 of	 the	 genes	 shown	 to	 be	 upregulated	 in	 SLE.	 N = the	 number	 of	
unique	 genes	 included	 in	 the	 analysis.	B.	 The	 degree	 of	 overlap	 between	 SLE-induced	 genes	 and	 IFNα-





To	 understand	 potential	 pathways	 regulating	 the	 LPS	 effect,	 we	 utilized	 p38	
(SB203580),	 ERK	 (U0126)	 and	 JNK	 (SP600125)	 inhibitors.	 The	 major	 effect	 of	 LPS	









Figure	 9.17	 –	 The	 effect	 of	 different	 MAP	 kinase	 inhibitors	 on	 LPS-induced	 novel	 loci	
expression.	MonoMac6	cells	(above)	and	primary	monocytes	(below)	were	treated	with	p38	(SB203580),	
ERK	 (U0126)	 and	 JNK	 (SP600125)	 inhibitors	 for	 30	 minutes	 and	 then	 stimulated	 with	 LPS.	 The	 y-axis	
represents	the	ratio	of	the	LPS	+	inhibitor-treated	cells	over	the	LPS	alone	treated	cells,	with	the	horizontal	












healthy.	 SLE	 patients	 had	 significantly	 higher	 endotoxin	 levels	 compared	 to	 controls	
(Figure	 9.18).	 When	 we	 examined	 clinical	 markers	 for	 associations	 with	 circulating	
endotoxin	 levels,	 we	 found	 no	 association	 with	 age,	 weight,	 ESR,	 C-reactive	 protein,	





























































































Figure	9.18	–	 SLE	patient	 circulating	endotoxin	 levels.	Circulating	endotoxin	was	quantitated	using	








With	 the	 advent	 of	 next-generation	 sequencing	 technologies	 a	 more	
comprehensive	and	accurate	 transcriptional	 analysis	has	become	 feasible.	We	 report	 a	




One	of	our	 goals	was	 to	 identify	 the	 transcript	 abundance	of	non-coding	RNAs,	
which	 have	 been	 demonstrated	 in	 subjects	 with	 Aicardi	 Goutières	 syndrome,	 and	 in	
murine	models,	to	drive	a	type	I	IFN	signature	(931–933).	In	this	study,	we	found	instead	






One	 class	 of	 non-coding	 RNA	 for	 which	 expression	 was	 clearly	 induced	 in	 SLE	
patients	 was	 that	 of	 the	 pri-miRNAs.	 These	 small	 non-coding	 RNAs	 are	 processed	 to	
repress	translation	by	augmenting	turnover	of	multiple	mRNAs.	In	our	study,	two	specific	
pri-miRNAs	 were	 significantly	 upregulated	 in	 SLE	 monocytes	 compared	 to	 healthy	
controls.	In	addition	we	were	able	to	demonstrate	that	the	targets	of	these	two	miRNAs	








The	 finding	 of	 SLE-specific	 isoforms	 and	 polyadenylation	 was	 particularly	
intriguing.	The	finding	of	disease-specific	 isoforms	 is	not	unique	to	this	study	but	 it	has	
not	 been	 reported	 this	 extensively	 outside	 of	 tumor-specific	 transcripts.	 Some	 studies	
have	 found	 functional	 effects	 of	 autoantibodies	 directed	 at	 nuclear	 constituents	 and	
altered	expression	of	splicing	factors	and	this	study	raises	the	question	of	the	mechanism	
driving	 altered	 processing	 (940–942).	 Altered	 expression	 of	 splicing	 factors	 could	 also	
contribute	to	the	altered	pattern	observed	here	(941,942).	
This	 study	 raises	 many	 questions.	We	 examined	 a	 cohort	 of	 patients	 with	 low	
disease	 activity	 to	 minimize	 the	 effect	 of	 medications.	 Whether	 patients	 with	 more	
severe	 disease	 could	 have	 a	 more	 disturbed	 transcriptome	 is	 not	 known.	 This	 is	 a	









If	 similar	 disruptions	 are	 found	 in	 additional	 cell	 types,	 it	 would	 suggest	 a	
systematically	altered	transcriptome.	Additional	 information	 is	 likely	to	be	forthcoming,	
allowing	 improved	 understanding	 of	 the	 regulation	 of	 these	 processes.	 Monocytes	
represent	a	cell	type	that	 is	uniquely	plastic	and	it	may	be	that	effects	are	magnified	in	
this	cell	type.			
We	 previously	 identified	 IRF1,	 IRF2,	 and	 RFX1	 as	 potential	 regulators	 of	 genes	
with	 altered	 histone	 H4	 acetylation	 (549–551).	 These	 transcription	 factors,	 now	
identified	as	potential	regulators	of	the	SLE	transcriptome,	could	integrate	inflammatory	
and	 IFN	 signals.	 The	 MAP	 kinase	 and	 NFkB	 pathways	 were	 identified	 as	 potential	
regulating	 pathways	 in	 the	 polyadenylation	 pattern	 specific	 to	 the	 SLE	 samples.	 These	
pathways	have	long	been	implicated	in	SLE	(943–948).			
To	further	implicate	the	MAP	kinase	pathway,	we	found	that	expression	of	many	
novel	 loci	 was	 inducible	with	 LPS	 and	 that	 it	 could	 be	 blocked	with	 the	 P38	 inhibitor,	
SB203580.	The	roles	of	the	novel	loci	are	not	yet	known	and	we	acknowledge	these	fall	





disease	 activity.	While	 the	 low	disease	 activity	 enabled	us	 to	 examine	patient	 samples	
without	the	perturbation	of	high-level	immune	suppression,	it	may	also	have	limited	our	
findings.	The	platform	used	and	the	sample	cell	count	may	also	have	limited	our	findings.	
The	 libraries	were	50	bp	 single	 reads	and	 total	RNA	was	used	with	post-run	 ribosomal	
RNA	exclusion.	Finally,	technical	aspects	such	as	RNA	quality	may	have	limited	our	ability	
to	 identify	 disease-specific	 variation	 in	 signal.	 Nevertheless,	 in	 spite	 of	 these	 potential	












minimized	 the	 effects	 of	 different	 cell	 populations	 and	 improved	 the	 specificity	 of	 our	
discoveries.	 The	 most	 significant	 finding	 of	 this	 study	 was	 identification	 of	 disease-
specific	novel	locus	expression,	regulated	by	endotoxin.		Circulating	endotoxin	has	been	




features	 contribute	 to	 the	 pathologic	 processes	 in	 this	 still	 enigmatic	 disease,	 the	
importance	 of	 this	 studies	 lies	 in	 the	 identification	 of	 multiple	 features	 of	 altered	
transcription	and	processing	in	SLE,	a	heretofore	unappreciated	facet	of	the	disease.		
This	is	the	first	RNA-seq	study	of	SLE	and	we	found	not	only	a	transcriptome	that	
exhibits	 quantitative	 alterations	 as	 defined	 by	 the	 level	 of	 gene	 expression	 but	 also	
qualitative	 differences	 with	 widely	 altered	 splicing	 preference	 and	 non-coding	 RNA	
transcription.	 Some	novel	 transcripts	expressed	at	higher	abundance	 in	 SLE	monocytes	
were	 inducible	by	 LPS,	 known	 to	activate	 type	 I	 IFNs.	 LPS	and	microbial	products	have	




Please	 refer	 to	 Appendix	 B.2	 for	 the	 paper	 The	 SLE	 Transcriptome	 Exhibits	






















As	 a	 Pediatrician	 I	 feel	 extremely	 challenging	 to	 take	 care	 of	 patients	 with	
juvenile-onset	 SLE.	 The	 great	 heterogeneity	 of	 phenotypes	 and	 the	 lack	 of	 robust	
biomarkers	 to	predict	 the	 course	of	 the	disease	are	 important	obstacles.	 Furthermore,	
the	current	treatment	strategies,	including	the	long-term	use	of	steroids,	are	associated	
with	 important	 side	 effects	 that	 have	 a	 profound	 effect	 in	 the	 quality	 of	 life	 of	 our	




unemployment	 in	 this	 group	of	patients	urge	us	 to	do	better	 and	 to	 find	new	ways	 to	
improve	the	care	of	SLE	patients.	The	main	quest	is	to	better	understand	the	mechanisms	
of	perpetuation	of	the	disease,	in	order	to	transform	it	from	chronic	to	curable.		
I	 used	 the	 modern	 tools	 of	 molecular	 biology	 to	 try	 to	 unveil	 new	 clinically	
relevant	pathways	in	SLE.	In	collaboration	with	my	colleagues	in	the	lab,	I	participated	in	
the	study	of	the	transcriptome	of	monocytes	and	showed	that	in	SLE	there	is	a	profound	
dysregulation	 of	 gene	 expression,	 not	 only	 quantitatively,	 but	 also	 qualitatively.	 Once	
again,	 it	 was	 revealed	 the	 interesting	 connection	 between	 the	 microbiome	 and	
autoimmunity,	since	the	novel	transcripts	identified	in	SLE	were	replicated	when	control	
monocytes	 were	 exposed	 to	 LPS.	 Furthermore,	 we	 showed	 that	 SLE	 patients	 have	
increased	 levels	of	 circulating	endotoxin.	 This	observation	propels	 the	 study	of	 the	gut	
integrity	 in	 this	 group	 of	 patients	 and	 its	 impact	 on	 disease	 activity	 and	 chronicity.	
Furthermore,	it	opens	the	door	for	new	studies	on	the	effect	of	diet	and	of	manipulating	
the	microbiome	to	control	the	disease.	
During	my	Ph.D.,	 I	mainly	 focused	on	 two	of	 the	most	 severe	manifestations	of	
SLE:	 lupus	nephritis	and	macrophage	activation	syndrome.	Considering	the	 latter,	 I	was	
intrigued	by	hemophagocytes	and	by	their	function.	Surprisingly,	we	demonstrated	that	
hemophagocytes	 from	a	mouse	model	of	 secondary	hemophagocytic	 syndrome	have	a	
transcriptome	similar	to	M2	macrophages.	Moreover,	in	a	very	diverse	cohort	of	patients	
with	hemophagocytic	 syndromes,	we	showed	that	hemophagocytes	universally	express	
CD	 163,	 an	 M2	 marker.	 These	 data	 work	 against	 the	 traditional	 notion	 that	





macrophage	 activation	 syndromes.	 Hemophagocytes	 are	 now	 presented	 as	 possible	
regulatory	cells,	which	opens	a	new	era	for	the	study	of	hemophagocytic	syndromes.	
Regarding	 lupus	 nephritis,	 the	 miRNA	 kidney	 signature	 of	 this	 disease	 was	
characterized	using	a	high-throughput	methodology.	It	was	found	that	miR-26a	and	miR-




levels	 were	 controlled	 by	 HER2.	We	 hypothesized	 that	 HER2	 also	 had	 a	 role	 in	 lupus	
nephritis	and	we	found	a	striking	overexpression	of	HER2	in	the	tubular	and	glomerular	




disease	 activity	 and	 with	 the	 levels	 of	 other	 well-known	 lupus	 nephritis	 biomarkers,	
namely	MCP1	and	VCAM1.		
The	results	from	this	research	led	to	original	conclusions,	which	can	be	translated	
into	 the	 clinic	 in	 the	 near	 future.	 HER2	 was	 identified	 as	 a	 new	 biomarker	 for	 lupus	
nephritis	 and	 it	 can	 easily	 be	 used	 in	 the	 clinical	 setting,	 since	 there	 are	 commercially	
available	ELISA	kits	 for	HER2	quantification.	 In	addition,	PET	scans	 targeting	HER2	have	
been	 developed	 to	 identify	 metastases	 of	 HER2+	 breast	 cancer.	 This	 methodology	 is,	
therefore,	 available	 to	evaluate	 the	 cell	 proliferation	 status	of	 lupus	nephritis	patients.	
Most	 importantly,	 this	 work	 also	 showed	 that	 anti-HER2	 drugs,	 already	 approved	 for	
different	types	of	cancer,	could	also	have	a	role	in	lupus	nephritis	treatment,	opening	the	
door	to	a	new	treatment	strategy	for	this	disease.	
Finally,	 on	 a	 personal	 note,	 I	 must	 emphasize	 that	 being	 devoted	 to	 research	
during	three	years	of	my	life	was	an	extraordinary	and	truly	rewarding	experience.	I	am	
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2. Major	 Infections	 in	 a	 cohort	 of	 120	 patients	 with	 Juvenile-onset	 Systemic	 Lupus	
Erythematosus		






















































7.The	 SLE	 Transcriptome	 Exhibits	 Evidence	 of	 Chronic	 Endotoxin	 Exposure	 and	 has	
Widespread	Dysregulation	of	Non-coding	and	Coding	RNAs		
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Abstract Genetics unquestionably contributes to systemic
lupus erythematosus (SLE) predisposition, progression and
outcome. Nevertheless, single-gene defects causing lupus-
like phenotypes have been infrequently documented. The
majority of the identified genetic SLE risk factors are, there-
fore, common variants, responsible for a small effect on the
global risk. Recently, genome wide association studies led to
the identification of a growing number of gene variants asso-
ciated with SLE susceptibility, particular disease phenotypes,
and antibody profiles. Further studies addressed the biological
effects of these variants. In addition, the role of epigenetics has
recently been revealed. These combined efforts contributed to
a better understanding of SLE pathogenesis and to the char-
acterization of clinically relevant pathways. In this review, we
describe SLE-associated single-gene defects, common vari-
ants, and epigenetic changes. We also discuss the limitations
of current methods and the challenges that we still have to face
in order to incorporate genomic and epigenomic data into
clinical practice.
Keywords Lupus . Systemic lupus erythematosus . SLE .
Genetics . Epigenetics . Autoimmune diseases
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune dis-
ease with a spectrum of clinical manifestations and outcomes.
In spite of this variability, epidemiological data indicating a
higher concordance ratio between monozygotic twins (24–
69 %) compared to dizygotic twins or siblings (2–5 %) have
made the role of genetics in SLE indubitable [1]. Neverthe-
less, single gene defects related to lupus-like phenotypes have
infrequently been described and patients with monogenic
causes of SLE are thought to comprise only about 1 % of
most adult SLE cohorts. The majority of the identified genetic
SLE risk factors are, therefore, common variants, with a
modest magnitude of risk, which suggests that different mech-
anisms contribute to the pathogenesis of this disease, includ-
ing epigenetic factors, which are just starting to be identified.
The proteins encoded by the SLE-associated genes partic-
ipate in a multiplicity of mechanisms, including: monocyte,
neutrophil, B and T-cell function; antigen presentation; type I
interferon, toll-like receptor (TLR) and NFκB signaling; apo-
ptosis, and clearance of cellular debris and immune complexes.
Some SLE susceptibility variants are also associatedwith other
autoimmune diseases, which may reflect common molecular
pathways.
The human leucocyte antigen (HLA) region is the most
gene-dense region in the human genome, including 120 func-
tional genes, many of those with a role in immunity [2]. This
region was identified as the strongest determinant of SLE
predisposition in all the genome-wide association studies
(GWAS) performed [3–6]. Furthermore, variants of HLA-
DRB1 were associated with SLE in multiple ethnic back-
grounds and an HLA-DR3 polymorphism (rs2187668)
seemed to have an impact on the propensity to produce
autoantibodies in SLE [7•].
In this review, we will focus on non-HLA genetic risk
factors for lupus. Single-gene defects will be briefly described,
followed by a summary of the variants and the broad epige-
netic changes that have been associated with SLE.
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Single Gene Defects and SLE
Single gene defects have been recognized as causing lupus
since the 1970s. Specifically, complete deficiencies of C1q,
C1r, C1s, C2, and C4 are strongly associated with SLE. A
penetrance higher than 90 % occurs in C1Q, with lower
penetrance for C4 (75 %) and C2 (10–30 %) [8, 9]. The role
of complement on immune complexes and apoptotic body
clearance is thought to be the underlying mechanism respon-
sible for this association. Although partial deficiencies of C4
and Mannose-Binding Lectin (MBL) have been described as
predisposing for SLE [10, 11], large-scale studies did not
support this finding, so it seems unlikely that they markedly
increase the susceptibility to lupus. They may, however, mod-
ify the disease phenotype [12].
Less commonly described are the associations of chronic
granulomatous disease (CGD) and the carrier state for X-
linked CGD with discoid and systemic lupus [13–16],
presumely due to an inability to clear apoptotic cells.
The apoptotic pathway is also affected in autoimmune
lymphoproliferative syndrome (ALPS). FAS and FASL are
the genes related to classic ALPS, which have been associated
with SLE predisposition [17–19]. Caspase 8 deficiency has
similar features and is often categorized as an ALPS disorder,
but the immunodeficiency dominates the phenotype. The
mechanism of autoimmunity is not fully understood, but
may relate to the excess of cytokines, like IL-10 and B-cell
activating factor (BAFF), that can break B-cell tolerance.
Finally, approximately 10 % of the patients with prolidase
deficiency develop lupus [20]. Cutaneous manifestations are
common, but nearly all of the lupus end-organ effects can be
seen. Prolidase participates in proline recycling, and its defi-
ciency is thought to lead to apoptosis of cells where collagen
synthesis is critical. The true mechanism, however, is not fully
understood.
SLE Associated Variants Divided by Their Proposed
Mechanisms
Apoptosis and Clearance of Nuclear Debris
In SLE, there is an imbalance of apoptosis and clearance of
nuclear debris, which increases the availability of autoantigens,
contributing to autoimmunity. Accordingly, several genes re-
lated to these mechanisms have been associatedwith SLE. One
example is ATG5 (autophagy related 5). Several variants of this
gene, which encodes for a protein that participates in caspase-
dependent apoptosis and autophagy, have been described in
European SLE patients [5]. Another example is TREX1 (three
prime repair exonuclease), which participates in DNA degra-
dation, granzyme A activated apoptosis and oxidative stress
response. TREX1 null mutations are associated with Aicardi-
Goutières syndrome, a disease with lupus-like features, and
familial chilblain lupus. Certain TREX1 variants were found to
be related to SLE suceptibility [21] and, in a large case–control
study, a TREX1 haplotype was found to be associated with the
risk of neurological manifestations in European SLE patients
[22]. In addition, mutations in ACP5 (acid phosphatase 5,
tartrate resistant), which encodes a protein that participates in
lysosomal digestion, were shown to cause bone dysplasia, as
well as an increase on α-interferon and multiple autoimmune
diseases, including SLE [23]. Although polymorphisms in
ACP5 have not been identified in GWAS, its major substrate,
osteopontin, has been found in several studies as disease
associated [24]. Finally, in a recent study of patients with
African ancestry, several novel associations were found be-
tween variants of genes associated with the production of
reactive oxygen species and SLE [25]. Collectively, these
findings demonstrate the critical role of clearing nuclear debris
in SLE pathogenesis.
Clearance of Immune Complexes
Genome-wide analysis and candidate gene association studies
of diverse human populations showed a consistent linkage to
1q21.1-24, a region that includes the receptors that recognize
the constant (Fc) portion of immunologlobulin (Ig) isotypes
(FcγRs).
FcγRs can activate (FcγRI, FcγRIIA/C, FcγRIII) or in-
hibit (FcγRIIB) cellular functions, such as phagocytosis,
antibody-dependent cellular cytotoxicity, degranulation, anti-
gen presentation, B-cell activation, cytokine production and
immune complex clearance. Numerous single nucleotide
polymorphisms (SNP) and copy number variants have been
characterized in the FcγR genes. Several of those variants
have been associated with an increased risk for SLE. For
instance, H131R of FCGR2A is a common variant that was
shown to have lower affinity for the ligand, leading to a pro-
found decrease on the phagocytosis of IgG2 opsonized particles
[26]. The also lower IgG binding FCGR2A allele 158 F was
associated with an increase risk for SLE in Caucasians [27],
but not in an African-American population [28]. Another
example is the single amino acid substitution that occurs on
the I232T variant of FCGR2B, which was also associated with
SLE in Asian populations [29, 30], but not in Caucasians [31].
Defective signaling by the risk FCGR2B variant increases the
inflammatory response of macrophages to immune com-
plexes, reduces the threshold for antigen presentation by den-
dritic cells and facilitates autoreactive B-cell activation [32],
thus contributing for autoimmunity.
FCγR variants are not only associated with disease suscep-
tibility, but also with disease progression and phenotypic
features. Variants of FCGR3A, for example, were associated
with end-stage renal disease in patients with lupus nephritis
[33, 34].





Finally, copy number variation is common in regions of the
genome coding for immune related genes and it is also asso-
ciated with SLE predisposition, namely a low copy number
variation at the FCGR3B locus was associated with SLE and it
affected the immune complex uptake by neutrophils [35].
Complement has a dual role in SLE. On the one hand, there
is clear evidence that complement activation contributes to the
pathogenesis of the glomerular injury that occurs in lupus
nephritis. On the other hand, complement participates in the
clearance of immune complexes and apoptotic bodies. As pre-
viously discussed, complete deficiencies of complement are
among the strongest known genetic risk factors for SLE. More-
over, genes associated with the regulation of the alternative
complement pathway have also been recently found to contrib-
ute to SLE risk, namely genes encoding complement factor H
regulator (CFHR) and five-related CFHR-proteins [36].
Toll Like Receptors and α- Interferon Pathway
Type I interferons (α and β interferon) participate in anti-viral
immune responses as key regulators of the proliferation, dif-
ferentiation, survival and activity of the majority of the im-
mune cells [37]. Increased expression of α-interferon and its
regulated genes has been described in SLE [38–42] and pro-
pelled the development of α-interferon inhibitors for the con-
trol of this disease. A number of variants in the receptors that
recognize nucleic acids (TLRs), their regulatory molecules
(UBE2L3), downstream transcription factors (IRFs, ETS1)
and the interferon signaling pathway itself (TLK2) have been
described in association with SLE. This large family of vari-
ants is a testament of the importance of this pathway in SLE
etiopathogenesis.
TLR activation contributes to the production of type I
interferons, which may explain the solid evidence connecting
TLRs to SLE pathogenesis. One of the possible examples is
the association between a functional variant of TLR7 and SLE
in an Asian population [43]. Other robust SLE associations
were found with variations in genes coding for the interferon
regulatory factors (IRFs): IRF5, IRF7 and IRF8 [44], the
transcription factors downstream of TLRs. IRF5 is a transcrip-
tion factor that induces the expression of multiple pro-
inflammatory cytokines, including α-interferon, tumor necro-
sis factor (TNF)-α, interleukin (IL)-6, IL-17, IL-23, MCP1
(monocyte chemotactic protein-1), and RANTES (regulated
on activation, normal T cell expressed and secreted) [45].
IRF5 is associated with SLE, as well as other autoimmune
diseases, including rheumatoid arthritis, Sjogren’s syndrome,
systemic sclerosis, multiple sclerosis, and inflammatory bow-
el disease [46]. The IRF5 locus was implicated in SLE
through candidate gene analysis [47] and later confirmed by
multiple independent case–control cohorts [48–51] and
GWAS [4–6, 7•]. Several IRF5 insertion and deletion poly-
morphisms and SNPs have been described in association with
increased or decreased levels of IRF5, α-interferon and, con-
sequently, SLE susceptibility [52, 53]. Interestingly, IRF5 is
necessary for the development of lupus-like disease in mice,
which demonstrates the importance of this transcription factor
in SLE pathogenesis [54]. IRF7 variants also contribute for
SLE predisposition. An IRF7 SNP (Q412R) is associated with
an increase in IRF7 levels and SLE risk in several ancestral
populations [55] and additional IRF7 risk alleles have been
associated with anti-double stranded DNA antibodies and
anti-Sm antibodies [56, 57]. UBE2L3 (Ubiquitin-conjugating
enzyme E2 L3) is known to participate in the degradation of
TLRs and genetic variations in UBE2L3 were also identified
as predisposing for SLE and other autoimmune diseases [5, 6,
7•, 58, 59]. ETS1 (v-ets erythroblastosis virus E26 oncogene
homolog 1 avian) is a transcription factor that binds the
interferon-stimulated response elements, controlling type I
interferon-induced transcription. It also participates in the
inhibition of Th17 and B-cell differentiation. Evidence of
animal models supports the role of ETS1 in SLE, since Ets1-
deficient mice develop a lupus-like phenotype, characterized
by the production of autoantibodies, glomerulonephritis and
local activation of complement [60]. In humans, ETS1 was
identified as one of the loci associated with SLE predisposi-
tion [6, 61, 62]. Finally, TYK2 (tyrosine kinase 2) variants
were also associated with higher interferon production, SLE
and discoid and subacute lupus [47, 63].
NFκB Pathway
The NFκB pathway is triggered by multiple stimuli, including
TLR activation. Several genes that participate in NFκB sig-
naling were associated with SLE risk, namely IRAK1 (inter-
leukin-1 receptor associated kinase 1) [64, 65], TNFAIP3
(Tumor necrosis factor, alpha-induced protein 3) [3, 6, 66],
TNIP1 (TNFAIP3 Interacting Protein 1) [6, 58], SLC15A4
(Solute Carrier Family 15Member 4) [6] and PRKCB (Protein
Kinase C, Beta) [67].
IRAK1 is involved in α-interferon and γ-interferon induc-
tion and is a central regulator of NFκB pathway. Five SNPs
spanning IRAK1, an X chromosome-encoded gene, were as-
sociated with both adult- and childhood-onset SLE, in four
different ethnic groups [64].
TNFAIP3 encodes A20, an ubiquitin-editing enzyme,
which participates in the termination of NFκB signaling.
TNFAIP3 is an established susceptibility locus for SLE [68,
69]. Recently, a novel TT>A polymorphic dinucleotide was
found to be associated with SLE in subjects of European and
Korean ancestry [66]. This haplotype resulted in reduced
TNFAIP3mRNA and A20 protein expression and the enzyme
variant bound a nuclear protein complex, which included
NFκB subunits, with reduced avidity [66]. This haplotype is,
thus, associated with a decreased inhibitory activity of A20,
which consequently causes an activation of the NFκB




pathway. The role of A20 in NFκB inhibition has been dem-
onstrated in animal models by the development of systemic
organ inflammation and death within six weeks of birth in A20
deficient mice [70], and by the existence of a lupus-like phe-
notype in mice with B lymphocyte specific A20 deletion [71].
Function of Monocytes and Neutrophils
The role of innate immunity in SLE has been increasingly
appreciated. Monocytes play essential roles in SLE pathogen-
esis, since they participate in lupus nephritis and atheroscle-
rosis, processes responsible for considerable morbidity and
mortality in SLE. Increased interest in neutrophils also arose
with the description of NETosis, the process by which neutro-
phils extrude fibrillary networks composed of DNA, histones
and granular antimicrobial proteins. These NETs trap micro-
organisms, decreasing their ability to spread, facilitate the
interaction with neutrophil-derived effector molecules and
induce the production of cytokines, such as α-interferon. A
positive feedback loop occurs, since this cytokine increases
NETosis. In SLE, circulating immune complexes activate
neutrophils and lead to an increase in the production of NETs.
The DNA present in the NETs is protected from nuclease
degradation, functioning as autoantigen and potentiating au-
toimmunity and chronic inflammation.
Genes coding for proteins related to adhesion and mi-
gration of both monocytes and neutrophils have been asso-
ciated with SLE. ITGAM (CD11b), a protein mainly
expressed by macrophages, monocytes and neutrophils,
encodes a leucocyte-specific integrin, important in the ad-
herence of neutrophils and monocytes to stimulated endo-
thelium. This receptor also participates in the phagocytosis
of complement coated particles and immune complexes,
since it is a receptor for iC3b. An association between
ITGAM variants and SLE susceptibility has been docu-
mented in multiple populations [4, 5, 7•, 72, 73].
B-cell Function
One of the hallmarks of SLE is the production of autoanti-
bodies and the formation of immune complexes that drive the
systemic inflammatory response. B-cells are thus key players
in the pathogenesis of this disease and the existence of effec-
tive drugs that target their function, as anti-BLyS (B lympho-
cyte stimulator) and rituximab (anti CD-20), further supports
their role in SLE. Numerous genes associated with B-cell
function and signaling have been found to predispose to
SLE [74•], including BLK (B lymphoid tyrosine kinase)
[4–6], BANK1 (B-cell scaffold protein with ankyrin repeats
gene) [7•, 75] and LYN (tyrosine protein kinase Lyn) [5, 76],
whose proteins participate in B-cell receptor signaling. The
SLE-risk variants found for BANK1 affect the regulatory sites
and functional domains of the protein and contribute to
sustained B-cell activation through a change in the intracellu-
lar calcium levels [75]. LYN, a src-tyrosine kinase, is a bind-
ing partner of BANK1, whose variants were also associated
with SLE in European-derived individuals, with rs6983130
described as a SLE protective factor [76]. The complement
receptor 2 (CR2/CD21) is a membrane glycoprotein, mainly
expressed onB-cells and follicular dendritic cells, that has also
been implicated in the tolerance to nuclear self-antigens such
as single and double stranded DNA, chromatin and histones
[77]. Reduced levels of CR2 have been described in SLE and
family-based analysis provided evidence for an association of
SNPs in CR2 and SLE in Caucasian and Chinese populations
[78]. This association was later confirmed in a case–control
study of a European-derived population [79]. NCF2, a cyto-
solic subunit of the NADPH oxidase, was found to participate
in B-cell activation and recently it was also implicated in SLE
susceptibility [44, 58]. IL-10 is a pivotal cytokine, responsible
for globally down-regulating the immune response. Interest-
ingly, IL-10 production by monocytes and B-cells has been
shown to correlate with disease activity in SLE. IL-10 poly-
morphisms were found to be associated with SLE in multiple
populations, including European and Asian [80, 81]. IKZF1
(IKAROS family zinc finger 1) is a transcription factor in-
volved in the regulation of lymphocyte differentiation and
proliferation, and B-cell receptor signaling. It also participates
in the control of STAT4 (Signal Transducer And Activator Of
Transcription 4) gene expression. Interestingly, the levels of
IKZF1 were found to be decreased in the serum of SLE
patients and, recently, a GWAS identified variants of IKZF1
associated with SLE in an Asian population [6] .
T-cell Function
The role of T-cells in the orchestration of the immune response
cannot be overstated, so, as expected, several genes implicated
in T-cell function have also been associated with SLE, includ-
ing PTPN22 (Protein phosphatase nonreceptor type 22),
TNFSF4 (Tumor Necrosis Factor (Ligand) Superfamily, Mem-
ber 4), STAT4 and CD247.
PTPN22 participates in the T-cell receptor signaling path-
way. APTPN22 SNP (rs2476601) was associatedwithmultiple
autoimmune diseases, including SLE [82]. This association was
shown in a GWAS [5] and verified in a replication study [58].
TNFSF4 is a co-stimulatory molecule found on the surface
of antigen-presenting cells. It binds to the T-cell receptor
OX40, contributing to the global activation of T-cells, with
the exception of regulatory T-cells, whose generation and
function is inhibited by this signal. Protective and risk haplo-
types of TNFSF4 have been reported for SLE [83].
STAT4 is a key regulator of IL-12, IL-17, IL-23 and α-
interferon signaling, having, therefore, a critical role in the
development of Th1 and Th17 immune responses. Associations
with SLE and multiple SNPs located within STAT4 gene have




been found in different ethnicities, including African Ameri-
cans, Hispanics and Asians [4–6, 7•, 84, 85]. There is also
evidence of an associationwith other autoimmune diseases [85].
CD247 is a component of the T-cell receptor—CD3 com-
plex, which was found to be decreased in SLE. Aberrant
CD247 transcript variants were detected in SLE T-cells and
an association between a CD247 SNP and SLE was detected
on a recent GWAS [86].
Table 1 provides a comprehensive list of variants associat-
ed with SLE susceptibility, according to the proposed mech-
anism of action.
Genetic Susceptibility for SLE and other Autoimmune
Diseases
The clustering of multiple autoimmune disorders in families,
in addition to the identification of variants associated with
increased susceptibility for different diseases, created the no-
tion of a common autoimmunity-related genetic background.
PTPN2 is one of those examples, since variants of this gene
have been associated with juvenile idiopathic arthritis, rheu-
matoid arthritis, systemic sclerosis, generalized vitiligo, alo-
pecia areata, type 1 diabetes, Graves disease, Hashimoto
thyroiditis, myasthenia gravis and Addison disease [2]. PS
Ramos and collaborators, however, showed that only a partial
pleiotropy exists among autoimmune diseases [87]. For in-
stance, genes like ITGAM and TNFSF4, which have been
clearly associated with SLE, were not found to be associated
with other autoimmune diseases, and the opposite was found
for IL23R, one of the loci found to be shared among the
highest number of autoimmune diseases, but not SLE. Thus,
SLE seems to have a distinct pattern of genetic susceptibility.
The Role of Epigenetics in SLE
The phenotype of a cell is broadly determined by the
epigenomic landscape, which modulates gene expression and
may serve to perpetuate pathologic mechanisms. The epigenet-
ic changes, including histone modifications, DNAmethylation,
and the microRNA pattern, globally determine the set of tran-
scribed and repressed genes. DNA methylation and histone
modifications change the chromatin structure to allow or pre-
vent the access of the transcription machinery to DNA.
microRNAs are non-coding RNAs responsible for post-
transcriptional gene silencing, by blocking the translation or
causing mRNA degradation. These regulatory molecules are
involved in essential cell mechanisms, including proliferation,
differentiation and apoptosis. microRNAs also exert control on
the immune system, particularly on the maintenance of immu-
nological tolerance, participating in the regulation of T-cell
selection in the thymus, B-cell selection in germinal centers,
and development of regulatory T-cells.
Epigenetic mechanisms are particularly important for au-
toimmunity, since the expression of pro-inflammatory genes,
like TNF-α, is regulated at the level of the chromatin [88].
A very well characterized epigenetic change seen in SLE is
the hypomethylation of DNA in T-cells, causing a state of
euchromatin and, consequently, a global activation of tran-
scription, which correlates with disease activity [89•]. Interest-
ingly, procainamide and hydralazine, which induce lupus-like
syndromes, were both found to inhibit DNAmethyltransferase
1, the former directly and the latter through the inhibition of the
ERK (extracellular-signal, regulated kinase) pathway [90].
Recently, a genome-wide DNA methylation study of naïve
CD4+ T-cells from SLE patients and controls found significant
hypomethylation in interferon-regulated genes [91]. Hypome-
thylation is, therefore, another mechanism responsible for the
characteristic type-I interferon hyper-responsiveness seen in
lupus T-cells.
Table 1 List of genes whose variants were associated with SLE
susceptibility
Pathway Genes
Function of Immune Cells
Monocytes and Neutrophils FCGR2B, FCGR3A/B, ICAMs,
IL10, IRF8, ITGAM.
B-cells AFF1, BANK1, BLK, ETS1,
FCGR2B, HLA-DR2, HLA-DR3,
IKZF1, IL10, IL21, IRF8, LYN,
MSH5, NCF2, PRDM1, PRKCB,
RASGRP3.
T-cells AFF1, CD44, CD247, ETS1, FYB,
HLA-DR2, HLA-DR3, IKZF1,




Toll-like receptor and α-
Interferon signaling
ACP5, ELF1, ETS1, IFIH1, IRAK1,
IRF5, IRF7/PHRF1, IRF8,
PRDM1, STAT4, TLR7, TREX1,
TYK2, UBE2L3.
NFkB signaling IRAK1, PRKCB, SLC15A4,
TNFAIP3, TNIP1, UBE2L3.
Other pathways
Clearance of immune complexes C1Q, C1R/C1S, C2, C4A/B,
FCGR2A/B, FCGR3A/B,
ITGAM.




Production or regulation of
reactive oxygen and nitrogen
intermediates
GSR, NDUFS4, NOS1.
Loci with unknown function CLEC16A, JAZF1, PTTG1, PXK,
TMEM39A, TNXB, UHRF1BP1,
WDFY4, XKR6.
Adapted from Rullo and Tsao [100]




Histone acetyltransferases and deacetytransferases also
control gene expression by adding or removing acetyl groups
on histone lysine residues. H4 acetylation is a histone modi-
fication associated with activation of transcription. This
epigenomic mechanism was found to be overall increased in
monocytes from SLE patients [92]. Notably, 63% of the genes
with a higher H4 acetylation had the potential of IRF1 regu-
lation. IRF1 is an interferon-inducedweak transcription factor,
which regulates the transcription of genes involved in immune
modulation. Interestingly, IRF1 can interact with p300 to
acetylate histones, which could explain the globally increased
H4 acetylation pattern seen in SLE.
MicroRNAs are also dysregulated in SLE [93•]. miR-146a,
which inhibits type I interferon expression by targeting IRF5
and STAT-1mRNA [94], was found to be decreased in SLE [94],
contributing, therefore, for the high levels of type I interferon
characteristic of this disease. Another example is miR-3148,
which was found to modulate the allelic expression of a TLR7
variant associated with SLE [95]. Finally, in a recent study a
four-miRNA SLE signature was identified in plasma [96].
The interactions and consequences of these mechanisms
are under intense study. Histone modifications and DNA
methylation can regulate the expression of microRNAs in
SLE, as is the case of miR-142 expression on T-cells from
lupus patients [97], while microRNAs, like miR-21 and miR-
148, which are increased in T-cells from SLE patients, de-
crease the expression of DNAmethyltransferase 1 [98]. These
findings suggest that the epigenome is globally affected in
SLE and that the persistence of the epigenomic changes could
lead to a durably aberrant gene expression, contributing to the
perpetuation of the disease mechanisms.
Limitations of the Current Methodologies
GWAS use a high throughput technology to analyze hundreds
of SNPs and capture genome common variants. Through this
approach, the joint effect of many weakly contributing vari-
ants across different loci can be studied and gene variants
associated with different complex diseases can be identified.
This type of study is particularly tailored for complex poly-
genic associations, being drastically more sensitive than fam-
ily studies. In comparison to linkage analysis and sequencing,
however, GWAS have less power in cases of allelic heteroge-
neity and may be affected by the occurrence of epistasis. The
majority of the variants associated with SLE susceptibility
only cause a modest increase on the risk, so large sample sizes
are necessary to find significant variations. Futhermore, since
the loci found by this kind of study have a weak additive
predictive power for a specific phenotype, their clinic rele-
vance may be small. Finally, occasionally results from GWAS
are not replicated across studies and in different populations.
Meta-analyses are an important tool to increase the statistical
power and analyze the effect of gene variations across groups of
different ancestries. Predictive mathematical models integrating
the weakly contributing loci may also be helpful. In addition, it
is necessary to understand how specific genetic variants are
responsible for the association and the biological effect. Finally,
fine mapping and resequencing studies are under way, as well as
new tools for the analysis of transcriptomics, proteomics and
metabolomics [99•], with the final goal of being able to risk-
stratify patents to truly develop a personalized approach to care.
Conclusions
For most patients the pattern of SLE heritability is not char-
acterized by a single gene with a causal Mendelian effect, but
by a multigenic mode of inheritance. Further studies are
necessary to understand how the identified susceptibility var-
iants contribute to SLE manifestations. Moreover, the major-
ity of the large-scale studies on SLE genetics were performed
in European and Asian populations. Since SLE is more fre-
quent and more severe in other groups, namely Hispanic and
African-American, new studies focusing on these populations
are essential. The trajectory of our understanding of the dis-
ease pathogenesis has been extraordinarily rapid since the
introduction of arrays, genomic approaches and epigenetic
strategies. Next generation sequencing efforts and other new
technologies are also likely to rapidly advance our knowledge.
The era of personalized medicine with genomic data incorpo-
rated into diagnosis, prognosis, treatment, and adverse event
prevention may truly be beginning.
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Abstract In order to describe the incidence and characteristics of major infections in juvenile-
onset systemic lupus erythematosus (jSLE), we studied a cohort of 120 patients (51% Hispanic and
28% African American, 49% with renal involvement and 12% with neuropsychiatric manifestations).
There were 101 major infections affecting 44 patients (37%) for an incidence of 169/1000
patient-years of follow-up. Active disease at jSLE diagnosis, renal involvement, neuropsychiatric
manifestations, higher cumulative dose of prednisone, and treatment with cyclophosphamide or
mycophenolate mofetil were all associated with major infection (p b 0.05). By logistic regression,
the combined effect of treatment with cyclophosphamide and cumulative dose of prednisone was
associated with major infection (p = 0.04). Two patients died, one due to cytomegalovirus
infection. Major infection was associated with damage (p = 0.004). In conclusion, in a large cohort
of jSLE patients, major infections were common, were associated with active disease and its
treatment, and resulted in noteworthy morbidity.
© 2013 Elsevier Inc. All rights reserved.
1. Introduction
In comparison with the general population, patients with
systemic lupus erythematosus (SLE) have an increased death
rate from infection [1]. In a multicenter study of 1000 SLE
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patients followed over 10 years, infections were the cause
of death in 25% of cases [2], with similar results observed
in other studies [1,3]. Infections and active disease are
responsible for the majority of deaths within the first
5 years, while myocardial infarction and thrombotic events
tend to occur later, leading to a bimodal distribution of the
causes of death in SLE [2]. Infections are also responsible for
significant morbidity, resulting in hospitalization in 15% of
patients [1]. The impact of infection on juvenile-onset SLE
(jSLE) would be expected to be even higher, inasmuch as
children are especially prone to infections and often have a
more aggressive course of SLE requiring more potent immu-
nosuppression [4].
Defects in innate and adaptive immunity contribute to
the intrinsic risk of infection that occurs in SLE patients [5].
Immunosuppressive agents, which have become the stan-
dard for the treatment of major organ involvement in SLE,
also increase this risk. Moreover, it has been reported that
recurrent major infections predict poorer disease outcome
in jSLE [6]. Prevention and careful monitoring for infections
are thus major challenges in managing patients with jSLE.
Clinical features and treatment-related factors predisposing
jSLE patients to major infection have not been adequately
delineated. Furthermore, therapy for patients with jSLE has
recently shifted to include increased use of steroid-sparing
agents, such as mycophenolate mofetil and biological agents.
New studies are, therefore, needed to clarify the risks of
infections associated with different immunosuppressive regi-
mens. The primary goal of this study was to describe the
incidence and characteristics of major infections in a cohort of
patients with jSLE. Our secondary aimwas to identify factors, at
the time of diagnosis or during the course of the disease,
associated with major infections.
2. Methods
2.1. Study design and patients
A retrospective chart review was performed of the clinical
courses of jSLE patients from the time of diagnosis or first
encounter until December 2009 or loss to follow-up (1991–
2009). The inclusion criteria were: diagnosis of SLE before the
age of 18, disease duration ≥6 months and, at least three
clinical encounters during the period 2007 to 2009 in the
Pediatric Rheumatology Division of New York-Presbyterian/
Morgan Stanley Children's Hospital — Columbia University
Medical Center.
A diagnosis of SLE was defined by the presence of four or
more of the 1997 revised American College of Rheumatology
criteria for the classification of SLE [7] or when a diagnosis of
lupus nephritis was confirmed by renal biopsy [8].
Demographic and clinical information were collected,
including: gender; ethnicity; age at disease diagnosis; disease
duration; duration of follow-up; involvement and timing of
renal and neuropsychiatric manifestations; co-morbidities and
treatment strategies employed. Renal lesions were catego-
rized according to the WHO classification system for lupus
nephritis [8]. Lupus activity was assessed, using the Safety
of Estrogens in Lupus Erythematosus National Assessment
(SELENA) version of SLE Disease Activity Index (SLEDAI) [9].
The Systemic Lupus International Collaborating Clinics
(SLICC) Damage Index (SDI) score was calculated at the
conclusion of the study [10,11]. The SDI measures irrevers-
ible changes secondary to inflammation, adverse effects of
medication and co-morbid conditions, which occurred since
the onset of SLE, and are present for at least 6 months.
Patients who died were excluded from the analysis of
damage.
The Columbia University Medical Center Institutional
Review Board granted ethical approval for this study.
2.2. Definition of major infections
Major infections were defined as those requiring treatment
with parenteral antimicrobial agents or an oral course lasting
one week or more, as previously described [6,12,13]. To
diagnose an infection, it was necessary to identify a causative
agent, or to have a diagnosis made by a pediatric infectious
disease specialist, pediatric rheumatologist, or other attending
pediatrician based on clinical findings, pathologic, and/or
radiologic results.
2.3. Statistical analysis
Potential factors associated with major infection were
studied, using the Chi-square test and the Mann–Whitney
U test. In order to account for the effect of multiple
comparisons, the Holm–Bonferroni correction was applied.
Multivariate logistic regression was performed using Forward
Stepwise Likelihood Ratio (LR) and Enter methods to identify
possible confounding or effect-modifying factors, and to
estimate adjusted odds ratios (OR) and 95% confidence
intervals (95% C.I.). Time free of major infection according
to jSLE disease activity and treatment was compared with
actuarial analysis and expressed graphically by Kaplan–
Meier survival curves. The paired t-test was used to detect
differences in SLE activity during and after an infection.
p-Values less than 0.05 were considered significant. Statis-
tical analysis was performed with IBM SPSS Statistics Version
20.0® (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Demographic data
During the study period, 120 patients with jSLE fulfilled the
eligibility criteria. The demographic and clinical character-
istics of the study population are shown in Table 1.
The patients were mainly Hispanic (61; 51%) and African-
American (34; 28%). The female to male ratio was 3.4:1. Most
(63; 52%) were diagnosed between the ages of 10 and 15 years
and 22 (18%) were diagnosed before 10 years of age. A family
history of autoimmune diseases was found in 47 patients
(39%).
The mean duration of disease at the end of the study
period was 5.3 ± 3.2 years (range 6 months–17 years), while
the mean duration of follow-up was 5.0 ± 3.2 years (range
6 months–17 years).






3.2. Clinical course of jSLE
At time of diagnosis, the mean SLEDAI was 9.6 ± 6.5, 7% of
the patients had leukopenia (white blood cells b3.0 × 109/L)
and 64% had lymphopenia (lymphocytes b1.5 × 109/L).
During the course of the disease, lupus nephritis was
diagnosed in 59 patients (49%), of whom 48 (81%) had
confirmation by biopsy; 35 (73%) had class IV lupus nephritis
and 3 patients developed end-stage renal disease.
Neuropsychiatric manifestations (NPSLE) occurred in 15
(12%) patients. Cognitive dysfunction was the most common
manifestation, followed by significant headache, seizures,
psychosis, and focal neurologic signs. NPSLE was diagnosed in
the first year of the disease in 10 patients (67%). Abnormalities
on brain magnetic resonance imaging were documented in
10 patients (67%). Cerebrovascular accidents occurred in 6
patients (5%).
All patients in this cohort were treated with hydroxy-
chloroquine. The mean cumulative prednisone dose was












Age (years) at jSLE diagnosis
b5 5 (4%)
5 ≤ Age b 10 17 (14%)
10 ≤ Age b 15 63 (52%)
≥15 35 (29%)
Disease activity
SLEDAI at diagnosis 9.6 ± 6.5
SLEDAI at time of major infection 8.2 ± 5.6




Leukopenia at diagnosis 8 (7%)
Lymphopenia at diagnosis 77 (64%)
Lupus nephritis 59 (49%)
Neuropsychiatric lupus 15 (12%)
Cerebrovascular accident 6 (5%)
Pericarditis 17 (14%)
Pleuritis 9 (8%)
Pulmonary hemorrhage 4 (3%)
Persistent thrombocytopenia 30 (25%)
Macrophage activation syndrome 2 (2%)
Treatment (ever use of)
Hydroxychloroquine 120 (100%)





Cumulative dose of prednisone (g) 14.4 ± 18.6




Number Causative organisms (n)
Skin and soft tissue
infections
19 Staphylococcus aureus 3
Unidentified 16




























Otomastoiditis 3 Unidentified 3
Retropharyngeal
abscess
1 Streptococcus pyogenes 1
Dental abscess 2 Unidentified 2


















Other infections a 7
a Other infections: 3 cases of cervical adenitis; 1 case of orbital
cellulitis; 1 case of sacroiliitis without identified pathogens; 1
case of meningitis caused by S. pneumoniae; 1 case of
endocarditis caused by Serratia marcescens.





14.4 ± 18.6 g (range: 0–126 g). Mycophenolate mofetil (MMF)
was used in 67 (56%), azathioprine in 55 (46%), cyclophospha-
mide in 44 patients (37%), and rituximab in 6 (5%). Four
patients (3%) required plasmapheresis.
Two patients died during the study. The causes of death
were disseminated cytomegalovirus infection in one patient
and macrophage activation syndrome in the other.
3.3. Frequency and types of infections
During the study period, 101 major infections were diag-
nosed, affecting 44 patients (37%), as shown in Table 2.
Twenty-three patients (19%) had recurrent episodes of
major infections (≥2 episodes). The annual incidence of
major infection was 169/1000 patient-years of follow-up
(C.I. 95% = 139/1000–205/1000). Major infection occurred
on average 4.3 ± 3.1 years after jSLE diagnosis.
The most common infections were skin and soft tissue
infections (n = 19 episodes), pneumonias (n = 17), urinary
tract infections with fever (n = 13), sepsis (n = 10), and herpes
zoster (n = 8). The causal agent of infection was established in
49 cases (48%). The majority of the cases of herpes zoster was
localized and did not require hospitalization. No cases of
Pneumocystis jiroveci pneumoniawere observed in our cohort.
The SLEDAI at time of infection (8.2 ± 5.6) was significantly
higher than that 6 months following (5.8 ± 5.7) the episode
(mean difference 2.4, 95% C.I. 0.8–4; p = 0.004). The median
SLEDAI at the time of infection with herpes zoster was 4 and
only one patient with zoster had a SLEDAI ≥8.
Leukopenia (white blood cells b3.0 × 109/L) was present
at time of major infection in 14% of episodes, lymphopenia
(lymphocytes b1.5 × 109/L) in 73% and neutropenia (neu-
trophils b1.0 × 109/L) in 2%.
3.4. Factors associated with major infection
Major infection was significantly more likely to occur in
patients with more active disease. A complement component
3 (C3) level b90 mg/dl at time of diagnosis was associated
with major infection, as shown in Table 3. We also found an
association between a higher SLEDAI at jSLE diagnosis and
major infection, as shown in Table 4. No association was found
between leukopenia or lymphopenia at diagnosis and major
infection (data not shown).
Disease activity was important not only at diagnosis, but
also during the course of SLE, since both renal involvement
and neuropsychiatric manifestations of SLE were found to be
associated with major infection (Table 3).
Uses of cyclophosphamide and mycophenolate mofetil
were each associated with major infection in our cohort
(Table 3). In order to reduce the confounding effect of
treatment with both medications, we also analyzed the
effect of mycophenolate mofetil in the subgroup of
patients who had never received cyclophosphamide. In
this group as well, treatment with mycophenolate mofetil
was associated with major infection (OR 4.0; 95% C.I. 1.4–
12.0; p = 0.01). The association between mycophenolate
mofetil and major infection remained statistically signif-
icant even after adjusting for the effect of the cumulative
dose of prednisone and disease duration (Table 3). Finally,
the duration of treatment with mycophenolate mofetil
was also associated with major infection, with the risk
increasing 16% (OR 1.2; 95% C.I. 1.0–1.3) after 6 months
and 34% after 12 months of treatment with this drug (OR
1.3; 95% C.I. 1.1–1.6). On the other hand, neither
treatment with azathioprine (Table 3) nor its duration of
administration increased the occurrence of major infec-
tions significantly (Table 4).




















1.5 (0.6–3.8) 0.389 1.3 (0.4–4.3) 0.634 1.4 (0.5–3.6) 0.501
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1.7 (0.8–3.7) 0.145 0.9 (0.3–2.6) 0.835 1.6 (0.7–3.4) 0.245
⁎ p-Values corrected according to the Holm–Bonferroni method. Chi-square tests were used to study the association between variables.
Logistic regression was used to determine the adjusted odds ratios. yr — years. OR - Odds Ratio.







Use of cyclophosphamidewas associatedwith the occurrence
of more severe infections, including sepsis (OR = 7.0; 95% C.I.
1.4–35.4; p = 0.012) and pneumonia (OR = 4.0; 95% C.I. 1.1–
14.2 p = 0.03), while use of mycophenolate mofetil was not.
While variability in use occurred in this cohort, the
cumulative dose of prednisone was significantly associated
with major infection (Table 4). It was estimated that a 10 g
increase in the cumulative dose of prednisone caused a 40%
increase in the risk of major infection (OR = 1.40; 95% C.I.
1.04–1.88).
We assessed the time free of major infection in the cohort
according to disease activity, SLEmanifestations, and treatment
as shown in the Figure. Patients with C3 b90 mg/dl at diagnosis
or those who developed neuropsychiatric manifestations of SLE
during the course of the disease had a significantly lower time
free of major infection (p = 0.037; p b 0.0001, respectively).
Patients treated with mycophenolate mofetil or those with a
cumulative dose of prednisone at the end of the study higher
than 15 g also had a significant decrease on the time free from
major infection (p = 0.015, on both cases) (Fig. 1).
Table 4 Association between continuous variables and infection in jSLE patients.





SLEDAI at diagnosis 8.2 ± 5.9 12.0 ± 6.9 0.006 ⁎ 0.242 0.012
MMF duration of treatment (months) 10.6 ± 20.4 24.3 ± 27.4 0.005 ⁎ 0.071 0.039
AZT duration of treatment (months) 5.2 ± 10.0 7.7 ± 13.6 0.246 0.764 0.348
Cumulative dose of prednisone (g) 11.0 ± 14.6 21.7 ± 23.9 0.004 ⁎ N/A 0.011
Mann–Whitney U test was used to study the association between variables. Logistic regression was the method performed to calculate the
confounding effect of cumulative dose of prednisone and disease duration. N/A - Non applicable.
⁎ p-Values corrected according to the Holm–Bonferroni method.
Figure 1 Kaplan–Meier analysis of time free of major infection in patients with jSLE according to disease activity and types of treatment.





The variables included in the logistic regression (For-
ward Stepwise Likelihood Ratio method) were history
of lupus nephritis, neuropsychiatric manifestations of the
disease, treatment with cyclophosphamide, treatment with
mycophenolate mofetil and cumulative dose of prednisone.
This analysis demonstrated that the combined effect of
treatment with cyclophosphamide and cumulative dose of
prednisone was significantly associated with major infection
(p = 0.04).
3.5. Major infection and damage
Damage (SDI≥1) was present at the conclusion of the study in
33% (39/118) of the surviving patients after a mean disease
duration of 5.3 ± 3.2 years. Damage to the musculoskeletal
system was observed most frequently (9%), followed by
neuropsychiatric (7%), ocular (7%), skin (7%), pulmonary
(5%) and renal (5%) systems. Avascular necrosis and osteopo-
rosis with fracture or vertebral collapse were the most
frequent types of musculoskeletal damage. No malignancies
were encountered.
Major infection was associated with damage (OR = 3.2; 95%
C.I. = 1.4–7.2; p = 0.004). This was especially true for patients
with sepsis (OR = 17.1; 95% C.I. = 2.0–144.3; p = 0.002).
4. Discussion
The remarkable improvement in survival of jSLE patients
over the past few decades, reported to be greater than 95%
after 5 years of disease [6,14,15], is likely due to earlier
diagnosis, better monitoring of disease activity, and more
judicious use of immunosuppressive agents. In this cohort of
120 jSLE patients, 2 deaths (2%) occurred after a mean
disease duration of 5.3 years.
With this increase in life expectancy, patients are faced
with morbidities due to sequelae of disease and adverse
effects of medication, including major infection. The focus
of management has now shifted from prevention of
premature death to minimizing permanent organ damage.
Identification of risk factors that lead to major infection
and long-term damage is therefore of increasing concern. In
our cohort, a statistically significant association between
major infection and damage was detected. Lee and
colleagues had already shown that recurrent major infec-
tions were associated with permanent damage in jSLE [6]
and Chen and coworkers also found that among SLE patients
an episode of bacteremia was associated with an unfavor-
able long-term outcome [16].
In our study, 37% of patients had at least one episode of
major infection. In a prospective and controlled study of
another 110 patients with SLE and 220 controls, Bosch and
colleagues found that 36% suffered at least one infection
versus 22% in the control group, RR 1.63 (p b 0.05) [17].
Others have reported rates of infection ranging from 38%
among adults with SLE [9] to 57% among children [6].
Variation in the rate of infection is most likely due to
differences in age groups, duration of follow-up, disease
activity, severity of organ involvement and immunosuppres-
sive regimens employed. Furthermore, the definitions of
infection have also been heterogeneous, with many studies
including minor infections. Despite the variability among the
criteria used, the spectrum of infections and causative
microorganisms has been similar in adults and children.
Skin and soft tissue infections, pneumonias, urinary tract
infections with fever, sepsis and herpes zoster were the most
common infections found in our study and reported in the
literature [1,6,17–19]. In addition to unusual opportunistic
infections, jSLE patients also experienced infections caused by
common pathogens that behaved more aggressively. For
example, a case series suggested an increased risk of
nontyphoidal Salmonella infection in SLE patients, in associ-
ation with cellular immune defects [20–23]. We also docu-
mented three cases of nontyphoidal Salmonella, including one
case of sepsis.
Herpes virus infections are also common. The reported
incidence of herpes zoster in SLE ranges from 6.4 to 16
events/1000 patient-years, which is remarkably greater
than the one reported in the general population [24–26].
The incidence found in our cohort was 13 events/1000
patients-years with a median SLEDAI at the time of herpes
zoster of 4. These results are in concordance with other
studies that showed that herpes zoster usually occurs during
periods of quiescent SLE activity [26].
It has been reported that over 90% of SLE patients are
seropositive for cytomegalovirus and while overt clinical
disease is rare, it carries a high risk of mortality [27–29]. In
the current study, we found similar results, considering that
only one case of cytomegalovirus infection was identified
and resulted in the death of the patient.
Infections caused by Parvovirus B19 and Epstein–Barr
virus were not documented in our cohort, but potentially
were underdiagnosed as these viruses were not routinely
investigated.
Wedid not encounter any case of P. jiroveci infection, even
though we do not routinely provide prophylaxis against this
organism. Gupta et al. have also shown that the number of
reported infections with this agent in SLE patients treated
with cyclophosphamide is very low (15.88/10,000 patients)
[30]. Our data complements, therefore, the growing body of
evidence against the need for prophylaxis against P. jiroveci in
jSLE.
Disease activity was clearly associated with the occur-
rence of major infection in this study, as a higher SLEDAI at
diagnosis, renal involvement, and neuropsychiatric manifes-
tations were all identified in univariate analysis as factors
associated with major infection. Others have found lung and
renal involvement [18] and SLEDAI N12 at diagnosis to be
predictors of infection [12]. In addition, similar to our
findings, low complement levels (C3 b90 mg/dl) have been
documented as predictors of major infection [12,17].
In our cohort, use of cyclophosphamide was associated
with major infection. Although Bosch and colleagues also
documented this association [17], it has not been consis-
tently noted by others [1,12].
We found that mycophenolate mofetil treatment was
strongly associated with major infection in jSLE, even in the
subgroup of patients who had never been treated with
cyclophosphamide and after adjusting for the effects of
cumulative dose of prednisone and disease duration. Further-
more, the duration of treatment with mycophenolate mofetil
was also found to be a risk factor for major infection in the
univariate analysis. On the other hand, azathioprine treatment
and its duration were not associated with major infection.






The cumulative dose of prednisone was associated with
major infections in our cohort as described in other series
[12,17], but not all [1]. Ruiz-Irastorza and colleagues concluded
that an increase of 10 mg per day of prednisone caused an
11-fold increase in the risk of serious infection [18].
In this cohort, according to multivariate analysis, the
combined effect of treatment with cyclophosphamide and
cumulative dose of prednisone was strongly associated with
major infection, which once again supports the need of a
judicious use of these drugs.
The relationship between SLE and infections is complex.
Not only can active disease lead to infection, but infections
can also act as environmental triggers that induce or
promote SLE flares. In our cohort, we found that the disease
was clearly more active at the time of infection when
compared to a clinical encounter 6 months later.
This study had limitations. This was a retrospective study
with the potential for missing data and lack of standardized
treatment. Our center serves as a tertiary referral center,
which most likely increases the severity of disease. Moreover,
in our cohort the majority of the patients are Hispanic or
African-American, which represent groups known to have more
severe courses of jSLE, and might not be generalizable to other
centers. We could not assess the effect of hydroxychloroquine
on major infections, as all patients in our cohort were treated
with this agent, nor could we assess the effect of rituximab
due to the small number of patients treated with this agent
prior to 2009. We did not include data on autoantibodies,
since there was great variability in the methods used for
their measurement. The retrospective nature of this study
also limited the possibility of assessing for the presence of
hypogammaglobulinemia at the time of infection. Finally, many
variables (e.g., lupus activity, hypocomplementemia, renal
disease, neuropsychiatric manifestations, treatment with cor-
ticosteroids and other immunosuppressive drugs) are inter-
related in clinical practice, and their relative weight and
interactions are difficult to determine, even with multivariate
analysis. Including a control group of age- and sex-matched
children with juvenile idiopathic arthritis might have allowed
further determination of the risk of major infection due to SLE
itself and what is truly related to immunosuppression.
In conclusion, in this large cohort of urban North American
children and adolescents with jSLE, major infections were
found to be common, were associated with active disease and
its treatment, and resulted in noteworthy morbidity. In order
to ensure optimal patient outcomes, it is essential, therefore
to perform regular surveillance for infections, with frequent
visits, particularly in patients with more active disease and
undergoing treatment with immunosuppressive drugs, and to
promptly initiate treatment on presumption of infection. In a
recent review of patients with SLE admitted to an Intensive
Care Unit, a delay in adequate antimicrobial therapy of more
than 24 h was associated with increased mortality [31].
Finally, many infections can be prevented with timely
immunization, reducing exposure to contagious contacts,
screening for latent infection, and minimizing exposure to
immunosuppressive drugs, which are essential to achieve
optimal control of SLE activity, but the judicious use of
which is equally important to avoid infections and other
associated adverse effects [32]. These measures will help to
reduce the burden of major infections in jSLE patients and
consequently improve patient outcomes.
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The Role of MicroRNAs and Human Epidermal Growth
Factor Receptor 2 in Proliferative Lupus Nephritis
Patr!ıcia Costa-Reis,1 Pierre A. Russo,2 Zhe Zhang,3 Lucrezia Colonna,3
Kelly Maurer,3 Stefania Gallucci,4 Steffan W. Schulz,5 Adnan N. Kiani,6
Michelle Petri,6 and Kathleen E. Sullivan2
Objective. To understand the roles of microRNAs
(miRNAs) in proliferative lupus nephritis (LN).
Methods. A high-throughput analysis of the miRNA
pattern of the kidneys of LN patients and controls was
performed by molecular digital detection. Urinary miRNAs
were measured by quantitative reverse transcription–
polymerase chain reaction (qRT-PCR). Target gene
expression in human mesangial cells was evaluated
by arrays and qRT-PCR. Human epidermal growth fac-
tor receptor 2 (HER-2) was analyzed by immunohisto-
chemistry in kidney samples from LN patients and in
a murine model of lupus. Urinary levels of HER-2,
monocyte chemotactic protein 1 (MCP-1), and vascular
cell adhesion molecule 1 (VCAM-1) were measured by
enzyme-linked immunosorbent assay.
Results. Levels of the miRNAs miR-26a and miR-
30b were decreased in the kidneys and urine of LN
patients. In vitro these miRNAs controlled mesangial
cell proliferation, and their expression was regulated by
HER-2. HER-2 was overexpressed in lupus-prone
NZM2410 mice and in the kidneys of patients with LN,
but not in other mesangioproliferative glomerulonephri-
tides. HER-2 was found to be up-regulated by interferon-
a and interferon regulatory factor 1. Urinary HER-2 was
increased in LN and reflected disease activity, and its
levels correlated with those of 2 other recognized LN bio-
markers, MCP-1 and VCAM-1.
Conclusion. The kidney miRNA pattern is broadly
altered in LN, which contributes to uncontrolled cell pro-
liferation. Levels of the miRNAs miR-26a and miR-30b
are decreased in the kidneys and urine of LN patients,
and they directly regulate the cell cycle in mesangial cells.
The levels of these miRNAs are controlled by HER-2,
which is overexpressed in NZM2410 mice and in the kid-
neys and urine of LN patients. HER-2, miR-26a, and
miR-30b are thus potential LN biomarkers, and blocking
HER-2 may be a promising new strategy to decrease cell
proliferation and damage in this disease.
Lupus nephritis (LN) is associated with consider-
able morbidity and mortality, particularly in children
(1,2). The diagnosis of LN is based on renal biopsy find-
ings, which have a modest predictive value for outcome.
Noninvasive strategies are thus needed for both the
diagnosis and monitoring of LN. Furthermore, treat-
ment of LN (3) is associated with several side effects,
including major infections (4) and infertility (5). The
identification of new biomarkers to guide the judicious
use of these therapeutic agents and the development of
new treatment strategies with fewer side effects would
have an enormous impact on the management of disease
in LN patients.
Cellular microRNAs (miRNAs) are noncoding
RNAs with a key role in the posttranscriptional regula-
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tion of gene expression. Each miRNA can regulate hun-
dreds of target messenger RNAs (mRNAs) and thereby
control almost every biologic pathway (6). MicroRNA
dysregulation can elicit a dramatic change in cell behav-
ior, therefore contributing to the pathogenesis of human
diseases. The development of high-throughput method-
ologies for the global measurement of miRNAs, and the
stability of these molecules in biologic fluids, have
allowed them to emerge as a new class of biomarkers.
Several studies of miRNAs in systemic lupus ery-
thematosus (SLE) have been performed in plasma (7),
in peripheral blood mononuclear cells (8–10), and in
the kidneys of LN patients (11,12). However, no un-
biased analysis of renal tissue has been performed.
We studied the miRNA-mediated mechanisms
of LN and identified the human epidermal growth factor
receptor 2 (HER-2) pathway as a regulator of miRNA
expression and cell proliferation. Our findings suggest a
model whereby type I interferons (IFNs) up-regulate
HER-2 expression, which down-regulates miRNA-26a
(miR-26a) and miR-30b, releasing cell cycle transcripts
from repression and contributing to the mesangial cell
proliferation seen in LN. These data identify a new path-
way for therapeutics and also a new robust biomarker.
PATIENTS AND METHODS
Patients and kidney specimens. Paraffin-embedded
kidney samples were selected from pediatric patients with LN
or poststreptococcal glomerulonephritis. The controls were
normal kidney samples from adult donors and 1 sample of
normal kidney tissue from a child with nephroblastoma. The
demographic and clinical characteristics of the LN cohort
are summarized in Supplementary Table 1, available on the
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39219/abstract. A pathologist (PAR) con-
firmed the diagnoses and classified the LN findings according to
the International Society of Nephrology/Renal Pathology Soci-
ety criteria (13). The Institutional Review Board (IRB) of The
Children’s Hospital of Philadelphia approved the study.
RNA extraction and miRNA quantification. RNA
was extracted with an miRNeasy FFPE Kit (Qiagen) and ana-
lyzed using a NanoDrop 2000 spectrophotometer. High-purity
samples were chosen, according to the absorbance ratios
260:280 and 260:230. Seven hundred thirty-four miRNAs were
analyzed by direct digital detection of molecular barcodes,
with an nCounter assay (NanoString). This method is ideal for
fragmented RNA samples and is highly sensitive for miRNAs.
Six negative miRNA assay controls, 6 positive miRNA spikes,
and 5 housekeeping mRNA controls (ACTB, B2M, GAPDH,
RPL19, and RPL0) were also quantified. The data were nor-
malized to the sum of the 6 positive control miRNA spikes. To
account for differences in miRNA content in each sample, the
data were normalized to the sum of all miRNA counts for
each assay. Principal components analysis (PCA) was per-
formed using R statistical computing language (www.r-project.
org), and pathway analysis was done using IPA. Statistical sig-
nificance was defined as a Benjamini-Hochberg false discovery
rate of ,0.05.
Kidney levels of miR-26a and miR-30b were studied
in the same cohort by quantitative reverse transcription–
polymerase chain reaction (qRT-PCR) using TaqMan miRNA
assays (Applied Biosystems) and a 7900HT sequence detec-
tion system (Applied Biosystems). Relative quantification was
applied using spiked Caenorhabditis elegans miR-238 as con-
trol (Qiagen). Commercially available primers were purchased
from Applied Biosystems (see Supplementary Table 2, available
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.39219/abstract).
Detection of miRNA in urine. Urine samples were
collected from healthy individuals and adult patients followed
up at the Hospital of the University of Pennsylvania. All of the
patients had demonstrated clinical and laboratory evidence of
active LN (hematuria, proteinuria, pyuria, and/or urinary
casts) at 1 or more encounters in the past 3 years. Characteris-
tics of this cohort are displayed in Supplementary Table 3,
available on the Arthritis & Rheumatology web site at http://onli-
nelibrary.wiley.com/doi/10.1002/art.39219/abstract.
Urine samples were centrifuged at 3,000 revolutions
per minute for 30 minutes at 48C, and aliquots of 100 ml of the
supernatants with 500 ml of QIAzol lysis reagent were kept at
2808C. RNA was extracted from these samples using a Qiagen
miRNeasy Serum/Plasma Kit. The miRNAs miR-26a and
miR-30b were measured by qRT-PCR.
Knockdown and overexpression of miRNAs in human
mesangial cells. Human renal mesangial cells (ScienCell)
were selected for in vitro studies, since the proliferation of this
type of cell is an important phenomenon of LN pathogenesis.
The cells were maintained according to the manufacturer’s
recommendations.
Mesangial cells were transduced with lentiviruses
(Applied Biological Materials) (see Supplementary Table 2,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39219/abstract) at a
multiplicity of infection of 1 and in the presence of polybrene
(3 mg/ml). The lentiviruses expressed miRNA inhibitors com-
plementary to the targeted mature miRNA sequence under
the control of the H1 promoter. Green fluorescent protein
and the puromycin resistance gene were under the control of
the cytomegalovirus (CMV) promoter. The infection effi-
ciency was evaluated by fluorescence with an Axio Observer
A1 microscope (Carl Zeiss). Stable cells with knockdown of
miRNA were obtained with puromycin selection and were
used as polyclonal populations. The controls were mesangial
cells transduced with a lentivirus vector and uninfected cells.
RNA was extracted with a Qiagen RNeasy kit and ana-
lyzed with a 2100 Bioanalyzer (Agilent). The transcriptome
was amplified with an Ovation Pico WTA System V2 (NuGEN).
Whole-genome expression of the cells with knockdown of
miRNA and controls was studied using Affymetrix GeneChip
Human Gene 2.0 ST arrays. Gene expression data were normal-
ized and quality controls were assessed before further analyses.
Canonical pathways were studied using IPA.
A Clontech Advantage RT kit was used to generate
complementary DNA for the study of transcripts. Gene
expression was detected by qRT-PCR and normalized to 18S
ribosomal RNA. Commercially available primers were pur-
chased from Applied Biosystems (see Supplementary Table 2,
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available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39219/abstract).
Overexpression of miRNA was achieved by transfection
of pCMV-MiR constructs for miR-26a and miR-30b (OriGene).
These cells were maintained in 20% calf serum. Gene expression
was evaluated by qRT-PCR.
Cell proliferation was analyzed using an MTT assay.
The cells were seeded at a density of 100,000 cells/well, cul-
tured for 3 days, and treated according to the protocol of the
manufacturer (Sigma). The number of viable cells was calcu-
lated according to a standard curve. As a validation strategy,
cell proliferation was also measured after 6 days of culture,
using propidium iodide (10 mg/ml; Sigma) staining with Igepal
permeabilization followed by spectrophotometric detection.
Effect of an anti–HER-2 drug in human mesangial
cells. Mesangial cells were exposed to 8 mg/ml trastuzumab
(kindly provided by Genentech). After 24 hours of culture,
miR-26a and miR-30b were quantified by qRT-PCR, using C
elegans miR-238 and U6 as controls. After 3 days of culture,
RNA was extracted and whole-genome expression arrays were
performed. The results were compared to those for mock-
treated mesangial cells.
Immunohistochemistry for HER-2 in humans. Fully
automated immunohistochemistry was performed on a Leica
Bond-Max with rabbit anti–HER-2 (1:500, staining for 1 hour;
Sigma-Aldrich) after antigen retrieval at low pH for 20 minutes.
A Bond Polymer Refine Detection system (Leica Biosystems)
was used. Images were obtained using an Aperio ScanScope
eSlide capture device. HER-2–positive breast cancer tissue was
used as a positive control. For every sample, negative staining
controls were executed without the primary antibody.
Immunohistochemistry for HER-2 in a mouse model
of LN. HER-2 expression was studied in NZM2410 mice (a
mouse model of LN) (14) and in BALB/c and C57BL/6 (B6)
mice (nonautoimmune controls). All 3 strains of mice were
obtained from The Jackson Laboratory. Blood and urine were
collected every other week from NZM2410 mice. The charac-
teristics of the mice are shown in Supplementary Table 4,
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39219/abstract.
Immunohistochemistry was performed on formalin-
fixed kidney tissue with rabbit anti–HER-2 (1:300, staining for
1 hour) after heat antigen retrieval with a low-pH citrate solu-
tion (Vector). Amplification was performed with Vectastain
avidin–biotinylated enzyme complex and Vector biotinylated
anti-rabbit antibody. Negative controls (without primary anti-
body) were performed in parallel. The number of HER-
2–positive cells in the glomeruli of NZM2410 mice was
compared to that in controls. On average, 113 glomeruli were
analyzed per mouse. A blood urea nitrogen (BUN) level of
.30 mg/dl was considered elevated. All experiments were
approved by the Institutional Animal Care and Use Commit-
tee of The Children’s Hospital of Philadelphia.
Expression studies in vitro. Mesangial cells were
treated with 100 units/ml IFNa (Biomedical Laboratories) for
3 days. HER-2 expression was evaluated by qRT-PCR and
compared to that in mock-treated cells (primers are listed in
Supplementary Table 2, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39219/abstract).
IFN regulatory factor 1 (IRF-1)–puromycin plasmids
and vector-only plasmids were transfected into mesangial cells
using an Amaxa Cell Line Nucleofector Kit V (Lonza). IRF-1
transfection was confirmed by qRT-PCR and also by immuno-
fluorescence, using mouse anti-human IRF-1 (1:50, incubation
for 1 hour; Santa Cruz Biotechnology) as primary antibody
and Alexa Fluor 546–conjugated goat anti-mouse IgG (Invi-
trogen) as secondary antibody. The corrected total cell fluores-
cence was calculated using Image J software (National
Institutes of Health). HER-2 expression was evaluated by
qRT-PCR. The miRNAs miR-26a and miR-30b were also
measured by qRT-PCR, using spiked C elegans miR-39 (Qiagen)
as control.
Quantification of HER-2, monocyte chemotactic protein
1 (MCP-1), and vascular cell adhesion molecule 1 (VCAM-1) in
urine. Using human urine samples, enzyme-linked immunosor-
bent assays for HER-2 (Abcam), MCP-1 (R&D Systems), and
VCAM-1 (R&D Systems) were performed according to the
manufacturers’ instructions. Spectrophotometry was performed
with an EL808 microplate absorbance reader (BioTek
Instruments).
Urine samples from LN patients were obtained from
the Johns Hopkins Lupus cohort (15). Samples from patients
with active LN at the time of urine collection (renal SLE Dis-
ease Activity Index [SLEDAI] [16] score of $4) were com-
pared to samples from adult, healthy, sex- and age-matched
individuals. The characteristics of the patients are shown in
Supplementary Table 5, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39219/abstract. Samples from patients with active LN were
also compared to samples from the same patients collected at
least 3 months before the identified flare, when their renal
SLEDAI score was zero. To assess the association between
HER-2 and biopsy results, we studied samples that were col-
lected from patients who underwent a kidney biopsy within 1
year from the date of the urine collection. The IRB offices of
The Children’s Hospital of Philadelphia and of the Johns
Hopkins University School of Medicine approved this study.
Urine samples were collected in sterile containers and a prote-
ase inhibitor was added (cOmplete Protease Inhibitor Cock-
tail; Roche). The samples were placed on ice or refrigerated at
48C within 1 hour of collection and stored at 2808C. HER-2,
MCP-1, and VCAM-1 values were normalized by dividing by
the urine creatinine concentration.
Statistical analysis. GraphPad Prism software ver-
sion 5.0 was used for the statistical analysis. Unpaired t-tests
and Mann-Whitney U tests were used for comparisons between
samples with normal and non-normal distributions, respectively.
The relationship between HER-2 and the other urinary
biomarkers was defined by Pearson’s correlation and linear
regression. P values less than 0.05 were considered significant.
In vitro experiments were performed at least 3 times.
RESULTS
LN has a characteristic kidney miRNA signa-
ture that reflects cell proliferation. The expression of
more than 700 miRNAs was analyzed in the kidneys of
controls and children with LN and poststreptococcal glo-
merulonephritis. PCA showed that broadly the 3 groups
clustered in different parts of the diagram (see Supplemen-
tary Figure 1, available on the Arthritis & Rheumatology
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web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.39219/abstract). No differences were seen between
the different types of controls. These findings suggested
that the renal LN miRNA pattern is characteristic of
the disease and reflects its specific pathogenesis.
Levels of 41 miRNAs were significantly decreased
in the kidneys of LN patients compared to controls (P ,
0.05) (see Supplementary Table 6, available on the Arthri-
tis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.39219/abstract). According to IPA,
these miRNAs were associated with cell cycle (P values
of 9.02 3 1025 to 2.26 3 1022). We selected 3 miRNAs
for further study (miR-26a, miR-30b, and miR-4286)
(Figure 1A) based on the magnitude of their differential
expression and P values (P , 0.0001, P 5 0.0045, and P ,
0.0001, respectively). There were no significant differences
in the expression of these miRNAs according to sex, eth-
nicity, age, or immunosuppressive regimen used (data not
shown). Patients without previous treatment also had a
statistically significant decrease in miR-26a, miR-30b, and
miR-4286 compared to controls (P 5 0.0005, P 5 0.0244,
and P 5 0.0003, respectively). Levels of housekeeping
genes were no different between LN patients and controls.
The data for miR-26a and miR-30b levels were validated
by qRT-PCR (see Supplementary Figure 2, available on
the Arthritis & Rheumatology web site at http://onlineli-
brary.wiley.com/doi/10.1002/art.39219/abstract).
We next focused our functional analyses on miR-
26a and miR-30b, since miR-4286 was recently described
and its cellular functions are still unknown. The frag-
mented RNA from the paraffin-embedded samples could
not be interrogated to confirm a transcriptome signature
related to dysregulation of miR-26a and miR-30b; how-
ever, we performed an in silico analysis of data available
publicly (17). The transcriptome in LN glomeruli showed
a significant de-repression of predicted miR-26a and
miR-30b targets (see Supplementary Figure 3, available
on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.39219/abstract). DAVID
terms enriched in the miR-26a targets up-regulated in
LN glomeruli were blood pressure, transmembrane pro-
teins, defense response, response to wounding, immune
response, and lipoproteins (P , 1024). For miR-30b, the
terms were immune response, disulfide bond, regulation
of blood pressure, and regulation of proliferation (P ,
1024). These data support the concept that miR-26a and
miR-30b dysregulation is biologically relevant in LN.
Decreased levels of miRNAs miR-26a and miR-
30b in the urine of LN patients. We analyzed the uri-
nary levels of miR-26a and miR-30b to explore their
potential role as LN biomarkers. We also observed
decreased levels of these miRNAs in the urine of adult
LN patients compared to healthy controls, as was the
case in renal tissues (P 5 0.0162 and P 5 0.0404, respec-
tively) (Figure 1B).
Control of cell cycle–related gene expression by
miR-26a, miR-30b, and miR-4286. Cell cycle pathways
were strongly enriched in our analysis of the LN miRNA
Figure 1. Levels of the microRNAs miR-26a and miR-30b are decreased in the kidneys and urine of patients with lupus nephritis (LN). A, Lev-
els of miR-26a, miR-30b, and miR-4286 in the kidneys of pediatric LN patients (n 5 12) and controls (n 5 6) were measured by direct digital
detection of molecular barcodes. B, Levels of miR-26a and miR-30b in the urine of adult LN patients (n 5 14) and controls (n 5 19) were ana-
lyzed by quantitative reverse transcription–polymerase chain reaction. Values are the mean 6 SEM.
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signature, and proliferation is a hallmark of LN. We
therefore investigated whether these miRNAs directly
regulated cell cycle gene transcript abundance. We
knocked down each implicated miRNA in human mes-
angial cells and analyzed the gene expression by arrays.
According to IPA, knockdown of miR-26a led to
increased expression of genes associated with cell cycle
(P values of 9.98 3 1029 to 1.98 3 1022) and DNA rep-
lication, recombination, and repair (P values of 1.10 3
1028 to 1.98 3 1022). Similar results were obtained for
miR-30b knockdown (P values of 1.47 3 10220 to 1.11
3 1022 for both types of genes) and miR-4286 knock-
down (P values of 9.39 3 10222 to 1.15 3 1022 for both
types of genes). These findings suggested that miR-26a,
miR-30b, and miR-4286 were directly regulating the
expression of genes involved in proliferation. The expres-
sion levels of 10 genes were validated by qRT-PCR
(Figure 2A). Conversely, when miR-26a and miR-30b
overexpression vectors were transfected into mesangial
cells, we saw decreased expression of the cell cycle genes
(see Supplementary Figure 4, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39219/abstract). Thus, the miRNA signa-
ture appears to be intimately involved in pathologic cell
cycle gene expression in LN.
Control of cell proliferation by miR-26a, miR-
30b, and miR-4286. We directly examined proliferation
by performing MTT assays. A statistically significant
increase in the number of viable mesangial cells was
seen with knockdown of miR-26a, miR-30b, or miR-4286
Figure 2. Mesangial cells with knockdown (KD) of microRNAs (miRNAs) miR-26a, miR-30b, or miR-4286 have higher expression of genes
related to cell cycle and proliferate more. A, Expression of different miRNA targets in mesangial cells with knockdown of miR-26a, miR-30b, or
miR-4286 and in vector-transduced control cells was evaluated by quantitative reverse transcription–polymerase chain reaction (qRT-PCR). B,
MTT assays were performed to study cell proliferation in mesangial cells with knockdown of miR-26a, miR-30b, or miR-4286, in cells transduced
with a lentivirus control vector, and in uninfected cells. C, Mesangial cells with knockdown of miR-26a, miR-30b, or miR-4286 were cultured for 6
days and evaluated with propidium iodide (PI). D, Levels of miRNAs were measured by qRT-PCR after treatment with 8 mg/ml trastuzumab for
24 hours. Values are the mean 6 SEM. Experiments were performed at least 3 times. cel-miR-238 5 Caenorhabditis elegans miR-238.
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compared to cells transduced with the lentivirus control
(P 5 0.0072, P , 0.0001, and P , 0.0001, respectively)
(Figure 2B) (see Supplementary Figure 5, available on
the Arthritis & Rheumatology web site at http://onlineli-
brary.wiley.com/doi/10.1002/art.39219/abstract). These
data were further confirmed using propidium iodide to
measure DNA content (Figure 2C).
Increased levels of miR-26a and miR-30b
induced by trastuzumab along with lowered expression
of cell cyle–related genes. Trastuzumab, a monoclonal
antibody that inhibits HER-2, causes arrest at the G1
phase in breast cancer cells by increasing miR-26a and
miR-30b (18). We hypothesized that trastuzumab might
also increase miR-26a and miR-30b in mesangial cells and
affect their cell cycle. Levels of miR-26a and miR-30b
were measured in trastuzumab-treated cells and were
found to be increased, using either C elegans miR-238 or
U6 as control (Figure 2D). Furthermore, trastuzumab-
treated cells had decreased expression of genes related to
cell cycle (P values of 3.96 3 1025 to 2.70 3 1022) and
DNA replication, recombination, and repair (P values of
1.39 3 1028 to 2.70 3 1022). These data confirm that in
mesangial cells, similar to breast cancer cells, trastuzu-
mab can increase miR-26a and miR-30b and inhibit the
expression of cell cycle–related genes.
Dramatically increased levels of HER-2 in LN,
but not in other proliferative glomerulonephriti-
des. The effects of trastuzumab led us to hypothesize
that increased HER-2 might be regulating miRNA
expression in LN. No prior studies of HER-2 expression
Figure 3. Human epidermal growth factor receptor 2 (HER-2) expression is increased in kidneys of patients with lupus nephritis (LN) com-
pared to its expression in normal kidneys and in kidneys of patients with other proliferative glomerulonephritides. A, Positive and negative con-
trols (with HER-2–positive breast cancer tissue and without primary antibody, respectively). B–D, Representative samples of kidneys from
healthy donors (n 5 2) (B), from LN patients (n 5 8) (C), and from patients with other proliferative glomerulonephritides (IgA nephropathy
[n 5 4], poststreptococcal glomerulonephritis [n 5 4], and granulomatosis with polyangiitis [n 5 4]) (D). Original magnification 3 100.
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had been performed in this disease. We found a dra-
matic increase in HER-2 expression in the kidneys of
LN patients, not only in the tubular compartment,
but also in the glomeruli, where mesangial cells, endo-
thelial cells, and podocytes were strongly stained. Nor-
mal kidneys and kidneys from patients with other
proliferative glomerulonephritides (IgA nephropathy,
poststreptococcal glomerulonephritis, and granulomato-
sis with polyangiitis) had light staining of tubules, but
no strongly HER-2–positive cells in the glomeruli
(Figure 3).
Increased HER-2 levels in the glomeruli of
NZM2410 mice. To further examine HER-2 in LN,
immunohistochemical studies were also conducted in
NZM2410 mice and in control B6 and BALB/c mice
(Figure 4). As expected, NZM2410 mice developed an
early-onset, aggressive, lupus-like diffuse proliferative
glomerulonephritis. While HER-2 staining was almost
absent from kidneys in healthy humans, tubules in
healthy B6 and BALB/c mice showed strong HER-2
staining, with glomeruli being mostly negative. How-
ever, kidneys from NZM2410 mice showed a signifi-
cantly higher number of HER-2–positive cells per
glomerulus compared to kidneys from B6 and BALB/c
mice (P , 0.0001 for both) (Figure 4C). In addition,
the number of HER-2–positive cells per glomerulus
was significantly higher in NZM2410 mice with higher
proteinuria and higher levels of BUN (Figure 4D),
suggesting that HER-2 expression correlates with
severity of disease.
Increased HER-2 expression induced by IFNa
and IRF-1 in human mesangial cells. Our data sug-
gested a model whereby increased HER-2 expression
drives decreased miR-26a and miR-30b levels, allowing
for de-repression of cell cycle transcripts. We next
wished to understand the etiology of the increased
HER-2 expression. Since type I IFNs have been impli-
cated in SLE, we analyzed whether IFNa could regu-
late HER-2 expression. We found that mesangial cells
exposed to IFNa indeed had significantly higher
expression of HER-2 than did control cells (P 5 0.02)
(Figure 5D).
IRF-1 is a key transcription factor induced by
IFNa. We therefore decided to examine its effect on
HER-2 expression. IRF-1 transfection was confirmed by
immunofluorescence and qRT-PCR, as shown in Figure
5A. HER-2 expression was significantly increased in IRF-
1–transfected cells (P 5 0.0009) (Figure 5B). Furthermore,
decreased levels of miR-26a and miR-30b were seen in
IRF-1–transfected cells (Figure 5C). These data suggested
that lupus-associated factors such as IFNa and IRF-1
contribute to HER-2 overexpression and to secondarily
decreased miR-26a and miR-30b levels seen in LN.
Increased HER-2 levels in urine of LN patients,
and association of HER-2 with disease activity. The
dramatic overexpression of HER-2 in LN renal tissue
Figure 4. Significantly more human epidermal growth factor receptor 2 (HER-2)–positive cells per glomerulus detected in NZM2410 mice than
in BALB/c or C57BL/6 (B6) mice. A, Negative control experiment performed on NZM2410 mouse kidneys without the use of the primary anti-
body. B, Immunohistochemical studies of HER-2 in the kidneys of BALB/c mice (n 5 3), B6 mice (n 5 10), and NZM2410 mice (n 5 9). Repre-
sentative results are shown. C, Numbers of HER-2–positive cells per glomerulus in BALB/c mice, B6 mice, and NZM2410 mice. D, Numbers of
HER-2–positive cells per glomerulus in NZM2410 mice, according to proteinuria (mg/dl) (left) and blood urea nitrogen (BUN) level at the time
that mice were killed (normal #30 mg/dl; high .30 mg/dl) (right). Values are the mean 6 SEM. Original magnification 3 40.
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Figure 5. Interferon-a (IFNa) and IFN regulatory factor 1 (IRF-1) increase the expression of human epidermal growth factor receptor 2
(HER-2) in human mesangial cells. A, Successful overexpression of IRF-1 in IRF-1–transfected cells, measured by immunofluorescence (left)
and quantitative reverse transcription–polymerase chain reaction (qRT-PCR) (right). CTCF 5 corrected total cell fluorescence. Original magnifi-
cation 3 100. B, Expression of HER-2 in mesangial cells transfected with IRF-1 or with the control vector, measured by qRT-PCR. C, Levels of
miR-26a and miR-30b in cells transfected with IRF-1 or with the control vector, measured by qRT-PCR. D, Expression of HER-2 in mesangial
cells with or without previous exposure to IFNa, measured by qRT-PCR. In A–C, values are the mean 6 SEM. In D, symbols represent individ-
ual samples; bars show the mean 6 SEM. Experiments were performed at least 3 times.
Figure 6. Human epidermal growth factor receptor 2 (HER-2) is increased in the urine of patients with active lupus nephritis (LN) and is asso-
ciated with disease activity. A, HER-2 levels in the urine of adult patients with active LN (n 5 47) and in sex- and age-matched healthy controls
(n 5 26) were measured by enzyme-linked immunosorbent assay. B, HER-2 levels were analyzed in 14 patients at 2 different time points (during
inactive LN and at the time of an LN flare). C, Urinary HER-2 levels were analyzed according to histologic class of LN (n 5 19). D, HER-2 lev-
els were correlated with the urine protein:creatinine (Cr) ratio (n 5 46) and with levels of monocyte chemotactic protein 1 (MCP-1) (n 5 31) and
vascular cell adhesion molecule 1 (VCAM-1) (n 5 31). In A–C, values are the mean 6 SEM.
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suggested that it could be a useful biomarker. We found
that HER-2 was significantly increased in the urine of
adult patients with active LN compared to healthy con-
trols (P 5 0.0002) (Figure 6A). Moreover, when we ana-
lyzed HER-2 levels longitudinally, we found that they
were significantly increased during LN flares (P 5 0.0270)
(Figure 6B). HER-2 was also significantly increased in the
urine of patients with class III and class IV LN compared
to the urine of patients with class V LN (P 5 0.0374 and
P 5 0.0004, respectively) (Figure 6C). Finally, HER-2 lev-
els correlated with the urine protein:creatinine ratio
(P 5 0.0227) and with levels of other LN biomarkers,
namely, MCP-1 (P 5 0.0304) and VCAM-1 (P , 0.0001)
(Figure 6D).
Regulation of MCP-1 and VCAM-1 levels by
miRNAs. MCP-1 and VCAM-1 are thought to partici-
pate in the infiltration of the kidneys by inflammatory
cells, a well-known process in LN pathogenesis. Our in
silico studies identified VCAM-1 as a possible miR-30b
target in LN kidneys (see Supplementary Figure 3, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39219/abstract).
We therefore examined MCP-1 and VCAM-1 levels in
mesangial cells overexpressing miR-26a and miR-30b,
and we found significantly decreased expression of both
MCP-1 and VCAM-1 in cells overexpressing miR-26a
and decreased expression of VCAM-1 in cells overex-
pressing miR-30b (see Supplementary Figure 4, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39219/abstract).
These data suggest that proliferation and inflammation
are both influenced by these miRNAs.
DISCUSSION
Our data support a model in which type I IFNs,
via the transcription factor IRF-1, induce the expression
of HER-2. This pathway down-regulates miR-26a and
miR-30b, thereby driving cell proliferation through
de-repression of genes involved in the cell cycle (see
Supplementary Figure 6, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.39219/abstract).
Our initial discovery study began with pediatric
SLE patients. The pediatric age group was selected
because LN is particularly prevalent and severe in chil-
dren with SLE (2,19), and comorbidities such as diabe-
tes mellitus or hypertension are not as frequent. We
found a kidney miRNA signature specific for LN, char-
acterized by a significant decrease in miR-26a, miR-30b,
and miR-4286. Manipulation of these miRNAs in
human mesangial cells showed that they participate in
cell cycle regulation by controlling the expression of sev-
eral key genes, including CCNE2 and E2F8, which are
involved in the G1/S transition (20,21). CCNE2 had also
been predicted to be a target of both miR-26a and miR-
30b by the miRanda algorithm.
In LN there is a large spectrum of morphologic
changes in the glomerular, tubulointerstitial, and vascu-
lar compartments of the kidneys, but cell proliferation is
central to LN pathogenesis. Not only is mesangial
hypercellularity one of the first manifestations of the
disease, but also the presence of crescents is a well-
known negative prognostic factor.
Decreased miR-26a expression has also been
identified in several malignancies (18,22–39). Consis-
tently, miR-26a overexpression inhibits cell proliferation
(25,28,29,40), usually through the control of CCNE2
expression (22,25,40). Dysregulation of miR-26a has also
been associated with other autoimmune diseases, such as
rheumatoid arthritis (41) and idiopathic pulmonary fibro-
sis (42).
Similarly, miR-30b is associated with cell prolifer-
ation (30,43). Down-regulation of miR-26a and miR-30b
has also been reported in the sera of patients with sclero-
derma and those with systemic sclerosis (44), which are
fibrotic diseases that affect multiple tissues. In our study,
significantly decreased miR-26a and miR-30b levels
were found in LN, a disease characterized precisely by
cell proliferation and fibrosis, the 2 processes found to
be associated with these miRNAs in other diseases.
The stability of miRNAs in urine and the ease of
obtaining such samples make these molecules promising
candidates as noninvasive biomarkers. We showed that
levels of miR-26a and miR-30b are significantly de-
creased not only in the kidneys of LN patients, but also
in the urine of these patients. These data should be fur-
ther validated with new robust strategies to quantify uri-
nary miRNAs using standardized internal controls.
Trastuzumab targets the HER-2 extracellular
domain and blocks its downstream pathways by inhibiting
the dimerization of HER-2 and by promoting the inter-
nalization and cleavage of HER-2 molecules. Currently,
trastuzumab is used for the treatment of patients with
HER-2–positive breast and gastric cancer, where it causes
arrest at the G1 phase by up-regulating miR-26a and
miR-30b (18). The mechanism by which HER-2 regulates
miR-26a and miR-30b is not known. Our studies showed
a dramatic increase of HER-2 expression in the kidneys
of NZM2410 mice and LN patients. Furthermore, mesan-
gial cells exposed to trastuzumab had elevated levels of
miR-26a and miR-30b and down-regulation of genes
associated with mitosis and cell proliferation, demonstrat-
ing that this pathway is central to the regulation of miR-
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26a and miR-30b. Whether this pathway could be
exploited therapeutically is an intriguing question.
Other members of the epidermal growth factor
(EGF) family have been shown to participate in the
pathogenesis of renal diseases. In a mouse model of
crescentic glomerulonephritis, the activation of EGF
receptor (EGFR) in podocytes resulted in development
or progression of the disease, while the pharmacologic
blockage or genetic deletion of one of its ligands
improved the course of the disease and prevented the
infiltration of inflammatory cells (45). Moreover, activa-
tion of EGFR in cultured podocytes led to proliferation,
dedifferentiation, and migration, processes that are
thought to occur in crescent formation in vivo (45).
However, we did not find HER-2 overexpression in
other types of glomerulonephritides also characterized
by mesangioproliferation, such as IgA nephropathy,
poststreptococcal glomerulonephritis, and granulomato-
sis with polyangiitis. We therefore hypothesized that
lupus-associated factors drive HER-2 overexpression.
The effects of IFNa and IRF-1 in human mesangial
cells were evaluated, since the role of these 2 factors in
SLE etiopathogenesis has been previously identified
(46–48). We showed that both IFNa and IRF-1 in-
creased HER-2 expression in human mesangial cells
and that IRF-1 was also associated with a significant
decrease of miR-30b. The ChIP-Seq data available on
the University of California, Santa Cruz Genome Bioin-
formatics platform (http://genome.ucsc.edu/) are con-
sistent with the binding of IRF-1 to the HER-2 pro-
moter region in K562 cells, which further supports our
hypothesis that IRF-1 controls HER-2 expression.
HER-2 in the urine was significantly increased in
LN patients and it was associated with proliferative disease,
as expected from its known role in cell growth. Urinary
HER-2 levels were also significantly correlated with the
urine protein:creatinine ratio as well as with levels of MCP-
1 and VCAM-1, which are recognized LN biomarkers
(49–51). HER-2 levels likely capture a distinct pathologic
mechanism in LN, and while the association between bio-
markers is statistically robust, there are clear differences
between inflammatory mediator detection and HER-2
detection, which will require additional investigation.
This study identified a novel pathway and poten-
tial biomarkers, using multiple confirmatory strategies.
Nevertheless, there are some limitations. While our ini-
tial miRNA analysis and pathologic studies relied on
pediatric cases of LN, the urine analyses were per-
formed in adults, where achieving an adequate sample
size was possible. This precluded direct analysis of the
association of expression of HER-2 with expression of
miRNA from the same patient. In addition, the majority
of patients were African American. New data should be
obtained in different age groups and in different racial
backgrounds in order to further validate our findings.
Larger, longitudinal studies will be needed. Neverthe-
less, our data highlight a novel, previously unexpected
pathway and provide a substantial foundation for fur-
ther investigation of these potential biomarkers. For
decades, proliferation has been recognized as the hall-
mark of LN, and the identification of this pathway
opens the door to novel therapeutic interventions.
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Clinical Images: Polyarteritis nodosa of the iliopsoas muscle
The patient, a 67-year-old man, presented with a 2-week history of fever, malaise, and low back pain. There had been no response to
antibiotic treatment. The biochemical profile showed elevated levels of C-reactive protein (CRP) (143 mg/liter; normal ,3) and ferri-
tin (39,924 ng/ml; normal 39.4–340); testing for antineutrophil cytoplasmic antibodies yielded negative results. Blood cultures were
negative, and hepatic and renal function were normal. Notably, gallium scintigraphy with computed tomography (CT) revealed a
swollen left iliopsoas muscle with high gallium uptake (A–C) (arrows). Enhanced CT showed no visceral aneurysms. CT-guided
needle biopsy of the iliopsoas muscle (D) demonstrated large collections of mononuclear inflammatory cells in the walls of a medium-
sized muscular artery, as also seen on histologic assessment with hematoxylin and eosin staining (E). Elastic2van Gieson staining
showed fragmentation in the internal elastic lamina in the same artery (F). The patient was diagnosed as having muscular polyarteritis
nodosa confined to the left iliopsoas muscle. Treatment with prednisolone was initiated, and high-dose intravenous immunoglobulin
therapy was later added. After treatment, his symptoms improved, and the serum CRP and ferritin levels normalized. The iliopsoas
muscle edema with high gallium uptake completely resolved. He was discharged without further complications. Polyarteritis nodosa
of a muscle is quite rare and has been reported to be restricted to the lower legs (1,2). To our knowledge, this is the first reported case
of polyarteritis nodosa confined to the iliopsoas muscle. This case should remind clinicians to consider single-organ vasculitis as a rare
cause of fever of unknown origin or isolated lesions found on imaging.
1. Khellaf M, Hamidou M, Pagnoux C, Michel M, Brisseau JM,
Chevallier X, et al. Vasculitis restricted to the lower limbs: a clini-
cal and histopathological study. Ann Rheum Dis 2007;66:554–6.
2. Hernandez-Rodriguez J, Molloy ES, Hoffman GS. Single-organ
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Abstract
,ĂĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶĚƌŽŵĞƐ ĂƌĞ ĐŚĂƌĂĐƚĞƌŝǌĞĚ ďǇ
ŽǀĞƌǁŚĞůŵŝŶŐŝŶŇĂŵŵĂƟŽŶƌĞůĂƚĞĚƚŽƵŶĐŽŶƚƌŽůůĞĚĂĐƟͲ
ǀĂƟŽŶŽĨŵĂĐƌŽƉŚĂŐĞƐ ĂŶĚdͲůǇŵƉŚŽĐǇƚĞƐ ĂŶĚŚǇƉĞƌƐĞͲ
ĐƌĞƟŽŶ ŽĨ ĐǇƚŽŬŝŶĞƐ͘ dŚĞƐĞ ƐǇŶĚƌŽŵĞƐ ĐĂŶ ďĞ ƉƌŝŵĂƌǇ͕ 
ǁŚĞŶĐĂƵƐĞĚďǇŐĞŶĞƟĐĚĞĨĞĐƚƐŝŶĐǇƚŽƚŽǆŝĐŝƚǇ͕ ŽƌƐĞĐŽŶͲ
ĚĂƌǇ ƚŽ ƌŚĞƵŵĂƟĐ ĚŝƐĞĂƐĞƐ͕ ŝŶĨĞĐƟŽŶ͕ Žƌ ŵĂůŝŐŶĂŶĐǇ͘ 




ĂŶĚ ŝŶĐƌĞĂƐĞ ƐƵƌǀŝǀĂů͘ ZĞĐĞŶƚůǇ ŶĞǁ ĐƌŝƚĞƌŝĂ ŚĂǀĞ ďĞĞŶ
ĚĞǀĞůŽƉĞĚ ƚŽ ĚŝĂŐŶŽƐĞ ŚĂĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶĚƌŽŵĞƐ ŝŶ
ĚŝīĞƌĞŶƚƐĞƫŶŐƐ͘ĂƚĂĨƌŽŵŵŽƵƐĞŵŽĚĞůƐŚĂǀĞŚĞůƉĞĚ
ƚŽďĞƩĞƌƵŶĚĞƌƐƚĂŶĚƚŚĞƉĂƚŚŽŐĞŶĞƐŝƐŽĨƚŚĞƐĞĐŽŶĚŝƟŽŶƐ
ĂŶĚĞƐƚĂďůŝƐŚĞĚƐƚƌŽŶŐ ĨŽƵŶĚĂƟŽŶƐ ĨŽƌ ƚŚĞƵƐĞŽĨďŝŽůŽͲ









 ƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽĐşƟĐĂ ĐĂƌĂĐƚĞƌŝǌĂͲƐĞƉŽƌ ŝŶŇĂŵĂͲ






ĐŽŶŚĞĐŝĚĂ ĐŽŵŽ ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ ŚĞŵĂĨŽŐŽĐşƟĐĂ ĨĂŵŝͲ
ůŝĂƌ͕ ƵŵŐƌƵƉŽĚĞĚŽĞŶĕĂƐŐĞŶĠƟĐĂƐƌĂƌĂƐĐĂƵƐĂĚĂƐƉŽƌ
ĂůƚĞƌĂĕƁĞƐĚĂĐŝƚŽƚŽǆŝĐŝĚĂĚĞ͖ŽƵƐĞĐƵŶĚĄƌŝĂĂ ŝŶĨĞĕƁĞƐ͕
ŶĞŽƉůĂƐŝĂƐ ŽƵ ĚŽĞŶĕĂƐ ƌĞƵŵĂƚŽůſŐŝĐĂƐ͘ K ƚĞƌŵŽ ͞ƐşŶͲ
ĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ͟ĠŵƵŝƚĂƐǀĞǌĞƐƵƟůŝǌĂĚŽ
ƉĂƌĂŶŽŵĞĂƌŽƷůƟŵŽŐƌƵƉŽ͘
K ĚŝĂŐŶſƐƟĐŽ Ġ ĚŝİĐŝů͕ ƉĂƌƟĐƵůĂƌŵĞŶƚĞ Ğŵ ĐŽŶƚĞǆƚŽ
ĚĞ ĐƵŝĚĂĚŽƐ ŝŶƚĞŶƐŝǀŽƐ͕ ĂƐƐĞŵĞůŚĂŶĚŽͲƐĞ ă ƐşŶĚƌŽŵĞ
ĚĞ ƌĞƐƉŽƐƚĂ ŝŶŇĂŵĂƚſƌŝĂ ŽƵ ă ĨĂůġŶĐŝĂ ŵƵůƟŽƌŐąŶŝĐĂ͘ϰ
ƐƵĂ ŝĚĞŶƟĮĐĂĕĆŽĠĐƌƵĐŝĂů͕ƵŵĂǀĞǌƋƵĞĂĞƐƚƌĂƚĠŐŝĂ
ƚĞƌĂƉġƵƟĐĂƉĂƐƐĂ ĨƌĞƋƵĞŶƚĞŵĞŶƚĞƉĞůŽ ƌĞĐƵƌƐŽĂ ŝŵƵͲ
ŶŽƐƐƵƉƌĞƐƐŽƌĞƐ͕ ĂďŽƌĚĂŐĞŵ ĚŝĨĞƌĞŶƚĞ ĚĂ ƵƟůŝǌĂĚĂ ŶĂ
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ŵĞŶƚĞ͕ƉŽĚĞŶĚŽŵĂŶŝĨĞƐƚĂƌͲƐĞƉŽƌ ĐĞĨĂůĞŝĂ͕ ůĞƚĂƌŐŝĂ͕ ŝƌƌŝƚĂďŝͲ
ůŝĚĂĚĞ͕ ĚĞƐŽƌŝĞŶƚĂĕĆŽ͕ ĂƚĂǆŝĂ͕ ŶĞƵƌŽƉĂƟĂ ƉĞƌŝĨĠƌŝĐĂ ƐĞŶƐŝƟǀĂ




ĨŽƌŵĂƐ ƐĞĐƵŶĚĄƌŝĂƐ͕ ƌĞƉƌĞƐĞŶƚĂŶĚŽ Ƶŵ ĨĂƚŽƌ ĚĞ ŵĂƵ ƉƌŽŐͲ
ŶſƐƟĐŽ͘14 KƵƚƌĂƐ ŵĂŶŝĨĞƐƚĂĕƁĞƐ ƉŽƐƐşǀĞŝƐ ŝŶĐůƵĞŵ ƐĞƌŽƐŝƚĞ͕
ŵŝŽĐĂƌĚŝƚĞ͕ĐĂƌĚŝŽŵĞŐĂůŝĂ͕ĂƌƌŝƚŵŝĂƐĞĨĂůġŶĐŝĂĐĂƌĚşĂĐĂ͘ϱ͕ϳ͕ϭϱ
KĞŶǀŽůǀŝŵĞŶƚŽƌĞŶĂůƚĂŵďĠŵƉŽĚĞŽĐŽƌƌĞƌ͕ ĐŽŵƉƌŽŐƌĞƐƐĆŽ













ĨĂŐŽĐşƟĐĂ͕ ƉĞƌŵŝƟŶĚŽ ĨĂǌĞƌ Ž ĚŝĂŐŶſƐƟĐŽ ĚŝĨĞƌĞŶĐŝĂů ĐŽŵ
ƐĠƉƐŝƐ Ğ ŝŶƐƵĮĐŝġŶĐŝĂ ŚĞƉĄƟĐĂ͘ϭϵ  ĨĞƌƌŝƟŶĞŵŝĂ Ġ ŝŵƉŽƌƚĂŶƚĞ
ŶĆŽ Ɛſ ƉĂƌĂ Ž ĚŝĂŐŶſƐƟĐŽ͕ŵĂƐ ƚĂŵďĠŵ ĐŽŵŽŵĂƌĐĂĚŽƌ ĚĂ
ĂƟǀŝĚĂĚĞĚĂĚŽĞŶĕĂ͕ƌĞƐƉŽƐƚĂăƚĞƌĂƉġƵƟĐĂĞƉƌŽŐŶſƐƟĐŽ͘ϲ͕ϵ
 ƚĂŵďĠŵ ĨƌĞƋƵĞŶƚĞĚĞƚĞƚĂƌͲƐĞĂƵŵĞŶƚŽĚĂƐĞŶǌŝŵĂƐŚĞƉĄͲ




ƉĂƌĐŝĂů ĂƟǀĂĚĂ ƉƌŽůŽŶŐĂĚŽƐ͕ ŚŝƉŽĮďƌŝŶŽŐĞŶĞŵŝĂ Ğ ƉƌĞƐĞŶĕĂ
ĚĞƉƌŽĚƵƚŽƐĚĞĚĞŐƌĂĚĂĕĆŽĚĞĮďƌŝŶĂ͘ϲ͕ϳ͕ϵ͕ϭϱ









EŽǀŽƐ ŵĂƌĐĂĚŽƌĞƐ ƉĂƌĂ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ƚġŵ ƐŝĚŽ
ƌĞĐĞŶƚĞŵĞŶƚĞ ĚĞƐĐƌŝƚŽƐ͘ K ƌĞĐĞƉƚŽƌ ƐŽůƷǀĞů ĂůĨĂ ĚĂ ŝŶƚĞƌůĞƵͲ
ĐŝŶĂ ;/>ͿͲϮ ;Ɛ/>ϮZɲͬƐϮϱͿ ĞƐƚĄ ŵƵŝƚŽ ĂƵŵĞŶƚĂĚŽ ŶĂ ĨĂƐĞ
ĂŐƵĚĂĚĂ ƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂƋƵĂŶĚŽ ĐŽŵƉĂͲ
ƌĂĚŽ ĐŽŵ/:^ ĚĞ ŝŶşĐŝŽ ƌĞĐĞŶƚĞ͘ϮϱK ϭϲϯ͕ ƌĞĐĞƚŽƌ ĚĂ ŚĂƉͲ
ƚŽŐůŽďŝŶĂ ĞŵĂƌĐĂĚŽƌ ĞƐƉĞĐşĮĐŽĚĞŵĂĐƌſĨĂŐŽƐ͕ ĞŶĐŽŶƚƌĂͲƐĞ
ŝŐƵĂůŵĞŶƚĞŵƵŝƚŽĂƵŵĞŶƚĂĚŽŶŽ ƐŽƌŽ͕ŵĞĚƵůĂſƐƐĞĂĞďĂĕŽ
ĚĞ ĚŽĞŶƚĞƐ ĐŽŵ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ͘Ϯϱ͕Ϯϲ K ϭϲϯ Ğ Ž
Ϯϱ ƐŽůƷǀĞů ;ƐϮϱͿ ĐŽƌƌĞůĂĐŝŽŶĂŵͲƐĞ ĐŽŵ Ă ĂƟǀŝĚĂĚĞ ĚĂ
ĚŽĞŶĕĂ͕ ƌĞŇĞƟŶĚŽŽ ŐƌĂƵĚĞ ĂƟǀĂĕĆŽĚŽƐŵĂĐƌſĨĂŐŽƐ Ğ ĚŽƐ
ůŝŶĨſĐŝƚŽƐdƌĞƐƉĞƟǀĂŵĞŶƚĞ͘Ϯϱ
Exame anatomopatológico
 ƉƌĞƐĞŶĕĂ ĚĞ ŚĞŵŽĨĂŐŽĐŝƚŽƐĞ ŶŽ ĂƐƉŝƌĂĚŽ ŽƵ ďŝſƉƐŝĂ ĚĞ
ŵĞĚƵůĂſƐƐĞĂƉŽĚĞƐĞƌƷƟů͕ŵĂƐŶĆŽĠƐƵĮĐŝĞŶƚĞŽƵŶĞĐĞƐƐĄƌŝĂ
ƉĂƌĂ Ž ĚŝĂŐŶſƐƟĐŽ ĚĞ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ͘ ĞƐƚĂĐĂͲƐĞ









ƟƉůŽƐĞƐơŵƵůŽƐ͕ ŝŶĐůƵŝŶĚŽ ŝŶĨĞĕĆŽ͕ŶĞŽƉůĂƐŝĂŽƵĚŽĞŶĕĂ ƌĞƵͲ
ŵĂƚŽůſŐŝĐĂ͘ WŽĚĞ ŽĐŽƌƌĞƌ ƚĂŵďĠŵ ŶŽ ĐŽŶƚĞǆƚŽ ĚĞ ĚĞĨĞŝƚŽƐ
ŐĞŶĠƟĐŽƐŶĂ ĐŝƚŽƚŽǆŝĐŝĚĂĚĞ͘EĞƐƚĞ ĐĂƐŽ͕ŽƐ ƐŝŶƚŽŵĂƐ ƐƵƌŐĞŵ
ŐĞƌĂůŵĞŶƚĞŶŽƐƉƌŝŵĞŝƌŽƐĂŶŽƐĚĞǀŝĚĂ͕ĐŽŵƵŵĂƐŽďƌĞǀŝǀġŶͲ
ĐŝĂŵĞĚŝĂŶĂŝŶĨĞƌŝŽƌĂĚŽŝƐŵĞƐĞƐŶĂĂƵƐġŶĐŝĂĚĞƚƌĂƚĂŵĞŶƚŽ͘Ϯϵ
EŽ ĐŽŶƚĞǆƚŽ ĚĞ ĚŽĞŶĕĂƐ ƌĞƵŵĂƚŽůſŐŝĐĂƐ͕ Ă ƐşŶĚƌŽŵĞ ĚĞ ĂƟͲ
ǀĂĕĆŽ ŵĂĐƌŽĨĄŐŝĐĂ Ġ ƉĂƌƟĐƵůĂƌŵĞŶƚĞ ĐŽŵƵŵ Ğŵ ĚŽĞŶƚĞƐ
ĐŽŵ/:^͕ŽĐŽƌƌĞŶĚŽĞŵƉĞůŽŵĞŶŽƐϳͲϭϯйĚŽƐĚŽĞŶƚĞƐϳ͕ϭϱ͕ϭϳ
ĞƉŽĚĞŶĚŽƐĞƌ ƐƵďĐůşŶŝĐĂŽƵĂƐƐƵŵŝƌƵŵĂ ĨŽƌŵĂŵĂŝƐ ůŝŐĞŝƌĂ
Ğŵ ŽƵƚƌŽƐ ϯϬͲϰϬй͘ϭϱͲϮϱ dĂŵďĠŵ ƉŽĚĞ ŽĐŽƌƌĞƌ Ğŵ ĚŽĞŶƚĞƐ
ĐŽŵ ůƷƉƵƐ ĞƌŝƚĞŵĂƚŽƐŽ ƐŝƐƚĠŵŝĐŽ͕ϯϬ ĚŽĞŶĕĂ ĚĞ ^ũŽŐƌĞŶ͕ϯϭ
ĚĞƌŵĂƚŽŵŝŽƐŝƚĞ͕ϯϭͲϯϯ ĞƐĐůĞƌŽƐĞ ƐŝƐƚĠŵŝĐĂ͕ ƉŽůŝĂƌƚĞƌŝƚĞ ŶŽĚŽƐĂ͕
ĚŽĞŶĕĂĚĞ<ĂǁĂƐĂŬŝ͕ĂƌƚƌŝƚĞƌĞƵŵĂƚŽŝĚĞ͕ϯϭĂƌƚƌŝƚĞƌĞůĂĐŝŽŶĂĚĂ
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ĨĞďƌĞ ƉĞƌŝſĚŝĐĂ͘ϭϳ͕ϯϰ͕ϯϱ WŽĚĞ ƐƵƌŐŝƌ ĞƐƉŽŶƚĂŶĞĂŵĞŶƚĞ ŽƵ ƐĞƌ
ĚĞƐĞŶĐĂĚĞĂĚĂƉŽƌ ƵŵĂ ŝŶĨĞĕĆŽŽƵƉĞůŽ ĞĨĞŝƚŽ ƚſǆŝĐŽĚĞƵŵ
ĨĄƌŵĂĐŽ͘ϱ͕ϭϳ
Ɛ ŶĞŽƉůĂƐŝĂƐ͕ ƐŽďƌĞƚƵĚŽ ůĞƵĐĞŵŝĂƐ Ğ ůŝŶĨŽŵĂƐ͕ ƚĂŵďĠŵ ƐĞ
ĂƐƐŽĐŝĂŵ Ă ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ͕ ĞǆŝƐƟŶĚŽ͕ ĨƌĞƋƵĞŶƚĞͲ
ŵĞŶƚĞƵŵĂŝŶĨĞĕĆŽĐŽŶĐŽŵŝƚĂŶƚĞ͘ϯϲͲϯϴƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽͲ
ĐşƟĐĂƉŽĚĞƉƌĞĐĞĚĞƌ͕ ŽĐŽƌƌĞƌƐŝŵƵůƚĂŶĞĂŵĞŶƚĞăŝĚĞŶƟĮĐĂĕĆŽ
ĚĂ ŶĞŽƉůĂƐŝĂϯϵ ŽƵ ƐĞƌ ĚĞƐĞŶĐĂĚĞĂĚĂ ƉĞůĂ ŝŵƵŶŽƐƐƵƉƌĞƐƐĆŽ
ŝŶĚƵǌŝĚĂƉĞůĂƋƵŝŵŝŽƚĞƌĂƉŝĂ͘ϯϲƉƌŽďĂďŝůŝĚĂĚĞĚĞƵŵĂĚŽĞŶĕĂ
ŵĂůŝŐŶĂƐƵďũĂĐĞŶƚĞĂƵŵĞŶƚĂĐŽŵĂŝĚĂĚĞ͘ϯϲ
/ŶĨĞĕƁĞƐ ǀŝƌĂŝƐ͕ ƉĂƌƟĐƵůĂƌŵĞŶƚĞ ƉĞůŽ ǀşƌƵƐ ƉƐƚĞŝŶͲĂƌƌ͕ 
ƉŽĚĞŵ ĚĞƐĞŶĐĂĚĞĂƌ ĨŽƌŵĂƐ ƉƌŝŵĄƌŝĂƐ ďĞŵ ĐŽŵŽ ƐĞĐƵŶĚĄͲ
ƌŝĂƐ ĚĞ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ͘ϳ͕ϯϯ͕ϰϬ͕ϰϭ KƵƚƌŽƐ ĞƐơŵƵůŽƐ
ŝŶĨĞĐŝŽƐŽƐ ĐŽŶŚĞĐŝĚŽƐ ŝŶĐůƵĞŵ ĐŝƚŽŵĞŐĂůŽǀşƌƵƐ͕ϰϭ ƉĂƌǀŽǀşƌƵƐ
ϭϵ͕ϳ͕ϯϯ͕ϰϮ ǀşƌƵƐŚĞƌƉĞƐ ƐŝŵƉůĞǆ͕ϰϯ͕ϰϰ ǀĂƌŝĐĞůůĂͲǌŽƐƚĞƌ͕ ϳ ǀşƌƵƐŚĞƌͲ
ƉĞƐ ŚƵŵĂŶŽͲϴ͕ϰϱ͕ϰϲ ĐŽǆƐĂĐŬŝĞ͕ϳ ŝŶŇƵĞŶǌĂ͕ϰϳ͕ϰϴ ƉĂƌĂŝŶŇƵĞŶǌĂ͕ϰϵ
ƉĂƌĞĐŚŽǀŝƌƵƐ50ĞǀşƌƵƐĚĞŝŵƵŶŽĚĞĮĐŝġŶĐŝĂŚƵŵĂŶĂ;s/,Ϳ͘51
ƉĞƐĂƌ ĚĞ ŵĞŶŽƐ ĐŽŵƵŵ͕ ĂƐ ƐşŶĚƌŽŵĞƐ ŚĞŵŽĨĂŐŽĐşƟĐĂƐ
ƉŽĚĞŵŽĐŽƌƌĞƌŝŐƵĂůŵĞŶƚĞŶŽĐŽŶƚĞǆƚŽĚĞŝŶĨĞĕƁĞƐďĂĐƚĞƌŝĂͲ
ŶĂƐƉŽƌStaphylococcus aureus͕41Escherichia coli͕41Salmonella 
ĞŶƚĞƌŝƟĚŝƐ͕ϳ Mycoplasma pneumoniae͕ϱϮ ŚƌůŝĐŚŝĂ ĐŚĂīĞĞŶͲ
sis͕ϱϯ Brucella mellitensis41 Ğ Mycobacterium tuberculosiƐ41͖
ƉĂƌĂƐŝƚĂƐ͕ ŝŶĐůƵŝŶĚŽ Leshmania spp41 ĞWůĂƐŵŽĚŝƵŵ ĨĂůĐŝƉĂͲ
rum54 Ğ Plasmodium vivax55͖ Ğ ĨƵŶŐŽƐ͕ϯϯ ĐŽŵŽ Histoplasma 
capsulatumϰϭ͕ϱϲĞCoccidiodes͘ϱϳ
 ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ƚĂŵďĠŵ ƉŽĚĞ ŽĐŽƌƌĞƌ ŶŽ ĐƵƌƐŽ
ĚĞ ŚŝƐƟŽĐŝƚŽƐĞ ĚĞ ĐĠůƵůĂƐ ĚĞ >ĂŶŐĞƌŚĂŶƐ͕ϯϯ ƐşŶĚƌŽŵĞ ĚĞ
ŚĠĚŝĂŬͲ,ŝŐĂƐŚŝ͕58 ƐşŶĚƌŽŵĞ ĚĞ 'ƌŝƐĐĞůůŝ ƟƉŽ Ϯϱϵ Ğ ƐşŶĚƌŽŵĞ
ĚĞ ,ĞƌŵĂŶƐŬŝͲWƵĚůĂŬ ƟƉŽ Ϯ͘60 /ŵƵŶŽĚĞĮĐŝġŶĐŝĂƐ ĂĚƋƵŝƌŝĚĂƐ͕
ŝŶĐůƵŝŶĚŽ s/,͕ ƚƌĂŶƐƉůĂŶƚĞ ĚĞ ĐĠůƵůĂƐ ŚĞŵĂƚŽƉŽŝĠƟĐĂƐ61 Ğ
ƚƌĂŶƐƉůĂŶƚĞ ĚĞ İŐĂĚŽͬƌŝŵϲϮͲϲϰ ƚĂŵďĠŵ ƐĞ ĂƐƐŽĐŝĂŵ Ă ŵĂŝŽƌ
ƌŝƐĐŽƉĂƌĂƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽĐşƟĐĂ͘
ŽĞŶƚĞƐ ĐŽŵ ŝŶƚŽůĞƌąŶĐŝĂ ă ƉƌŽƚĞşŶĂ ůŝƐŝŶƷƌŝĐĂ͕65 ŝŵƵŶŽĚĞĮͲ
ĐŝġŶĐŝĂĐŽŵďŝŶĂĚĂŐƌĂǀĞ͕66ƐşŶĚƌŽŵĞĚĞŝ'ĞŽƌŐĞ͕66ƐşŶĚƌŽŵĞ





ŚĞŵŽĨĂŐŽĐşƟĐĂ͕ ĞŶƚƌĞ ĂƐ ƋƵĂŝƐ Ă ƐşŶĚƌŽŵĞ ůŝŶĨŽƉƌŽůŝĨĞƌĂƟǀĂ
ĂƵƚŽŝŵƵŶĞ͕ Ă ƉƷƌƉƵƌĂ ƚƌŽŵďſƟĐĂ ƚƌŽŵďŽĐŝƚŽƉĠŶŝĐĂ͕ Ă ƐşŶͲ
ĚƌŽŵĞ ŚĞŵŽůşƟĐĂ ƵƌĠŵŝĐĂ͕ Ă ŵŝĐƌŽĂŶŐŝŽƉĂƟĂ ƚƌŽŵďſƟĐĂ͕
ĚŽĞŶĕĂƐŚĞƉĄƟĐĂƐƉƌŝŵĄƌŝĂƐĞĂƌĞĂĕĆŽĂĚƌŽŐĂƐĐŽŵĞŽƐŝŶŽͲ
ĮůŝĂĞƐŝŶƚŽŵĂƐƐŝƐƚĠŵŝĐŽƐ͘
Critérios de diagnóstico 
K ĚŝĂŐŶſƐƟĐŽ ĚĞ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ƉƌŝŵĄƌŝĂ Ġ ĨĞŝƚŽ
ĚĞĂĐŽƌĚŽĐŽŵŽƐ ĐƌŝƚĠƌŝŽƐƉƌŽƉŽƐƚŽƐƉĞůĂ,ŝƐƟŽĐǇƚĞ^ŽĐŝĞƚǇ
Ğŵ ϮϬϬϰ͕68 ƋƵĞ ŝŶĐůƵĞŵ ĨĞďƌĞ͕ ĞƐƉůĞŶŽŵĞŐĂůŝĂ͕ ďŝĐŝƚŽƉĞŶŝĂ͕
ŚŝƉĞƌƚƌŝŐůŝĐĞƌŝĚĞŵŝĂ ĞͬŽƵ ŚŝƉŽĮďƌŝŶŽŐĞŶĞŵŝĂ͕ ŚŝƉĞƌĨĞƌƌŝƟŶĞͲ
ŵŝĂ͕Ɛ/>ϮZɲͬƐϮϱĞůĞǀĂĚŽ͕ĂƟǀŝĚĂĚĞĚĞĐĠůƵůĂƐE<ĚŝŵŝŶƵşĚĂ
ŽƵĂƵƐĞŶƚĞĞĞǀŝĚġŶĐŝĂĚĞŚĞŵŽĨĂŐŽĐŝƚŽƐĞŶĂŵĞĚƵůĂſƐƐĞĂ͕




ŶŽ ĞŶƚĂŶƚŽ͕ ƉĂƌĂ Ž ĚŝĂŐŶſƐƟĐŽ ĚĞ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ
ƐĞĐƵŶĚĄƌŝĂ͘




























 ƉĂƌƟĐƵůĂƌŵĞŶƚĞ ĚŝİĐŝů ĚŝƐƟŶŐƵŝƌ ĞŶƚƌĞ ƐşŶĚƌŽŵĞ ĚĞ ĂƟǀĂͲ
ĕĆŽ ŵĂĐƌŽĨĄŐŝĐĂ Ğ ĂŐƵĚŝǌĂĕĆŽ ĚĞ /:^͕ ĚĂĚŽ ƋƵĞ ƚġŵ ƵŵĂ
ĂƉƌĞƐĞŶƚĂĕĆŽĐůşŶŝĐĂƐĞŵĞůŚĂŶƚĞ͘KƐĐƌŝƚĠƌŝŽƐĚĂ/ŶƚĞƌŶĂƟŽŶĂů
>ĞĂŐƵĞŽĨƐƐŽĐŝĂƟŽŶƐ ĨŽƌZŚĞƵŵĂƚŽůŽŐǇ ƉĂƌĂŽĚŝĂŐŶſƐƟĐŽ








ZĞĐĞŶƚĞŵĞŶƚĞ͕ ŶŽǀŽƐ ĐƌŝƚĠƌŝŽƐ ĐůşŶŝĐŽƐ Ğ ůĂďŽƌĂƚŽƌŝĂŝƐ ĨŽƌĂŵ
ĞƐƚĂďĞůĞĐŝĚŽƐ ƉĂƌĂ Ž ĚŝĂŐŶſƐƟĐŽ ĚĞ ƐşŶĚƌŽŵĞ ĚĞ ĂƟǀĂĕĆŽ
ŵĂĐƌŽĨĄŐŝĐĂĞŵĚŽĞŶƚĞƐĐŽŵ/:^ƋƵĞƐĞĞŶĐŽŶƚƌĞŵĨĞďƌŝƐϳϰ͗:
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 ĂŶĂŵŶĞƐĞ ĚĞǀĞ ŝŶĐůƵŝƌ ƋƵĞƐƚƁĞƐ ƐŽďƌĞ ŝŶĨĞĕƁĞƐ ƌĞĐĞŶƚĞƐ͕
ŶĞŽƉůĂƐŝĂƐ͕ ŝŵƵŶŽĚĞĮĐŝġŶĐŝĂƐ͕ ĚŽĞŶĕĂƐ ƌĞƵŵĂƚŽůſŐŝĐĂƐ͕ ĨĄƌͲ
ŵĂĐŽƐĞŚŝƐƚſƌŝĂĨĂŵŝůŝĂƌĚĞƐŝŶƚŽŵĂƐƐĞŵĞůŚĂŶƚĞƐ͘EŽĞǆĂŵĞ
ŽďũĞĐƟǀŽĚĞǀĞƐĞƌƉĞƐƋƵŝƐĂĚĂĂĞǆŝƐƚġŶĐŝĂĚĞŚĞƉĂƚŽĞƐƉůĞŶŽͲ
ŵĞŐĂůŝĂ͕ ůŝŶĨŽĂĚĞŶŽƉĂƟĂƐ͕ ĞǆĂŶƚĞŵĂ͕ ŚĞŵŽƌƌĂŐŝĂƐ ĐƵƚąŶĞŽͲ
ͲŵƵĐŽƐĂƐĞĂůƚĞƌĂĕƁĞƐŶĞƵƌŽůſŐŝĐĂƐ͘
Ă ĂǀĂůŝĂĕĆŽ ůĂďŽƌĂƚŽƌŝĂů Ğ ŝŵĂŐŝŽůſŐŝĐĂ͕ ĚĞǀĞ ĨĂǌĞƌ ƉĂƌƚĞ
ĞĐŽŐƌĂĮĂ ĂďĚŽŵŝŶĂů͕ϳϱ ŚĞŵŽŐƌĂŵĂ͕ ĞƐƚƵĚŽ ĚĂ ĐŽĂŐƵůĂĕĆŽ͕
ĮďƌŝŶŽŐĠŶŝŽ͕ ^d͕  ĂůĂŶŝŶĂ ĂŵŝŶŽƚƌĂŶƐĨĞƌĂƐĞ ;>dͿ͕ ĂůďƵŵŝŶĂ͕
ƉĞƌĮůůŝƉşĚŝĐŽĞĨĞƌƌŝƟŶĂ͘ϳϱ
^Ğ ŶĞŶŚƵŵ ĞƐơŵƵůŽ ĨŽƌ ŝĚĞŶƟĮĐĂĚŽ͕ ĚĞǀĞŵ ƐĞƌ ƉƌŽĐƵƌĂĚĂƐ
ĚŽĞŶĕĂƐŝŶĨĞĐĐŝŽƐĂƐ͕ĐŽŵƌĂĚŝŽŐƌĂĮĂĚĞƚſƌĂǆ͕ŚĞŵŽĞƵƌŽĐƵůͲ
ƚƵƌĂ͕ĞƐĨƌĞŐĂĕŽƐĂŶŐƵşŶĞŽ͕ ƐĞƌŽůŽŐŝĂƐƉĂƌĂǀşƌƵƐƉƐƚĞŝŶͲĂƌƌ͕ 
ĐŝƚŽŵĞŐĂůŽǀşƌƵƐ͕ ŚĞƌƉĞƐ ƐŝŵƉůĞǆ͕ ǀĂƌŝĐĞůůĂͲǌŽƐƚĞƌ͕ ƉĂƌǀŽǀŝƌƵƐ͕
ŝŶŇƵĞŶǌĂ͕ ĂĚĞŶŽǀŝƌƵƐ͕ ŚĞƉĂƟƚĞ ͕ ŚĞƉĂƟƚĞ  Ğ s/,͘ϳϱ EĂ
ƐƵƐƉĞŝƚĂĚĞŶĞŽƉůĂƐŝĂ͕ĐŝƚŽŵĞƚƌŝĂĚĞŇƵǆŽƉĞƌŝĨĠƌŝĐĂ͕ĞƐƚƵĚŽƐ
ĚĞ ŝŵĂŐĞŵĞďŝſƉƐŝĂĚĂŵĞĚƵůĂſƐƐĞĂƐĆŽĞǆĂŵĞƐĂƉƌŽƉƌŝĂͲ
ĚŽƐ͘ϳϱ ZĞĐŽŵĞŶĚĂͲƐĞ Ž ƌĂƐƚƌĞŝŽ ĚĂ ĚĞĮĐŝġŶĐŝĂ ĚĞ ƉĞƌĨŽƌŝŶĂ
ƉŽƌ ĐŝƚŽŵĞƚƌŝĂ ĚĞŇƵǆŽ͘ϳϲYƵĂŶĚŽ ĂůƚĞƌĂĚŽ͕ ĚĞǀĞŵ ƐĞƌ ĞƐƚƵͲ
ĚĂĚĂƐŵƵƚĂĕƁĞƐ ŶŽƐ ŐĞŶĞƐPRF1, UNC13D, STX11, STXBP2 Ğ
RAB27A͘ϳϱ
Tratamento 
ŵ ĚŽĞŶƚĞƐ ĐůŝŶŝĐĂŵĞŶƚĞ ĞƐƚĄǀĞŝƐ Ğ ĐŽŵ Ƶŵ ĞƐơŵƵůŽ ŝĚĞŶͲ




ŵĞŶĚĂĚŽ ƌŝƚƵǆŝŵĂďĞ͕ Ƶŵ ĂŶƟĐŽƌƉŽ ŵŽŶŽĐůŽŶĂů ĂŶƟ ϮϬ͕
ϯϳϱŵŐͬŵϮƐĞŵĂŶĂůŵĞŶƚĞ͕ĚƵƌĂŶƚĞƵŵĂĂƋƵĂƚƌŽƐĞŵĂŶĂƐ͘
ZĞůĂƟǀĂŵĞŶƚĞ ă ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĨĂŵŝůŝĂƌ Ž
















ƌĞŵŝƐƐĆŽ ƉĂƌĐŝĂů Ğŵ ĚƵĂƐ ƐĞŵĂŶĂƐ͕ ĨŽŝ ŝŵƉůĞŵĞŶƚĂĚŽ ƚƌĂƚĂͲ
ŵĞŶƚŽ ĐŽŵ ĚŽǆƵƌƌƵďŝĐŝŶĂ͕ ĞƚŽƉŽƐŝĚŽ Ğ ŵĞƟůƉƌĞĚŶŝƐŽůŽŶĂ͘
KƐ ƌĞƐƵůƚĂĚŽƐ ĨŽƌĂŵ ďĂƐƚĂŶƚĞ ƉƌŽŵŝƐƐŽƌĞƐ͕ ŽĐŽƌƌĞŶĚŽ ƵŵĂ
ƌĞƐƉŽƐƚĂĂŽƚƌĂƚĂŵĞŶƚŽĞŵϳϲйĚŽƐĚŽĞŶƚĞƐ͘81
ZĞůĂƟǀĂŵĞŶƚĞ Ă ĚŽĞŶƚĞƐ ĐŽŵ ƐşŶĚƌŽŵĞ ĚĞ ĂƟǀĂĕĆŽŵĂĐƌŽͲ
ĨĄŐŝĐĂ͕ ƌĞĐŽŵĞŶĚĂͲƐĞ ƋƵĞ Ž ƚƌĂƚĂŵĞŶƚŽ ŝŶŝĐŝĂů ƐĞũĂ ĞĨĞƚƵĂĚŽ
ĐŽŵĐŽƌƟĐŽƐƚĞƌŽŝĚĞƐŝƐŽůĂĚĂŵĞŶƚĞ͕ƐĞŵƌĞĐƵƌƐŽĂĞƚŽƉŽƐŝĚŽ͘




 ĐŝĐůŽƐƉŽƌŝŶĂ  ďůŽƋƵĞŝĂ Ă ĂƟǀĂĕĆŽ ĚĞ ůŝŶĨſĐŝƚŽƐ d͕  ƌĞĚƵǌ Ă
ƉƌŽĚƵĕĆŽ ĚĞ ĐŝƚŽĐŝŶĂƐ ŝŶŇĂŵĂƚſƌŝĂƐ Ğ ŝŶŝďĞ Ă ĞǆƉƌĞƐƐĆŽ ĚĞ
ŵŽůĠĐƵůĂƐ ĐŽĞƐƟŵƵůĂĚŽƌĂƐ ŶĂ ƐƵƉĞƌİĐŝĞ ĚĞ ĐĠůƵůĂƐ ĚĞŶĚƌşƟͲ
ĐĂƐ͘ϴϯͲϴϱ  ĞĮĐĂǌ ŶŽ ƚƌĂƚĂŵĞŶƚŽ ĚĂ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ
ƉƌŝŵĄƌŝĂĞĞŵĐĂƐŽƐĚĞƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂŐƌĂͲ
ǀĞƐ ŽƵ ĐŽƌƟĐŽͲƌĞƐŝƐƚĞŶƚĞƐ͘ϱ͕ϳ͕ϭϳ͕ϴϲͲϴϴ ŵ ĂůŐƵŶƐ ĚŽĞŶƚĞƐ ŽĐŽƌƌĞ
ĂƉŝƌĞǆŝĂĞŵĞůŚŽƌŝĂĚŽƐǀĂůŽƌĞƐůĂďŽƌĂƚŽƌŝĂŝƐŶĂƐƉƌŝŵĞŝƌĂƐϭϮ
ĂϮϰŚŽƌĂƐĂƉſƐŽ ŝŶşĐŝŽĚĂƚĞƌĂƉġƵƟĐĂĐŽŵĐŝĐůŽƐƉŽƌŝŶĂ͘ϴϵ
ƐƚĞƐĚĂĚŽƐ ůĞǀĂƌĂŵĂůŐƵŶƐ ĂƵƚŽƌĞƐ ĂƉƌŽƉƀƌ ĂƵƟůŝǌĂĕĆŽĚĞ
ĐŝĐůŽƐƉŽƌŝŶĂ͕ϮͲϱŵŐͬŬŐͬĚŝĂ͕ ĐŽŵŽƚƌĂƚĂŵĞŶƚŽĚĞƉƌŝŵĞŝƌĂ
ůŝŶŚĂŶĂƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ͘ϴϵ͕ϵϬ
KƐ ƉƌŝŵĞŝƌŽƐ ĨĄƌŵĂĐŽƐ ďŝŽůſŐŝĐŽƐ ƵƐĂĚŽƐ ƉĂƌĂ ƚƌĂƚĂƌ Ă ƐşŶͲ
ĚƌŽŵĞĚĞ ĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ ĨŽƌĂŵŽƐ ŝŶŝďŝĚŽƌĞƐ ĚŽ ĨĂƚŽƌ
ĚĞŶĞĐƌŽƐĞƚƵŵŽƌĂůɲ͘ϵϭͲϵϰƚƵĂůŵĞŶƚĞĚĞŝǆĂƌĂŵĚĞĞƐƚĂƌƌĞĐŽͲ
ŵĞŶĚĂĚŽƐ͕ ƵŵĂ ǀĞǌ ƋƵĞ ĨŽƌĂŵ ŝĚĞŶƟĮĐĂĚŽƐ ǀĄƌŝŽƐ ĚŽĞŶƚĞƐ
ĞŵƋƵĞĂ ƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂƉŽĚĞƌĄ ƚĞƌ ƐŝĚŽ
ĚĞƐĞŶĐĂĚĞĂĚĂƉĞůŽƵƐŽĚĞƐƚĞƐĨĄƌŵĂĐŽƐ͘ϵϱͲϵϴ
KďůŽƋƵĞŝŽĚĂ ŝŶƚĞƌůĞƵĐŝŶĂ ;/>ͿͲϭĞĚĂ />ͲϲƉĂƌĞĐĞŵƐĞƌŵĂŝƐ
ƉƌŽŵŝƐƐŽƌĞƐ͘ ŶĂŬŝŶƌĂ͕ Ƶŵ ĂŶƚĂŐŽŶŝƐƚĂ ĚŽ ƌĞĐĞƉƚŽƌ ĚĂ />Ͳϭ͕
ĠĂůƚĂŵĞŶƚĞĞĮĐĂǌŶŽƚƌĂƚĂŵĞŶƚŽĚĂ/:^͘ϵϵǆŝƐƚĞŵƚĂŵďĠŵ
ŵƷůƟƉůĂƐ ĚĞƐĐƌŝĕƁĞƐ ĚĞ ĚŽĞŶƚĞƐ ĐŽŵ /:^ Ğ ƐşŶĚƌŽŵĞ ĚĞ







ŵĞůŚŽƌŝĂ ĚŽ ƋƵĂĚƌŽ ƋƵĂŶĚŽ ƵƟůŝǌĂĚĂƐ ĚŽƐĞƐ ƐƵƉĞƌŝŽƌĞƐ͘
ŶĂŬŝŶƌĂĐŽŶƟŶƵĂ͕ĂƐƐŝŵ͕ĂƐĞƌƵŵĂƚĞƌĂƉġƵƟĐĂƌĞĐŽŵĞŶĚĂĚĂ
ƉĂƌĂĂƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂƌĞĨƌĂƚĄƌŝĂ͘Ϯ




K ƚŽĐŝůŝǌŝŵĂď͕ Ƶŵ ĂŶƟĐŽƌƉŽ ŵŽŶŽĐůŽŶĂů ĂŶƟͲ/>Ͳϲ͕ Ġ ƵƐĂĚŽ
ĐŽŵďŽŶƐƌĞƐƵůƚĂĚŽƐĞŵĚŽĞŶƚĞƐĐŽŵ/:^͘ϭϬϴ͕ϭϬϵKƐĞƵƉĂƉĞů
ŶŽ ĐŽŶƚƌŽůŽĚĂ ƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ ĂŝŶĚĂŶĆŽ
ĞƐƚĄ ďĞŵ ĚĞĮŶŝĚŽ͕ ƐŽďƌĞƚƵĚŽ ƉŽƌƋƵĞ ĞǆŝƐƚĞŵ ǀĄƌŝŽƐ ĐĂƐŽƐ
ĚĞƐĐƌŝƚŽƐ ĚĞ ĚŽĞŶƚĞƐ ĐŽŵ /:^ ĐƵũĂ ƐşŶĚƌŽŵĞ ĚĞ ĂƟǀĂĕĆŽ
ŵĂĐƌŽĨĄŐŝĐĂ ĨŽŝĚŝƌĞƚĂŵĞŶƚĞ ƌĞůĂĐŝŽŶĂĚĂĐŽŵĂƵƟůŝǌĂĕĆŽĚĞ
ƚŽĐŝůŝǌƵŵĂď͘ϭϭϬͲϭϭϮ
ZĞĐĞŶƚĞŵĞŶƚĞ͕ ĨŽƌĂŵ ĚĞƐĐƌŝƚŽƐ ϯϬ ĚŽĞŶƚĞƐ ƋƵĞ ĚĞƐĞŶǀŽůͲ
ǀĞƌĂŵ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĂƉſƐ ƌĞĐĞďĞƌĞŵ ƚĞƌĂƉŝĂƐ
ďŝŽůſŐŝĐĂƐ͕ƚĞŶĚŽͲƐĞĐŽŶĐůƵşĚŽƋƵĞĂƐŝŶĨĞĕƁĞƐŝŶĚƵǌŝĚĂƐƉĞůŽƐ
ĂŐĞŶƚĞƐ ďŝŽůſŐŝĐŽƐ ĞƌĂŵ ŽƐ ĞƐơŵƵůŽƐŵĂŝƐ ƉƌŽǀĄǀĞŝƐ ƉĂƌĂ Ă
ƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽĐşƟĐĂĞŶĆŽŽĨĄƌŵĂĐŽĞŵƐŝ͘41
ŵĐŽŶĐůƵƐĆŽ͕ĐŽƌƟĐŽƐƚĞƌŽŝĚĞƐĞĐŝĐůŽƐƉŽƌŝŶĂƐĆŽŽƐĂŐĞŶͲ
ƚĞƐ ŵĂŝƐ ĨƌĞƋƵĞŶƚĞŵĞŶƚĞ ƵƟůŝǌĂĚŽƐ ƉĂƌĂ Ž ƚƌĂƚĂŵĞŶƚŽ ĚĂ
ƐşŶĚƌŽŵĞ ĚĞ ĂƟǀĂĕĆŽ ŵĂĐƌŽĨĄŐŝĐĂ͘ ZĞĐŽŵĞŶĚĂŵͲƐĞ ƉƵůƐŽƐ
ĚĞ ŵĞƟůƉƌĞĚŶŝƐŽůŽŶĂ ŝŶƚƌĂǀĞŶŽƐĂ ϯϬ ŵŐͬŬŐ Ğŵ ƚƌġƐ ĚŝĂƐ







ĨĂŐŽĐşƟĐĂ ĨĂŵŝůŝĂƌ͕  ƐşŶĚƌŽŵĞƐ ŚĞŵŽĨĂŐŽĐşƟĐĂƐ ƐĞĐƵŶĚĄƌŝĂƐ Ă




ĚŽ ƐŝƐƚĞŵĂŶĞƌǀŽƐŽ ĐĞŶƚƌĂů ĞƐƚĄ ƌĞĐŽŵĞŶĚĂĚŽŽ ƚƌĂŶƐƉůĂŶƚĞ
ĚĞ ĐĠůƵůĂƐ ŚĞŵĂƚŽƉŽŝĠƟĐĂƐ͘ K ƉƌŽŐŶſƐƟĐŽ Ġ ŵĞůŚŽƌ ƐĞ Ž
ĚŽĞŶƚĞĞƐƟǀĞƌĞŵƌĞŵŝƐƐĆŽŶŽŵŽŵĞŶƚŽĚŽƚƌĂŶƐƉůĂŶƚĞ͘ϭϴ͕ϭϭϰ
dĞƌĂƉġƵƟĐĂ ƉƌĠͲƚƌĂŶƐƉůĂŶƚĞ ĐŽŵ ĂůĞŵƚƵǌƵŵĂď ;ĂŶƟĐŽƌƉŽ
ŵŽŶŽĐůŽŶĂů ĂŶƟ ϱϮͿ͕ ŇƵĚĂƌĂďŝŶĂ Ğ ŵĞůĨĂůĂŶŽ ĞƐƚĄ ĂƐƐŽͲ
ĐŝĂĚĂ ĂŵĞŶŽƌ ƌŝƐĐŽĚĞ ƚŽǆŝĐŝĚĂĚĞ ĞŵĂŝŽƌ ƉƌŽďĂďŝůŝĚĂĚĞĚĞ
ƐŽďƌĞǀŝǀġŶĐŝĂ͘ϭϭϱ͕ϭϭϲ
EŽǀĂƐ ŵŽĚĂůŝĚĂĚĞƐ ƚĞƌĂƉġƵƟĐĂƐ ĞƐƚĆŽ ĂƚƵĂůŵĞŶƚĞ Ă ƐĞƌ
ĚĞƐĞŶǀŽůǀŝĚĂƐ͕ ŝŶĐůƵŝŶĚŽ ƚĞƌĂƉŝĂ ŐĠŶŝĐĂ ƉĂƌĂ Ă ĐŽƌƌĞĕĆŽ ĚĞ
ĚĞĨĞŝƚŽƐĚĂƉĞƌĨŽƌŝŶĂĞĂƵƟůŝǌĂĕĆŽĚĞƵŵĂŶƟĐŽƌƉŽŵŽŶŽĐůŽͲ







ŽĞŶƚĞƐ ĐŽŵ ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĨĂŵŝůŝĂƌ ƚġŵ
Ƶŵ ƚĞŵƉŽ ŵĠĚŝŽ ĚĞ ƐŽďƌĞǀŝǀġŶĐŝĂ ĚĞ ĂƉƌŽǆŝŵĂĚĂŵĞŶƚĞ
ĚŽŝƐŵĞƐĞƐ ĂƉſƐ Ž ĚŝĂŐŶſƐƟĐŽ͕ ƐĞ ŶĆŽ ƚƌĂƚĂĚŽƐ͘Ϯϵ͕ϳϳEŽ ĐĂƐŽ
ĚŽƐ ĚŽĞŶƚĞƐ ƐƵďŵĞƟĚŽƐ ĂŽ ƉƌŽƚŽĐŽůŽ ,>,Ͳϵϰ Ă ƚĂǆĂ ĚĞ
ƐŽďƌĞǀŝǀġŶĐŝĂĠĚĞϱϰйĂŽƐϲ͕ϮĂŶŽƐ͕ϭϴ͕ϭϭϰ ƐĞŶĚŽ ŝŶĨĞƌŝŽƌŶĂƐ
ĐƌŝĂŶĕĂƐ ĚŝĂŐŶŽƐƟĐĂĚĂƐ ĂŶƚĞƐ ĚŽƐ ϲ ŵĞƐĞƐ Ğ ŶŽƐ ĚŽĞŶƚĞƐ
ĐŽŵ ĂƟŶŐŝŵĞŶƚŽ ŶĞƵƌŽůſŐŝĐŽ͘ϭϴ͕ϭϭϰ Ğ ϭϮϰ ĚŽĞŶƚĞƐ ƐƵďŵĞͲ
ƟĚŽƐ Ă ƚƌĂŶƐƉůĂŶƚĞ ĚĞ ĐĠůƵůĂƐ ĞƐƚĂŵŝŶĂŝƐ ŚĞŵĂƚŽƉŽŝĠƟĐĂƐ
ĂůŽŐĠŶŝĐŽ͕Ă ƐŽďƌĞǀŝǀġŶĐŝĂĂŽƐ ĐŝŶĐŽĂŶŽƐ ĨŽŝĚĞϲϲй͕ ƐĞŶĚŽ
ŵĞůŚŽƌ ŶŽ ƐƵďŐƌƵƉŽ ĚĞ ĚŽĞŶƚĞƐ Ğŵ ƌĞŵŝƐƐĆŽ ŶĂ ĂůƚƵƌĂ ĚŽ
ƚƌĂŶƐƉůĂŶƚĞ͘ϭϴ͕ϭϭϰ
Ɛ ƚĂǆĂƐ ĚĞ ƐŽďƌĞǀŝǀġŶĐŝĂ ƐĆŽ ŵĂŝŽƌĞƐ ŶĂ ƐşŶĚƌŽŵĞ ĚĞ ĂƟͲ




ƐŝŐŶŝĮĐĂƟǀĂ ĚĞƐƚĞƐ ŶşǀĞŝƐ ĐŽŵŽ ƚƌĂƚĂŵĞŶƚŽ ƐĆŽ ĨĂĐƚŽƌĞƐ ĚĞ
ŵĂƵƉƌŽŐŶſƐƟĐŽĞŵ ƚŽĚŽƐŽƐƟƉŽƐĚĞ ƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽͲ
ĐşƟĐĂ͘ϭϮϬ
WŽĚĞŵ ǀĞƌŝĮĐĂƌͲƐĞ ƌĞĐŽƌƌġŶĐŝĂƐ ĚĂ ƐşŶĚƌŽŵĞ͕ ƐĞŶĚŽ ŵĂŝƐ
ƉƌŽǀĄǀĞůŶŽƉƌŝŵĞŝƌŽĂŶŽĂƉſƐĂĚŽĞŶĕĂĂŐƵĚĂŝŶŝĐŝĂů͘KƌŝƐĐŽ
ĚĞ ƌĞĐŽƌƌġŶĐŝĂ ƉŽĚĞ ƐĞƌ ŵŝŶŝŵŝǌĂĚŽ ƌĞĚƵǌŝŶĚŽ Ă ĞǆƉŽƐŝĕĆŽ




Novos dados sobre a patogénese da 
síndrome hemofagocítica
ŵ ϭϵϵϴ͕ ĚĞƐĐŽďƌŝƵͲƐĞ ƋƵĞ ĚŽĞŶƚĞƐ ĐŽŵ ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ
ŚĞŵŽĨĂŐŽĐşƟĐĂ ĨĂŵŝůŝĂƌ ĂƉƌĞƐĞŶƚĂǀĂŵ ĚĞĨĞŝƚŽƐ ĂŽ ŶşǀĞů ĚĂ
ĨƵŶĕĆŽ ĚĂƐ ĐĠůƵůĂƐ E<͘ϭϮϮ EŽ ĂŶŽ ƐĞŐƵŝŶƚĞ ĨŽŝ ĚĞƐĐƌŝƚĂ͕ ƉĞůĂ
ƉƌŝŵĞŝƌĂ ǀĞǌ͕ Ă ĂƐƐŽĐŝĂĕĆŽ ĂŵƵƚĂĕƁĞƐĚŽ ŐĞŶĞƋƵĞ ĐŽĚŝĮĐĂ









dĞŵ ƐŝĚŽ ŝŐƵĂůŵĞŶƚĞ ƐƵŐĞƌŝĚŽ ƋƵĞ Ă ƉĞƌĨŽƌŝŶĂ ĐŽŶƚƌŽůĂ Ă
ƉƌŽůŝĨĞƌĂĕĆŽ ůŝŶĨŽĐŝƚĄƌŝĂ͘ϭϮϯ  ĚĞĮĐŝġŶĐŝĂ ĚĞ ƉĞƌĨŽƌŝŶĂ ƉŽĚĞ
ĐŽŶƚƌŝďƵŝƌĚĞƐƚĞŵŽĚŽƉĂƌĂĂĂƟǀĂĕĆŽůŝŶĨŽĐŝƚĄƌŝĂƉĞƌƐŝƐƚĞŶƚĞ
Ğ͕ ĐŽŶƐĞƋƵĞŶƚĞŵĞŶƚĞ͕ ƉĂƌĂ Ă ƉƌŽĚƵĕĆŽ ĚĞ ĐŝƚŽĐŝŶĂƐ ƉƌŽͲ
ͲŝŶŇĂŵĂƚſƌŝĂƐ͕ŝŶĐůƵŝŶĚŽŽŝŶƚĞƌĨĞƌĆŽࢢƋƵĞĂƟǀĂŽƐŵĂĐƌſĨĂͲ
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ŵĞŶƚŽŶĆŽĨŽŝŶĞĐĞƐƐĄƌŝĂ͕ƚĞŶĚŽͲƐĞǀĞƌŝĮĐĂĚŽŝŶĐůƵƐŝǀĂŵĞŶƚĞ
ŵĞůŚŽƌŝĂ ĚŽ ƋƵĂĚƌŽ ƋƵĂŶĚŽ ƵƟůŝǌĂĚĂƐ ĚŽƐĞƐ ƐƵƉĞƌŝŽƌĞƐ͘
ŶĂŬŝŶƌĂĐŽŶƟŶƵĂ͕ĂƐƐŝŵ͕ĂƐĞƌƵŵĂƚĞƌĂƉġƵƟĐĂƌĞĐŽŵĞŶĚĂĚĂ
ƉĂƌĂĂƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂƌĞĨƌĂƚĄƌŝĂ͘Ϯ




K ƚŽĐŝůŝǌŝŵĂď͕ Ƶŵ ĂŶƟĐŽƌƉŽ ŵŽŶŽĐůŽŶĂů ĂŶƟͲ/>Ͳϲ͕ Ġ ƵƐĂĚŽ
ĐŽŵďŽŶƐƌĞƐƵůƚĂĚŽƐĞŵĚŽĞŶƚĞƐĐŽŵ/:^͘ϭϬϴ͕ϭϬϵKƐĞƵƉĂƉĞů
ŶŽ ĐŽŶƚƌŽůŽĚĂ ƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ ĂŝŶĚĂŶĆŽ
ĞƐƚĄ ďĞŵ ĚĞĮŶŝĚŽ͕ ƐŽďƌĞƚƵĚŽ ƉŽƌƋƵĞ ĞǆŝƐƚĞŵ ǀĄƌŝŽƐ ĐĂƐŽƐ
ĚĞƐĐƌŝƚŽƐ ĚĞ ĚŽĞŶƚĞƐ ĐŽŵ /:^ ĐƵũĂ ƐşŶĚƌŽŵĞ ĚĞ ĂƟǀĂĕĆŽ
ŵĂĐƌŽĨĄŐŝĐĂ ĨŽŝĚŝƌĞƚĂŵĞŶƚĞ ƌĞůĂĐŝŽŶĂĚĂĐŽŵĂƵƟůŝǌĂĕĆŽĚĞ
ƚŽĐŝůŝǌƵŵĂď͘ϭϭϬͲϭϭϮ
ZĞĐĞŶƚĞŵĞŶƚĞ͕ ĨŽƌĂŵ ĚĞƐĐƌŝƚŽƐ ϯϬ ĚŽĞŶƚĞƐ ƋƵĞ ĚĞƐĞŶǀŽůͲ
ǀĞƌĂŵ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĂƉſƐ ƌĞĐĞďĞƌĞŵ ƚĞƌĂƉŝĂƐ
ďŝŽůſŐŝĐĂƐ͕ƚĞŶĚŽͲƐĞĐŽŶĐůƵşĚŽƋƵĞĂƐŝŶĨĞĕƁĞƐŝŶĚƵǌŝĚĂƐƉĞůŽƐ
ĂŐĞŶƚĞƐ ďŝŽůſŐŝĐŽƐ ĞƌĂŵ ŽƐ ĞƐơŵƵůŽƐŵĂŝƐ ƉƌŽǀĄǀĞŝƐ ƉĂƌĂ Ă
ƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽĐşƟĐĂĞŶĆŽŽĨĄƌŵĂĐŽĞŵƐŝ͘41
ŵĐŽŶĐůƵƐĆŽ͕ĐŽƌƟĐŽƐƚĞƌŽŝĚĞƐĞĐŝĐůŽƐƉŽƌŝŶĂƐĆŽŽƐĂŐĞŶͲ
ƚĞƐ ŵĂŝƐ ĨƌĞƋƵĞŶƚĞŵĞŶƚĞ ƵƟůŝǌĂĚŽƐ ƉĂƌĂ Ž ƚƌĂƚĂŵĞŶƚŽ ĚĂ
ƐşŶĚƌŽŵĞ ĚĞ ĂƟǀĂĕĆŽ ŵĂĐƌŽĨĄŐŝĐĂ͘ ZĞĐŽŵĞŶĚĂŵͲƐĞ ƉƵůƐŽƐ
ĚĞ ŵĞƟůƉƌĞĚŶŝƐŽůŽŶĂ ŝŶƚƌĂǀĞŶŽƐĂ ϯϬ ŵŐͬŬŐ Ğŵ ƚƌġƐ ĚŝĂƐ







ĨĂŐŽĐşƟĐĂ ĨĂŵŝůŝĂƌ͕  ƐşŶĚƌŽŵĞƐ ŚĞŵŽĨĂŐŽĐşƟĐĂƐ ƐĞĐƵŶĚĄƌŝĂƐ Ă




ĚŽ ƐŝƐƚĞŵĂŶĞƌǀŽƐŽ ĐĞŶƚƌĂů ĞƐƚĄ ƌĞĐŽŵĞŶĚĂĚŽŽ ƚƌĂŶƐƉůĂŶƚĞ
ĚĞ ĐĠůƵůĂƐ ŚĞŵĂƚŽƉŽŝĠƟĐĂƐ͘ K ƉƌŽŐŶſƐƟĐŽ Ġ ŵĞůŚŽƌ ƐĞ Ž
ĚŽĞŶƚĞĞƐƟǀĞƌĞŵƌĞŵŝƐƐĆŽŶŽŵŽŵĞŶƚŽĚŽƚƌĂŶƐƉůĂŶƚĞ͘ϭϴ͕ϭϭϰ
dĞƌĂƉġƵƟĐĂ ƉƌĠͲƚƌĂŶƐƉůĂŶƚĞ ĐŽŵ ĂůĞŵƚƵǌƵŵĂď ;ĂŶƟĐŽƌƉŽ
ŵŽŶŽĐůŽŶĂů ĂŶƟ ϱϮͿ͕ ŇƵĚĂƌĂďŝŶĂ Ğ ŵĞůĨĂůĂŶŽ ĞƐƚĄ ĂƐƐŽͲ
ĐŝĂĚĂ ĂŵĞŶŽƌ ƌŝƐĐŽĚĞ ƚŽǆŝĐŝĚĂĚĞ ĞŵĂŝŽƌ ƉƌŽďĂďŝůŝĚĂĚĞĚĞ
ƐŽďƌĞǀŝǀġŶĐŝĂ͘ϭϭϱ͕ϭϭϲ
EŽǀĂƐ ŵŽĚĂůŝĚĂĚĞƐ ƚĞƌĂƉġƵƟĐĂƐ ĞƐƚĆŽ ĂƚƵĂůŵĞŶƚĞ Ă ƐĞƌ
ĚĞƐĞŶǀŽůǀŝĚĂƐ͕ ŝŶĐůƵŝŶĚŽ ƚĞƌĂƉŝĂ ŐĠŶŝĐĂ ƉĂƌĂ Ă ĐŽƌƌĞĕĆŽ ĚĞ
ĚĞĨĞŝƚŽƐĚĂƉĞƌĨŽƌŝŶĂĞĂƵƟůŝǌĂĕĆŽĚĞƵŵĂŶƟĐŽƌƉŽŵŽŶŽĐůŽͲ







ŽĞŶƚĞƐ ĐŽŵ ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĨĂŵŝůŝĂƌ ƚġŵ
Ƶŵ ƚĞŵƉŽ ŵĠĚŝŽ ĚĞ ƐŽďƌĞǀŝǀġŶĐŝĂ ĚĞ ĂƉƌŽǆŝŵĂĚĂŵĞŶƚĞ
ĚŽŝƐŵĞƐĞƐ ĂƉſƐ Ž ĚŝĂŐŶſƐƟĐŽ͕ ƐĞ ŶĆŽ ƚƌĂƚĂĚŽƐ͘Ϯϵ͕ϳϳEŽ ĐĂƐŽ
ĚŽƐ ĚŽĞŶƚĞƐ ƐƵďŵĞƟĚŽƐ ĂŽ ƉƌŽƚŽĐŽůŽ ,>,Ͳϵϰ Ă ƚĂǆĂ ĚĞ
ƐŽďƌĞǀŝǀġŶĐŝĂĠĚĞϱϰйĂŽƐϲ͕ϮĂŶŽƐ͕ϭϴ͕ϭϭϰ ƐĞŶĚŽ ŝŶĨĞƌŝŽƌŶĂƐ
ĐƌŝĂŶĕĂƐ ĚŝĂŐŶŽƐƟĐĂĚĂƐ ĂŶƚĞƐ ĚŽƐ ϲ ŵĞƐĞƐ Ğ ŶŽƐ ĚŽĞŶƚĞƐ
ĐŽŵ ĂƟŶŐŝŵĞŶƚŽ ŶĞƵƌŽůſŐŝĐŽ͘ϭϴ͕ϭϭϰ Ğ ϭϮϰ ĚŽĞŶƚĞƐ ƐƵďŵĞͲ
ƟĚŽƐ Ă ƚƌĂŶƐƉůĂŶƚĞ ĚĞ ĐĠůƵůĂƐ ĞƐƚĂŵŝŶĂŝƐ ŚĞŵĂƚŽƉŽŝĠƟĐĂƐ
ĂůŽŐĠŶŝĐŽ͕Ă ƐŽďƌĞǀŝǀġŶĐŝĂĂŽƐ ĐŝŶĐŽĂŶŽƐ ĨŽŝĚĞϲϲй͕ ƐĞŶĚŽ
ŵĞůŚŽƌ ŶŽ ƐƵďŐƌƵƉŽ ĚĞ ĚŽĞŶƚĞƐ Ğŵ ƌĞŵŝƐƐĆŽ ŶĂ ĂůƚƵƌĂ ĚŽ
ƚƌĂŶƐƉůĂŶƚĞ͘ϭϴ͕ϭϭϰ
Ɛ ƚĂǆĂƐ ĚĞ ƐŽďƌĞǀŝǀġŶĐŝĂ ƐĆŽ ŵĂŝŽƌĞƐ ŶĂ ƐşŶĚƌŽŵĞ ĚĞ ĂƟͲ




ƐŝŐŶŝĮĐĂƟǀĂ ĚĞƐƚĞƐ ŶşǀĞŝƐ ĐŽŵŽ ƚƌĂƚĂŵĞŶƚŽ ƐĆŽ ĨĂĐƚŽƌĞƐ ĚĞ
ŵĂƵƉƌŽŐŶſƐƟĐŽĞŵ ƚŽĚŽƐŽƐƟƉŽƐĚĞ ƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽͲ
ĐşƟĐĂ͘ϭϮϬ
WŽĚĞŵ ǀĞƌŝĮĐĂƌͲƐĞ ƌĞĐŽƌƌġŶĐŝĂƐ ĚĂ ƐşŶĚƌŽŵĞ͕ ƐĞŶĚŽ ŵĂŝƐ
ƉƌŽǀĄǀĞůŶŽƉƌŝŵĞŝƌŽĂŶŽĂƉſƐĂĚŽĞŶĕĂĂŐƵĚĂŝŶŝĐŝĂů͘KƌŝƐĐŽ
ĚĞ ƌĞĐŽƌƌġŶĐŝĂ ƉŽĚĞ ƐĞƌ ŵŝŶŝŵŝǌĂĚŽ ƌĞĚƵǌŝŶĚŽ Ă ĞǆƉŽƐŝĕĆŽ




Novos dados sobre a patogénese da 
síndrome hemofagocítica
ŵ ϭϵϵϴ͕ ĚĞƐĐŽďƌŝƵͲƐĞ ƋƵĞ ĚŽĞŶƚĞƐ ĐŽŵ ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ
ŚĞŵŽĨĂŐŽĐşƟĐĂ ĨĂŵŝůŝĂƌ ĂƉƌĞƐĞŶƚĂǀĂŵ ĚĞĨĞŝƚŽƐ ĂŽ ŶşǀĞů ĚĂ
ĨƵŶĕĆŽ ĚĂƐ ĐĠůƵůĂƐ E<͘ϭϮϮ EŽ ĂŶŽ ƐĞŐƵŝŶƚĞ ĨŽŝ ĚĞƐĐƌŝƚĂ͕ ƉĞůĂ
ƉƌŝŵĞŝƌĂ ǀĞǌ͕ Ă ĂƐƐŽĐŝĂĕĆŽ ĂŵƵƚĂĕƁĞƐĚŽ ŐĞŶĞƋƵĞ ĐŽĚŝĮĐĂ









dĞŵ ƐŝĚŽ ŝŐƵĂůŵĞŶƚĞ ƐƵŐĞƌŝĚŽ ƋƵĞ Ă ƉĞƌĨŽƌŝŶĂ ĐŽŶƚƌŽůĂ Ă
ƉƌŽůŝĨĞƌĂĕĆŽ ůŝŶĨŽĐŝƚĄƌŝĂ͘ϭϮϯ  ĚĞĮĐŝġŶĐŝĂ ĚĞ ƉĞƌĨŽƌŝŶĂ ƉŽĚĞ
ĐŽŶƚƌŝďƵŝƌĚĞƐƚĞŵŽĚŽƉĂƌĂĂĂƟǀĂĕĆŽůŝŶĨŽĐŝƚĄƌŝĂƉĞƌƐŝƐƚĞŶƚĞ
Ğ͕ ĐŽŶƐĞƋƵĞŶƚĞŵĞŶƚĞ͕ ƉĂƌĂ Ă ƉƌŽĚƵĕĆŽ ĚĞ ĐŝƚŽĐŝŶĂƐ ƉƌŽͲ
ͲŝŶŇĂŵĂƚſƌŝĂƐ͕ŝŶĐůƵŝŶĚŽŽŝŶƚĞƌĨĞƌĆŽࢢƋƵĞĂƟǀĂŽƐŵĂĐƌſĨĂͲ
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DƵƚĂĕƁĞƐ ŶŽ ŐĞŶĞ UNC13D͕ Ž ƋƵĂů ĐŽĚŝĮĐĂ Ă ƉƌŽƚĞşŶĂ





ŝŶĚŝŶŐ WƌŽƚĞŝŶ ϮͿ ĐŽĚŝĮĐĂĚŽƌĞƐ ĚĞ ƉƌŽƚĞşŶĂƐ ŝŐƵĂůŵĞŶƚĞ
ŝŵƉŽƌƚĂŶƚĞƐŶŽƚƌĄĨĞŐŽĚĞŐƌąŶƵůŽƐĐŝƚŽƚſǆŝĐŽƐ͕ƚĂŵďĠŵƚġŵ













ŚĞŵŽĨĂŐŽĐşƟĐĂ ĐůĂƐƐŝĮĐĂĚŽƐ ĐŽŵŽ ĨŽƌŵĂƐŶĆŽ ĨĂŵŝůŝĂƌĞƐ͕ ϰϯ
;ϭϱйͿƟŶŚĂŵŵƵƚĂĕƁĞƐŵŽŶŽĂůĠůŝĐĂƐĞŵƵŵĚŽƐŐĞŶĞƐĂƐƐŽͲ




ŽŶĐĞƉƚƵĂůŵĞŶƚĞ͕ ĞƐƚĞƐ ĚĂĚŽƐ ƐĆŽ ĐŽŶƐŝƐƚĞŶƚĞƐ ĐŽŵ Ƶŵ
ŵŽĚĞůŽ ŵƵůƟͲŚŝƚ͗ ŝŶĚŝǀşĚƵŽƐ ŐĞŶĞƟĐĂŵĞŶƚĞ ƐƵƐĐĞơǀĞŝƐ
ƋƵĂŶĚŽ ĞǆƉŽƐƚŽƐ Ă ĚĞƚĞƌŵŝŶĂĚŽƐ ĞƐơŵƵůŽƐ ĚĞƐĞŶǀŽůǀĞŵ
ŚŝƉĞƌͲŝŶŇĂŵĂĕĆŽ͘ϮϲdŽĚŽƐĞƐƚĞƐĚĂĚŽƐƉĞƌŵŝƚĞŵĐŽŶĐůƵŝƌƋƵĞ
Ă ĨƵŶĕĆŽ ĐŝƚŽƚſǆŝĐĂ ŶĆŽ Ġ ĂƉĞŶĂƐ ŝŵƉŽƌƚĂŶƚĞ ĐŽŵŽ ĨƵŶĕĆŽ
ĞĨĞƚŽƌĂŝŵƵŶĞ͕ŵĂƐƚĂŵďĠŵƉĂƌĂƌĞƐŽůƵĕĆŽĚĂŝŶŇĂŵĂĕĆŽ͘Ϯϲ
DŽĚĞůŽƐĂŶŝŵĂŝƐƉĞƌŵŝƟƌĂŵĐŽŵƉƌĞĞŶĚĞƌĐŽŵŵĂŝƐĞǆĂƟĚĆŽ
Ă ƉĂƚŽŐĠŶĞƐĞ ĚĂ ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ͘ ZĂƟŶŚŽƐ ĐŽŵ
ĚĞĮĐŝġŶĐŝĂĚĞƉĞƌĨŽƌŝŶĂ;WƌĨͲͬͲͿŝŶĨĞƚĂĚŽƐĐŽŵǀşƌƵƐůŝŶĨŽĐşƟĐŽ
ĚĞĐŽƌŝŽŵĞŶŝŶŐŝƚĞĞǆŝďĞŵĐĂƌĂĐƚĞƌşƐƟĐĂƐĐůşŶŝĐĂƐƐĞŵĞůŚĂŶƚĞƐ
ăƐ ĚĞ ĚŽĞŶƚĞƐ ĐŽŵ ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĨĂŵŝͲ









ĨĄŐŝĐĂ ŶĆŽ ĚĞƐĞŶǀŽůǀĞŵ ŚĞŵŽĨĂŐŽĐŝƚŽƐĞ Ğ ĞƐƚĆŽ ƉƌŽƚĞŐŝĚŽƐ
ĚĞĂŶĞŵŝĂƋƵĂŶĚŽŝŶũĞƚĂĚŽƐĐŽŵŝŶƚĞƌĨĞƌĆŽɶ͘ϭϯϮƐƚĞƐĚĂĚŽƐ
ƐƵŐĞƌĞŵ͕ ĂƐƐŝŵ͕ ƋƵĞ Ž ŝŶƚĞƌĨĞƌĆŽ ɶ ĚĞǀĞ ĂƚƵĂƌ ĚŝƌĞƚĂŵĞŶƚĞ
ŶŽƐŵĂĐƌſĨĂŐŽƐƉĂƌĂĂŽĐŽƌƌġŶĐŝĂĚĞŚĞŵŽĨĂŐŽĐŝƚŽƐĞin vivo͘
Ğ ĂĐŽƌĚŽ ĐŽŵŽŵŽĚĞůŽ ĂƚƵĂů ĚĂ ƐşŶĚƌŽŵĞŚĞŵŽĨĂŐŽĐşƟĐĂ
ƉƌŝŵĄƌŝĂ͕ŽƐůŝŶĨſĐŝƚŽƐdĐŝƚŽƚſǆŝĐŽƐĞĐĠůƵůĂƐE<ĨĂůŚĂŵŶĂƐƵĂ
ĨƵŶĕĆŽĚĞŵŽƌƚĞĚĞĐĠůƵůĂƐŝŶĨĞƚĂĚĂƐ͕ĐĂƵƐĂŶĚŽĂƉĞƌƐŝƐƚġŶĐŝĂ
ĚŽ ĂŶƟŐĠŶŝŽ͘ ĚŝĐŝŽŶĂůŵĞŶƚĞ͕ ĐĠůƵůĂƐ ĐŝƚŽƚſǆŝĐĂƐ ĨĂůŚĂŵ ŶŽ
ĞŶǀŝŽ ĚĞ ƐŝŶĂŝƐ ĂƉŽƉƚſƟĐŽƐ ĂƉƌŽƉƌŝĂĚŽƐ ƉĂƌĂ Ă ƌĞŵŽĕĆŽ ĚĞ
ůŝŶĨſĐŝƚŽƐdĂƟǀĂĚŽƐĞŵĂĐƌſĨĂŐŽƐ͕ĐĂƵƐĂŶĚŽĞǆƉĂŶƐĆŽƉĞƌƐŝƐͲ
ƚĞŶƚĞĚĞƐƚĂƐ ĐĠůƵůĂƐĞ ƐĞĐƌĞĕĆŽĂƵŵĞŶƚĂĚĂĚĞĐŝƚŽĐŝŶĂƐƉƌŽͲ





/ͮϲ͕ ŽƐ ƋƵĂŝƐ ƉƌŽĚƵǌĞŵĂůƚŽƐ ŶşǀĞŝƐ ĚĞ />Ͳϲ͘ϭϯϳ ƐƚĞƐ ƌĂƟŶŚŽƐ
ƋƵĂŶĚŽ ĞƐƟŵƵůĂĚŽƐ ĐŽŵ ůŝŐĂŶĚŽƐ ĚĞ ƌĞĐĞƉƚŽƌĞƐ dŽůůͲůŝŬĞ
;d>ZͿ ĂƉƌĞƐĞŶƚĂŵ ƵŵĂ ŵŽƌƚĂůŝĚĂĚĞ ĂƵŵĞŶƚĂĚĂ͕ Ž ƋƵĞ ƉĞƌͲ
ŵŝƚĞ ĞƐƉĞĐƵůĂƌ ƐŽďƌĞ ƵŵĂ ƉŽƐƐşǀĞů ĐĂƵƐĂ ĚĞ ƐşŶĚƌŽŵĞ ĚĞ
ĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ ŶŽ ĐŽŶƚĞǆƚŽ ĚĞ /:^͘ EşǀĞŝƐ ĐŝƌĐƵůĂŶƚĞƐ
ĂůƚŽƐ ĚĞ />Ͳϲ͕ ơƉŝĐŽƐ ĚĞƐƚĂ ĚŽĞŶĕĂ͕ ƉŽĚĞŵ ƉƌĞĚŝƐƉŽƌ Ă ƵŵĂ




ĚĂ ĞǆŽĐŝƚŽƐĞ ĚĞ ŐƌąŶƵůŽƐ͘ϭϯϴ ƐƚĞ Ġ ƵŵĂ ŶŽǀĂ Ğ ŝŶƚĞƌĞƐƐĂŶƚĞ
ĐŽŶĞǆĆŽ ĞŶƚƌĞ ĂƐ ƐşŶĚƌŽŵĞƐ ŚĞŵŽĨĂŐŽĐşƟĐĂƐ ƉƌŝŵĄƌŝĂƐ Ğ
ƐĞĐƵŶĚĄƌŝĂƐ͘






ŵƷůƟƉůŽƐ ĞƐƚƵĚŽƐ ƋƵĞ ĂƐƐŽĐŝĂŵ Ă ŚŝƉĞƌĂƟǀĂĕĆŽ ĚŽ dZ>Ͳϵ ă






ƉĞƌŵŝƚĞ ƋƵĞ Ă ƐşŶĚƌŽŵĞĚĞ ĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ ŽĐŽƌƌĂ Ğŵ
ŚŽƐƉĞĚĞŝƌŽƐ ŐĞŶĞƟĐĂŵĞŶƚĞ ƉƌĞĚŝƐƉŽƐƚŽƐ͘ ZĂƟŶŚŽƐ ƐƵďŵĞƟͲ
ĚŽƐĂĞƐƟŵƵůĂĕĆŽĚĞd>ZͲϵĚĞƐĞŶǀŽůǀĞŵĐĂƌĂĐƚĞƌşƐƟĐĂƐƐŝŵŝͲ
ůĂƌĞƐă ƐşŶĚƌŽŵĞĚĞĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ͘ϭϯϵĚŽĞŶĕĂŶĞƐƚĞ
ŵŽĚĞůŽ Ġ ĨƵůŵŝŶĂŶƚĞ͕ ƐĞ ĞǆŝƐƟƌ Ƶŵ ďůŽƋƵĞŝŽ ĐŽŶĐŽŵŝƚĂŶƚĞ
ĚĞ />ͲϭϬ͘ϭϯϵ ƵƌŝŽƐĂŵĞŶƚĞ͕ ƉŽůŝŵŽƌĮƐŵŽƐ ĚĞ />ϭϬ ĂƐƐŽĐŝĂĚŽƐ
Ă ŵĞŶŽƌ ĨƵŶĕĆŽ ĞƐƚĆŽ ĂƐƐŽĐŝĂĚŽƐ Ă /:^͕ ŵŽƐƚƌĂŶĚŽ ƋƵĞ Ă
/>ͲϭϬ ƉŽĚĞ ĚĞƐĞŵƉĞŶŚĂƌ Ƶŵ ƉĂƉĞů ƉƌŽƚĞƚŽƌ͘ ϭϰϮ Ž ĐŽŶƚƌĄƌŝŽ
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/E&ͲɲĞ/E&Ͳɴ͕ĚĞŵŽŶƐƚƌĂŶĚŽƋƵĞĞƐƚĂĐŽŶĚŝĕĆŽƐĞĚĞǀĞĂƵŵĂ
ƌĞĚĞ ĐŽŵƉůĞǆĂ ĚĞ ĐŝƚŽĐŝŶĂƐ Ğ Ġ ŝŶĚĞƉĞŶĚĞŶƚĞ ĚĞ ƋƵĂůƋƵĞƌ
ĐŝƚŽĐŝŶĂŝƐŽůĂĚĂŵĞŶƚĞ͘ϭϰϯ
KƵƚƌĂ ĐŽŶƚƌŝďƵŝĕĆŽ ŝŵƉŽƌƚĂŶƚĞ ĚĞƐƚĞ ŵŽĚĞůŽ ĨŽŝ Ă ĚŝƐƐŽĐŝĂͲ
ĕĆŽ ĞŶƚƌĞ ĂŶĞŵŝĂ Ğ ŚĞŵŽĨĂŐŽĐŝƚŽƐĞ͘ ZĂƟŶŚŽƐ ƚƌĂƚĂĚŽƐ ĐŽŵ
ĞƐƟŵƵůĂĕĆŽ ƌĞƉĞƟĚĂ ĚŽ d>ZͲϵ ĞǆŝďĞŵ ĂŶĞŵŝĂ ŶĂ ĂƵƐġŶͲ
ĐŝĂ ĚĞ ŚĞŵŽĨĂŐŽĐŝƚŽƐĞ͕ ĞŶƋƵĂŶƚŽ ƌĂƟŶŚŽƐ ŝŶƚĞƌĨĞƌĆŽ ͲͬͲࢢ
ĐŽŵ ďůŽƋƵĞŝŽ ĚĞ />ͲϭϬ ĂƉƌĞƐĞŶƚĂǀĂŵ ŚĞŵŽĨĂŐŽĐŝƚŽƐĞ ƐĞŵ
ĂŶĞŵŝĂ͘ϭϯϵ͕ϭϰϯ ƐƚĞƐ ĚĂĚŽƐ ƐƵŐĞƌĞŵ ƋƵĞ Ġ Ă ĚŝƐĞƌŝƚƌŽƉŽŝĞƐĞ
ŵĞĚŝĂĚĂƉŽƌ ŝŶƚĞƌĨĞƌĆŽ͕ࢢĞŶĆŽĂŚĞŵŽĨĂŐŽĐŝƚŽƐĞ͕ŽŵĞĐĂͲ
ŶŝƐŵŽ ĚŽŵŝŶĂŶƚĞ ĚĂ ĂŶĞŵŝĂ ŶŽ ĐŽŶƚĞǆƚŽ ĚĂ ƐşŶĚƌŽŵĞ ĚĞ
ĂƟǀĂĕĆŽŵĂĐƌŽĨĄŐŝĐĂ͘ϭϰϯ
ŝŶĚĂ ƋƵĞ ŶŽ ƉĂƐƐĂĚŽ Ă ƉƌĞƐĞŶĕĂ ĚĞ ŚĞŵŽĨĂŐŽĐŝƚŽƐĞ ƚĞŶŚĂ










ŵĂĐƌſĨĂŐŽƐ͕ ƵŵĂ ĐĂƌĂĐƚĞƌşƐƟĐĂ ŝŶĚŝĐĂƟǀĂ ĚĞ ĨƵŶĕĆŽ ĂŶƟͲ
ͲŝŶŇĂŵĂƚſƌŝĂ͘ϯϯĞƐƚĂĐĂͲƐĞĂŝŶĚĂƋƵĞŽϭϲϯ͕ƵŵŵĂƌĐĂĚŽƌ
ĚŽ ĨĞŶſƟƉŽ DϮ ĚŽƐ ŵĂĐƌſĨĂŐŽƐ͕ Ġ ĂůƚĂŵĞŶƚĞ ĞǆƉƌĞƐƐŽ Ğŵ
ŚĞŵŽĨĂŐſĐŝƚŽƐŚƵŵĂŶŽƐ͘145
ƵƌŝŽƐĂŵĞŶƚĞ͕ĨŽŝĚĞƐĐŽďĞƌƚŽƋƵĞŽƐŚĞŵŽĨĂŐſĐŝƚŽƐƐĆŽƵŵĂ
ĨŽŶƚĞ ŝŵƉŽƌƚĂŶƚĞ ĚĞ />ͲϭϬ͕ ƵŵĂ ĐŝƚŽĐŝŶĂ ŝŵƉŽƌƚĂŶƚĞ ƉĂƌĂ Ž
ĐŽŶƚƌŽůŽĚĂƌĞƐƉŽƐƚĂŝŶŇĂŵĂƚſƌŝĂ͕ĞƋƵĞƋƵĂŶĚŽƐĆŽŝŶĐĂƉĂǌĞƐ
ĚĞĂƉƌŽĚƵǌŝƌ͕ ĂŵŽƌƚĂůŝĚĂĚĞŝŶĚƵǌŝĚĂƉŽƌǀşƌƵƐĂƵŵĞŶƚĂ͘146KƐ





ƟƉůŽƐ ĞƐơŵƵůŽƐ͕ ŵĂƐ͕ ŝŶĚĞƉĞŶĚĞŶƚĞŵĞŶƚĞ ĚĂ ƐƵĂ ĐĂƵƐĂ͕ Ġ
ĐĂƌĂĐƚĞƌŝǌĂĚĂ ƉŽƌ Ƶŵ ĞƐƚĂĚŽ ĚĞ ŚşƉĞƌͲŝŶŇĂŵĂĕĆŽ͘ ĂĚŽƐ ĚĂ
ĐŝġŶĐŝĂ ďĄƐŝĐĂ ĐŽŶĚƵǌŝƌĂŵ Ă Ƶŵ ŵŽĚĞůŽ ĚĂ ƉĂƚŽŐĠŶĞƐĞ ĚĂ
ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ŶŽ ƋƵĂů ŝŶĚŝǀşĚƵŽƐ ŐĞŶĞƟĐĂŵĞŶƚĞ
ƐƵƐĐĞơǀĞŝƐ ĚĞƐĞŶǀŽůǀĞŵ ŝŶŇĂŵĂĕĆŽ ŶĆŽ ĐŽŶƚƌŽůĂĚĂ ƋƵĂŶĚŽ
ĞǆƉŽƐƚŽƐĂĚĞƚĞƌŵŝŶĂĚŽƐĞƐơŵƵůŽƐ͘ /ƐƚŽǀĞƌŝĮĐĂͲƐĞŶĆŽĂƉĞͲ
ŶĂƐ ŶŽƐ ĚŽĞŶƚĞƐ ĐŽŵ ůŝŶĨŽŚŝƐƟŽĐŝƚŽƐĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĨĂŵŝͲ
ůŝĂƌ͕ ŽƐƋƵĂŝƐĂƉƌĞƐĞŶƚĂŵĚĞĨĞŝƚŽƐ ŝŶĂƚŽƐŶĂĐŝƚŽƚŽǆŝĐŝĚĂĚĞ͕Ğ
ĚĞƐĞŶǀŽůǀĞŵ Ă ƐşŶĚƌŽŵĞ ŚĞŵŽĨĂŐŽĐşƟĐĂ ĂƉſƐ Ƶŵ ĚĞƐĞŶĐĂͲ
ĚĞĂŶƚĞ ŝŶĨĞĐĐŝŽƐŽ͕ŵĂƐ ƚĂŵďĠŵŶĂƐ ĨŽƌŵĂƐ ƐĞĐƵŶĚĄƌŝĂƐ͘ŵ
ĚŽĞŶƚĞƐ ĐŽŵ/:^͕ ƉŽƌ ĞǆĞŵƉůŽ͕ Ă ĞǆƉŽƐŝĕĆŽ ĐŽŶơŶƵĂ Ă />Ͳϲ
ĞƐƚĄĂƐƐŽĐŝĂĚĂĂƵŵĂŚŝƉĞƌͲƌĞƐƉŽƐƚĂĂĞƐơŵƵůŽƐŝŶĨĞĐĐŝŽƐŽƐ͘
KƵƚƌĂ ŵĂŶŝĨĞƐƚĂĕĆŽ ĐŽŵƵŵ Ğŵ ƚŽĚĂƐ ĞƐƚĂƐ ƐşŶĚƌŽŵĞƐ Ġ Ă









ĨƵŶĚĂ ŶĂ ĂďŽƌĚĂŐĞŵ ĐůşŶŝĐĂ ĚĂƐ ƐşŶĚƌŽŵĞƐ ŚĞŵŽĨĂŐŽĐşƟĐĂƐ͕
Ğŵ ƋƵĞ ŶŽǀŽƐ ĐƌŝƚĠƌŝŽƐ ĚĞ ĚŝĂŐŶſƐƟĐŽ ĨŽƌĂŵ ĞƐƚĂďĞůĞĐŝĚŽƐ















ϭ͘ 'ƌŽŵ ͕ DĞůůŝŶƐ ͘ DĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ͗
ĚǀĂŶĐĞƐ ƚŽǁĂƌĚƐ ƵŶĚĞƌƐƚĂŶĚŝŶŐ ƉĂƚŚŽŐĞŶĞƐŝƐ͘ Ƶƌƌ KƉŝŶ
ZŚĞƵŵĂƚŽůϮϬϭϬ͖ϮϮ͗ϱϲϭͲϲ͘
Ϯ͘ ZĂǀĞůůŝ ͕ 'ƌŽŵ ͕ ĞŚƌĞŶƐ D͕ ƌŽŶ ZY͘ DĂĐƌŽƉŚĂŐĞ




ƐǇŶĚƌŽŵĞ ŝŶ ƚŚĞĞƌĂŽĨďŝŽůŽŐŝĐ ƚŚĞƌĂƉǇ͘EĂƚZĞǀZŚĞƵŵĂƚŽů
ϮϬϭϲ͖ϭϮ͗ϮϱϵͲϲϴ͘
ϰ͘ĂƐƟůůŽ>͕ĂƌĐŝůůŽ:͘^ĞĐŽŶĚĂƌǇŚĞŵŽƉŚĂŐŽĐǇƟĐůǇŵƉŚŽŚŝƐͲ
ƟŽĐǇƚŽƐŝƐĂŶĚ ƐĞǀĞƌĞ ƐĞƉƐŝƐͬƐǇƐƚĞŵŝĐ ŝŶŇĂŵŵĂƚŽƌǇ ƌĞƐƉŽŶƐĞ
ƐǇŶĚƌŽŵĞͬŵƵůƟŽƌŐĂŶ ĚǇƐĨƵŶĐƟŽŶ ƐǇŶĚƌŽŵĞͬŵĂĐƌŽƉŚĂŐĞ
ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ ƐŚĂƌĞ ĐŽŵŵŽŶ ŝŶƚĞƌŵĞĚŝĂƚĞ ƉŚĞŶŽͲ
ƚǇƉĞƐŽŶĂƐƉĞĐƚƌƵŵŽĨ ŝŶŇĂŵŵĂƟŽŶ͘WĞĚŝĂƚƌƌŝƚĂƌĞDĞĚ
ϮϬϬϵ͖ϭϬ͗ϯϴϳͲϵϮ͘
ϱ͘DŝŶŽŝĂ &͕  ĂǀŞ ^͕ ,ŽƌŶĞ ͕ ĞŵŝƌŬĂǇĂ ͕ ŽǀŝƐ &͕  >ŝ ͕ Ğƚ
Ăů͘ůŝŶŝĐĂů ĨĞĂƚƵƌĞƐ͕ ƚƌĞĂƚŵĞŶƚ͕ĂŶĚŽƵƚĐŽŵĞŽĨŵĂĐƌŽƉŚĂŐĞ
ĂĐƟǀĂƟŽŶƐǇŶĚƌŽŵĞĐŽŵƉůŝĐĂƟŶŐƐǇƐƚĞŵŝĐũƵǀĞŶŝůĞŝĚŝŽƉĂƚŚŝĐ
ĂƌƚŚƌŝƟƐ͗ ŵƵůƟŶĂƟŽŶĂů͕ŵƵůƟĐĞŶƚĞƌ ƐƚƵĚǇ ŽĨ ϯϲϮ ƉĂƟĞŶƚƐ͘
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ƌƚŚƌŝƟƐZŚĞƵŵĂƚŽů͘ϮϬϭϰ͖ϲϲ͗ϯϭϲϬͲϵ͘
ϲ͘ ZĂǀĞůůŝ ͘ DĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ͘ Ƶƌƌ KƉŝŶ
ZŚĞƵŵĂƚŽůϮϬϬϮ͖ϭϰ͗ϱϰϴͲϱϮ͘




ϴ͘ ĞŚƌĞŶƐ D͕ ĞƵŬĞůŵĂŶ d͕  ƌŽŶ ZY͘ :ƵǀĞŶŝůĞ ŝĚŝŽƉĂƚŚŝĐ
ĂƌƚŚƌŝƟƐ ĐůĂƐƐŝĮĐĂƟŽŶ ĐƌŝƚĞƌŝĂ͗ ůŽŽƉŚŽůĞƐ ĂŶĚ ĚŝĂŐŶŽƐŝƐ ƐŽŌͲ
ǁĂƌĞ͘:ZŚĞƵŵĂƚŽů͘ϮϬϬϳ͖ϯϰ͗Ϯϯϰ͖ĂƵƚŚŽƌƌĞƉůǇϮϯϰͲϱ͘
ϵ͘ZĂǀĞůůŝ͕ĂǀŞ^͕DŝŶŽŝĂ&͕ DĂƌƟŶŝ͕ƌŽŶZY͘DĂĐƌŽƉŚĂŐĞ





ϭϭ͘ ,ĞŶƚĞƌ :/͕ ƌŝĐž D͕ ŐĞůĞƌ ZD͕ ůŝŶĚĞƌ '͕ &ĂǀĂƌĂ ͕
&ŝůŝƉŽǀŝĐŚ,͕ĞƚĂů͘,>,Ͳϵϰ͗ ƚƌĞĂƚŵĞŶƚƉƌŽƚŽĐŽů ĨŽƌŚĞŵŽͲ
ƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ ,>, ƐƚƵĚǇ ŐƌŽƵƉ ŽĨ ƚŚĞ
,ŝƐƟŽĐǇƚĞ^ŽĐŝĞƚǇ͘DĞĚWĞĚŝĂƚƌKŶĐŽůϭϵϵϳ͖Ϯϴ͗ϯϰϮͲϳ͘
ϭϮ͘ &ĞůĚŵĂŶŶ :͕ DĠŶĂƐĐŚĠ '͕ ĂůůĞďĂƵƚ /͕ DŝŶĂƌĚͲŽůŝŶ s͕
ĂĚĞƌͲDĞƵŶŝĞƌ͕>ĞůĂŝŶĐŚĞ>͕ĞƚĂů͘^ĞǀĞƌĞĂŶĚƉƌŽŐƌĞƐƐŝǀĞ
ĞŶĐĞƉŚĂůŝƟƐ ĂƐ Ă ƉƌĞƐĞŶƟŶŐ ŵĂŶŝĨĞƐƚĂƟŽŶ ŽĨ Ă ŶŽǀĞů ŵŝƐͲ
ƐĞŶƐĞƉĞƌĨŽƌŝŶŵƵƚĂƟŽŶĂŶĚŝŵƉĂŝƌĞĚĐǇƚŽůǇƟĐĂĐƟǀŝƚǇ͘ůŽŽĚ
ϮϬϬϱ͖ϭϬϱ͗ϮϲϱϴͲϲϯ͘
ϭϯ͘ ĞŝǀĂ <͕ DĂŚůĂŽƵŝ E͕ ĞĂƵĚŽŶŶĞƚ &͕  ĚĞ ^ĂŝŶƚ ĂƐŝůĞ '͕
ĂƌŝĚĂĚĞ'͕DŽƐŚŽƵƐ͕ĞƚĂů͘E^ ŝŶǀŽůǀĞŵĞŶƚĂƚ ƚŚĞŽŶƐĞƚ
ŽĨ ƉƌŝŵĂƌǇ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ EĞƵƌŽůŽŐǇ
ϮϬϭϮ͖ϳϴ͗ϭϭϱϬͲϲ͘
ϭϰ͘ ^ĞŐƵŝŶ ͕ 'ĂůŝĐŝĞƌ >͕ ŽƵƚďŽƵů ͕ >ĞŵŝĂůĞ s͕ ǌŽƵůĂǇ ͘
WƵůŵŽŶĂƌǇŝŶǀŽůǀĞŵĞŶƚŝŶƉĂƟĞŶƚƐǁŝƚŚŚĞŵŽƉŚĂŐŽĐǇƟĐůǇŵͲ
ƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ŚĞƐƚϮϬϭϲ͖ϭϰϵ͗ϭϮϵϰͲϯϬϭ͘
ϭϱ͘ ĞŚƌĞŶƐ D͕ ĞƵŬĞůŵĂŶ d͕  WĂĞƐƐůĞƌD͕ ƌŽŶ ZY͘ KĐĐƵůƚ









'ĂĚŶĞƌ ,͕ Ğƚ Ăů͘ ŚĞŵŽŝŵŵƵŶŽƚŚĞƌĂƉǇ ĨŽƌ ŚĞŵŽƉŚĂŐŽĐǇƟĐ
ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͗ >ŽŶŐͲƚĞƌŵ ƌĞƐƵůƚƐ ŽĨ ƚŚĞ ,>,Ͳϵϰ ƚƌĞĂƚͲ
ŵĞŶƚƉƌŽƚŽĐŽů͘ůŽŽĚϮϬϭϭ͖ϭϭϴ͗ϰϱϳϳͲϴϰ͘




,ĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ŝŶ dĞǆĂƐ͗ KďƐĞƌǀĂƟŽŶƐ
ŽŶĞƚŚŶŝĐŝƚǇĂŶĚƌĂĐĞ͘WĞĚŝĂƚƌůŽŽĚĂŶĐĞƌϮϬϭϬ͖ϱϰ͗ϰϮϰͲϴ͘
Ϯϭ͘ WĂůĂǌǌŝ >͕DĐůĂŝŶ <>͕ <ĂƉůĂŶ ^>͘ ,ĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶͲ
ĚƌŽŵĞ ŝŶ ĐŚŝůĚƌĞŶ͗ Ŷ ŝŵƉŽƌƚĂŶƚ ĚŝĂŐŶŽƐƟĐ ĐŽŶƐŝĚĞƌĂƟŽŶ ŝŶ
ĨĞǀĞƌŽĨƵŶŬŶŽǁŶŽƌŝŐŝŶ͘ůŝŶ/ŶĨĞĐƚŝƐϮϬϬϯ͖ϯϲ͗ϯϬϲͲϭϮ͘
ϮϮ͘ :ŽƌĚĂŶD͕ůůĞŶ͕tĞŝƚǌŵĂŶ^͕&ŝůŝƉŽǀŝĐŚ,͕DĐůĂŝŶ
<>͘ ,Žǁ / ƚƌĞĂƚ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ ůŽŽĚ
ϮϬϭϭ͖ϭϭϴ͗ϰϬϰϭͲϱϮ͘
Ϯϯ͘ KŬĂŵŽƚŽD͕ zĂŵĂŐƵĐŚŝ ,͕ /ƐŽďĞ z͕  zŽŬŽƐĞ E͕ DŝǌƵŬŝ d͕ 
dĂũŝŬĂ <͕ Ğƚ Ăů͘ ŶĂůǇƐŝƐ ŽĨ ƚƌŝŐůǇĐĞƌŝĚĞ ǀĂůƵĞ ŝŶ ƚŚĞ ĚŝĂŐŶŽƐŝƐ
ĂŶĚ ƚƌĞĂƚŵĞŶƚ ƌĞƐƉŽŶƐĞ ŽĨ ƐĞĐŽŶĚĂƌǇ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶͲ
ĚƌŽŵĞ͘/ŶƚĞƌŶDĞĚϮϬϬϵ͖ϰϴ͗ϳϳϱͲϴϭ͘
Ϯϰ͘ 'ŽƌĞůŝŬD͕ &Ăůů E͕ ůƚĂǇĞD͕ ĂƌŶĞƐD'͕ dŚŽŵƉƐŽŶ ^͕






Ed͕  Ğƚ Ăů͘ dŚĞ ĚŝĂŐŶŽƐƟĐ ƐŝŐŶŝĮĐĂŶĐĞ ŽĨ ƐŽůƵďůĞ ϭϲϯ ĂŶĚ
ƐŽůƵďůĞŝŶƚĞƌůĞƵŬŝŶͲϮƌĞĐĞƉƚŽƌĂůƉŚĂͲĐŚĂŝŶŝŶŵĂĐƌŽƉŚĂŐĞĂĐƟͲ
ǀĂƟŽŶ ƐǇŶĚƌŽŵĞ ĂŶĚƵŶƚƌĞĂƚĞĚŶĞǁͲŽŶƐĞƚ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ
ŝĚŝŽƉĂƚŚŝĐĂƌƚŚƌŝƟƐ͘ƌƚŚƌŝƟƐZŚĞƵŵϮϬϬϳ͖ϱϲ͗ϵϲϱͲϳϭ͘





Ϯϴ͘ DĂĐŚĂĐǌŬĂ D͕ sĂŬƚŶćƐ :͕ <ůŝŵŬŽǁƐŬĂ D͕ ,ćŐŐůƵŶĚ ,͘
DĂůŝŐŶĂŶĐǇͲĂƐƐŽĐŝĂƚĞĚ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ
ŝŶ ĂĚƵůƚƐ͗  ƌĞƚƌŽƐƉĞĐƟǀĞ ƉŽƉƵůĂƟŽŶͲďĂƐĞĚ ĂŶĂůǇƐŝƐ ĨƌŽŵ Ă
ƐŝŶŐůĞĐĞŶƚĞƌ͘ >ĞƵŬ>ǇŵƉŚŽŵĂϮϬϭϭ͖ϱϮ͗ϲϭϯͲϵ͘
Ϯϵ͘ :ĂŶŬĂ '͘ &ĂŵŝůŝĂů ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘
Ƶƌ:WĞĚŝĂƚƌϭϵϴϯ͖ϭϰϬ͗ϮϮϭͲϯϬ͘
ϯϬ͘&ƵŬĂǇĂ^͕zĂƐƵĚĂ^͕,ĂƐŚŝŵŽƚŽd͕ KŬƵ<͕<ĂƚĂŽŬĂ,͕,ŽƌŝƚĂ
d͕  Ğƚ Ăů͘ ůŝŶŝĐĂů ĨĞĂƚƵƌĞƐ ŽĨ ŚĂĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶĚƌŽŵĞ ŝŶ
ƉĂƟĞŶƚƐǁŝƚŚ ƐǇƐƚĞŵŝĐ ĂƵƚŽŝŵŵƵŶĞ ĚŝƐĞĂƐĞƐ͗ ŶĂůǇƐŝƐ ŽĨ ϯϬ
ĐĂƐĞƐ͘ZŚĞƵŵĂƚŽůŽŐǇϮϬϬϴ͖ϰϳ͗ϭϲϴϲͲϵϭ͘
ϯϭ͘ ƩĞƌŝƚĂŶŽ D͕ ĂǀŝĚ ͕ ĂŐŶĂƚŽ '͕ ĞŶŝŶĂƟ ͕ &ƌŝƐŝŶĂ
͕ /ĂƌŝĂ ͕ Ğƚ Ăů͘ ,ĂĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶĚƌŽŵĞ ŝŶ ƌŚĞƵŵĂƟĐ
ƉĂƟĞŶƚƐ͘  ƐǇƐƚĞŵĂƟĐ ƌĞǀŝĞǁ͘ Ƶƌ ZĞǀ DĞĚ WŚĂƌŵĂĐŽů ^Đŝ
ϮϬϭϮ͖ϭϲ͗ϭϰϭϰͲϮϰ͘
ϯϮ͘ tĂŬŝŐƵĐŚŝ ,͕ ,ĂƐĞŐĂǁĂ ^͕ ,ŝƌĂŶŽ Z͕ <ĂŶĞǇĂƐƵ ,͕
tĂŬĂďĂǇĂƐŚŝͲdĂŬĂŚĂƌĂD͕KŚŐĂ^͘^ƵĐĐĞƐƐĨƵůĐŽŶƚƌŽůŽĨ ũƵǀĞͲ
ŶŝůĞ ĚĞƌŵĂƚŽŵǇŽƐŝƟƐͲĂƐƐŽĐŝĂƚĞĚ ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶͲ
ĚƌŽŵĞĂŶĚŝŶƚĞƌƐƟƟĂůƉŶĞƵŵŽŶŝĂ͗ĚŝƐƟŶĐƚŬŝŶĞƟĐƐŽĨŝŶƚĞƌůĞƵͲ
ŬŝŶͲϲĂŶĚͲϭϴůĞǀĞůƐ͘WĞĚŝĂƚƌZŚĞƵŵĂƚŽůKŶůŝŶĞ:ϮϬϭϱ͖ϭϯ͗ϰϵ͘
ϯϯ͘ ĂŶŶĂ ^t͕ ŽƐƚĂͲZĞŝƐ W͕  ĞƌŶĂůt͕ ŚƵ E͕ ^ƵůůŝǀĂŶ <͕
WĂĞƐƐůĞƌ D͕ Ğƚ Ăů͘ ƌŝĞĨ ƌĞƉŽƌƚ͗ ůƚĞƌŶĂƟǀĞ ĂĐƟǀĂƟŽŶ ŽĨ
ůĂƐĞƌͲĐĂƉƚƵƌĞĚŵƵƌŝŶĞ ŚĞŵŽƉŚĂŐŽĐǇƚĞƐ͘ ƌƚŚƌŝƟƐ ZŚĞƵŵĂƚŽů
ϮϬϭϰ͖ϲϲ͗ϭϲϲϲͲϳϭ͘
ϯϰ͘ ZŝŐĂŶƚĞ ͕ ĂƉŽůƵŽŶŐŽ ͕ ĞƌƚŽŶŝ ͕ ŶƐƵŝŶŝ s͕ ŚŝĂƌĞƫ
͕WŝĂƐƚƌĂD͕ĞƚĂů͘&ŝƌƐƚƌĞƉŽƌƚŽĨŵĂĐƌŽƉŚĂŐĞĂĐƟǀĂƟŽŶƐǇŶͲ
ĚƌŽŵĞ ŝŶ ŚǇƉĞƌŝŵŵƵŶŽŐůŽďƵůŝŶĞŵŝĂ  ǁŝƚŚ ƉĞƌŝŽĚŝĐ ĨĞǀĞƌ
ƐǇŶĚƌŽŵĞ͘ƌƚŚƌŝƟƐZŚĞƵŵϮϬϬϳ͖ϱϲ͗ϲϱϴͲϲϭ͘
ϯϱ͘ ZŽƐƐŝͲ^ĞŵĞƌĂŶŽ >͕ ,ĞƌŵĞǌŝƵ ͕ &ĂďƌĞ D͕ <ŽŶĠͲWĂƵƚ
/͘ DĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ ƌĞǀĞĂůŝŶŐ ĨĂŵŝůŝĂů
DĞĚŝƚĞƌƌĂŶĞĂŶĨĞǀĞƌ͘ ƌƚŚƌŝƟƐĂƌĞZĞƐϮϬϭϭ͖ϲϯ͗ϳϴϬͲϯ͘
ϯϲ͘ >ĞŚŵďĞƌŐ <͕ EŝĐŚŽůƐ <͕ ,ĞŶƚĞƌ :/͕ 'ŝƌƐĐŚŝŬŽĨƐŬǇ D͕
'ƌĞĞŶǁŽŽĚ d͕  :ŽƌĚĂŶD͕ Ğƚ Ăů͘ ŽŶƐĞŶƐƵƐ ƌĞĐŽŵŵĞŶĚĂƟŽŶƐ
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ϯϳ͘WĂƐƋƵĂůŝŶŝ͕:ŽƌŝŶŝD͕ĂƌůŽŶŝ/͕'ŝĂŶŐŝĂĐŽŵŝD͕ĞƟĐĂs͕
ƌŝĐžD͕ Ğƚ Ăů͘ ǇƚŽƉŚĂŐŝĐ ŚŝƐƟŽĐǇƟĐ ƉĂŶŶŝĐƵůŝƟƐ͕ ŚĞŵŽƉŚĂͲ
ŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ĂŶĚ ƵŶĚĞƚĞƌŵŝŶĞĚ ĂƵƚŽŝŵŵƵŶĞ
ĚŝƐŽƌĚĞƌ͗ZĞĐŽŶĐŝůŝŶŐƚŚĞƉƵǌǌůĞ͘/ƚĂů:WĞĚŝĂƚƌϮϬϭϰ͖ϰϬ͗ϭϳ͘
ϯϴ͘ůůŽƌǇ z͕  ŚĂůůŝŶĞ͕,ĂŝŽƵŶ͕ŽƉŝĞͲĞƌŐŵĂŶ͕ĞůĨĂƵͲ
>ĂƌƵĞD,͕ŽƵĐŚĞƌ͕ĞƚĂů͘ŽŶĞŵĂƌƌŽǁŝŶǀŽůǀĞŵĞŶƚŝŶůǇŵͲ





ĂƐƐŽĐŝĂƟŽŶ ǁŝƚŚ ũƵǀĞŶŝůĞ ŵǇĞůŽŵŽŶŽĐǇƟĐ ůĞƵŬĞŵŝĂ͘ ŶŶ
,ĞŵĂƚŽůϮϬϭϬ͖ϴϵ͗ϯϱϵͲϲϰ͘
ϰϬ͘ DĐůĂŝŶ <͕ 'ĞŚƌǌ Z͕ 'ƌŝĞƌƐŽŶ ,͕ WƵƌƟůŽ ͕ &ŝůŝƉŽǀŝĐŚ
͘ sŝƌƵƐͲĂƐƐŽĐŝĂƚĞĚ ŚŝƐƟŽĐǇƟĐ ƉƌŽůŝĨĞƌĂƟŽŶƐ ŝŶ ĐŚŝůĚƌĞŶ͘
&ƌĞƋƵĞŶƚ ĂƐƐŽĐŝĂƟŽŶ ǁŝƚŚ ƉƐƚĞŝŶͲĂƌƌ ǀŝƌƵƐ ĂŶĚ ĐŽŶŐĞŶŝƚĂů
ŽƌĂĐƋƵŝƌĞĚŝŵŵƵŶŽĚĞĮĐŝĞŶĐŝĞƐ͘ŵ:WĞĚŝĂƚƌ,ĞŵĂƚŽůKŶĐŽů
ϭϵϴϴ͖ϭϬ͗ϭϵϲͲϮϬϱ͘
ϰϭ͘ ƌŝƚŽͲĞƌſŶ W͕  ŽƐĐŚ y͕ WĠƌĞǌͲĚĞͲ>ŝƐ D͕ WĠƌĞǌͲůǀĂƌĞǌ Z͕
&ƌĂŝůĞ '͕ 'ŚĞŝƚĂƐŝ ,͕ Ğƚ Ăů͘ /ŶĨĞĐƟŽŶ ŝƐ ƚŚĞ ŵĂũŽƌ ƚƌŝŐŐĞƌ ŽĨ
ŚĞŵŽƉŚĂŐŽĐǇƟĐƐǇŶĚƌŽŵĞŝŶĂĚƵůƚƉĂƟĞŶƚƐƚƌĞĂƚĞĚǁŝƚŚďŝŽͲ
ůŽŐŝĐĂůƚŚĞƌĂƉŝĞƐ͘^ĞŵŝŶƌƚŚƌŝƟƐZŚĞƵŵϮϬϭϲ͖ϰϱ͗ϯϵϭͲϵ͘
ϰϮ͘ <ŝƐŚŽƌĞ :͕ <ŝƐŚŽƌĞ ͘ &ĂƚĂů ŵŝƐƐĞĚ ĐĂƐĞ ŽĨ ŚĞŵŽƉŚĂŐŽͲ
ĐǇƟĐůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐĐŽͲŝŶĨĞĐƚĞĚǁŝƚŚƉĂƌǀŽǀŝƌƵƐϭϵĂŶĚ
ƉƐƚĞŝŶͲĂƌƌ ǀŝƌƵƐ ŝŶ ĂŶ ŝŶĨĂŶƚ͗ dĞƐƚŚǇƉĞƌĨĞƌƌŝƟŶĂĞŵŝĂĞĂƌůǇ͘
/ŶĚŝĂŶ:DĞĚDŝĐƌŽďŝŽůϮϬϭϰ͖ϯϮ͗ϭϴϭͲϯ͘








Ğƚ Ăů͘,ƵŵĂŶŚĞƌƉĞƐǀŝƌƵƐ ϴͲĂƐƐŽĐŝĂƚĞĚŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵͲ
ƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ŝŶ ŚƵŵĂŶ ŝŵŵƵŶŽĚĞĮĐŝĞŶĐǇ ǀŝƌƵƐͲŝŶĨĞĐƚĞĚ
ƉĂƟĞŶƚƐ͘ůŝŶ/ŶĨĞĐƚŝƐϮϬϬϯ͖ϯϳ͗ϮϴϱͲϵϭ͘






ϰϴ͘,ĂƌŵƐWt͕ ^ĐŚŵŝĚƚ >͕ ^ŵŝƚŚ >͕EĞǁƚŽŶt͕ WůĞƚŶĞǀĂ
D͕tĂůƚĞƌƐ>>͕ĞƚĂů͘ƵƚŽƉƐǇĮŶĚŝŶŐƐŝŶĞŝŐŚƚƉĂƟĞŶƚƐǁŝƚŚ
ĨĂƚĂů,ϭEϭŝŶŇƵĞŶǌĂ͘ŵ:ůŝŶWĂƚŚŽůϮϬϭϬ͖ϭϯϰ͗ϮϳͲϯϱ͘




Ğƚ Ăů͘ ,ƵŵĂŶ ƉĂƌĞĐŚŽǀŝƌƵƐͲϯ ŝŶĨĞĐƟŽŶ ŝŶ ŶŝŶĞ ŶĞŽŶĂƚĞƐ ĂŶĚ





ϱϮ͘ ,ŝďŝŶŽ D͕ ^ĂƚŽ ^͕ ^ŚŝŵŝǌƵ d͕  zĂŵĂŵŽƚŽ ^͕ KŚĞ D͕
<ŽŶĚŽ d͘  ,ĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ƐĞĐŽŶĚĂƌǇ
ƚŽ DǇĐŽƉůĂƐŵĂ ƉŶĞƵŵŽŶŝĂĞ ŝŶĨĞĐƟŽŶ ǁŝƚŚŽƵƚ ƉŶĞƵŵŽŶŝĂ͘
/ŶƚĞƌŶDĞĚϮϬϭϰ͖ϱϯ͗ϭϲϳϵͲϴϯ͘
ϱϯ͘ ^ƚĂƚůĞƌ s͕ DĂƌƐŚĂůů '^͘ ,ĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽͲ
ŚŝƐƟŽĐǇƚŽƐŝƐ ŝŶĚƵĐĞĚ ďǇ ŵŽŶŽĐǇƟĐ ĞŚƌůŝĐŚŝŽƐŝƐ͘ : WĞĚŝĂƚƌ
ϮϬϭϱ͖ϭϲϲ͗ϰϵϵ͘Ğϭ͘
ϱϰ͘ KŚŶŽ d͕  ^ŚŝƌĂƐĂŬĂ ͕ ^ƵŐŝǇĂŵĂ d͕  &ƵƌƵŬĂǁĂ ,͘
,ĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶĚƌŽŵĞ ŝŶĚƵĐĞĚ ďǇ WůĂƐŵŽĚŝƵŵ ĨĂůĐŝƉĂͲ
ƌƵŵŵĂůĂƌŝĂŝŶĨĞĐƟŽŶ͘/Ŷƚ:,ĞŵĂƚŽůϭϵϵϲ͖ϲϰ͗ϮϲϯͲϲ͘
ϱϱ͘ ^ƵŶŐ W^͕ <ŝŵ /,͕ >ĞĞ :,͕ WĂƌŬ :t͘,ĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵͲ


































ƟŽŶ͗ĂƐĞ ƌĞƉŽƌƚĂŶĚ ƌĞǀŝĞǁŽĨ ƚŚĞ ůŝƚĞƌĂƚƵƌĞ͘WĞĚŝĂƚƌůŽŽĚ
ĂŶĐĞƌϮϬϬϱ͖ϰϰ͗ϮϳϬͲϲ͘
ϲϱ͘ƵǀĂůD͕&ĞŶŶĞƚĞĂƵK͕ŽŝƌĞĂƵs͕&ĂǇĞ͕ŵŝůŝĞ͕zŽƚŶĚĂ
W͕  Ğƚ Ăů͘ /ŶƚĞƌŵŝƩĞŶƚ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ŝƐ
Ă ƌĞŐƵůĂƌ ĨĞĂƚƵƌĞ ŽĨ ůǇƐŝŶƵƌŝĐ ƉƌŽƚĞŝŶ ŝŶƚŽůĞƌĂŶĐĞ͘ : WĞĚŝĂƚƌ
ϭϵϵϵ͖ϭϯϰ͗ϮϯϲͲϵ͘
ϲϲ͘ ŽĚĞ ^&͕  ŵŵĂŶŶ ^͕ ůͲ,Ğƌǌ t͕ ĂƚĂŶĞĂŶƚ D͕ ǀŽƌĂŬ
͕'ĞŚƌŝŶŐ ^͕ Ğƚ Ăů͘ dŚĞ ƐǇŶĚƌŽŵĞŽĨ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵͲ
ƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ŝŶƉƌŝŵĂƌǇ ŝŵŵƵŶŽĚĞĮĐŝĞŶĐŝĞƐ͗ /ŵƉůŝĐĂƟŽŶƐ
ĨŽƌ ĚŝīĞƌĞŶƟĂů ĚŝĂŐŶŽƐŝƐ ĂŶĚ ƉĂƚŚŽŐĞŶĞƐŝƐ͘ ,ĂĞŵĂƚŽůŽŐŝĐĂ
ϮϬϭϱ͖ϭϬϬ͗ϵϳϴͲϴϴ͘
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ϲϴ͘ ,ĞŶƚĞƌ :/͕ ,ŽƌŶĞ ͕ ƌŝĐſ D͕ ŐĞůĞƌ ZD͕ &ŝůŝƉŽǀŝĐŚ ,͕
/ŵĂƐŚƵŬƵ ^͕ Ğƚ Ăů͘ ,>,ͲϮϬϬϰ͗ ŝĂŐŶŽƐƟĐ ĂŶĚ ƚŚĞƌĂƉĞƵƟĐ




ƐǇƐƚĞŵŝĐ ůƵƉƵƐ ĞƌǇƚŚĞŵĂƚŽƐƵƐ͗  ŵƵůƟŶĂƟŽŶĂů ŵƵůƟĐĞŶƚĞƌ
ƐƚƵĚǇŽĨ ƚŚŝƌƚǇͲĞŝŐŚƚƉĂƟĞŶƚƐ͘ƌƚŚƌŝƟƐZŚĞƵŵϮϬϬϵ͖ϲϬ͗ϯϯϴϴͲ
ϵϵ͘
ϳϬ͘ WĞƩǇ Z͕ ^ŽƵƚŚǁŽŽĚ dZ͕DĂŶŶĞƌƐ W͕  ĂƵŵ :͕ 'ůĂƐƐ E͕
'ŽůĚĞŶďĞƌŐ :͕ Ğƚ Ăů͘ /ŶƚĞƌŶĂƟŽŶĂů ůĞĂŐƵĞ ŽĨ ĂƐƐŽĐŝĂƟŽŶƐ ĨŽƌ
ƌŚĞƵŵĂƚŽůŽŐǇ ĐůĂƐƐŝĮĐĂƟŽŶ ŽĨ ũƵǀĞŶŝůĞ ŝĚŝŽƉĂƚŚŝĐ ĂƌƚŚƌŝƟƐ͗
^ĞĐŽŶĚƌĞǀŝƐŝŽŶ͕ĚŵŽŶƚŽŶ͕ϮϬϬϭ͘:ZŚĞƵŵĂƚŽůϮϬϬϰ͖ϯϭ͗ϯϵϬͲϮ͘








ŽĨ ƚŚĞ ŚĂĞŵŽƐƚĂƟĐ ƐǇƐƚĞŵ ŝŶ ĐŚŝůĚƌĞŶ ǁŝƚŚ ũƵǀĞŶŝůĞ ƌŚĞƵͲ
ŵĂƚŽŝĚ ĂƌƚŚƌŝƟƐ ĐŽƌƌĞůĂƚĞƐǁŝƚŚ ĚŝƐĞĂƐĞ ĂĐƟǀŝƚǇ͘ dŚƌŽŵďZĞƐ
ϭϵϵϴ͖ϵϮ͗ϮϲϳͲϳϮ͘
ϳϰ͘ ZĂǀĞůůŝ ͕DŝŶŽŝĂ &͕  ĂǀŞ ^͕ ,ŽƌŶĞ ͕ ŽǀŝƐ &͕  WŝƐƚŽƌŝŽ ͕
Ğƚ Ăů  ϮϬϭϲ ĐůĂƐƐŝĮĐĂƟŽŶ ĐƌŝƚĞƌŝĂ ĨŽƌ ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ
ƐǇŶĚƌŽŵĞ ĐŽŵƉůŝĐĂƟŶŐ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ ŝĚŝŽƉĂƚŚŝĐ ĂƌƚŚƌŝƟƐ͗
 ĞƵƌŽƉĞĂŶ ůĞĂŐƵĞ ĂŐĂŝŶƐƚ ƌŚĞƵŵĂƟƐŵͬŵĞƌŝĐĂŶ ŽůůĞŐĞ
ŽĨ ZŚĞƵŵĂƚŽůŽŐǇͬWĂĞĚŝĂƚƌŝĐ ZŚĞƵŵĂƚŽůŽŐǇ /ŶƚĞƌŶĂƟŽŶĂů








ϳϳ͘ ,ĞŶƚĞƌ :/͕ ůŝŶĚĞƌ '͕ ^ƂĚĞƌK͕ ,ĂŶƐƐŽŶD͕ ŶĚĞƌƐƐŽŶ ͕
ŶĚĞƌƐƐŽŶ h͘ ,ǇƉĞƌĐǇƚŽŬŝŶĞŵŝĂ ŝŶ ĨĂŵŝůŝĂů ŚĞŵŽƉŚĂŐŽĐǇƟĐ
ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ůŽŽĚϭϵϵϭ͖ϳϴ͗ϮϵϭϴͲϮϮ͘
ϳϴ͘ &ŝƐĐŚĞƌ ͕ ĞƌĨͲĞŶƐƵƐƐĂŶ E͕ ůĂŶĐŚĞ ^͕ >Ğ ĞŝƐƚ &͕ 
ƌĞŵĂƌĚͲKƵƌǇ ͕ >ĞǀĞƌŐĞƌ '͕ Ğƚ Ăů͘ ůůŽŐĞŶĞŝĐ ďŽŶĞŵĂƌƌŽǁ
ƚƌĂŶƐƉůĂŶƚĂƟŽŶ ĨŽƌ ĞƌǇƚŚƌŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ :
WĞĚŝĂƚƌϭϵϴϲ͖ϭϬϴ͗ϮϲϳͲϳϬ͘
ϳϵ͘ :ĂďĂĚŽ E͕ ĚĞ 'ƌĂĞīͲDĞĞĚĞƌ Z͕ ĂǀĂǌǌĂŶĂͲĂůǀŽ D͕
,ĂĚĚĂĚ͕>ĞĞŝƐƚ&͕ ĞŶŬĞƌƌŽƵD͕ĞƚĂů͘dƌĞĂƚŵĞŶƚŽĨĨĂŵŝůŝĂů
ŚĞŵŽƉŚĂŐŽĐǇƟĐůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐǁŝƚŚďŽŶĞŵĂƌƌŽǁƚƌĂŶƐͲ
ƉůĂŶƚĂƟŽŶ ĨƌŽŵ ,> ŐĞŶĞƟĐĂůůǇ ŶŽŶŝĚĞŶƟĐĂů ĚŽŶŽƌƐ͘ ůŽŽĚ
ϭϵϵϳ͖ϵϬ͗ϰϳϰϯͲϴ͘
ϴϬ͘ >Ă ZŽƐĠĞ W͘  dƌĞĂƚŵĞŶƚ ŽĨ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽͲ
ĐǇƚŽƐŝƐŝŶĂĚƵůƚƐ͘,ĞŵĂƚŽůŽŐǇŵ^ŽĐ,ĞŵĂƚŽůĚƵĐWƌŽŐƌĂŵ
ϮϬϭϱ͖ϮϬϭϱ͗ϭϵϬͲϲ͘
ϴϭ͘ tĂŶŐ z͕  ,ƵĂŶŐ t͕ ,Ƶ >͕ ĞŶ y͕ >ŝ >͕ tĂŶŐ :͕ Ğƚ Ăů͘
DƵůƟĐĞŶƚĞƌ ƐƚƵĚǇ ŽĨ ĐŽŵďŝŶĂƟŽŶ W ƌĞŐŝŵĞŶ ĂƐ Ă ƐĂůǀĂŐĞ
ƚŚĞƌĂƉǇ ĨŽƌ ĂĚƵůƚ ƌĞĨƌĂĐƚŽƌǇ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽͲ
ĐǇƚŽƐŝƐ͘ůŽŽĚϮϬϭϱ͖ϭϮϲ͗ϮϭϴϲͲϵϮ͘





















ϴϴ͘ ŽƌƟƐ ͕ /ŶƐĂůĂĐŽ͘DĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ ŝŶ
ũƵǀĞŶŝůĞ ŝĚŝŽƉĂƚŚŝĐ ĂƌƚŚƌŝƟƐ͘ ĐƚĂ WĂĞĚŝĂƚƌ ^ƵƉƉů ϮϬϬϲ͖ϵϱ͗ϯϴͲ
ϰϭ͘
ϴϵ͘ZĂǀĞůůŝ͕sŝŽůĂ^͕ĞĞŶĞĚĞƫ&͕ DĂŐŶŝͲDĂŶǌŽŶŝ^͕dǌŝĂůůĂ
͕ DĂƌƟŶŝ ͘ ƌĂŵĂƟĐ ĞĸĐĂĐǇ ŽĨ ĐǇĐůŽƐƉŽƌŝŶĞ  ŝŶ ŵĂĐƌŽͲ
ƉŚĂŐĞĂĐƟǀĂƟŽŶƐǇŶĚƌŽŵĞ͘ůŝŶǆƉZŚĞƵŵĂƚŽůϮϬϬϭ͖ϭϵ͗ϭϬϴ͘




ϵϭ͘ WƌĂŚĂůĂĚ ^͕ ŽǀĞ <͕ ŝĐŬĞŶƐ ͕ >ŽǀĞůů :͕ 'ƌŽŵ ͘
ƚĂŶĞƌĐĞƉƚ ŝŶ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ŽĨ ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶͲ
ĚƌŽŵĞ͘:ZŚĞƵŵĂƚŽůϮϬϬϭ͖Ϯϴ͗ϮϭϮϬͲϰ͘
ϵϮ͘,ĞŶǌĂŶd͕ EĂŐĂĨƵũŝ<͕dƐƵŬĂŵŽƚŽ,͕DŝǇĂŵŽƚŽd͕ 'ŽŶĚŽ,͕
/ŵĂƐŚƵŬƵ ^͕ Ğƚ Ăů͘ ^ƵĐĐĞƐƐǁŝƚŚ ŝŶŇŝǆŝŵĂď ŝŶ ƚƌĞĂƟŶŐ ƌĞĨƌĂĐͲ
ƚŽƌǇ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ ŵ : ,ĞŵĂƚŽů
ϮϬϬϲ͖ϴϭ͗ϱϵͲϲϭ͘
ϵϯ͘DĂŬĂǇ͕zŝůŵĂǌ^͕dƺƌŬǇŝůŵĂǌ͕hŶĂůE͕KƌĞŶ,͕hŶƐĂů͘
ƚĂŶĞƌĐĞƉƚ ĨŽƌ ƚŚĞƌĂƉǇͲƌĞƐŝƐƚĂŶƚ ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶͲ
ĚƌŽŵĞ͘WĞĚŝĂƚƌůŽŽĚĂŶĐĞƌϮϬϬϴ͖ϱϬ͗ϰϭϵͲϮϭ͘
ϵϰ͘ ^ĞůůŵĞƌ ͕ ^ƚĂƵƐďƆůͲ'ƌƆŶ ͕ <ƌĂŐͲKůƐĞŶ ͕ ,ĞƌůŝŶ d͘ 
^ƵĐĐĞƐƐĨƵů ƵƐĞ ŽĨ ŝŶŇŝǆŝŵĂď ŝŶ ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶͲ
ĚƌŽŵĞ ǁŝƚŚ ƐĞǀĞƌĞ E^ ŝŶǀŽůǀĞŵĞŶƚ͘ ^ĐĂŶĚ : ZŚĞƵŵĂƚŽů
ϮϬϭϭ͖ϰϬ͗ϭϱϲͲϳ͘
ϵϱ͘ ZĂŵĂŶĂŶ s͕ ^ĐŚŶĞŝĚĞƌ Z͘ DĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶͲ
ĚƌŽŵĞ ĨŽůůŽǁŝŶŐ ŝŶŝƟĂƟŽŶ ŽĨ ĞƚĂŶĞƌĐĞƉƚ ŝŶ Ă ĐŚŝůĚ ǁŝƚŚ
ƐǇƐƚĞŵŝĐ ŽŶƐĞƚ ũƵǀĞŶŝůĞ ƌŚĞƵŵĂƚŽŝĚ ĂƌƚŚƌŝƟƐ͘ : ZŚĞƵŵĂƚŽů
ϮϬϬϯ͖ϯϬ͗ϰϬϭͲϯ͘
ϵϲ͘ ^ĂŶĚŚƵ ͕ ŚĞƐŶĞǇ ͕ WŝůŝŽƟƐ ͕ ƵĐŬƐƚĞŝŶ Z͕ <ŽƌĞŶ ^͘
DĂĐƌŽƉŚĂŐĞĂĐƟǀĂƟŽŶƐǇŶĚƌŽŵĞĂŌĞƌĞƚĂŶĞƌĐĞƉƚƚƌĞĂƚŵĞŶƚ͘
:ZŚĞƵŵĂƚŽůϮϬϬϳ͖ϯϰ͗ϮϰϭͲϮ͘
ϵϳ͘ <ĂŶĞŬŽ<͕ <ĂďƵƌĂŬŝD͕DƵƌĂŽŬĂ ^͕ dĂŶĂŬĂE͕ zĂŵĂŵŽƚŽ
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d͕ <ƵƐƵŶŽŬŝz͕ ĞƚĂů͘ǆĂĐĞƌďĂƟŽŶŽĨĂĚƵůƚͲŽŶƐĞƚ^Ɵůů Ɛ͛ĚŝƐĞĂƐĞ͕
ƉŽƐƐŝďůǇ ƌĞůĂƚĞĚ ƚŽ ĞůĞǀĂƟŽŶ ŽĨ ƐĞƌƵŵ ƚƵŵŽƌ ŶĞĐƌŽƐŝƐ ĨĂĐͲ
ƚŽƌͲĂůƉŚĂ ĂŌĞƌ ĞƚĂŶĞƌĐĞƉƚ ĂĚŵŝŶŝƐƚƌĂƟŽŶ͘ /Ŷƚ : ZŚĞƵŵ ŝƐ
ϮϬϭϬ͖ϭϯ͗ĞϲϳͲϵ͘






ƚŚĞƌĂƉǇ ŝŶ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ ŝĚŝŽƉĂƚŚŝĐ ĂƌƚŚƌŝƟƐ͗ ZĞƉŽƌƚ ŽĨ
ĨŽƌƚǇͲƐŝǆ ƉĂƟĞŶƚƐ ĨƌŽŵ ĂŶ ŝŶƚĞƌŶĂƟŽŶĂů ŵƵůƟĐĞŶƚĞƌ ƐĞƌŝĞƐ͘
ƌƚŚƌŝƟƐZŚĞƵŵϮϬϭϭ͖ϲϯ͗ϱϰϱͲϱϱ͘
ϭϬϬ͘ ƵƌĂŶĚ D͕ dƌŽǇĂŶŽǀ z͕  >ĂŇĂŵŵĞ W͕  'ƌĞŐŽŝƌĞ '͘
DĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ ƚƌĞĂƚĞĚ ǁŝƚŚ ĂŶĂŬŝŶƌĂ͘ :
ZŚĞƵŵĂƚŽůϮϬϭϬ͖ϯϳ͗ϴϳϵͲϴϬ͘
ϭϬϭ͘ƌƵĐŬE͕^ƵƩŽƌƉD͕<ĂďƵƐD͕,ĞƵďŶĞƌ'͕'ĂŚƌD͕WĞƐƐůĞƌ
&͘  ZĂƉŝĚ ĂŶĚ ƐƵƐƚĂŝŶĞĚ ƌĞŵŝƐƐŝŽŶ ŽĨ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ ŝĚŝŽͲ
ƉĂƚŚŝĐ ĂƌƚŚƌŝƟƐͲĂƐƐŽĐŝĂƚĞĚ ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ
ƚŚƌŽƵŐŚ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ĂŶĂŬŝŶƌĂ ĂŶĚ ĐŽƌƟĐŽƐƚĞƌŽŝĚƐ͘ : ůŝŶ
ZŚĞƵŵĂƚŽůϮϬϭϭ͖ϭϳ͗ϮϯͲϳ͘
ϭϬϮ͘ <ĞůůǇ ͕ ZĂŵĂŶĂŶ s͘   ĐĂƐĞ ŽĨŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ
ƐǇŶĚƌŽŵĞ ƐƵĐĐĞƐƐĨƵůůǇ ƚƌĞĂƚĞĚ ǁŝƚŚ ĂŶĂŬŝŶƌĂ͘ EĂƚ ůŝŶ WƌĂĐƚ
ZŚĞƵŵĂƚŽůϮϬϬϴ͖ϰ͗ϲϭϱͲϮϬ͘
ϭϬϯ͘ZĞĐŽƌĚ :>͕ĞƵŬĞůŵĂŶ d͕ ƌŽŶZY͘ŽŵďŝŶĂƟŽŶ ƚŚĞƌĂƉǇ





ĚŝƐĞĂƐĞͲĂƐƐŽĐŝĂƚĞĚ ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ ǁŝƚŚ




͕ Ğƚ Ăů͘ ŶĂŬŝŶƌĂ ĨŽƌ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ ĂƌƚŚƌŝƟƐ͗ dŚĞ ZŽĐŬǇ
DŽƵŶƚĂŝŶ ĞǆƉĞƌŝĞŶĐĞ͘ : ůŝŶ ZŚĞƵŵĂƚŽů WƌĂĐƚ ZĞƉ ZŚĞƵŵ
DƵƐĐƵůŽƐŬĞůĞƚŝƐϮϬϬϵ͖ϭϱ͗ϭϲϭͲϰ͘
ϭϬϲ͘ZƵƉĞƌƚŽE͕ƌƵŶŶĞƌ,/͕YƵĂƌƟĞƌW͕ ŽŶƐƚĂŶƟŶd͕ tƵůīƌĂĂƚ
E͕ ,ŽƌŶĞī '͕ Ğƚ Ăů͘ dǁŽ ƌĂŶĚŽŵŝǌĞĚ ƚƌŝĂůƐ ŽĨ ĐĂŶĂŬŝŶƵͲ
ŵĂď ŝŶ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ ŝĚŝŽƉĂƚŚŝĐ ĂƌƚŚƌŝƟƐ͘ E ŶŐů : DĞĚ
ϮϬϭϮ͖ϯϲϳ͗ϮϯϵϲͲϰϬϲ͘
ϭϬϳ͘ <ŽƐƟŬ DD͕ ƵďŬŽ D&͕  DĂƐĂůŽǀĂ ss͕ ^ŶĞŐŝƌĞǀĂ >^͕
<ŽƌŶŝƐŚŝŶĂ d>͕ ŚŝŬŽǀĂ /͕ Ğƚ Ăů͘ /ĚĞŶƟĮĐĂƟŽŶ ŽĨ ƚŚĞ ďĞƐƚ
ĐƵƚŽīƉŽŝŶƚƐĂŶĚĐůŝŶŝĐĂůƐŝŐŶƐƐƉĞĐŝĮĐĨŽƌĞĂƌůǇƌĞĐŽŐŶŝƟŽŶŽĨ
ŵĂĐƌŽƉŚĂŐĞ ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞ ŝŶ ĂĐƟǀĞ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ
ŝĚŝŽƉĂƚŚŝĐĂƌƚŚƌŝƟƐ͘^ĞŵŝŶƌƚŚƌŝƟƐZŚĞƵŵϮϬϭϱ͖ϰϰ͗ϰϭϳͲϮϮ͘
ϭϬϴ͘zŽŬŽƚĂ^͕/ƚŽŚz͕ DŽƌŝŽd͕ KƌŝŐĂƐĂ,͕^ƵŵŝƚŽŵŽE͕dŽŵŽďĞ
D͕ Ğƚ Ăů͘ dŽĐŝůŝǌƵŵĂď ŝŶ ƐǇƐƚĞŵŝĐ ũƵǀĞŶŝůĞ ŝĚŝŽƉĂƚŚŝĐ ĂƌƚŚƌŝƟƐ
ŝŶĂƌĞĂůͲǁŽƌůĚĐůŝŶŝĐĂůƐĞƫŶŐ͗ZĞƐƵůƚƐĨƌŽŵϭǇĞĂƌŽĨƉŽƐƚŵĂͲ
ƌŬĞƟŶŐ ƐƵƌǀĞŝůůĂŶĐĞ ĨŽůůŽǁͲƵƉ ŽĨ ϰϭϳ ƉĂƟĞŶƚƐ ŝŶ :ĂƉĂŶ͘ ŶŶ
ZŚĞƵŵŝƐϮϬϭϲ͖ϳϱ͗ϭϲϱϰͲϲϬ͘
ϭϬϵ͘ Ğ ĞŶĞĚĞƫ &͕  ƌƵŶŶĞƌ ,/͕ ZƵƉĞƌƚŽ E͕ <ĞŶǁƌŝŐŚƚ
͕ tƌŝŐŚƚ ^͕ ĂůǀŽ /͕ Ğƚ Ăů͘ ZĂŶĚŽŵŝǌĞĚ ƚƌŝĂů ŽĨ ƚŽĐŝůŝǌƵͲ











ϭϭϯ͘ ^ĐŚƵůĞƌƚ '^͕ 'ƌŽŵ ͘ WĂƚŚŽŐĞŶĞƐŝƐ ŽĨ ŵĂĐƌŽƉŚĂŐĞ
ĂĐƟǀĂƟŽŶ ƐǇŶĚƌŽŵĞĂŶĚƉŽƚĞŶƟĂů ĨŽƌ ĐǇƚŽŬŝŶĞͲĚŝƌĞĐƚĞĚ ƚŚĞͲ
ƌĂƉŝĞƐ͘ŶŶƵZĞǀDĞĚϮϬϭϱ͖ϲϲ͗ϭϰϱͲϱϵ͘
ϭϭϰ͘ ,ĞŶƚĞƌ :/͕ ^ĂŵƵĞůƐƐŽŶͲ,ŽƌŶĞ ͕ ƌŝĐž D͕ ŐĞůĞƌ ZD͕
ůŝŶĚĞƌ'͕&ŝůŝƉŽǀŝĐŚ,͕ĞƚĂů͘dƌĞĂƚŵĞŶƚŽĨŚĞŵŽƉŚĂŐŽĐǇƟĐ
ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐǁŝƚŚ ,>,Ͳϵϰ ŝŵŵƵŶŽĐŚĞŵŽƚŚĞƌĂƉǇ ĂŶĚ
ďŽŶĞŵĂƌƌŽǁƚƌĂŶƐƉůĂŶƚĂƟŽŶ͘ůŽŽĚϮϬϬϮ͖ϭϬϬ͗ϮϯϲϳͲϳϯ͘
ϭϭϱ͘ ŽŽƉĞƌ E͕ ZĂŽ <͕ 'ŝůŵŽƵƌ <͕ ,ĂĚĂĚ >͕ ĚĂŵƐ ^͕ ĂůĞ
͕ Ğƚ Ăů͘ ^ƚĞŵ ĐĞůů ƚƌĂŶƐƉůĂŶƚĂƟŽŶ ǁŝƚŚ ƌĞĚƵĐĞĚͲŝŶƚĞŶƐŝƚǇ




ŽĨ ƉĂƟĞŶƚƐǁŝƚŚŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ƵŶĚĞƌͲ
ŐŽŝŶŐ ĂůůŽŐĞŶĞŝĐ ŚĞŵĂƚŽƉŽŝĞƟĐ ĐĞůů ƚƌĂŶƐƉůĂŶƚĂƟŽŶ͘ ůŽŽĚ
ϮϬϭϬ͖ϭϭϲ͗ϱϴϮϰͲϯϭ͘
ϭϭϳ͘ ĂƌŵŽD͕ ZŝƐŵĂ <͕ ƌƵŵƵŐĂŵ W͕  dŝǁĂƌŝ ^͕ ,ŽŶƚǌ ͕
DŽŶƟĞůͲƋƵŝŚƵĂ͕ĞƚĂů͘WĞƌĨŽƌŝŶŐĞŶĞƚƌĂŶƐĨĞƌŝŶƚŽŚĞŵĂƚŽͲ







ĚŝƐĞĂƐĞ ŝŶŵƵƌŝŶĞŵŽĚĞůƐ ŽĨ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽͲ
ĐǇƚŽƐŝƐ͘ůŽŽĚϮϬϭϲ͖ϭϮϳ͗ϭϲϲϲͲϳϱ͘
ϭϮϬ͘>ŝŶd&͕ &ĞƌůŝĐͲ^ƚĂƌŬ>>͕ůůĞŶ͕<ŽǌŝŶĞƚǌ͕DĐůĂŝŶ<>͘
ZĂƚĞ ŽĨ ĚĞĐůŝŶĞ ŽĨ ĨĞƌƌŝƟŶ ŝŶ ƉĂƟĞŶƚƐ ǁŝƚŚ ŚĞŵŽƉŚĂŐŽĐǇƟĐ




ƟĐ ďĂƐŝƐ͕ ĚŝĂŐŶŽƐŝƐ ĂŶĚ ŵĂŶĂŐĞŵĞŶƚ͘ ůŝŶ ǆƉ /ŵŵƵŶŽů
ϮϬϭϭ͖ϭϲϯ͗ϮϳϭͲϴϯ͘
ϭϮϮ͘ ^ƵůůŝǀĂŶ <͕ ĞůĂĂƚ ͕ ŽƵŐůĂƐ ^͕ &ŝůŝƉŽǀŝĐŚ ,͘
ĞĨĞĐƟǀĞ ŶĂƚƵƌĂů ŬŝůůĞƌ ĐĞůů ĨƵŶĐƟŽŶ ŝŶ ƉĂƟĞŶƚƐ ǁŝƚŚ ŚĞŵŽͲ
ƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ĂŶĚ ŝŶ ĮƌƐƚ ĚĞŐƌĞĞ ƌĞůĂƟǀĞƐ͘
WĞĚŝĂƚƌZĞƐϭϵϵϴ͖ϰϰ͗ϰϲϱͲϴ͘
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&ƌŽĞůŝĐŚ:͕ĞƚĂů͘ŶĂŶƟŵŝĐƌŽďŝĂůĂĐƟǀŝƚǇŽĨĐǇƚŽůǇƟĐdĐĞůůƐ
ŵĞĚŝĂƚĞĚďǇŐƌĂŶƵůǇƐŝŶ͘^ĐŝĞŶĐĞϭϵϵϴ͖ϮϴϮ͗ϭϮϭͲϱ͘
ϭϮϲ͘ &ĞůĚŵĂŶŶ :͕ ĂůůĞďĂƵƚ /͕ ZĂƉŽƐŽ '͕ ĞƌƚĂŝŶ ^͕ ĂĐƋ ͕
ƵŵŽŶƚ͕ĞƚĂů͘DƵŶĐϭϯͲϰ ŝƐĞƐƐĞŶƟĂů ĨŽƌĐǇƚŽůǇƟĐŐƌĂŶƵůĞƐ
ĨƵƐŝŽŶ ĂŶĚ ŝƐŵƵƚĂƚĞĚ ŝŶ Ă ĨŽƌŵ ŽĨ ĨĂŵŝůŝĂů ŚĞŵŽƉŚĂŐŽĐǇƟĐ
ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ;&,>ϯͿ͘ĞůůϮϬϬϯ͖ϭϭϱ͗ϰϲϭͲϳϯ͘
ϭϮϳ͘ǌƵƌ^ƚĂĚƚh͕ZŽŚƌ:͕^ĞŝĨĞƌƚt͕<ŽĐŚ&͕ 'ƌŝĞǀĞ^͕WĂŐĞů:͕Ğƚ
Ăů͘&ĂŵŝůŝĂůŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ ƚǇƉĞϱ ;&,>Ͳ
ϱͿ ŝƐĐĂƵƐĞĚďǇŵƵƚĂƟŽŶƐŝŶDƵŶĐϭϴͲϮĂŶĚŝŵƉĂŝƌĞĚďŝŶĚŝŶŐ
ƚŽƐǇŶƚĂǆŝŶϭϭ͘ŵ:,Ƶŵ'ĞŶĞƚϮϬϬϵ͖ϴϱ͗ϰϴϮͲϵϮ͘




ϭϮϵ͘ ^ƉĞƐƐŽƩ t͕ ^ĂŶŵŝůůĂŶ D>͕ DĐŽƌŵŝĐŬ D͕ WĂƚĞů E͕
sŝůůĂŶƵĞǀĂ :͕ ŚĂŶŐ <͕ Ğƚ Ăů͘ ,ĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽͲ
ĐǇƚŽƐŝƐ ĐĂƵƐĞĚ ďǇ ĚŽŵŝŶĂŶƚͲŶĞŐĂƟǀĞ ŵƵƚĂƟŽŶƐ ŝŶ ^dyWϮ
ƚŚĂƚ ŝŶŚŝďŝƚ ^EZͲŵĞĚŝĂƚĞĚ ŵĞŵďƌĂŶĞ ĨƵƐŝŽŶ͘ ůŽŽĚ
ϮϬϭϱ͖ϭϮϱ͗ϭϱϲϲͲϳϳ͘
ϭϯϬ͘WĂĐŚůŽƉŶŝŬ^ĐŚŵŝĚ :͕^ĐŚŵŝĚ :W͕ ƀƚĞD͕DĠŶĂŐĞƌDD͕
ƵƌŐĞƐƐ ͕ EĞŚŵĞE͕ Ğƚ Ăů͘ /ŶŚĞƌŝƚĞĚ ĚĞĨĞĐƚƐ ŝŶ ůǇŵƉŚŽĐǇƚĞ
ĐǇƚŽƚŽǆŝĐĂĐƟǀŝƚǇ͘/ŵŵƵŶŽůZĞǀϮϬϭϬ͖Ϯϯϱ͗ϭϬͲϮϯ͘
ϭϯϭ͘ ĞƟĐĂ s͕ ^ŝĞŶŝ ͕ WĞŶĚĞ ͕ ĂŶĞƐŝŶŽ ͕ Ğ &ƵƐĐŽ ͕
>ŽĐĂƚĞůůŝ &͕  Ğƚ Ăů͘ 'ĞŶĞƟĐ ƉƌĞĚŝƐƉŽƐŝƟŽŶ ƚŽ ŚĞŵŽƉŚĂŐŽĐǇƟĐ
ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͗ ZĞƉŽƌƚŽŶϱϬϬƉĂƟĞŶƚƐ ĨƌŽŵ ƚŚĞ /ƚĂůŝĂŶ
ƌĞŐŝƐƚƌǇ͘:ůůĞƌŐǇůŝŶ/ŵŵƵŶŽůϮϬϭϲ͖ϭϯϳ͗ϭϴϴͲϵϲ͘Ğϰ͘
ϭϯϮ͘ ŽůůĞƌ ͕ >ǇŬĞŶƐ :͕ dĞƌƌĞůů ͕ ůŝďĞƌƟ :͕ &ŝůŝƉŽǀŝĐŚ,͕
,ĞŶƐŽŶ WD͕ Ğƚ Ăů͘ ,ĞŵŽƉŚĂŐŽĐǇƚŽƐŝƐ ĐĂƵƐĞƐ Ă ĐŽŶƐƵŵƉƟǀĞ
ĂŶĞŵŝĂŽĨŝŶŇĂŵŵĂƟŽŶ͘:ǆƉDĞĚϮϬϭϭ͖ϮϬϴ͗ϭϮϬϯͲϭϰ͘
ϭϯϯ͘dĂŬĂĚĂ,͕KŚŐĂ^͕DŝǌƵŶŽz͕ EŽŵƵƌĂ͕,ĂƌĂd͘ /ŶĐƌĞĂƐĞĚ
/>Ͳϭϲ ůĞǀĞůƐ ŝŶŚĞŵŽƉŚĂŐŽĐǇƟĐ ůǇŵƉŚŽŚŝƐƟŽĐǇƚŽƐŝƐ͘ :WĞĚŝĂƚƌ
,ĞŵĂƚŽůKŶĐŽůϮϬϬϰ͖Ϯϲ͗ϱϲϳͲϳϯ͘
ϭϯϰ͘ DĂǌŽĚŝĞƌ <͕ DĂƌŝŶ s͕ EŽǀŝĐŬ ͕ &ĂƌŶĂƌŝĞƌ ͕ ZŽďŝƚĂŝů
^͕ ^ĐŚůĞŝŶŝƚǌ E͕ Ğƚ Ăů͘ ^ĞǀĞƌĞ ŝŵďĂůĂŶĐĞ ŽĨ />Ͳϭϴͬ/>ͲϭϴW ŝŶ
ƉĂƟĞŶƚƐ ǁŝƚŚ ƐĞĐŽŶĚĂƌǇ ŚĞŵŽƉŚĂŐŽĐǇƟĐ ƐǇŶĚƌŽŵĞ͘ ůŽŽĚ
ϮϬϬϱ͖ϭϬϲ͗ϯϰϴϯͲϵ͘
ϭϯϱ͘ >ǇŬĞŶƐ :͕ dĞƌƌĞůů ͕ ŽůůĞƌ ͕ ZŝƐŵĂ <͕ :ŽƌĚĂŶ D͘








D͕ WĞƚƌŝŶŝ ^͕ Ğƚ Ăů͘ ŵƉůŝĮĐĂƟŽŶ ŽĨ ƚŚĞ ƌĞƐƉŽŶƐĞ ƚŽ dŽůůͲůŝŬĞ




^͕ Ğƚ Ăů͘ ZWϭ ƌĞŐƵůĂƚĞƐ ŶĂƚƵƌĂů ŬŝůůĞƌ ĐĞůů ĨƵŶĐƟŽŶ ďǇ ĐŽŶͲ
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BRIEF REPORT
Alternative Activation of Laser-Captured Murine Hemophagocytes
Scott W. Canna,1 Patrı́cia Costa-Reis,2 William E. Bernal,3 Niansheng Chu,2 Kathleen E. Sullivan,4
Michele E. Paessler,4 and Edward M. Behrens4
Objective. Hemophagocytes (HPCs) are activated
macrophages that have engulfed other hematopoietic
cells. Although HPCs are rarely identified in normal
spleen tissue and bone marrow, an excess of these
macrophages characterizes many cytokine storm syn-
dromes, particularly macrophage activation syndrome
and hemophagocytic lymphohistiocytosis. This study
was undertaken to assess the functions of HPCs and
their significance in acute inflammatory conditions.
Methods. HPCs were generated in wild-type mice
using repeated stimulation with Toll-like receptor 9
(TLR-9) and interleukin-10 receptor blockade. RNA was
extracted from HPCs that had been isolated by laser-
captured microdissection. Transcriptional profiles of
the HPCs were then compared to those of resting splenic
macrophages. In addition, bone marrow samples were
obtained from a diverse cohort of patients in whom
excess hemophagocytosis was identified by clinical bone
marrow biopsy or aspiration. The bone marrow samples
were analyzed by immunohistochemistry for markers of
classic (CD64) or alternative (CD163 and CD206) mac-
rophage activation.
Results. Differential gene expression and gene set
enrichment analyses of murine HPCs identified up-
regulation of genes and gene sets associated with alter-
native activation of HPCs. Immunohistochemical ana-
lyses of HPCs in human bone marrow samples showed
universal staining of HPCs for CD163, but rarely for
CD206 or CD64.
Conclusion. Laser-captured murine TLR-9–
induced HPCs had a transcriptional profile similar to
that of alternatively activated macrophages. In addition,
HPC expression of CD163 was confirmed in a uniquely
diverse cohort of patients with hemophagocytic syn-
dromes. Collectively, these data support the hypothesis
that HPCs have both immunoregulatory and clean-up
functions.
Macrophages reside in organs throughout the
body, where they are involved in diverse functions,
including pathogen sensing, pro- and antiinflammatory
immune responses, and wound healing. Macrophage
activation has been described in a continuum from
classically activated (M1) to alternatively activated
(broadly categorized as M2) (1). M1 macrophages have
proinflammatory functions that often result in tissue
damage, while M2 macrophages participate in immuno-
regulation and tissue remodeling. Thus, macrophage
functions can be fluid and varied, with either proinflam-
matory or antiinflammatory actions, depending on the
mix of signals being received.
Morphologically, hemophagocytes (HPCs) are
macrophages that have engulfed other hematopoietic
cells. Detection of hemophagocytosis is an important
aspect in the diagnosis and management of macrophage
activation syndrome (MAS) and hemophagocytic lym-
phohistiocytosis (HLH). MAS and HLH are complex
cytokine storm disorders that can complicate various
infectious, rheumatic, or malignant diseases (2). HLH
can also be caused by primary genetic defects in cytotoxi-
city.
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Studies in animals and humans have suggested
that HPCs have both pro- and antiinflammatory roles.
Evidence for a proinflammatory role derives from the
important effects of interferon-! (IFN!) on macro-
phages, whereby IFN! acts to drive disease progression
in animal models of MAS and HLH (3), and from the
localization of proinflammatory cytokines in liver biopsy
specimens from patients with MAS (4). The evidence
pertaining to alternative activation includes observations
of the expression of a scavenger receptor, CD163, on
HPCs (2), as well as detection of antiinflammatory
functions in murine erythrophagocytes, identified by
flow cytometry (3,5).
In this study, we show that the transcriptional
program of morphologically identified murine HPCs is
consistent with a profile of alternative activation. In
addition, we confirm the expression of CD163 on human
bone marrow HPCs from a uniquely broad cohort of
patients with hemophagocytic syndromes. While the
roles of macrophages in hemophagocytic syndromes
remain imprecise, these results suggest that murine
Toll-like receptor 9 (TLR-9)–induced HPCs are alter-
natively activated and that their presence may be bene-
ficial to the control or clearance of inflammation.
MATERIALS AND METHODS
Isolation of murine HPCs. Fulminant MAS was in-
duced in mice using repeated stimulation with TLR-9 (via CpG
administration) and interleukin-10 receptor (IL-10R) block-
ade, as previously described (6). Splenic touch preparations
(touch preps) were made on nuclease-free polyethylene naph-
thalate membrane–coated slides (Zeiss), followed immediately
by staining of the touch preps with Wright-Giemsa stain. A
pediatric hematopathologist (MEP) with expertise in hemo-
phagocytic syndromes morphologically identified HPCs from
TLR-9–stimulated, IL-10R–blocked mice or resting macro-
phages from saline-treated mice. From each mouse, 20 cells
were captured using a Zeiss PALM (photoactivated localiza-
tion microscopy) laser microdissection system (Figures 1A and
B). Thereafter, the cells were isolated, pooled, and processed
in aggregate.
RNA isolation and microarray. Complementary DNA
(cDNA) libraries were generated from the RNA of pooled,
microdissected cells using a WT-Ovation One-Direct Amplifi-
cation System (NuGEN) according to the manufacturer’s
instructions. Fragmented cDNA was then hybridized to
Affymetrix GeneChip Mouse Gene 1.0 ST Arrays, and then
washed, stained, and scanned with an Affymetrix GeneChip
Scanner 3000 7G system.
Transcriptional analysis. Affymetrix Expression Con-
sole software was used to perform quality control, excluding 2
chips from each group and leaving 4 biologic replicates per
group for analysis. Microarrays were preprocessed using robust
multiarray analysis (Gene Expression Omnibus accession no.
GSE47430) (7). Probe sets lacking gene symbol annotation or
with a mean log2 intensity of !5 among the HPC samples were
filtered out. Log2-transformed expression data were analyzed
using R statistical computing language. Differentially ex-
pressed genes (DEGs) were defined as those with at least
1.5-fold difference in expression in HPCs as compared to
resting macrophages. DEGs were tested for statistical signifi-
cance using Student’s t-tests, with correction for multiple
testing using the false discovery rate (FDR). Functional en-
richment analysis among DEGs was performed using the
DAVID database (version 6.7) (8). Gene Ontology terms for
biologic pathways, molecular function, and cellular compo-
nents were tested, as were Kyoto Encyclopedia of Genes and
Genomes (KEGG) biologic pathways. Genes that passed the
filtering criteria were used as the background gene list in the
enrichment analysis.
Gene set enrichment analysis (GSEA). Gene sets were
identified by searching the Molecular Signatures database for
the term “inflammation” (9). Gene sets with substantial over-
lap were excluded. Initially, 17 gene sets were included in this
analysis, but the Phagocytosis gene set was excluded because
too few probes were included in our data set (Table 1).
MOgene expression data were translated into Human Genome
Organisation (HUGO) gene symbols before comparison with
selected gene sets, as per GSEA protocol. Gene sets were
analyzed using gene set permutation, and prior to analysis, we
chose the following threshold for significant enrichment: a
nominal P value of "0.05 and FDR of "5% (9).
Patient selection and immunohistochemical analysis.
We performed an unbiased, retrospective search of the pathol-
ogy database of the Children’s Hospital of Philadelphia be-
Figure 1. Evaluation of the transcriptional profile of murine and
human hemophagocytes (HPCs). A and B, Resting murine splenic
macrophages (A) and murine HPCs (B) were isolated by laser-
captured microdissection and assessed for activation status. C and D,
HPCs in bone marrow biopsy specimens from patients with hemo-
phagocytic disease were immunostained for CD163, CD206, or CD64
(D). As positive controls for the respective immunohistochemical
stains, tonsil tissue from patients without hemophagocytic disease was
assessed (C). Original magnification " 100; counterstaining with
hematoxylin.








tween 1998 and 2011, for bone marrow specimens obtained
from pediatric patients whose clinical report documented a
history of excessive hemophagocytosis. Thirty-seven samples
from 34 patients were identified and verified as having excess
hemophagocytosis. These samples had been decalcified, fixed
in acetic acid–zinc–formalin (AZF), and paraffin-embedded,
according to the institution’s protocol.
Markers of classic macrophage activation (CD64) (1:
25, clone 10.1; Abcam) or alternative macrophage activation
(CD163 [1:200, clone 10D6; Vector Laboratories] and CD206
[1:500, clone 5C11; Abnova/Novus Biologicals]) were detected
in the bone marrow samples by immunohistochemistry. Heat
antigen retrieval was utilized for CD64 and CD163 (at pH 6
and pH 9, respectively). Avidin–biotin complex signal am-
plification was then used for CD206, and a polymeric-
based method was used for CD64 and CD163. Detection was
performed with horseradish peroxidase and 3,3!-
diaminobenzidine chromogen, and the sections were counter-
stained with hematoxylin. AZF-fixed tonsils from patients
without hemophagocytic disease were used as controls (Figure
1C) for the assessment of adequate positive or negative
staining. All bone marrow samples from patients with hemo-
phagocytic syndromes were evaluated for the presence or
absence of immunostained HPCs (Figure 1D), performed in a
blinded manner by a hematopathologist (MEP) with expertise
in hemophagocytic diseases.
Chart review identified the specific clinical information
related to each sample (details available from the correspond-
ing author upon request). This study was approved by the
Institutional Review Board of the Children’s Hospital of
Philadelphia.
RESULTS
Up-regulation of genes associated with macro-
phage activation and regulation of inflammation in
TLR-9–induced murine HPCs. Forty-five genes met our
criteria for differential expression (Table 2 and results
not shown). No genes with decreased expression in
HPCs as compared to resting macrophages were found
to be statistically significantly down-regulated. Genes
encoding the ribosomal protein subunits Rps20 and
Rpl35a were among the most highly up-regulated, sug-
gesting that HPCs may regulate global protein synthesis.
Consistent with this notion, functional enrichment ana-
lysis of all DEGs suggested that “translation” was a
significant biologic function of HPCs (Benjamini-
corrected P " 0.002 for this Gene Ontology biologic
process annotation). We further found that the KEGG
“Ribosome” pathway was significantly enriched
(Benjamini-corrected P " 1.6 # 10$7).
Another group of up-regulated genes comprised
those related to cellular energetics. Two genes encoding
Table 1. Gene set enrichment analysis of TLR-9–induced hemo-
phagocytes compared to resting macrophages*
Gene set Size N-ES Nominal P FDR
Proteasome† 43 2.42 %0.001 %0.001
Up-regulated in M2 vs. M1† 73 1.85 %0.001 0.009
NOD-like receptor
signaling†
54 1.74 0.002 0.022
Innate immunity signaling 97 1.49 0.015 0.133
Actin regulation 195 1.48 0.007 0.116
Cytosolic DNA sensing 46 1.48 0.058 0.101
TLR signaling 90 1.41 0.044 0.127
Up-regulated in M1 vs. M2 76 1.32 0.080 0.188
Endocytosis 160 1.23 0.12 0.283
TLR-3 cascade 56 1.04 0.391 0.545
TLR-4 cascade 25 0.93 0.556 0.717
IL-10 pathway 17 0.84 0.663 0.839
Integrin pathway 37 0.61 0.963 1
TLR-9 cascade 20 0.54 0.969 0.989
Inflammatory pathway 25 $0.95 0.547 1
IL-1R pathway 30 $0.67 0.921 0.946
* TLR-9 " Toll-like receptor 9; N-ES " normalized enrichment score;
FDR " false discovery rate; IL-10 " interleukin-10; IL-1R " IL-1
receptor.
† Significantly enriched gene set, as defined in Materials and Methods.
Table 2. Highly differentially expressed genes in Toll-like receptor 9–induced hemophagocytes compared to resting macrophages*
Gene Protein product Fold change P FDR
Rps20 Ribosomal protein S20 22.6 0.0063 0.146
!2m !2-microglobulin 12.5 0.0292 0.206
Rpl35a† Ribosomal protein L35A 8.5 4.29 # 10$4 0.055
Saa3 Serum amyloid A3 7.9 0.0014 0.055
Ifitm2 Interferon-inducible transmembrane protein 3 6.7 0.0445 0.210
Cox6c Cytochrome c oxidase, subunit Vic 6.2 0.0238 0.174
Ftl† Ferritin light chain 5.8 0.0028 0.055
Tmsb10 Thymosin !10 4.9 0.0430 0.210
GAPDH† Glyceraldehyde 3 phosphate dehydrogenase 4.9 0.0019 0.055
Cox6a1 Cytochrome c oxidase subunit VIa, polypeptide 1 4.2 0.0388 0.210
Usmg5 Up-regulated during skeletal muscle growth 5 4.2 0.0412 0.210
Tmsb4x Thymosin !4 4.1 0.0427 0.210
S100a6 S100 calcium binding protein A6 (calcyclin) 4.1 6.27 # 10$4 0.055
* Genes associated with "4-fold induction in hemophagocytes as compared to resting macrophages. FDR " false discovery rate.
† Target identified by more than one probe.








subunits of the mitochondrial respiratory protein com-
plex cytochrome c oxidase (Cox6c, Cox6a1) were up-
regulated, as was the gene for the glycolytic enzyme
GAPDH. Accordingly, the KEGG “Oxidative Phosphor-
ylation” pathway was significantly enriched in genes
differentially expressed by HPCs (Benjamini-corrected
P ! 4.2 " 10#4). Thus, these data suggest that TLR-9–
induced HPCs are acting to meet the demands for
energy and protein synthesis.
Genes associated with macrophage stimulation
and activation were also among the most differentially
expressed in murine HPCs. The !2-microglobulin (B2m)
and interferon-inducible transmembrane protein 3
(Ifitm2) genes, both of which are associated with antivi-
ral responses, were up-regulated, as were the genes for
serum amyloid A3 (Saa3) and S100 calcium binding
protein A6 (S100a6), both of which have a role in the
acute-phase response. Up-regulation of the ferritin light
chain (Ftl) gene by HPCs is consistent with the presence
of hyperferritinemia, a characteristic of MAS/HLH.
Finally, the homologs thymosin !10 (Tmsb10) and !4
(Tmsb4) may play regenerative and antiinflammatory
roles in macrophages.
GSEA findings of alternative polarization of mu-
rine TLR-9–induced HPCs. To refine our analysis of
differential gene expression, we tested for up-regulation
of gene sets associated with a variety of relevant tran-
scriptional programs in HPCs. Only 3 gene sets fulfilled
our criteria for significance: genes involved in protea-
somal degradation, NOD-like receptor signaling genes,
and the set of genes up-regulated by M2-polarized
macrophages as compared to M1-polarized macro-
phages (10) (see Table 1 and results available from the
corresponding author upon request). Notably, the set of
genes up-regulated in M1 macrophages as compared to
M2 macrophages was not significantly enriched in HPCs.
Uniform expression of CD163, but only rare
expression of CD206 or CD64, in HPCs from a diverse
human cohort. We identified a longitudinal cohort of
patients whose bone marrow samples by biopsy or
aspiration showed excess hemophagocytosis, regardless
of the diagnosis. These samples represented hemato-
logic malignancies (lymphoma [n ! 1], Langerhans’ cell
histiocytosis [n ! 3], and posttransplant lymphoprolif-
erative disease [n ! 3]), infections (Epstein-Barr virus
[n ! 6], bacterial [n ! 2], parvovirus [n ! 1], and fungal
virus [n ! 1]), immunodeficiencies (paroxysmal noctur-
nal hemoglobinuria [n ! 1] and Munc13-4 deficiency
[n ! 1]), rheumatic diseases (systemic and other forms of
juvenile idiopathic arthritis [n ! 9] and dermatomyositis
[n ! 1]), and idiopathic causes of hemophagocytosis
(n ! 9).
Regardless of the origin of disease or treatment
stage, the bone marrow samples demonstrated positive
staining of HPCs for CD163 in all tested samples (Figure
1D). CD163 is a scavenger receptor that binds and
internalizes hemoglobin–haptoglobin complexes, which
then activate heme oxygenase 1 and induce the synthesis
of ferritin (11). Five samples, representing diverse dis-
eases, stained positively for CD206 (Figure 1D), a
mannose receptor and marker of alternative activation
or M2 macrophage activation (1). Two samples, both
from patients with systemic infections, showed positive
staining of HPCs for CD64, the Fc" receptor type I and
a marker of classic/M1 macrophage activation (Figure
1D) (1). No samples demonstrated positive staining of
HPCs for both CD64 and CD206.
DISCUSSION
Hemophagocytes are enigmatic cells that appear
in a variety of inflammatory contexts. Their presence as
part of the diagnostic criteria for MAS and HLH often
influences important medical decisions regarding evalu-
ation and treatment. However, our poor understanding
of the function of these cells complicates interpretation
of their presence or absence. Our analysis of the tran-
scriptional program of morphologically identified mu-
rine TLR-9–induced HPCs suggests that they are alter-
natively activated.
The fulminant TLR-9–induced MAS model,
which includes IL-10R blockade, was chosen on the basis
of the homogeneity of hemophagocytosis, the absence of
confounding by infection or genetic alteration, and the
fact that mice treated with TLR-9 stimulation alone or
IL-10R blockade alone failed to develop HPCs (6).
Examination of the genes most up-regulated by HPCs
showed induction of Ftl and Saa3, among other genes.
Astoundingly high ferritin levels are characteristic of
MAS/HLH, and ferritin has been associated with anti-
inflammatory transcripts in systemic juvenile idiopathic
arthritis (12). Production of both ferritin and serum
amyloid A3 has been associated with antiinflammatory
activity in macrophages (11,13).
We also found that cytochrome oxidase genes,
oxidative phosphorylation pathways, and the canonically
glycolytic enzyme GAPDH were up-regulated in HPCs.
Although this might suggest that both glycolysis and
oxidative phosphorylation are induced, GAPDH is in-
creasingly associated with a variety of nonglycolytic






functions, including inhibition of cytokine translation
(14).
The M2 versus M1 gene set was generated by
evaluating genes that were up-regulated by in vivo–
skewed M2 macrophages as compared to M1 macro-
phages (10). We found that this M2-associated gene set,
but not the M1 gene set, was strongly associated with
genes differentially up-regulated by HPCs (Table 1),
thus supporting the notion that HPCs have a transcrip-
tional profile of alternative activation. The other en-
riched gene sets, comprising those associated with NOD-
like receptor signaling and proteasome activity, may be
associated with scavenger receptor activity (15) or the
degrading requirements of hemophagocytosis, respec-
tively.
RNA from laser-captured splenic macrophages
served as the basis for our microarrays. Notably, macro-
phages derived from splenic touch preps may not be
entirely comparable to those found in the bone marrow.
Moreover, our gene expression analyses were limited by
the necessary pooling of RNA from individual cells from
any single mouse, and by small input amounts of RNA.
Thus, the potential for M1 versus M2 heterogeneity
exists within mice and even within individual cells.
Furthermore, these results have not been vali-
dated by quantitation of specific targets. The limited
starting material made protein quantitation impossible.
In addition, the process of amplifying small-input RNA
limited our ability to quantitate at the RNA level: the
RNA fragments that result from this process, while of
ideal size for microarray, were of insufficient length for
conventional quantitative polymerase chain reaction.
However, our analyses were able to detect changes
associated with macrophage activation. Specifically, our
transcriptomic data suggested that the dominant pro-
gram of murine HPCs induced by TLR-9 stimulation
and IL-10R blockade is skewed toward alternative acti-
vation. Accordingly, recent data support the notion that
TLR-9–driven HPCs arise independent of a number of
proinflammatory cytokines, including IFN! (6), and may
exert antiinflammatory effects (5). Given the prominent
role of IL-10 in alternative macrophage activation (1),
future investigations may help illuminate the specific
role of IL-10 in the development of HPCs.
Our immunohistochemical analyses for selected
markers in human bone marrow samples identified
CD163 expression by HPCs in a cohort that, to our
knowledge, is unique in terms of its breadth of diagno-
ses. The association of CD163 with alternative activation
is well established (11). Future studies should attempt to
further validate the findings from TLR-9–stimulated
murine HPCs through the evaluation of human samples.
In this study of morphologically identified HPCs,
we have shown transcriptional evidence for alternative
activation of murine HPCs from an infection-free
model, as well as immunohistochemical evidence that
human HPCs from diverse sources express CD163.
These data support the body of literature suggesting that
HPCs are alternatively activated macrophages that occur
as a common response to systemic inflammation. In
MAS/HLH, it is likely that there is heterogeneity in
macrophage function, and therapeutic depletion of all
macrophages could actually be detrimental. Further
study is warranted to better understand the induction of
hemophagocytosis, the precise functions of HPCs, and
the roles that these cells play in regulating the immuno-
pathologic processes in hemophagocytic syndromes.
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Errata
DOI 10.1002/art.38706
In Table 2 of the article by Freed et al in the December 2011 issue of Arthritis & Rheumatism (pages
3733–3739), the numbers of rheumatoid arthritis patients and control subjects positive for the resistance
epitope D70 were shown incorrectly. The correct numbers of rheumatoid arthritis patients and control
subjects, respectively, were 209 and 299.
DOI 10.1002/art.38693
In the article by Kanno et al in the February 2013 issue of Arthritis & Rheumatism (pages 492–502), the
concentration of !2-antiplasmin (!2AP) used in experiments was shown incorrectly in several figures and/or
figure legends. In Figures 1C and E, Figures 2A and B, Figures 4A and B, and Figures 5D and E, the !2AP
concentration should have been shown as 2 nM.
DOI 10.1002/art.38707
In the lower panel of Figure 1 of the article by Hanly et al in the November 2013 issue of Arthritis &
Rheumatism (pages 2887–2897), the data points for intractable headaches and cluster headaches at the
enrollment visit were inadvertently reversed. The correct values are 6.49% for intractable headaches at the
enrollment visit and 2.36% for cluster headaches at the enrollment visit. Additionally, in the text of the article
the prevalence of headache at 10 years was incorrectly stated. The first full sentence on page 2888 should
have read, “The prevalence of headache increased to 42% after 10 years” and the last sentence on page
2890 (continuing onto page 2891) should have read, “The established proportion of patients who ever
reported a headache (Kaplan-Meier estimate) increased to 42% after 10 years (Figure 2).”
DOI 10.1002/art.38708
In the article by Golding et al published in the November 2013 issue of Arthritis & Rheumatism (pages
2898–2906), acknowledgment of an author’s funding was inadvertently omitted. The paragraph on funding
support in the footnotes on the first page of the article should have included the statement, “Dr. Golding’s
work was supported by a VA Career Development Award (IK2 CX-000649).”
DOI 10.1002/art.38709
The byline of the Reply letter by Golding et al published in the May 2014 issue of Arthritis & Rheumatology
(pages 1403–1404) contained several errors. First, the correct spelling of the second author’s name is Ethan
M. Shevach, MD. Second, the correct name of the institute where Dr. Hasni is employed is the National
Institute of Arthritis and Musculoskeletal and Skin Diseases. Third, Dr. Illei is currently employed by
MedImmune, Gaithersburg, MD.
We regret the errors.
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Progress in understanding systemic lupus erythema-
tosus (SLE) has been hampered by disease hetero-
geneity. Patients with SLE can present with diverse organ 
involvement as well as diverse autoantibodies. In fact, 
SLE probably represents several heterogeneous diseases 
that fall into a broad clinical phenotype of systemic auto-
immunity. Many patients with SLE have mild disease, 
whereas others have a catastrophic presentation and 
life-threatening progression. Our current understand-
ing of the factors that drive the different phenotypes in 
SLE is limited; however, in spite of an imperfect under-
standing of the pathogenesis of SLE, great progress has 
been made over the past 50 years and mortality is now 
only 10% within 10 years (compared with 50% within 
3 years in the 1960s)1. Nevertheless, infections related to 
immune suppression, cardiovascular disease, and renal 
failure constitute a substantial burden, and medical costs 
and costs related to lost productivity are high2.
The pathogenesis of SLE hinges on loss of tolerance 
and sustained autoantibody production (FIG. 1). Unlike 
self-limited autoantibody processes, such as auto-
immune haemolytic anaemia, SLE is generally a life-
long condition. One of the key concepts in pathogenesis 
is an imbalance between apoptotic cell production and 
disposal of apoptotic material (FIG. 2). Nuclear antigens 
are typically not accessible to the immune system, but 
during the course of apoptosis the cell membrane forms 
blebs that pinch off from the cell and contain fragmented 
cellular material, including nuclear antigens3. Such apop-
totic debris is normally cleared rapidly and would not be 
accessible to the immune system. In humans, approxi-
mately 1 billion neutrophils undergo apoptosis every day 
and increases in the apoptotic cell load can be generated 
by exposure to ultraviolet light, infections, and toxins, 
which are all known to be associated with SLE. Persistent 
apoptotic debris containing nucleic acids can stimulate 
an inflammatory response through the activation of 
nucleic acid recognition receptors, such as members 
of the Toll-like receptor (TLR) family4. Circulating apop-
totic microparticles also prime neutrophils for extrusion 
of nuclear material, providing yet more antigen5. Nucleic 
acid recognition receptors control endogenous retro-
viruses, recognize viral pathogens, and defend against 
intracellular bacteria, and are strongly associated with 
type I interferon (IFN) production. Defects in these 
pathways are now strongly implicated in the pathogen-
esis of SLE, as both increasing disease susceptibility and 
directly causing monogenic forms of SLE (TABLES 1,2).
Type I IFNs and other cytokines promote B-cell dif-
ferentiation and loss of tolerance. B cells can respond 
to nucleic acids through direct antigen recognition and 
via surface IgM receptors for proteins complexed with 
nucleic acids. Once autoantibodies have formed, B cells 
can also take up nucleic acids through Fc receptors and 
B-cell receptors recognizing Fc (rheumatoid factor)6. 
Once activated, these B cells mature, expand, and begin 
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New insights into the 
immunopathogenesis of systemic 
lupus erythematosus
George C. Tsokos1, Mindy S. Lo2, Patricia Costa Reis3 and Kathleen E. Sullivan4
Abstract | The aetiology of systemic lupus erythematosus (SLE) is multifactorial, and includes 
contributions from the environment, stochastic factors, and genetic susceptibility. Great gains 
have been made in understanding SLE through the use of genetic variant identification, mouse 
models, gene expression studies, and epigenetic analyses. Collectively, these studies support the 
concept that defective clearance of immune complexes and biological waste (such as apoptotic 
cells), neutrophil extracellular traps, nucleic acid sensing, lymphocyte signalling, and interferon 
production pathways are all central to loss of tolerance and tissue damage. Increased 
understanding of the pathogenesis of SLE is driving a renewed interest in targeted therapy, and 
researchers are now on the verge of developing targeted immunotherapy directed at treating 
either specific organ system involvement or specific subsets of patients with SLE. Accordingly, 
this Review places these insights within the context of our current understanding of the 
pathogenesis of SLE and highlights pathways that are ripe for therapeutic targeting.
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to secrete more antibody, which enhances the adaptive 
immune response. T-cell and B-cell abnormalities have 
long been described in SLE and are thought to be central 
to the disease process. The autoantibodies identified in 
SLE are generally high-affinity, somatically mutated IgG, 
which suggests that they have arisen in germinal centres, 
where T cells provide help for class switching.
This framework for understanding SLE has been our 
model for the past ten years. It is founded on genetic 
data, in vitro analyses, and observations in mouse mod-
els. In this Review, we cover new insights that extend this 
model and offer the potential for novel therapeutic inter-
ventions in SLE. We discuss environmental and genetic 
factors that contribute to the risk of developing SLE, and 
examine how gene expression and regulation contributes 
to the phenotype of the disease and how these effects 
provide a window into the clinical features. Subsequent 
sections investigate mechanisms as we understand them 
from a cell biology perspective, and three examples of 
local tissue effects that can contribute to organ damage 
and modulate disease are also presented (FIG. 1).
Environmental risk factors
Imperfect disease concordance between monozygotic 
twins suggests that environmental factors influence the 
pathogenesis of SLE. Hormones and ultraviolet light 
have long been recognized as contributors to SLE7,8. 
Women comprise 90% of most SLE cohorts, and oestro-
gen and prolactin enhance immune responses through 
diverse mechanisms9,10. Ultraviolet light is thought to 
drive apoptosis, providing an immunologic stimulus. 
A possible connection between sunlight exposure and 
drug-induced lupus has also been identified. Ultraviolet 
light converts propranolol into a proinflammatory aryl 
hydrocarbon receptor ligand, possibly explaining its 
association with lupus-like disease11.
Infections have been implicated in SLE for many 
years. Epstein–Barr virus and cytomegalovirus are con-
sidered to be SLE triggers12, whereas Helicobacter pylori13, 
hepatitis B virus14, and parasite infections are thought 
to be protective15. One study found that herpes simplex 
virus type 2 transcripts were overexpressed in patients 
with systemic autoimmune diseases, although the role of 
immunosuppression in increased viral gene expression 
could not be eliminated16. Further data support a role 
for microorganisms in general. Lipopolysaccharide is a 
component of the cell wall of Gram-negative bacteria 
that can activate TLR4. Serum levels of lipopolysaccha-
ride are increased in patients with SLE17 and bio markers 
of lipopolysaccharide engagement by TLR4, such as 
shedding of CD14, correlate with disease activity18. 
TLR4 activation promotes disease in mouse models of 
lupus19. Microbial stimulation of myeloid cells by TLRs 
is critical for antigen presentation to T cells20. These data 
suggest that chronic microbial translocation contributes 
to the pathogenesis of SLE. Bacterial biofilms represent 
another mechanism by which microorganisms interact 
with the immune system. Amyloid–DNA complexes, 
found in many biofilms, greatly increased the produc-
tion of autoantibodies in lupus-prone mice21. At this 
point, the evidence seems clear that SLE is not uniformly 
caused by a single infection, but the role of bacteria and 
viruses generally in SLE represents an emerging area 
of study, and TLR antagonists are being evaluated as 
therapeutic agents.
The microbiome represents the collection of bacteria, 
viruses, and fungi that coexist on and in the human body. 
Collectively, microbial cells far outnumber human cells 
within the body and, while many were previously 
thought to be silent passengers, we now know that some 
can modulate the immune system22. Interest in the 
microbiome has grown exponentially, as it represents 
an attractive therapeutic target. In women with SLE, a 
lower Firmicutes to Bacteroidetes ratio was seen than in 
healthy individuals, even during times of remission23. 
In humans, microbiome studies are largely correla-
tive, but mouse studies support a mechanistic role for 
the microbiome. Increased levels of Bacteroidetes were 
also seen in lupus-prone mice24. In a separate study, a 
manipulation that aimed to normalize the microbiome 
was beneficial in MRL/lpr mice25. The mechanism of 
the effect is not fully understood, but certain gut bac-
teria foster the development of regulatory T cells (Treg 
cells)26,27. Developing the ‘correct’ (that is, healthy) 
microbiome might require neonatal exposure; one study 
found that development of antinuclear antibodies was 
dependent on bacterial colonization during the neonatal 
period in mice28. Although therapeutic alteration of the 
microbiome in humans has been limited to the setting of 
infections and inflammatory bowel disease, these studies 
represent an important proof of concept for the pursuit 
of additional studies in patients with SLE.
Genes and gene expression
One of the great advantages of pursuing genetic analyses 
in a highly heterogeneous disorder such as SLE is that it 
is otherwise difficult to understand which facets of dis-
ease represent susceptibility features, and which represent 
consequences of the disease.
Heritability of SLE and genetic studies
The heritability of SLE has long been recognized; 
a higher concordance rate in monozygotic twins than in 
dizygotic twins and the high sibling recurrence risk ratio 
support a strong heritability29. The major histocompat-
ibility complex (MHC) was the first risk locus to be 
associated with SLE, and alleles within the MHC locus 
still confer the strongest genetic susceptibility for SLE 
in the general population today30. This seminal finding 
supports a disease process in which T cells play a cen-
tral part, as their activation is dependent on MHC pro-
teins (FIG. 2). In the past decade, numerous genome-wide 
Key points
• Our understanding of the pathogenesis of systemic lupus erythematosus (SLE) has 
changed rapidly over the past decade
• 4GHKPGOGPVUKPQWTWPFGTUVCPFKPIQXGTVJGRCUV|[GCTUJCXGNGFVQVJGRQVGPVKCNHQT
precision targeting of therapeutic strategies
• Advances in epigenetic therapeutic agents and the manipulation of cells GZ|XKXQ have 
the potential to further improve patient care
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association studies (GWAS) have been performed and 
we now recognize over 40 loci that are confirmed to 
be associated with SLE31. Variants rarely lie in the 
coding exons, however, and most are instead thought 
to affect regulatory regions32. Regulatory risk variants 
may affect proximal genes or may act at a distance 
through chromosomal looping33; such variants might 
also have effects on multiple genes.
Genes associated with SLE are listed in TABLE 1. The 
overall genetic risks identified to date are limited, with 
each gene generally conferring a relative risk <2. The 
yet to be identified heritability could lie in rare vari-
ants that are individual to each kindred, or epigenetic 
effects. Most of the identified loci are associated with 
multiple autoimmune diseases32,34. The GWAS data have 
focused interest on three major cellular pathways, each 
influenced by many variants35: lymphocyte signalling, 
either within T cells or B cells; IFN signalling pathways 
involving either nucleic acid sensing or the production 
and response to IFNs; and clearance of immune com-
plexes and other waste. Interestingly, a number of mono-
genic disorders are associated with an increased risk of 
developing SLE or a related phenotype (TABLE 2), and can 
be similarly categorized according to these same three 
pathophysiological pathways36. The key findings from 
these GWAS are identification of these three disease- 
 associated pathways, variant sharing with other auto-
immune diseases, and heterogeneity across populations 
and ethnic groups. Although GWAS have been criticized 
for failure to identify ‘druggable’ targets or major ‘caus-
ative’ variants, they have unquestionably moulded key 
concepts around the pathogenesis of SLE.
Epigenetic mechanisms in SLE
Genetics and genomics can be applied to evaluate her-
itable risks of disease. By contrast, epigenetics refers to 
the study of durable changes in gene expression that 
are not accompanied by alterations to the nucleotide 
sequence. Epigenetics is beginning to receive atten-
tion in the field of rheumatology. Epigenetic processes 
include DNA methylation, post-translational histone 
modifications, and noncoding RNAs that regulate gene 
expression.
DNA methylation was the first epigenetic change 
identified in patients with SLE. DNA methylation regu-
lates gene expression by serving as a platform for repres-
sive protein binding. Procainamide and other drugs 
known to induce lupus-like features are inhibitors of 
DNA methylation37. T cells from mice treated with these 
drugs are capable of inducing lupus in recipient mice38. 
These data not only clearly implicate the epigenome 
in SLE, but also highlight the central role of T cells. In 
humans, T cells from patients with active SLE have global 
DNA hypomethylation39, especially those from patients 
with lupus nephritis40. The consequence of this hypo-
methylation is typically overexpression of genes, because 
DNA methylation is usually repressive. When examined 
on a genome-wide basis, IFN-stimulated genes (ISGs) 
were specifically hypomethylated in patients with SLE40. 
Further study revealed that, during a flare, naive CD4+ 
T cells become primed for TH2, TH17, and T follicular 
helper (TFH) cell immune responses through the activ-
ity of the chromatin-modifying enzyme histone–lysine 
N-methyltransferase EZH2 (REF. 41). Diet is known to 
influence DNA methylation, which may be one mech-
anism by which diet contributes to SLE susceptibil-
ity42,43. A further DNA modification is the formation of 
5-hydroxymethylcytosine; levels of this modified form 
of cytosine are increased in T cells of patients with SLE 
and are also associated with increased gene expression44.
Histones undergo a number of post-translational 
modifications that can serve as binding sites for proteins 
involved in regulation of gene expression. Histone modi-
fications were initially studied in mouse models of lupus, 
in which treatment with histone deacetylase inhibitors 
improved disease features45. Furthermore, histone 
deacetylase 6 is overexpressed in MRL/lpr mice, and 
treatment directed at normalizing this enzyme improved 
the features of lupus46,47. The mechanisms by which these 
agents work is controversial, because these treatments 
seem to be highly immunosuppressive48. Nevertheless, 
these studies provide an important proof of principle 
that agents acting on epigenetic mechanisms could be 
useful in the treatment of human SLE. Our understand-
ing of histone modifications in humans has been driven 
by two distinct approaches. In the first approach, total 
Figure 1 | The current model of the pathogenesis of SLE. The progression of systemic lupus erythematosus (SLE) can be 
divided into discrete stages. Environmental and genetic factors contribute to the development of disease. Triggers such as 
infection can elicit autoimmunity, but the elements that drive a sustained loss of tolerance and spreading of autoimmunity 
are poorly understood. Epigenetic changes, immune-complex deposition and autoantibody-mediated tissue damage can 
drive chronic inflammation and irreversible damage in end organs. IFN, interferon.
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histone modifications were measured and shown to be 
aberrant in T cells from patients with SLE. These aber-
rations were corrected by treatment with mycophenolate 
mofetil49. The second approach utilized genome-wide 
analyses. In the initial analysis, histone H4 acetylation 
was shown to be globally increased in monocytes from 
patients with SLE50. This finding is consistent with those 
from DNA methylation studies51 because both DNA 
hypomethylation and histone H4 hyperacetylation drive 
increased expression of target genes. Within the sites 
with increased H4 acetylation, potential binding sites for 
IFN regulatory factor 1 (IRF1) were identified, and IRF1 
binding was directly shown to be increased in SLE52. 
IRF1 is a transcription factor downstream of type I IFN, 
which ties this finding of an altered epigenome back to 
the known influence of type I IFNs. Multiple histone 
modifications in enhancer regions were globally altered 
in SLE monocytes, which no doubt dictates altered cell 
behaviour53. Some histone modifications persist after 
stimulation, thereby ‘bookmarking’ genes for facilitated 
re-expression. This feature might contribute to disease 
chronicity54,55. One of the therapeutic efforts directed 
at the epigenome utilizes inhibitors of bromodomain- 
containing protein 4 (BRD4), a protein critical for 
enhancer function56. One such BRD4 inhibitor was 
demonstrated to be effective in a mouse model of lupus57, 
again demonstrating the power of these genome-wide 
approaches to identify novel therapeutic targets.
MicroRNA regulation in SLE
MicroRNAs (mi RNAs) target specific mRNAs for deg-
radation and can regulate the abundance of multiple 
mRNAs58. Changes in miRNA expression have been 
identified in peripheral blood mononuclear cells and 
renal tissue from patients with SLE59–61. Plasma mi RNAs 
can also be isolated and are presumed to be released from 
cells as a result of death, stress, or exocytosis62. Several 
of the mi RNAs identified in patients with SLE seem to 
affect pathways that are central to the disease processes 
of SLE61, such as TLR signalling and expression of ISGs63. 
Expression of mi RNAs is very tissue-specific, and stud-
ies of mi RNAs in kidney and peripheral blood samples 
from patients with SLE, have found none in either tis-
sue59,60. Other data from human studies have implicated 
miR-30a in B cells, where this miRNA was thought to 
regulate expression of LYN, a critical signalling mole-
cule64. In MRL/lpr mice, overexpression of miR-21 and 
miR-148a is responsible for the reduction in levels of 
Figure 2 | Cellular contributions to the development of SLE. Neutrophils and apoptotic cells are at the apex of the 
cascade of pathogenetic mechanisms in systemic lupus erythematosus (SLE). They provide the critical ligands to drive 
GZRTGUUKQPQHV[RG|+KPVGTHGTQPU
+(0U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DNA methyltransferase 1 (DNMT1), an enzyme that 
creates epigenetic changes by DNA hypomethylation65. 
The influence of mi RNAs was demonstrated when a 
transgenic mouse overexpressing miR-17-92 sponta-
neously developed lupus-like disease. The mechanism 
seemed to be diminished expression of TFH cell regulators 
phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase 
and dual-specificity protein phosphatase PTEN and PH 
domain leucine-rich repeat-containing protein phos-
phatase 2 (REFS 66,67). Deficiency of miR-155 in MRL/lpr 
mice suppresses lupus, indicating that the effects of mi R-
NAs are context-specific and site-specific, as would be 
expected68. In addition to studying the role of mi RNAs in 
the pathogenesis of SLE, researchers are showing increas-
ing enthusiasm for using these stable nucleic acids as 
biomarkers. For example, miR-21 regulates lymphocyte 
signalling, and levels of miR-21 in T cells correlate with 
SLE disease activity index (SLEDAI) scores69. The first 
miRNA-based therapeutic agent was approved in 2013 for 
the treatment of familial hypercholesterolaemia70, and this 
field is likely to expand rapidly.
Differences in gene expression
Transcript abundance represents the final balance 
between active transcription and mRNA turnover, and 
integrates both transcript production and destruction 
effects. Levels of transcripts ultimately control cell activ-
ities. Early studies of gene expression were performed 
on peripheral blood mononuclear cells or whole blood 
and uniformly identified a set of ISGs71–73. Inflammatory 
and granulocyte signatures were also seen. These pivotal 
studies, now over ten years old, led to focused efforts on 
understanding the role of type I IFN and neutrophils. 
Gene expression has been examined in sorted cells from 
patients of varied ancestry74; ISGs could be identified 
in each cell population but the expression of specific 
genes varied dramatically between cell types, as well 
as between people of different ancestry74. This study is 
an important reminder that our current understanding 
of ethnic and population differences is disappointingly 
rudimentary. Array studies on human T cells have shown 
changes in gene expression related to disease activity and 
clinical presentation75–77. In oncology, arrays and other 
measures of gene expression are now routinely used to 
stratify patients’ level of risk and direct therapy. Their 
use in rheumatology has been limited to research efforts, 
but a study utilizing advanced informatics found clear 
disease activity profiles78. Clinical use of gene expression 
for disease profiling could, therefore, become a reality in 
rheumatology clinics.
Apoptosis and nucleic acid sensors
Aberrant apoptotic cell clearance
The dysregulation of apoptosis and nuclear debris clear-
ance that is characteristic of SLE contributes to an increase 
in autoantigen exposure3. The imbalance in apoptotic 
cell production and clearance is highly influenced by 
infection, ultraviolet light exposure, and cytokines. 
Accumulated apoptotic debris can trigger TLRs and 
nucleic acid sensors. Immune cells, including B cells, some 
T cells, dendritic cells (DCs), and macrophages, as well as 
nonimmune cells, such as epithelial cells and fibroblasts, 
express TLRs. Several pathways have evolved to prevent 
immune activation in response to endogenous cellular 
debris. Apoptotic cells become coated with complement 
component C1q, C-reactive protein, pentraxin 3, and 
serum amyloid P, which enhances phagocytosis without 
immune stimulation79,80. Additionally, DNase I contrib-
utes to degradation of chromatin79. Decreased DNase I 
activity has been described both in patients with SLE and 
in lupus-prone mice81. Characterization of the patho-
genesis of monogenic forms of SLE has emphasized the 
role of aberrant apoptotic clearance. Sequencing analysis 
of seven consanguineous families with highly penetrant, 
auto somal recessive lupus-like disease identified inactivat-
ing mutations in DNASE1L3 (REF. 82). Another family with 
a Mendelian pattern of SLE inheritance was found to carry 
loss-of-function mutations in PRKCD, which encodes the 
enzyme protein kinase Cδ83. This enzyme is activated in 
multiple apoptotic pathways. These rare monogenic dis-
eases represent useful models of SLE because the disease 
process can be clearly defined. Although affected patients 
often have a phenotype that is not typical of classic SLE, 
they provide important insights.
Table 1 | GWAS-identified SLE susceptibility genes
Pathway(s) Loci implicated in SLE and other autoimmune diseases Loci implicated only in SLE
Lymphocyte 
activation
PTPN22, TNFSF4, IL10, SPRED2, STAT4, PXK, AFF1, IL12A, BANK1, 
TCF7, SKP1, /*%IGPGU IKZF1 and IKZF3, BLK, ARID5B, CD44, 




IFIH1, PRDM1, UHRF1BP1, TNFAIP3, IRF5-TNPO3, IRF7 and IRF8, 
SOCS1, PRKCB, UBE2L3, IRAK1
None 
Inflammation TNIP1 None 
Immune complex 
or waste clearance
FCGR2A, FCGR2B, FCGR3B, ATG5, CLEC16A NCF2, LYST
7PMPQYP ABHD6 (may be related to lymphocyte activation), RAD51B 
(may be related to IFN pathways), MECP2 (may be related to IFN 
pathways), RASGRP3, TMEM39A, PITG1, TNXB, JAZF1, XKR6, 
FAM167A–AS1, WDFY4, WPMPQYPIGPGUTUTU
TUTU
SMG7 (may be related 
to interferon pathways), 










Apoptotic cells are cleared largely by cells in the reticulo-
endothelial compartment. Clearance is generally silent 
but when the burden of apoptotic cells exceeds that 
which can be cleared, the apoptotic debris can elicit 
immune responses84. Mouse models have been instru-
mental in defining the role of TLRs in lupus; however, 
extrapolation of findings from these models to humans 
is controversial because not all features are consistent 
with our current understanding of SLE in humans. 
Nevertheless, in the analysis of specific pathways, mouse 
models of lupus offer great advantages. Collectively, they 
have provided confirmation of the importance of TLR 
trafficking.
Table 2 | Monogenic causes of SLE and lupus-like disease
Gene Effect Features Pathway Refs
C1QA, C1QB, 
C1QC
Complement C1 deficiency 'CTN[QPUGVUGXGTG5.'KPHGEVKQPUJKIJRGPGVTCPEG#4 Immune complex and 
waste clearance
210,211
C1R, C1S Complement C1 deficiency 'CTN[QPUGVUGXGTG5.'KPHGEVKQPUJKIJRGPGVTCPEG#4 Immune complex and 
waste clearance
212,
C4A, C4B %QORNGOGPV%FGHKEKGPE[ 'CTN[QPUGVUGXGTG5.'KPHGEVKQPUJKIJRGPGVTCPEG#4 Immune complex and 
waste clearance

C2 Complement C2 deficiency +PHGEVKQPUEWVCPGQWUFKUGCUGOQFGTCVGRGPGVTCPEG#4 Immune complex and 
waste clearance

C3 %QORNGOGPV%FGHKEKGPE[ /GODTCPQRTQNKHGTCVKXGINQOGTWNQPGRJTKVKU 
NQYRGPGVTCPEG#4







Immune complex and 
waste clearance

PEPD :CC2TQFKRGRVKFCUGFGHKEKGPE[ %WVCPGQWUWNEGTUNQYRGPGVTCPEG#4 Immune complex and 
waste clearance

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#& Nucleic acid sensing 222


















































PSMB8 0CMCLQU[PFTQOG (GXGTEQPVTCEVWTGUPGWVTQRJKNKEFGTOCVKVKU 
NQYRGPGVTCPEG#4
Immune complex and 
YCUVGENGCTCPEGV[RG|++(0

FAS, FASLG Autoimmune lymphoproliferative 









PTPN11 Noonan syndrome 1 5JQTVUVCVWTGECTFKCECPQOCNKGUNQYRGPGVTCPEG#& Lymphocyte signalling 
RAG1, RAG2 Several types of severe combined 
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TLR3, TLR7, TLR8 and TLR9 reside in the endo-
plasmic reticulum. Transfer of TLRs to endosomes is 
regulated by the trafficking protein unc-93 homologue 
B1 (UNC93B1). The importance of intracellular traf-
ficking cannot be overstated, as it represents a key regu-
latory strategy. In plasmacytoid DCs (pDCs), UNC93B1 
sorts large complexes of DNA into early endosomes, 
where TLR9 and IRF7 drive a strong IFN response. 
Small monomeric DNA is sorted into late endosomes, 
where TLR9 and NF-κB drive a proinflammatory 
cytokine response85. Correct localization of TLRs lim-
its their access to self-antigens86. In pristane-treated 
mice, TLR7 (which senses single-stranded RNA) was 
specifically required for the production of RNA-reactive 
autoantibodies and for the development of glomeru-
lonephritis87. Data from studies of pharmacologic or 
genetic manipulation of TLR7 expression or function 
support a central role for TLR7 in inflammation, loss 
of tolerance, and type I IFN production88–91.
The relationship of TLR9 to SLE is more com-
plex than that of TLR7. TLR9 is a receptor for DNA 
containing unmethylated CpG sequence motifs. SLE 
patients with active disease had a higher number of 
TLR9-expressing B  cells and monocytes than did 
patients with low disease activity, and levels of these cells 
correlated with levels of antibodies to double-stranded 
DNA (anti-dsDNA)92. In TLR9-deficient lupus-
prone mice, the generation of anti-dsDNA and anti- 
chromatin autoantibodies was specifically inhibited, 
while levels of other autoantibodies (such as anti-Sm) 
were maintained or even increased93. However, in one 
lupus model, TLR9 deficiency exacerbated disease 
through a mechanism that might relate to competition 
with TLR7 for UNC93B1 (REF. 94). TLR3 and TLR8 also 
recognize RNA and limited data support a role for these 
additional receptors in susceptibility to SLE. These data 
have led to a model of SLE in which TLRs engage nucleic 
acids and drive a type I IFN response (FIG. 3).
Cytosolic nucleic acid sensors
Cytosolic nucleic acid sensors recognize viral infections 
and initiate defences focused on type I IFN production. 
These sensors can also detect endogenous ligands and 
elicit inflammation independent of infection. Signalling 
pathways for these sensors converge on stimulator of 
IFN genes protein (STING, encoded by TMEM173)95. 
Additional protection from the deleterious effects 
of endogenous nucleic acids comes from nucleases, 
which degrade nucleic acids. Three cytosolic RNA hel-
icases have been identified: probable ATP-dependent 
RNA helicase DDX58, interferon-induced helicase C 
domain-containing protein 1 (IFIH1, also known as 
MDA5), and probable ATP-dependent RNA helicase 
DHX58 (also known as LGP2). These sensors act in 
the cytoplasm to complement the function of endo-
somal TLRs96. The cytosolic sensors activate both IFN 
and inflammatory cytokine production96. Variants in 
IFIH1 have been linked to SLE97. Cytosolic DNA sen-
sors also exist. All three main types of inflammasomes 
can respond to DNA; however, the process that drives 
these responses is not well understood (with the excep-
tion of the AIM2 inflammasome, which is activated by 
STING)98. Mouse models of lupus support a key role for 
this pathway in the aetiopathogenesis of SLE99.
(KIWTG| Nucleic acid sensors in SLE. The importance of the immune response to nucleic acids in systemic lupus 
erythematosus (SLE) has been emphasized by data from mouse models and patients with monogenic diseases associated 
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Here again, extraordinary insights have come from 
the study of rare monogenic disorders with a lupus-like 
phenotype in humans. Aicardi–Goutières syndrome 
has features that are reminiscent of a congenital infec-
tion; however, this syndrome is caused by gene defects 
that drive overproduction of type I IFN. Specifically, 
mutations in genes encoding cytosolic nucleic acid sen-
sors or their regulators, such as TREX1, RNASEH2A, 
RNASEH2B, RNASEH2C, SAMHD1, ADAR, or IFIH1, 
are all associated with this phenotype100 (TABLE 2). The 
Aicardi–Goutières phenotype has a more prominent 
neurologic component than is typical of adult-onset SLE; 
however, autoantibodies are prolifically produced and 
some pathologic features overlap with those of SLE100,101. 
In addition, common variants in these same genes have 
been associated with SLE (TABLE 1).
Soluble mediators
Cytokines can contribute to susceptibility to SLE, but 
are more strongly implicated in loss of tolerance and 
end-organ effects (FIG. 1). Levels of many cytokines are 
elevated in SLE (such as TNF, IL-4, IL-6, and IL-10) and 
their main effects are the promotion of autoantibody 
production and inflammation (FIG. 4). Type I and type II 
IFNs have emerged as key cytokines in the pathogenesis 
of SLE (as well as other autoimmune diseases) and 
increases in their levels precede autoantibody develop-
ment102,103. Upregulation of TNF can increase type I IFN 
expression104,105. IFNα, a type I IFN typically produced 
as part of the innate immune response to viral infection, 
has multiple effects consistent with known immunologic 
features of SLE, such as upregulation of B-cell activating 
factor (BAFF, also known as TNF ligand super family 
member 13B or BLyS), decreased Treg cell function, 
and induction of plasma cells106. Transcripts of IFNα and 
ISGs have been detected in inflamed kidney and skin 
tissues from patients with SLE107,108. A direct pathogenic 
role for IFN in mouse models of lupus is also supported 
by studies in which exogenous administration of IFNα 
exacerbates disease109,110. Unfortunately, despite these 
compelling data, clinical trials of IFN inhibitors have 
been disappointing. Levels of two other cytokines, IL-18 
and IL-38, are also increased in SLE. IL-18 is a potent 
proinflammatory cytokine produced via the inflamma-
some, and IL-38 is thought to be an anti-inflammatory 
cytokine with key regulatory functions111,112.
Patients with SLE may also have an imbalanced T cell 
cytokine profile characterized by decreased IL-2 and 
increased IL-17 levels113. Production of IL-2 is impaired 
on multiple levels114,115. IL-2, in addition to being critical 
for Treg cell development and function, is also necessary 
for restricting expression of IL-17. In SLE, IL-17 may 
mediate local tissue damage through the induction of 
inflammatory cytokines and chemokines, and by recruit-
ing other immune cells. The differentiation of the T helper 
cell subset producing IL-17 (TH17 cells) is dependent on 
IL-23, and an anti-IL-23 antibody ameliorated disease in 
one mouse model of lupus116.
B-cell activation and autoantibody production are 
promoted in SLE by BAFF. Serum levels of BAFF 
are increased in patients with SLE and positively correlate 
with autoantibody titres117. Transgenic overexpression of 
BAFF in a mouse model of lupus exacerbated disease118, 
emphasizing the role of this cytokine in supporting auto-
immunity. BAFF is a critical factor for B-cell homeosta-
sis and high BAFF levels might reduce the stringency of 
B-cell selection, allowing autoreactive clones to persist 
in the periphery119. Notably, B-cell-depletion therapy in 
patients with SLE is followed by an increase in BAFF lev-
els, raising concern that the repopulating B cells could 
have a phenotype of increased autoreactivity120. BAFF 
thus represents an important therapeutic target; indeed, 
belimumab, an anti-BAFF monoclonal antibody, is the 
first drug to be approved for the treatment of SLE in 
more than 50 years121. BAFF-directed therapy has demon-
strated clinical efficacy but the magnitude of the benefi-
cial effect is modest, as has been true for B-cell-depleting 
approaches122,123. The message might be that narrowly tar-
geted approaches in humans with established disease can-
not reverse pathologic downstream processes that have 










previously been initiated. Targeting of other cytokines 
is nonetheless a priority for the pharmaceutical indus-
try because therapeutic monoclonal antibodies are an 
established pipeline.
Major cell types involved in SLE
Dendritic cells
Inappropriate or dysfunctional antigen presentation by 
DCs might promote the breakdown of T-cell and B-cell 
tolerance in SLE and other autoimmune diseases (FIG. 2). 
Patients with SLE show multiple DC abnormalities, 
including a reduced number of circulating conventional 
DCs, but increased numbers of pDCs124. The pDC subset 
is the primary cell type responsible for type I IFN secre-
tion in response to nucleic acid, via TLR7 and TLR9. The 
pDCs take up immune complexes via FcγRIIa and access 
TLR7 and TLR9 in the endosomal compartment125. In 
SLE, conventional DCs promote autoreactivity rather 
than tolerance126. In turn, activated T cells also promote 
increased IFN production by pDCs127. Conventional 
DCs have been demonstrated to be critical for the devel-
opment of lupus nephritis in a mouse model128. Thus, 
both types of DCs are thought to be pivotal to the disease 
process in SLE.
Myeloid cells
Neutrophils show several facets of dysregulation in SLE. 
Impaired phagocytosis by neutrophils in SLE has been 
described in multiple reports, and might contribute to 
the increased susceptibility to infection associated with 
this disease129. In one study, neutrophils from patients 
with SLE showed reduced production of reactive oxygen 
species (ROS), which correlated with disease severity and 
end-organ damage130. Patients with chronic granuloma-
tous disease, in which ROS production is defective, have 
a high incidence of SLE131,132 (TABLE 2). Increased levels 
of ISG products, autoantibodies, and glomerulonephritis 
have been described in a mouse model of chronic gran-
ulomatous disease, and lupus-prone mice deficient in 
ROS production also show an exacerbation of lupus-like 
disease133,134. Deficient ROS generation might alter the 
apoptotic pathway, which connects this finding to the rec-
ognized contribution of defective clearance of apoptotic 
cells to the pathogenesis of SLE. Immune complexes can 
drive the generation of mitochondrial ROS, and oxidized 
mitochondrial DNA can be highly immune-stimulatory, 
providing a feed-forward loop135. Neutrophils are short-
lived and so represent the dominant cell type in the daily 
burden of apoptotic cells. Small changes in neutrophil 
apoptosis could markedly impact waste clearance. In an 
adoptive cell transfer model, neutrophils from mice with 
chronic granulomatous disease could drive autoantibody 
production in control (disease-free) recipient mice136. 
The converse was also true; apoptotic neutrophils from 
control animals were capable of driving autoantibody 
production when transferred to recipients with chronic 
granulomatous disease. This study provides direct mech-
anistic evidence for a central role of myeloid cells in SLE.
Patients with SLE have an abnormal subset of 
neutrophils (termed low-density granulocytes) with 
an increased propensity for NETosis137. NETosis is a 
mechanism of cell death that occurs in response to vari-
ous stimuli, including infectious organisms and oxidative 
stress. NETosis involves the extrusion of chromatin and 
other nuclear, cytoplasmic, and granular material from 
the cell (FIG. 2). This extruded material, called neutro-
phil extracellular traps (NETs), contains proinflamma-
tory cytokines, antimicrobial peptides, enzymes such as 
myeloperoxidase, and potentially antigenic citrullinated 
histones and dsDNA138. NETosis contributes to the type I 
IFN signature of SLE by stimulating IFN production by 
pDCs137. This effect occurs via TLR9 activation by DNA 
and anti-DNA antibodies in complex with NET-derived 
antimicrobial peptides such as cathelicidin anti microbial 
peptide (also known as LL-37)139,140. In turn, type I IFN 
primes neutrophils for NET release in patients with 
SLE, suggesting a possible positive feedback loop. The 
extruded nuclear material from NETs represents a major 
source of the nuclear antigens that drive autoantibody 
development in SLE.
Monocytes from patients with SLE consistently have 
increased baseline expression of CC chemokine ligand 2 
(CCL2, also known as monocyte chemoattractant pro-
tein 1 (MCP-1))141. MCP-1 is regulated by lipopolysac-
charide and IFNs, and is important in regulation of cell 
migration. Monocyte infiltration into kidneys influences 
renal damage, and monocyte infiltration into blood ves-
sels contributes to atherosclerosis, two key morbidities 
in SLE142,143. Renal macrophage infiltration is a particu-
larly strong prognostic biomarker for progression of 
lupus nephritis144. Monocytes are, therefore, a pivotal 
cell type in organ damage. Monocyte-depletion ther-
apy was attempted in one clinical trial, which did not 
demonstrate clinical effectiveness, but this approach did 
not deplete tissue macrophages, which are thought to be 
important drivers of end-organ damage in SLE145.
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T cells are thought to be central to the pathogenesis of 
SLE because of their association with MHC proteins, and 
because adoptive transfer of these cells confers lupus-like 
disease in some mouse models. Loss of T-cell tolerance is 
implied in autoimmune diseases. Conceptually, this loss 
of tolerance could happen centrally at the time of thymic 
education or peripherally; however, mouse models sup-
port the importance of defects in peripheral tolerance146. 
Deficient or defective Treg cells have been identified both 
in mouse models and human studies147. GWAS have also 
identified defects in lymphocyte signalling that could 
centrally alter thymic deletion of autoreactive cells. 
Thus, multiple pathways exist by which T-cell tolerance 
could be defective in SLE. One of the first phenomena 
to be described was that of aberrant signalling through 
the T-cell receptor. This phenomenon is not cell- 
intrinsic, and can be induced in normal T cells by serum 
IgG from patients with SLE148. In T cells from patients 
with SLE, the CD3 ζ chain (which mediates signalling 
via tyrosine-protein kinase ZAP-70) is downregulated 
owing to increased mTOR activity, causing ZAP-70 to be 
replaced by FcRγ. FcRγ then pairs with tyrosine-protein 
kinase SYK rather than with ZAP-70, resulting in hyper-
activation of the T-cell-receptor signalling pathway149,150. 
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Despite this hyperactivated phenotype, T-cell production 
of IL-2 is actually impaired. Expression of IL-2 in SLE 
T cells is compromised by decreased levels of the transcrip-
tion factor AP-1 and suppression by cAMP-responsive 
element modulator (CREMα)114,115. Treatment with the 
mTOR inhibitor rapamycin in vitro reversed this effect, 
and mTOR inhibitor treatment in vivo has been clinically 
efficacious, supporting the importance of this pathway 
in SLE151.
Patients with SLE also show altered T-cell subset pop-
ulations. TH17 cells are a subset of CD4+ T cells found 
infiltrating the kidneys of patients with lupus nephritis, 
and in the skin lesions of patients with SLE152. Polarization 
to TH17 involves changes to the epigenome that can be 
driven by microbial products153. Double-negative T cells 
(CD4−CD8−) seem to be the primary source of IL-17 in 
SLE154. Double-negative T cells are expanded in patients 
with SLE as well as in lupus-prone mice and are thought 
to contribute to loss of tolerance155,156, as they also express 
IL-1β and IFNγ, and promote B-cell differentiation and 
antibody production.
T cells provide more than just signals for class switch-
ing. They represent a key checkpoint for autoreactive 
B cells in SLE. T-cell–B-cell interactions are a key focus 
of current SLE research because these interactions occur 
outside their usual locations, in secondary lymphoid 
organs, and are more transient than in healthy individ-
uals, suggesting that the very essence of the interaction 
is pathologic157,158. These aberrant T-cell–B-cell interac-
tions are also reflected in the somatic mutations seen 
in autoantibody gene segments159. Somatic mutations 
reflect both T cell help and germinal centre passage. 
TFH cells specifically support B-cell differentiation by 
producing IL-21 and receptor engagement in the ger-
minal centre (FIG. 5). Expansion of the TFH cell subset has 
been described in several mouse models of lupus160,161 
and increased levels of TFH cells correlate with increased 
disease activity and severity in patients with SLE162–164. 
TFH cells can be seen within lymphoid aggregates in 
kidney biopsy samples from patients with active lupus 
nephritis, and activated TFH cells correlate with auto-
antibody titres in these patients165,166. Emerging evi-
dence suggests that the expansion of TFH cells in SLE is 
directed by interaction with OX40 ligand (also known 
as TNF ligand superfamily member 4 (TNFSF4)), which 
is expressed on myeloid antigen-presenting cells167. In 
SLE, the expression of OX40 ligand on myeloid antigen- 
presenting cells is induced (via TLR7 activation) by cir-
culating RNA-containing immune complexes167 (FIG. 5). 
The pathologically expanded and activated TFH cell 
compartment markedly affects B-cell differentiation. 
Enhanced antibody production and loss of tolerance 
are both expected in this setting.
Treg cells have an important role in maintaining toler-
ance. Both T cells and B cells are subject to Treg cell con-
trol. Normal development of Treg cells (a subset of CD4+ 
cells that inhibit and suppress autoreactive lymphocytes) 
is dependent on IL-2. Treatment of patients with SLE with 
low-dose IL-2 for 5 days caused a dramatic increase in 
peripheral blood CD25+FoxP3+ Treg cells, although the 
clinical consequences of long-term IL-2 therapy have not 
yet been determined168. This study might be seen as an 















Although SLE is a clinically heterogeneous disease, 
patients are near-universally characterized by the pres-
ence of autoantibodies, particularly those directed 
against nuclear antigens. Loss of tolerance and altered 
B-cell differentiation might be genetically determined, 
by variants present from birth or acquired as part of the 
disease process169. Activation of B cells through the TLR 
pathway promotes loss of tolerance. Mouse models have 
demonstrated that transitional B cells that have recently 
emigrated from bone marrow are susceptible to accel-
erated maturation by TLR9, which bypasses tolerance 
checkpoints170. Tolerance can also be broken by B-cell 
stimulation via cytokines; BAFF in particular has been 
implicated in this process. BAFF antagonism in mice 
clearly leads to improved self-tolerance, and conversely 
BAFF overexpression leads to autoimmunity171–173. 
Tolerance does not seem to be an all-or-nothing phenom-
enon, however. An elegant demonstration of the evolu-
tion of autoantibodies in SLE was performed using stored 
plasma from members of the armed forces. This study 
demonstrated progressive development of autoantibodies 
over the 5–8 years preceding onsert of the clinical man-
ifestations of SLE174. Human studies have clearly impli-
cated both environmental and genetic contributions in 
loss of tolerance. Early immature B cells show increased 
levels of polyreactivity and autoreactivity in SLE, possibly 
owing to a break in central B-cell tolerance that enables 
increased numbers of autoreactive clones to reach the 
periphery175. B-cell subsets are skewed to the more mature 
subsets, those poised to become antibody-secreting 
plasma cells176. In addition, IL-10-secreting B cells with 
regulatory capabilities show functional impairment in 
SLE177,178. These observations support the concept that 
B-cell development is aberrant in SLE.
B cells contribute to SLE through their responses 
to antigen, regulation of other cells, and autoantibody 
production. Autoantibodies contribute to SLE through 
the formation of immune complexes, direct agonist or 
antagonist action, and by interference with intracellular 
functions179. Immune complexes activate complement 
and, through binding Fc receptors, drive inflamma-
tion. A unique indirect mechanism of action occurs 
through binding of RNA. The 60 kDa SSA/Ro protein 
binds RNA, preferring Alu retroelement RNA. Anti-Ro 
antibodies deliver this Alu RNA to the endosomal com-
partment via Fc receptors, thereby activating TLRs180. 
Antibody production in patients with SLE in general 
seems to favour high-affinity versions, as even anti- 
influenza virus antibodies have higher affinity in patients 
with SLE than their counterparts in healthy controls 
do181. A previously unanticipated B-cell phenomenon is 
the production of pathologic IgE antibodies. IgE is typ-
ically associated with allergic responses, and little effort 
was made to characterize IgE in patients with SLE until 
researchers showed that half of SLE patients have IgE 
directed to dsDNA182. Levels of self-reactive IgE increase 
with increased disease activity in patients with SLE and 
the IgE immune complexes can stimulate type I IFN in 
pDCs183. High total IgE concentrations have also been 
described in patients with SLE184, but even in the absence 
of high IgE levels, autoantibodies of the IgE isotype and 
dysregulated basophils have now been observed in both 
mouse models of lupus and patients with SLE185. High 
numbers of basophils in mouse models of lupus contrib-
ute to a TH2 cell polarization186. Importantly, depletion of 
either IgE or basophils in mice with lupus led to dimin-
ished renal disease, supporting their mechanistic role in 
SLE182,185–187 and providing support for a clinical trial of 
IgE-directed therapy.
Organ-specific disease features
New experiments highlight that loss of tolerance and tis-
sue damage are two distinct processes. Autoimmunity 
and kidney damage in NZM2328 lupus-prone mice are 
controlled by variants in Agnz1 and Cgnz1. Replacement 
of the pathologic Cgnz1 allele with the normal allele did 
not affect the expression of autoimmunity, but pre-
vented kidney failure188. In another example, when the 
gld.apoE−/− mouse (a lupus-prone mouse with profound 
atherosclerosis) was rendered IRF5-deficient, it was pro-
tected from autoimmunity but displayed increased num-
bers of atherosclerotic lesions189. Thus, tissue effects are 
regulated independently of tolerance. These local tissue 
effects, which are also independent of haemato poietic 
cell influence, are major contributors to end-organ dam-
age in SLE. These effects have been best described for 
kidney, skin, and the central nervous system (CNS).
Nephritis
Among women with SLE, approximately 30–40% of 
those with European ancestry, and nearly 50% of those 
with Afro-Caribbean ancestry develop lupus nephritis, 
which is associated with substantial morbidity and mor-
tality190,191. Central features are immune-complex dep-
osition and cell proliferation. Anti-dsDNA antibodies 
crossreact with several renal cell types and are thought 
to be central to the nephritis process. GWAS identified a 
lupus-nephritis-associated variant near the gene encod-
ing the platelet-derived growth factor (PDGF) recep-
tor192. Expression of PDGF and its receptor is increased 
in kidney tissue from patients with SLE193, and anti-
PDGF antibodies inhibit mesangial cell proliferation in 
animal models194.
HER2 (also known as ERBB2) is also overexpressed 
in lupus nephritis61 and can be upregulated by IFNs and 
IRF1 (REF. 61). HER2 regulates miR-26a, which in turn 
regulates cell proliferation195. The HER2-miR-26a path-
way may be of clinical interest because anti-HER2 agents 
have already been developed for breast cancer treatment. 
Mesangial cells are capable of producing IFNs, which may 
amplify local inflammatory processes196, regulate HER2 
expression, and inhibit renal progenitor cell differentia-
tion into podocytes, which compromises healing. In turn, 
mesangial proliferation and podocyte function are con-
trolled in SLE by local activity of calcium/calmodulin- 
dependent protein kinase type IV (CaMK IV)197,198. 
Treatment of MRL/lpr mice with a CaMK IV inhibitor 
decreased IFN production and ameliorated nephritis199. 
Local cytokine production is thought to amplify the cell 
infiltrate. In the MRL/lpr model, TNF and IFNγ are 
produced in glomeruli before active cellular infiltrate200. 
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Thus, therapies that limit tissue damage by targeting 
renal parenchymal cells may also prove useful in the 
treatment of lupus nephritis.
Skin
Cutaneous involvement is common in SLE and skin can 
constitute the only organ affected. Skin lesions are sel-
dom life-threatening, but represent an important source 
of morbidity in SLE. Different subsets of cutaneous lupus 
erythematosus (which have distinct natural histories) are 
classified as acute, subacute, discoid, and intermittent 
(lupus erythematosus tumidus). Ultraviolet light is a typ-
ical precipitant of an SLE flare as a result of keratinocyte 
apoptosis. Immune complexes can be seen in skin biop-
sies from patients with SLE (termed the ‘lupus band’) 
and this finding is in fact diagnostic of SLE.
Common autoantibodies seen in patients with cuta-
neous forms of SLE are anti-ribosomal P protein and 
anti-galectin-3. Antibodies to Ro52 (also known as 
TRIM21) are also found, and deficiency of Ro52 in mice 
induces a lupus-like skin disease201. Why the effects of 
Ro52 deficiency were localized to the skin is unclear, 
but Ro52 is highly expressed in inflamed skin202, and 
this finding might reflect the role of Ro52 as a nucleic- 
acid-binding protein rather than as having a direct role 
in providing protection to the skin203. Cutaneous lesions 
in SLE might, therefore, reflect the presence of specific 
autoantibodies, but also seem to relate to the cutaneous- 
dominant expression of certain proteins.
CNS disease
CNS disease remains one of the most troubling and 
puzzling clinical features of SLE. A meta-analysis indi-
cated that polymorphisms in genes associated with 
immune-complex clearance, such as FCGR3A and 
FCGR3B (encoding low affinity IgG Fc region recep-
tors IIIa and IIIb (FcγRIIIa and FcγRIIIb)) and ITGAM 
(encoding integrin αM) are potential susceptibility genes 
for neuropsychiatric lupus204. Polymorphisms in TREX1 
(which encodes 3ʹ repair exonuclease 1, also known 
as DNase III), have also been associated with seizures 
in SLE205.
Dysfunction of the blood–brain barrier enables 
immunoglobulins, cytokines, and immune cells to gain 
access to the brain tissue, and is a central mechanism of 
neuropsychiatric lupus. The complement system has a 
key role in disrupting the integrity of the blood–brain 
barrier. Treatment with a C5a receptor antagonist or a 
C5a antibody improved the function of the blood–brain 
barrier and decreased CNS inflammation in mouse mod-
els of lupus206,207. Complement inhibition also improved 
neuronal survival in these studies206,207.
Autoantibodies, including antiphospholipid anti-
bodies and those targeting ribosomal P peptides, the 
NMDA receptor, and matrix metalloproteinase-9, could 
participate in the pathogenesis of neuropsychiatric lupus 
through multiple mechanisms, including by directly caus-
ing neuronal cell death208. In MRLlpr/lpr mice, CNS disease 
was amplified by the cytokine TNF-related weak inducer 
of apoptosis (TWEAK, also known as TNF ligand super-
family member 12). Mice deficient in the TWEAK recep-
tor had better cognition and integrity of the blood–brain 
barrier than their littermates209. These studies open the 
door for therapeutics for CNS disease, for which there is 
a critical unmet need.
Conclusions
Conventional therapy for SLE has utilized broad-based 
immunosuppression. Advances in our understanding 
of SLE pathogenesis, as described here, will enable the 
development of targeted therapies that may lead to indi-
vidualized approaches to care. Many of the advances made 
over the past decade are driving interest in developing tar-
geted therapeutics and repurposing of drugs. Cytokines, 
tolerance pathways, local tissue mediators, and epigenetic 
mechanisms show promise as novel targets in SLE.
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Abstract
Background: Gene expression studies of peripheral blood mononuclear cells from patients with systemic lupus
erythematosus (SLE) have demonstrated a type I interferon signature and increased expression of inflammatory cytokine
genes. Studies of patients with Aicardi Goutières syndrome, commonly cited as a single gene model for SLE, have suggested
that accumulation of non-coding RNAs may drive some of the pathologic gene expression, however, no RNA sequencing
studies of SLE patients have been performed. This study was designed to define altered expression of coding and non-
coding RNAs and to detect globally altered RNA processing in SLE.
Methods: Purified monocytes from eight healthy age/gender matched controls and nine SLE patients (with low-moderate
disease activity and lack of biologic drug use or immune suppressive treatment) were studied using RNA-seq. Quantitative
RT-PCR was used to validate findings. Serum levels of endotoxin were measured by ELISA.
Results: We found that SLE patients had diminished expression of most endogenous retroviruses and small nucleolar RNAs,
but exhibited increased expression of pri-miRNAs. Splicing patterns and polyadenylation were significantly altered. In
addition, SLE monocytes expressed novel transcripts, an effect that was replicated by LPS treatment of control monocytes.
We further identified increased circulating endotoxin in SLE patients.
Conclusions: Monocytes from SLE patients exhibit globally dysregulated gene expression. The transcriptome is not simply
altered by the transcriptional activation of a set of genes, but is qualitatively different in SLE. The identification of novel loci,
inducible by LPS, suggests that chronic microbial translocation could contribute to the immunologic dysregulation in SLE, a
new potential disease mechanism.
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Introduction
Systemic lupus erythematosus (SLE) is the quintessential
systemic autoimmune disease. The etiopathogenesis is still not
fully understood and there are over 20,000 published studies
evaluating various aspects of cellular dysfunction in this disease.
Over the past 10 years, insights have come from genome-wide
association (GWA) studies as well as gene expression studies. In
both cases, a type I interferon pathway was implicated [1,2].
One of the hallmarks of lupus is the presence of autoantibodies
directed against nucleic acid targets and other nuclear antigens.
The process of apoptosis exposes the immune system to nucleic
acids and nuclear antigens, particularly when the apoptotic cells
are not cleared appropriately and degrade into smaller compo-
nents [3]. The apoptotic debris are believed to drive much of the
type I interferon signature and the type I interferon itself can drive
additional apoptosis. Nevertheless, much remains unknown about
the pathogenesis of SLE, particularly at the level of nucleic acid
accumulation and dysregulated gene expression. Dysregulated
gene expression, with the accumulation of aberrant transcripts,
could theoretically contribute to apoptosis or increased type I
interferon expression and has been shown to mimic lupus
[4,5,6,7,8,9].
We utilized next generation sequencing of transcripts (RNA-seq)
to characterize the SLE transcriptome in monocytes. Monocytes
are a critical cell in SLE. They are implicated in renal damage,
which is the major cause of morbidity in SLE, and in
atherosclerosis, which is the major cause of mortality in SLE
[10,11,12,13]. Monocytes are, therefore, central to the disease







process, but are also of interest because they respond to
environmental stimuli, alter their function accordingly, and reflect
that information back to other immunologically competent cells.
They offer the additional advantage of representing a relatively
homogeneous population [14]. This is the first RNA-seq study of
SLE and we found not only a transcriptome that exhibits
quantitative alterations as defined by the level of gene expression,
but also qualitative differences with widely altered splicing
preferences and non-coding RNA transcription. Some novel
transcripts expressed at higher abundance in SLE monocytes
were inducible by LPS, known to activate type I interferons
[15,16,17]. LPS and microbial products have been demonstrated
to accelerate renal disease and induce lupus-like processes in mice
[18,19,20,21]. This finding provides an additional perspective
from which to understand SLE.
Methods
Patients and cell purification
Investigators at Johns Hopkins University (JHU) School of
Medicine obtained written informed consent and HIPAA Autho-
rization of study subjects for all SLE samples. The Institutional
Review Board at Johns Hopkins reviewed and approved the study
of SLE patients. The use of the anomyzed Red Cross samples was
approved by the Red Cross Institutional Review Board. Control
samples were obtained from The Center For Aids Research, which
supplies blood samples on a fee for service basis. They have
obtained consent for the use of the samples and their protocols
were approved by the University of Pennsylvania Institutional
Review Board.
Primary human monocytes were purified using elutriation and
adherence from eight healthy controls and nine SLE patients with
no other autoimmunity, as previously described [22,23,24,25].
The purity of monocytes was more than 90% by flow cytometry
for CD14 staining. All controls and patients were female and an
average of approximately 40 years of age. All SLE patients’ disease
activity was mild-moderate and no one was on high-level immune
suppression (Table S1). All subjects were enrolled in an IRB-
approved study and provided informed consent, except the red
cross serum samples which were provided as anomyzed discarded
samples.
RNA isolation and library preparation
Total RNA was isolated from 2–3 million primary monocytes
using the Qiagen RNeasy kit and DNA was removed by on-
column DNase digestion (Qiagen, Valencia, CA). This method
recovers predominantly RNA species .200 bases. 1 mg of total
RNA was used to prepare the library with the SOLiDTM whole
transcriptome analysis kit (Applied Biosystems, Foster City, CA),
providing strand-specific data. The procedure followed the
instructions of the manufacturer. For miRNA validation, we used
miRNeasy from Qiagen. Table S2 provides RNA quality and cell
count information. The OD 260/280 ratio ranged from 1.8–1.98.
RIN scores were not consistently obtained prior to fragmentation
but were .7 for those where the RIN was defined. Post
fragmentation, the RIN score averaged 2.3. The RNA quality
and counts were not different between patients and controls.
RNA abundance validation
qRT-PCR was used to define quantitative differences in RNA
abundance. The Clontech Advantage RT for PCR kit (Clontech,
Mountain View, CA) was used to generate cDNA. Gene
expression was detected by real-time PCR using the TaqMan
9600. Transcript levels were normalized to the 18S or b-actin
signal, as has been previously used in SLE studies [26,27,28].
Mature miRNAs were detected with Taqman miRNA assays.
Relative quantitation was performed using spiked Caenorhabditis
elegans miRNA-238 as an exogenous control (Qiagen Syn-cel-miR-
238-3p miScript miRNA Mimic). Commercially available primers
were purchased from Applied Biosystems for: cel-miR-238 (248
primer for isoform cel-miR-238-3p - MIMAT0000293); hsa-miR-
212 (515 primer for isoform hsa-miR-212-3p - MIMAT0000269
and 461768_mat for isoform hsa-miR-212-5p - MIMAT0022695);
and CCR2 (Hs00174150 primer for CCR2 isoform
NM_001123041.2 and Hs00704702_s1* for CCR2 isoform
NM_001123396.1) and from Qiagen for RND3
(QT00002744),TSLP (QT01670809), RGPD1 (QT01678425),
CD177 (QT02452849), TUBB1 (QT00049574), and ITG-B
(QT01003121). Novel loci were detected with custom primers
using SYBR green. Primer sequences are listed in the Methods S1.
The Mann Whitney U test was used to analyze the differences
between SLE and controls.
Endotoxin analyses
MonoMac 6 cells and primary monocytes from healthy donors
were stimulated with 100 U/ml a2-interferon (PBL Biomedical
Laboratories, Piscataway, NJ), 10 ng/ml c–interferon (R&D
Systems, Inc., Minneapolis, MN), 10 ng/ml tumor necrosis factor
(TNF-a) (Sigma, Saint Louis, MO) for 16 hours, or 1 mg/ml of
LPS for two hours. SB203580 was used as a p38- MAPK inhibitor
by pretreating the cells for 30 minutes at a concentration of
10 mM. SP600125 (Calbiochem, Darmstadt, Germany) was used
as a JNK inhibitor at a concentration of 10 mM and U0126 (Cell
signaling, Danvers, MA) was used as an ERK inhibitor at a
concentration of 10 mM. Cells were harvested after stimulation
and RNA was prepared as above. To measure circulating
endotoxin, serum samples from 99 SLE patients and 112 Red
Cross blood donors were analyzed using the Limulus assay
(Thermo Scientific, Rockford, IL). The Wilcoxon method was
used to compare the levels across groups.
Bioinformatics
We used the Tophat-Cufflinks pipeline and further refinements
[29] to assemble the monocyte transcriptome and detect novel loci
and isoforms, followed by mapping short reads to a collection of
reference RNA sequences, including isoforms of coding genes,
small RNAs, long non-coding RNAs (lncRNAs), and repetitive
elements. The number of reads mapped to each transcript was
used for evaluating differential expression between control and
SLE samples. Data has been submitted to GEO as GSE53419.
The following steps were used in data analysis:
N Use TopHat to align 50 bp sequencing reads to reference
genome hg19. TopHat also searched for reads partially
mapped to distant locations to identify exon-exon junctions.
As a result, TopHat mapped ,22 million reads per sample on
average and stored the aligned reads in BAM files. This step
did not use any known gene annotation
N Use Cufflinks to assemble transcriptomes of individual samples
while using RefSeq gene annotation as reference. On average,
Cufflinks reported 65,008 genes and 83,430 transcripts in
individual transcriptomes.
N Use Cuffmerge to combine individual transcriptomes, also
using RefSeq as reference. The merging improved the
reliability of novel loci and isoforms by taking a consensus of
individual transcriptomes. Cuffmerge reported 59,887 tran-
scripts of 34,307 genes in a consensus transcriptome.
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N Use Cuffcompare to categorize transcripts by comparing the
consensus transcriptome to RefSeq annotation. For example, a
class ‘‘ = ’’ transcript had the same exon-exon junctions as a
known RefSeq transcripts and a class ‘‘u’’ transcripts had no
overlapping to any known genes. As a result, Cuffcompare
identified 10,200 novel transcribed loci and 10,313 isoforms
including novel exon-exon junctions of known genes.
N Use the gene annotation tracks downloaded from UCSC
Genome Browser to evaluate the novelty of the new loci and
isoforms reported by Cuffcompare. The tracks were UCSC
Genes, Ensembl Genes, GENCODE Genes V12, CCDS, H-
Inv 7.0, sno/miRNA and lincRNA Transcripts, including
evidence-based gene annotation, computationally generated
gene prediction, and collections of non-coding RNAs. The
comparison identified 2,280 and 4,000 high novelty loci and
isoforms not included in any of the seven annotation tracks.
N Repeat the TopHat-to-Cuffcompare steps without using a
reference annotation for assembling and merging transcrip-
tomes. Cuffcompare identified 774 transcripts having the exact
same exon-exon junctions as known RefSeq transcripts. These
true positives had higher read counts and consistency across
samples. Surprisingly, they were also longer and included more
exons on average, which presumably made them more difficult
to be completely assembled. High read count and high
consistency were then used as the criteria to filter the novel loci
and isoforms identified by previous steps to obtain 3,725 and
1,327 high-confidence novel loci and isoforms respectively.
Align reads to reference transcriptome using
Novoalign. NovoalignCS was used to align reads to a reference
transcriptome to obtain the read count per transcript. Each entry
of the reference transcriptome was the full sequence of a transcript
without introns. The reference transcriptome included all RefSeq
transcripts and novel loci/isoforms reported by Cuffmerge, as well
as three classes of non-coding RNAs: small RNAs from
snoRNABase and miRBase), lincRNAs (UCSC Genome Browser
lincRNAs track), and repetitive elements (Repbase).
Reads mapped to the same transcript were counted to define
the transcription level. Reads mapped to different RNA classes or
transcripts of different genes were excluded. The number of
unique reads mapped to different transcripts of the same genes
were used as gene-level read count. Only reads mapped to the
sense strand were counted, whereas reads mapped to the antisense
strand of coding genes were used to quantitate antisense
transcription.
Statistical analysis of transcriptional data. We noticed
that the fold change of patients and controls was slightly
dependent on the baseline expression level (r = 0.15, p,0.01),
and applied Loess adjustment to remove this bias by assuming an
equal amount of total RNA between samples. The global average
of patient-control difference was very close to zero (0.4% higher in
SLE) after the adjustment.
Statistical analysis of differential expression was performed
within R environment using Bioconductor packages. Rsamtools
package was used to import aligned reads from BAM files to R
environment. Gene-level differential expression between SLE and
control samples was analyzed with the Bioconductor EdgeR
package. Genes without at least three read counts in at least three
samples were excluded.
Gene-gene correlation analysis was performed by the following
steps: calculate the correlation coefficients between genes in
control and SLE groups separately; convert correlation coefficients
to z scores using Fisher’s transformation; take the average of z
scores, and convert the average z score back to a single combined
correlation coefficient r. Enrichment studies utilized DAVID
which reports adjusted p values based on the Benjamini Hochberg
algorithm [30].
39 Untranslated analysis. For analysis of the 39 untranslated
regions, RNA-Seq reads were aligned to reference genome
(UCSC, hg19) using Tophat 1.3.1 by default parameters for
Applied Biosystems’ Colorspace format. Uniquely mapped reads
were kept for downstream analysis. PolyA_DB together with the 39
ends of transcripts from UCSC, RefSeq, Aceview annotations
were collected as a comprehensive APA database [31]. For each
annotated cleavage site, the number of reads in the upstream
200 nt window were computed as the estimation for the expression
level of the mRNA isoform terminating at that 39end. The read
count for each isoform was added up in nine case samples and
eight control samples, respectively. We required at least 10 reads
supporting each isoform resulting in ,6600 APA genes for
analysis. The relative ratio of expression at proximal to distal sites,
in addition with a p-value, was calculated by Fisher’s Exact test
using R (http://www.r-project.org/). Relative ratio.2 and p-
value,0.01 were used to predict different isoform usage.
Analysis of published gene sets. Five data sets were created
from four monocyte GEO data series, GSE15219, GSE19627,
GSE5504, and GSE21909 (one from each of the first three and
two from GSE21909, which used saline and cortisol for
intravenous delivery of LPS). Samples and groups were selected
so that each group had matched replicates/donors. (Table 1)
Results
Transcriptome characterization
Monocyte transcriptomes from Nine female SLE patients and
eight female healthy controls were studied using RNA-seq. Total
RNA was purified from monocytes and used for library
preparation. Our first goal in this study was to reconstruct the
human monocyte transcriptome using the entire dataset. The
Tophat-Cufflinks pipeline reported four major classes of tran-
scripts (Figure S1A), including 10,313 isoforms of known genes
and 10,200 transcribed loci not included in the RefSeq annotation.
The processed data are given in an excel spreadsheet in Data S1.
The novel isoforms had a more complex structure (Figure S1B).
On the other hand, the novel loci were shorter on average than
known genes and over 97% of them included only one exon.
To further define the monocyte transcriptome, we counted the
total number of reads solely aligned to each of the four major
RNA classes: coding RNAs, long non coding (lncRNAs), small
RNAs, and repetitive elements. Ribosomal RNAs (rRNA) were
excluded from this summary. Close to 80% of the non-rRNA
reads were mapped to coding RNAs while the other three classes
evenly shared the remaining reads (Figure S1C). Small RNAs had
the highest molar concentration after read counts were adjusted by
the total length of the RNA classes, followed by repetitive
elements, coding RNAs, and lncRNAs (Figure S1D). These data
were comparable to the distribution seen in other systems [32].
The classifications of transcripts were refined. We identified
4,000 high-novelty isoforms that were not present in seven
additional annotated databases and included at least one unknown
exon-exon junction, as well as 2,271 high-novelty loci that had no
overlap with either exons or introns of any previously reported
transcripts. We then defined 1,327 high-confidence isoforms,
having at least 10 uniquely mapped reads not mapped to any other
genes or isoforms of the same gene in at least six samples, and
3,725 high-confidence novel loci having at least 10 uniquely
mapped reads in at least six samples and more than 106 overall
sequencing depth. After this refinement, 448 novel isoforms and
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778 novel loci that had both high-novelty and high-confidence
were identified. There was no association between high-novelty
and high-confidence (Figure S2). We manually examined a subset
of the 778 novel loci for protein coding potential and the possibility
that they are orthologs of coding genes in other species using
BLAST. Most did not exhibit similarity to any annotated genes
and the majority had limited protein coding potential (,100
contiguous amino acids). We selected 27 novel loci and validated
transcription from all 27 using RT-PCR (Figure S3, Table S3).
Class-specific transcripts in SLE
The major goal of this study was to identify a unique signature
of the monocyte transcriptome in SLE as a strategy to improve our
understanding of the pathogenic mechanisms. We found that there
were a large number of known protein coding genes expressed in
normal monocytes, but silenced in SLE (Figure 1A). These genes
were highly enriched with ones related to embryo development
(p = 6.0E-60), suggesting that SLE monocytes are more differen-
tiated. Antisense transcripts were also more likely to be silenced in
SLE (Figure 1B). On the other hand, the numbers of novel loci
and novel isoforms transcribed only in patients were 3.95 and 1.49
times higher, respectively, than the numbers of control-specific
ones (Figure 1C and 1D).
We evaluated the differential expression between the two groups
of samples in six classes of genes/transcripts: known RefSeq
protein coding genes, novel loci identified by Cufflinks, lncRNAs,
small RNAs, repetitive elements, and the antisense transcripts of
coding genes. These genes/transcripts were filtered by a statistical
analysis, so all the remaining 33,760 (72% of 47,171 total reads)
were mapped by at least three sequencing reads in at least three
samples. We applied the negative binomial test implemented by
the edgeR package of Bioconductor [33] and identified 1,754
differentially expressed genes/transcripts with p values less than
0.01 and a false discovery rate (FDR) of 0.2. Classes of
differentially expressed genes (DEGs) are shown in Table S4.
The patient-control difference of total transcription varied
dramatically between RNA classes (Figure 2A). Total transcription
of both sense and antisense transcripts of known coding genes was
reduced by approximately 15% in SLE (p = 5.6E-61 and 7.4E-105
respectively). Total transcription of novel loci was strikingly
increased by over 45% in SLE (p,1.0E-300), as SLE patients
produced many previously undiscovered transcripts that had low
or no transcription in healthy monocytes. Although expression of
small RNAs was downregulated by about 5%, expression of 91
pri-miRNAs was dramatically increased by 38% (p = 0.01),
whereas the three classes of small nucleolar RNAs were all
downregulated in SLE patients (Figure 2B). The overall up-
regulation of pri-miRNAs and down-regulation of coding genes
jointly suggested a modified miRNA regulatory system in SLE.
Subclasses of repetitive elements also had different directions of
change in SLE (Figure 2C). All endogenous retroviral (ERV)
subclasses were consistently downregulated (p = 4.7E-4 to 3.8E-
29). Other retrotransposons such as LTR retrotransposons, SINE,
and LINE (L1) elements were variably decreased in SLE patients,
while expression of SINE1/7SL elements was increased.
Protein-coding genes
Functional analysis of the protein coding genes identified a large
number of pre-defined gene sets whose members were enriched
within differentially expressed genes (DEGs), partially listed in
Table S5. Most noticeably, DEGs upregulated in SLE were
enriched with genes related to immune response and cytokine
activity, while the downregulated DEGs were enriched with genes
related to cell adhesion and motion. According to Genetic
Association Database (GAD), eleven upregulated DEGs were
associated with SLE in previous studies (Table S6). In addition, the
combined gene set of up- and downregulated DEGs was enriched
with potential targets of transcription factors highly relevant to
SLE, including AP1 (p = 3.4E-09), E47 (p = 1.1E-8), RFX1 (5.8E-
7), IRF1 (p = 1.4E-3), and IRF2 (p = 1.3E-3). We selected six
DEGs, five upregulated and one downregulated in SLE, to be
validated in new samples using qRT-PCR. Five of the genes were
significantly different between controls and patients (p = 0.049 to
Table 1. GEO sources.







Figure 1. Comparison of SLE and control transcriptomes. The
Venn diagrams demonstrate the overlap of actively transcribed A)
coding genes, B) antisense transcripts, C) novel loci, and D) novel











0.0001) and all six were changed in the same direction in both
patient cohorts (Figure S4).
Polyadenylation
Polyadenylation along with mRNA cleavage and termination
are regulated in a gene-specific manner and these steps appear to
be particularly important for the regulation of genes involved in
inflammation [34,35,36]. Tissue-specific and developmentally-
regulated polyadenylation have been described with differentiation
favoring longer 39 UTRs [37,38,39]We examined the structure of
the coding genes by defining the 39 untranslated region for each
gene. Sixty-seven genes had longer 39UTRs in patients compared
to controls and 54 genes had shorter 39UTRs in patients (defined
by a ratio of .2.0 and a p,0.01). The longer 39UTR gene set was
characterized by pathways centered on NFkB, Akt, UBC and
HNF4A. The shorter 39UTR gene set was characterized by
pathways centered on UBC, NFkB, and ERK (Figure S5). As
shorter 39UTRs can escape regulation by miRNAs and the
inflammatory pathways implicated by the pathway analysis are
concordant with what is known about SLE, these gene sets are
notable and may given insight into the SLE process [38,40].
Antisense transcription
We analyzed antisense transcription because of the potential for
sense-antisense duplex RNA to drive type I interferon expression
and because antisense transcripts can regulate transcription in cis
[41]. The gene-level read counts of sense and antisense transcripts
were positively, but weakly, correlated (r = 0.19, p,0.01). Overall,
examining patients and controls together, the total number of
reads mapped to the antisense transcripts was about 1/30 of the
total number of reads mapped to the sense transcripts. However, a
small set of genes demonstrated much higher antisense transcrip-
tion than sense transcription (Figure S6), such as USP5, a ubiquitin
peptidase, and CMTM5, a chemokine-like factor gene.
In SLE, some coding genes had significantly changed antisense
transcription in the opposite direction of their sense counterparts,
most noticeably IVNS1A BASES (influenza virus NS1A binding
protein), RACGAP1 (Rac GTPase activating protein 1) and THBS1
(thrombospondin 1). All three genes had significantly upregulated
sense transcripts and significantly downregulated antisense tran-
scripts in SLE. The reversed change of sense and antisense
transcripts of these genes suggested that the two transcripts are
distinctly regulated.
LncRNA expression
LncRNAs can regulate nearby coding genes as cis-regulatory
elements. We summarized the correlation of transcription between
pairs of lncRNAs and coding genes (Figure S7). When the
lncRNAs were located within 100 kb upstream of coding genes,
the pairs had a positive correlation on average, regardless of
whether the lncRNAs were on the same strand as the coding genes
or not. The correlation increased as the distance between
lncRNAs and coding genes became closer. On the other hand,
when the lncRNAs were located downstream of coding genes,
there was no association between the two classes of transcripts if
they were on the opposite strands, and a much stronger association
if they were on the same strand. The latter might suggest the
misclassification of extended 39 UTR transcription of coding genes
as lncRNAs. Although lncRNAs were less likely to change in SLE
compared to other RNA classes (Table S4), the locations of some
significantly changed lncRNAs suggested their involvement in
SLE. For example, both HIVEP2 itself and a lncRNA about 800 to
1,500 bases upstream of its transcription start site (TSS) were
significantly upregulated in SLE, although their RNA abundance
was over 50 times different. There were also two significantly
upregulated lncRNAs located within 50 kb of each other on
chromosome 6 and surrounded by a group of signficantly
dysregulated coding genes including TAGAP, FNDC1, SOD2,
WTAP, and ACAT2 (Figure S8).
Pri-miRNA expression
Our RNA purification method did not retain miRNAs,
however, pri-miRNAs were easily detected and the combination
of increased pri-miRNAs and decreased targets suggested an
impact of the miRNAs (Figure S9). Two pri-miRNAs, miR 193a
and miR-212, were statistically significantly increased in SLE
samples with concomitantly diminished target mRNA levels. MiR-
193a, regulating k-ras and survival, was increased by 776%
(p = 0.009) [42]. MiR-212, regulating apoptosis, was increased by
148% (p = 0.009) [43]. Thesetwo cellular processes are known to
be aberrant in SLE monocytes [44,45].
We validated mature miR-212-3p differential expression in SLE
using qRT-PCR on new samples from six controls and 13 SLE
patients (Figure S10). An exogenous control was used because we
could not identify an miRNA in monocytes that was unaffected by
cytokine treatment (data not shown). The expression of miR-212-
5p was too low to be detected in this ligation-based detection
strategy. The predicted targets of miR-193a-3p, miR-193a-5p and
miR-212 were downregulated by 14.0% to 16.7% in SLE, which
Figure 2. Differential expression of RNA classes. A) The average
transcriptional changes of five RNA classes in SLE. B) The average
transcriptional change of four sub-classes of small RNAs in SLE. C) The
average transcriptional change of 17 subclasses of repetitive elements
in SLE. The eight control and nine SLE libraries were used for this
analysis. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0093846.g002
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was more than the average down-regulation of all other genes
(Figure S11).
Repetitive element expression
Repetitive elements were globally downregulated in SLE
(Figure 2C). A closer look at the downregulated repetitive elements
showed that they were predominantly ERV classes and were
closely correlated with each other, suggesting that they were co-
regulated via an upstream mechanism. Interferon is known to
repress retroviral activation and over-expression of interferon in
SLE has been documented in several studies [1,2,46,47,48].
Coding genes having the highest positive correlation with the
downregulated repetitive elements were potential targets of
transcription factors AP1 (p = 3.0E-8), E47 (p = 2.2E-9), RFX1
(p = 3.7E-8), IRF1 (p = 3.5E-2), and IRF2 (p = 4.3E-3), also
supporting an effect of interferons.
Isoform analysis
The proportions of the total reads assigned to each isoform for
each gene were compared between the control and SLE samples
to evaluate differential isoform transcription. Therefore, this
analysis only considered the change of relative isoform abundance
while ignoring the gene-level differential expression. This
comparison identified 54 genes having one or more isoforms
where the relative abundance was significantly changed (p,0.05)
by at least 5%, such as CCR2, HIVEP1, HIVEP2, IL1B, IL1R2 and
TLR2. SNAPC3 encodes a subunit of a protein complex that
activates snRNA. It was previously known as having a single
isoform, while our Cufflinks assembly identified a novel splicing
site within its 39UTR (Figure S12). The relative abundance of
these two alternative transcripts was changed by about 12% with
p = 0.003.
We observed that isoforms where the relative abundance was
increased in SLE had significantly more exons than those with
decreased relative abundance (Figure S13). This result indicates
higher RNA splicing activity and/or more complex RNA
processing in SLE monocytes.
We selected two biologically relevant genes to validate the
expression of their novel isoforms in monocytes. Primers were
designed to selectively bridge the novel exon-exon junction. IL1R1
and IRF8 were both found to include a large intragenic exon by
RNA-seq (Figures S14 and S15). These exons have no protein
coding potential. For IL1R1, the novel exon is an extra 59
untranslated region. In both cases, PCR demonstrated incorpo-
ration of the novel exon (Figure S16).
Novel loci transcription
92% differentially expressed novel loci had higher transcription
in SLE (Table S4). Many of the novel loci formed clusters located
close to each other. For example, three of the four novel loci,
located within a 5 kb region on chromosome 18, were among the
most significantly upregulated transcripts (Figure S17). Another
example was a cluster of 26 novel loci located within a 34 kb
region on chromosome 8, most of which were significantly
upregulated in SLE and none of which were downregulated
(Figure S18). We selected 22 novel transcripts upregulated in SLE
to be validated in new samples using qRT-PCR. Ten of the
transcripts were significantly upregulated (p = 0.034 to 0.0006) in
SLE (Figure 3A), and only two were not upregulated at all
(Figure 3B). The other loci were upregulated without reaching
statistical significance (Figure 3B and Figure S19).
The fact that these loci were preferentially or exclusively
transcribed in SLE monocytes indicates they are very cell-specific.
They were not present in seven annotated gene databases
supporting SLE-specificity. To examine potential mechanisms
driving expression, we initially treated MonoMac 6 cells with
TNF-a, a2-interferon, c–interferon, or LPS. Time course exper-
iments identified the optimal stimulation time. Only LPS
replicated the pattern of expression of novel loci seen in the SLE
samples (Figure 4A). These findings were further validated using
published datasets and examining concordance. In this analysis,
genes over-expressed in SLE were equally likely to be represented
in the a2-interferon- and LPS-induced genesets (Figure S20). We
then confirmed the effect using monocytes from healthy adult
donors (Figure 4B). To understand potential pathways regulating
the LPS effect, we utilized p38 (SB203580), ERK (U0126) and
JNK (SP600125) inhibitors. The major effect of LPS induction of
the novel transcripts was p38 mediated (Figures 4C and 4D,
Figures S21 and S22).
Circulating endotoxin
Although endotoxin has been previously implicated in murine
lupus models and LPS is known to activate interferon pathways via
TLR4, there has been no direct measurement of endotoxin in SLE
patients [16,17,18,19,20,21]. We compared, therefore, serum
levels from 99 female SLE patients and those from 112 female
healthy adult blood donors. This patient set comprised new
samples. The SLE patients were 91% female, 46% black, 54%
Caucasian, mean age 37.1 years, mean SLEDAI (Systemic Lupus
Erythematosus Disease Activity Index) of 2.6 and mean physician
global estimate of 0.45. The mean prednisone dose was 9 mg/day.
The red cross blood donors were females who were self declared as
healthy. SLE patients had significantly higher endotoxin levels
compared to controls (Figure 5). When we examined clinical
markers for associations with circulating endotoxin levels, we
found no association with age, weight, erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), specific organ damage,
specific autoantibodies or complete blood count (CBC) parame-
ters. Because LPS/endotoxin can induce type I interferon
expression, we examined the concordance of coding genes
expressed in SLE, after stimulation with LPS and after stimulation
with a-interferon using our prior results and published array
results [49,50]. There was substantial overlap, demonstrating that
endotoxin can in part mimic the type I interferon signature seen in
SLE (Figure S21).
Discussion
With the advent of next-generation sequencing technologies a
more comprehensive and accurate transcriptional analysis has
become feasible. We report a whole transcriptome analysis of
patients with SLE and compare gene expression with that of
healthy controls. We detected many instances of SLE-specific
alternative splicing, alternative polyadenylation, and novel loci
transcription. Splicing and polyadenylation in SLE both favored
longer, more complex transcripts.
One of our goals was to identify the transcript abundance of
non-coding RNAs, which have been demonstrated in subjects with
Aicardi Goutières syndrome, an infantile-onset disorder with
features of lupus, and in murine models, to drive a type I
interferon signature [51,52,53]. In this study, we found instead
decreased expression of many non-coding RNAs. We hypothesize
that repression of endogenous retroviral sequences may be
mediated by the type I interferon that is known to be
overexpressed in SLE patients [54]. One class of non-coding
RNA for which expression was clearly induced in SLE patients
was that of the pri-miRNAs. These small non-coding RNAs are
processed to repress translation and regulate multiple messenger
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RNAs. In our study, two specific pri-miRNAs were significantly
upregulated in SLE monocytes compared to healthy controls. In
addition, we were able to demonstrate that the targets of these two
miRNAs exhibited decreased message levels. These observations
suggest that the elevated pri-miRNA levels that we identified in
SLE monocytes are functionally relevant.
Among known protein-coding genes, there was evidence of
global repression, and many genes downregulated in SLE
monocytes were related to cell proliferation and cell adhesion.
The genes upregulated in SLE monocytes reflected active
inflammation. These observations are concordant with what has
been seen using arrays and what is known about monocyte
behavior in SLE [1,2,25,55,56,57,58,59]. Monocytes are known to
have a shortened life span and to exhibit characteristics related to
type I interferon exposure [1,23,45]. The overall repression of
gene expression could be consistent with increased differentiation
and our previous studies demonstrated altered surface expression
of several proteins [14].
The finding of SLE-specific isoforms and polyadenylation was
particularly intriguing. The finding of disease-specific isoforms is
not unique to this study, but it has not been reported this
extensively outside of tumor-specific transcripts. Some studies have
found functional effects of autoantibodies directed at nuclear
constituents and altered expression of splicing factors and this
study raises the question of the mechanism driving altered
processing [60,61,62]. Altered expression of splicing factors could
also contribute to the pattern observed here [61,62].
This study raises many questions. We examined a cohort of
patients with low disease activity to minimize the effect of
medications. Whether patients with more severe disease could
have a more disturbed transcriptome is not known. This is a
relatively small cohort size, and additional studies will be required
to replicate these findings. We did not perform extensive validation
of the many classes of RNA found to have altered expression,
instead capturing a snapshot of the SLE transcriptome in a single
cell type and focusing on the breadth of the effect. We validated
using new samples from controls and patients for the DEGs and
found similar changes in nearly all DEGs, supporting that these
effects are consistently seen in the disease. If similar disruptions are
found in additional cell types, it would suggest a systematically
altered transcriptome. Nevertheless, analyses of isoforms and un-
annotated loci is a moving target and additional information is
likely to be forthcoming, allowing improved understanding of the
regulation of these processes. Monocytes represent a cell type that
is uniquely plastic and it may be that effects are magnified in this
cell type.
IRF1, IRF2, and RFX1 were previously identified by us as
potential regulators of genes with altered histone H4 acetylation
[23,24,25]. These transcription factors, now identified as potential
regulators of the SLE transcriptome, could integrate inflammatory
and interferon signals. The MAP kinase and NFkB pathways were
Figure 3. PCR validation in new samples. A) Ten novel loci (70, 107, 122, 142, 171, 172, 282. 721, 772, and 775) were amplified using 11 controls
(8 new controls and 3 controls used for the RNA-seq libraries) and 11 new SLE patients. Transcript levels were normalized to b-actin. In each case, the
differential expression between SLE and controls was statistically significant with p,0.05, according to the Mann-Whitney test. The cross bars indicate
mean and standard error. Primers and locations are given in Methods S1. B) There was a good agreement of expression fold changes in SLE between











Figure 4. LPS stimulation of monocytes. A) MonoMac 6 cells were stimulated for 16 hours as indicated and qRT-PCR was performed for the
novel loci. Only LPS (1 mg/ml) stimulation consistently upregulated these loci. TNF-a (10 ng/ml) led to upregulation of 16/25 (fold change.1.5), aIFN
(100 U/ml) led to upregulation of 9/25 (fold change.1.5), cIFN (10 ng/ml) led to upregulation of 5/25 (fold change.1.5), and LPS led to upregulation
of 22/25 (fold change.1.5). Three experiments with duplciates or triplicates were averaged. The error bars indicate standard deviation. B) Human
primary monocytes were stimulated as above and the abundance of the novel transcripts quantitated by qRT-PCR. TNF-a led to upregulation of 9/25
(fold change.1.5), aIFN led to upregulation of 7/25 (fold change.1.5), cIFN led to upregulation of 9/25 (fold change.1.5), and LPS led to
upregulation of 23/25 (fold change.1.5). Pre-treatment of cells with the p38 inhibitor, SB203580 led to markedly diminished induction of expression
by LPS. Three experiments with duplciates or triplicates were averaged. The error bars indicate standard deviation. C) The average fold change for the
aggregated novel upregulated loci in SLE were calculated for MonoMac 6 cells and D) healthy human primary monocytes stimulated by LPS, TNF-a,
aIFN,or cIFN. Locus 896 was down-regulated and locus 477 was not changed in the orignal SLE samples and were included as controls. The error bars
indicate standard deviation in C and D.
doi:10.1371/journal.pone.0093846.g004
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identified as potential regulating pathways in the polyadenylation
pattern specific to the SLE samples. These pathways have long
been implicated in SLE [63,64,65,66,67,68]. To further implicate
the MAP kinase pathway, we found that expression of many novel
loci were inducible with LPS and that inducibility could be
blocked with the P38 inhibitor, SB203580. The roles of the novel
loci are not yet known and we acknowledge that these fall into a
bioinformatic limbo. Nevertheless, endotoxin has been implicated
in a variety of diseases and induces type I IFN
[69,70,71,72,73,74,75,76]. Our findings of significant overlap of
the genes induced by LPS/endotoxin, SLE and a-interferon along
with increased endotoxin in peripheral blood supports a role for
endotoxin in the pathologic gene expression pattern identified
here. This is the first RNA-seq study of SLE monocytes and our
analysis revealed a surprisingly distorted transcriptome. The
strengths of the study include the comprehensive approach to
the characterization of the transcriptional landscape, use of a
purified cell type, validation of the findings using a new cohort,
and a mechanistic insight into the expression of novel loci.
Limitations of this study include a small sample size focused on
mild to moderate disease activity. While the low disease activity
enabled us to examine patient samples without the perturbation of
high-level immune suppression, it may also have limited our
findings. The platform used and the sample cell count may also
have limited our findings. The libraries were 50 bp single reads
and total RNA was used with post-run ribosomal RNA exclusion.
Finally, technical aspects such as RNA quality may have limited
our ability to identify disease-specific variation in signal. Never-
theless, in spite of these potential limitations, our analyses were
robust and identified many changes specific to the SLE
transcriptome.
In summary, we found a broadly altered transcriptome. By
using a single cell type, we minimized the effects of different cell
populations and improved the specificity of our discoveries. The
most significant finding of this study was identification of disease-
specific novel loci expression, regulated by endotoxin. Circulating
endotoxin has been negatively associated with prognosis in a
number of diseases and is thought to drive a type of immune
exhaustion [77,78]. Whether endotoxin could be responsible for
other features of the altered transcriptome or could represent a
biomarker for disease severity remains to be determined. While
additional studies will be required to determine which features
contribute to the pathologic processes in this still enigmatic
disease, the importance of this study lies in the identification of
multiple features of altered transcription and processing in SLE, a
heretofore unappreciated facet of the disease.
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Figure S1 Overall transcriptome characteristics. A) The
Tophat-Cufflinks pipeline identified four major classes of tran-
scripts from 17 RNA-seq libraries. RefSeq genes constituted the
majority of the transcripts. B) Novel isoforms and loci were
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numbers of exons on average. C) Coding RNA was the most
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isoforms and loci. A) Novel isoforms including at least one
unknown exon-exon junction or mapped by $10 unique reads in
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high-confidence, respectively. B) Novel loci not overlapping any
known transcribed region or mapped by $10 unique reads in at
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Figure S3 Validation of novel transcripts. Transcripts
were validated for 27 identified novel loci using qRT-PCR (black
bars). Primary monocyte RNA was used as the source and control
amplifications using non-reverse-transcribed RNA were used as
the negative control (No RT bars). Globin, not expected to be
expressed in monocytes, was used as an additional negative
control. Beta-actin was used for normalization. Most of these novel
loci were generally expressed at low levels. The locations of the
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Figure S4 Validation of differential gene expression.
The differential expression of six coding genes in SLE were
validated by qRT-PCR. The samples consisted of 11 controls
(including 3 internal validation samples from which the RNA-seq
libraries were made) and 11 new SLE patients. Five of the genes
were validated as having significant change in SLE. The sixth
gene, CD177, had the same direction of change in SLE samples
but the change did not reach statistical significance. The cross bars
indicate mean and standard error according to the Mann-Whitney
test.
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Figure S5 39 UTR length networks. A) The genes with
longer 39UTRs in SLE patients were networked using Ingenuity.
The two most dominant networks are shown. NFkB, AKT, and
UBC are the dominant nodes. B) The genes with shorter 39UTRs
in SLE patients were networked using Ingenuity. The two most
dominant networks are shown. MAP kinases and UBC were the
Figure 5. SLE patient circulating endotoxin levels. Circulating
endotoxin was quantitated using the Limulus assay. 99 female SLE
patients and 112 female Red Cross blood donors were anlayzed. SLE
patients had significantly more endotoxin on average than controls (P,
0.0001). The cross bars indicate the mean and standard error.
doi:10.1371/journal.pone.0093846.g005
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Figure S6 Sense- antisense expression. About 5,000
coding genes had detectable antisense transcription in monocytes.
A) The average transcription of antisense transcripts was less than
the half of the corresponding sense transcripts; but a small number
of antisense transcripts had over ten-fold higher transcription of
their sense counterparts. B) The transcription of sense and
antisense pairs tended to be positively correlated. The correlation
between each pair was first calculated across samples in the control
and SLE groups separately, then the two correlation coefficients
were combined using Fisher’s transformation.
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Figure S7 LncRNA association with adjacent transcrip-
tion. The co-regulation of lncRNAs and their nearby coding
genes was dependent on their distance and relative location. The
horizontal black line is indicates the average correlation of random
pairs of lncRNAs and coding genes. (Oppo: opposite strand.)
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Figure S8 Chromosome 6 lncRNA cluster. A cluster of
coding genes and lncRNAs located on chr6q25.3 were commonly
dysregulated in SLE monocytes. Four coding genes with medium
to high transcription levels were all upregulated in SLE while the
other coding gene, FNDC1, had a very low transcription level and
was downregulated in SLE. Both highlighted lncRNAs were
significantly upregulated in SLE. Three other lncRNAs within this
region had detectable transcription, but no significant changes in
SLE. The Table demonstrates the read counts for each locus.
(DOCX)
Figure S9 MicroRNA- target correlation. Ten pri-miRNAs
and their predicted targets had a negative correlation in
monocytes. The correlation was calculated using normalized read
counts of pri-miRNAs and target coding genes. The correlation
coefficients of each miRNA-target pair were obtained from the
control and SLE groups separately and then combined using
Fisher’s transformation. Each bar represents the average and
standard error of correlation coefficients of a target list. Target lists
were downloaded from miRBase.
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Figure S10 miRNA validation. The increased expression of
miR-212-3p in SLE was validated by qRT-PCR with cel-miR-238
as a control. Six new controls and 13 new SLE samples were used.
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Figure S11 High expression miRNA target transcript
expression. Three miRNAs whose pri-miRNAs had higher
expression in SLE were examined for an effect on potential target
transcripts. For these three miRNAs, target transcript expression
was significantly downregulated on average. While coding genes
were generally downregulated in SLE, the target genes tended to
be downregulated even more. Target lists were downloaded from
miRBase database.
(DOCX)
Figure S12 Isoform distribution for SNAPC3. A) Cufflinks
assembly based on our RNA-seq data identified a novel splicing
site within the 39 UTR of SNAPC3. B) The relative abundance of
the two isoforms was changed in SLE. C) The difference in relative
abundance was statistically significant.
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Figure S13 Isoforms with increased expression in SLE
are more complex. The isoforms where the relative abundance
was increased in SLE had a higher number of exons than those
where the relative abundance was decreased (p = 0.007). On
average, the SLE-favored isoforms had about 0.5 exons more than
the control-favored isoforms.
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Figure S14 Novel isoforms of IL1R1. Tophat-Cufflinks
identified three isoforms of IL1R1 not included in the RefSeq
annotation. Two of them have been included in GENCODE
database version 14 (A&B), and both had histone patterns at their
transcription start sites consistent with expression according to
ENCODE histone modification data sets generated from CD14+
monocytes (C&D). The other isoform, TCONS_00030117, had
,6 kb extra 59 UTR exon (E). According to the ENCODE data,
this exon has a strong H3K9me3 footprint (F), which is known as a
repressive histone modification, suggesting unique transcriptional
regulation at this region.
(DOCX)
Figure S15 Novel isoform of IRF8. Tophat-Cufflinks
identified a novel isoform of IRF8, which included a prolonged
exon 4. The existence of this isoform was supported by an
ENCODE RNA-seq data set generated from 9 cell lines, including
lymphoblastoid cell line GM12878. Transcription was detected in
GM12878 cross the full gene body of IRF8, but the extended
region of exon 4 in the novel isoform had higher transcription level
than those of the introns. This isoform is likely an intermediate
product of RNA processing and not present in the mature mRNA.
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Figure S16 Novel isoform validation. A) Tophat-Cufflinks
identified multiple novel isoforms of IL1R1, each with a new exon-
exon junction in the 59 UTR. One of the isoforms (in red) was
validated by qRT-PCR using a pair of primers across two exons
(F4/R4). B) IRF8 was known to have a single isoform. Tophat-
Cufflinks identified a novel isoform, which was validated by qRT-
PCR. These gels are representative of three experiments, with
comparable results.
(DOCX)
Figure S17 Novel transcripts located on Chromosome
18. The detailed annotation of a cluster of novel transcripts
located on chromosome 18 using public genomic data. A) Four
novel transcripts identified by the Tophat-Cufflinks pipeline in
monocytes about 20 kb upstream of coding gene SERPINB2 are
shown. All four transcripts were transcribed at the opposite
direction as SERPINB2, and three of them were significantly
upregulated in SLE by 303% to 671% (p = 1.3E-6 to 1.5E-8). All
four transcripts were validated by qPCR. B) These transcripts are
not included in commonly used gene annotation databases. Two
predicted genes partially overlap with these transcripts, but both
are transcribed in the opposite direction. C) Sequences within this
region are evolutionarily conserved. D) A very low level of
transcription was detected within this region according to an
ENCODE RNA-seq data set that measured transcriptomes in nine
cell lines, not including monocytes. E) This region has a DNase I
hypersensitive site in CD14+ monocytes according to another
ENCODE data set. F) Furthermore, an ENCODE data set
measuring various histone marks in CD14+ monocytes showed
that this region has a nucleosome pattern indicative of active
transcription.
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Figure S18 Novel transcripts located on Chromosome 8.
A cluster of 26 novel transcripts located on chromosome 8 within a
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,34 kb region upstream of coding gene ADAM28. A) All of the
loci are transcribed in the opposite direction of ADAM28. B) None
of them are included in a common gene annotation databases.
Fifteen of these transcripts were significantly upregulated in SLE
(p,0.01) by 80% to 3435% and none of them were downregu-
lated in SLE. C) Most of the transcripts are located within
evolutionarily conserved regions. D) ENCODE data detected very
low levels of transcripts within this region in 9 cell lines. E)
According to ENCODE data sets generated from monocytes,
there is a DNase I hypersensitivity site within this region. F) The
same sites showed a histone modification pattern of active
nucleosomes.
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Figure S19 Differential expression of novel loci. Twelve
novel loci were amplified using 11 controls (including three
internal validation controls used for the RNA-seq libraries and
eight new controls) and 11 new SLE samples using qRT-PCR. All
genes were normalized to b-actin. P values according to Mann-
Whitney in each case are given in parentheses. Only two failed to
demonstrate increased expression in this new SLE cohort.
Locations are given in Table S3. The cross bars indicate mean
and standard error.
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Figure S20 Concordance of LPS, interferon and SLE
gene expression. Five LPS data sets were created from four
GEO monocyte data series (additional information on methods
available in Methods S1). The a-interferon data set is from our
previously published work. The coding genes shown to be
upregulated in SLE were analyzed for upregulation after LPS
stimulation and a-interferon (aIFN) treatment. A) All three LPS
data sets demonstrated that LPS treatment also increased
expression of the genes shown to be upregulated in SLE.
N = the number of unique genes included in the analysis. B) The
degree of overlap between SLE-induced genes and aIFN-induced
genes was comparable to the degree of overlap between SLE-
induced genes and LPS-induced genes.
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Figure S21 The effect of different MAP kinase inhibitors
on LPS-induced novel loci expression. MonoMac6 cells
(above) and primary monocytes (below) were treated with p38
(SB203580), ERK (U0126) and JNK (SP600125) inhibitors for
30 minutes and then stimulated with LPS. The y-axis represents
the ratio of the LPS+ inhibitor-treated cells over the LPS alone
treated cells, with the horizontal line indicating equivalence. The
p38 inhibitor led to most diminished expression of the novel loci.
At the right of the graph, loci 477 and 896 were included as
controls, which were novel loci that were not altered in SLE.
N = 3.
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Figure S22 The average of the novel loci expression. The
expression levels of the novel loci, demonstrated in Figure S21,
were averaged to better highlight the effect of the inhibitors. p38
(SB203580), ERK (U0126) and JNK (SP600125) inhibitors were
used to define the role of this pathway on the novel loci expression.
A) MonoMac6 cell results from Figure S21 were averaged to
demonstrate the overall effect of the MAP kinase inhibitors. B)
Similarly, in primary monocytes, the results from Figure S21 were
averaged. TNF was used as a positive control for the LPS
stimulation in C) MonoMac6 cells and D) primary monocytes.
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